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SUMMARY
This thesis is  concerned w ith  the iden tifica tion  of soluble 
fib rin o g e n -fib rin  complexes by plasma fibrinogen chromatography. 
These soluble complexes are thought to re fle c t in travascu la r 
coagulation in  v ivo . The studies, which w ill be described, were 
undertaken to  investigate fu rth e r the proposed association between 
pre-eclam psia and dissem inated in travascu lar coagulation by 
searching fo r soluble fib rin o g e n -fib rin  complexes in  plasma 
samples fro m  pre-eclam ptic  patients.
P re-eclam psia rem ains an im portant obste trica l syndrome 
of unknown p rim a ry  aetiology. There is , nevertheless, considerable 
evidence based on anim al experim ental work and on both h isto log ica l 
and haem atological studies in patients to suggest that low -grade 
dissem inated in travascu la r coagulation may be associated w ith  
pre-eclam psia (Chapter V. 2). Such an association m ight be of 
im portance not only in  the pathogenesis and c lin ic a l management of 
pre-eclam psia, but m ight also contribute to a greater understanding 
of dissem inated in travascu la r coagulation its e lf.
In Chapter I  the b iochem istry of fibrinogen, fib rin o g e n -fib rin  
degradation products and soluble fib rin o g e n -fib rin  complexes is  
discussed in  de ta il. The methods cu rre n tly  available fo r the 
iden tifica tion  of soluble complexes (and soluble fib r in ) in  plasma 
samples and the resu lts  obtained in  various c lin ic a l conditions are 
then described (Chapter I. 6). In Chapter H the development of the 
technique of plasma fibrinogen chromatography is  traced and details 
are given of the methods used fo r the studies to be described in  the 
thesis.
I t  was confirm ed in  a series of in  v itro  experim ents (Chapter
III) that soluble complexes could be produced by the action of
XXI
coagulant enzymes (throm bin and ancrod) and that these complexes 
could be p a rtia lly  separated from  fibrinogen by the plasma fibrinogen 
chromatography technique. Patients were then studied during the 
in itia l stages of intravenous infusion w ith  the coagulant enzyme, 
ancrod (Chapter IV ). Increased plasma soluble complex levels 
were found 6 hours a fte r s ta rting  treatm ent, thus con firm ing that 
soluble complexes can be produced in  v ivo  by a coagulant enzyme 
and iden tified  using the plasma fibrinogen chromatography technique.
Follow ing these p re lim in a ry  studies plasma samples from  
pregnant patients were examined (Chapters V -V IÎ). In  order to 
assess the resu lts  in  pre-eclam psia several other obste trica l 
groups were studied. Sm all, but s ta tis tica lly  s ign ifican t increases 
in  plasma soluble complex concentration were found to  occur in  
norm al pregnancy (Chapter V and V II). In patients w ith  in tra ­
u terine growth re ta rdation a fu rth e r sm all but s ign ifican t increase 
in  soluble complex levels was noted (Chapter V II), w h ile  a m ore 
marked increase was found in  association w ith  pre-eclam psia 
(Chapter V and V I). Th is did not appear to be sim ply re lated to 
the combination of hypertension and pregnancy, as pregnant 
patients w ith  essential hypertension were found to have soluble 
complex levels s im ila r to  those found in  norm al pregnancy (Chapter 
V II). In addition, plasma soluble complex leve ls were found to be 
s lig h tly  increased in  women taking oestrogen-containing o ra l 
contraceptive drugs (Chapter vm), a state which in  some ways 
resem bles ea rly  pregnancy.
Although soluble fib rin o g e n -fib rin  complexes probably re fle c t 
activation of the coagulation pathway in  v ivo  and there fore  in  th is  
sense in travascu la r coagulation, it  is  not possible to  d istinguish 
between the d iffe ren t form s of in travascu lar coagulation (see the 
de fin itions in  the Preface) by th is  technique or^indeed, to  make any 
firm  conclusions regard ing insoluble fib r in  deposition from  the
xüi
resu lts . Insoluble fib r in  deposition occurs in  lo ca l throm bosis and 
in  loca l and dissem inated in travascu lar coagulation. In each of 
these states increased plasma soluble fib rin o g e n -fib rin  complex 
levels m ight be found, but i t  is  also possible that a pure hyper- 
coagulable state can exist in  which soluble complexes are form ed 
w ithout insoluble fib r in  deposition.
The resu lts  described in  th is  thesis are , however, compatible 
w ith  hyper coagulability in  women taking oestrogen-containing drugs 
and in  norm al pregnancy, w ith  in  addition a degree of loca l in tra ­
vascular coagulation w ith in  the m aternal placental vasculature in  
norm al pregnancy, a tendency which is  increased in  in trau te rine  
growth re ta rdation , and w ith  disseminated in travascu la r coagulation 
in  pre-eclam psia.
The soluble complex leve ls were most m arkedly increased in  
pre-eclam psia and during ancrod therapy. F ib rinogeno lys is / 
fib rin o ly s is , however, was much more marked in  the ancrod- 
treated patients. I t  may be that fib r in  m icroclo ts are lysed 
ve ry  ra p id ly , perhaps even as they fo rm , in  ancrod therapy; w hile 
in  pre-eclam psia they pe rs is t w ith in  the placenta, kidney, liv e r  and 
other organs leading to the development of some of the c lin ica l 
features of the syndrome. The theory that dissem inated in tra ­
vascular coagulation is  an in tegra l pa rt of the pathology of the p re ­
eclam ptic syndrome is  therefore strongly supported by the w ork 
described in  th is  thesis.
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The abbreviations used in  th is  thesis are in  the main w idely 
accepted and are explained in  the text. The less commonly 
accepted abbreviations are lis te d  below: -
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F
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%
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IV
IVP
MAHA
N -te rm in a l
OD
blood pressure 
systo lic  blood pressure 
d iasto lic  blood pressure 
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dissem inated in travascu lar coagulation
deep venous throm bosis
ethanol gelation test
coagulation Factor V
coagulation Factor X  etc,
fibrinogen
fib r in  monomer produced by throm bin 
(deprived of fibrinopeptides A and B)
fib r in  monomer produced by ancrod or 
Reptilase (deprived of fibrinopeptide A)
fibrinogen degradation p ro d u c ts /fib rin  
degradation products
fib rin o g e n -fib rin  related antigen
fib r in  s tab iliz ing  factor
generalised Shwartzman reaction
in trau te rine  growth re ta rda tion
intravenous
intravenous pyelogram
m icroangiopathic haem olytic anaemia
am ino-te rm ina l
op tica l density
XV
PET pre-eclam psia
SCT staphylococcal clumping test
SD standard deviation
SEM standard e rro r of estim ate of mean value
SK streptokinase
TCP throm bin clottable pro te in
TCT throm bin c lo tting  tim e
TBC H Il tanned red ce ll haemagglutination immuno­
assay
void volume
elution volumee
W /V  weight per volume
X, y , D, E successive degradation products form ed
by plasm in digestion of fibrinogen (F0P)
X, y, d, e successive degradation products form ed by
by plasm in digestion of f ib r in  (fdp)
Abbreviations in  Tables 
ND not done
NS not s ign ificant
E rra ta
B iogel should be spelt B io -G e l 
B iorad should be spelt B io-Bad
PREFACE
This thesis is  concerned w ith  the iden tifica tion  of soluble 
fib rin o g e n -fib rin  complexes in  plasma using the re la tive ly  new 
technique of plasma fibrinogen chromatography. This technique, 
o rig in a lly  developed by F le tcher, AUcjaersig and th e ir colleagues, 
is  claim ed to  provide a sensitive method fo r detecting in travascu lar 
coagulation (F le tcher, A lk ja e rs ig , O 'B rien et a l, , 1970), The 
technique was set up fo r the pro ject described in  th is  thesis, w ith  
the p rim e aim  of studying plasma samples from  obste trica l patients 
w ith  pre-eclam psia, a condition thought to  be associated w ith  low 
grade dissem inated in travascu la r coagulation.
D efin itions and nomenclature in  the fie ld  of in travascu lar 
coagulation rem ain somewhat confused. F or the purposes of th is  
thesis the te rm  "in trava scu la r coagulation" w ill be defined as the 
conversion of fibrinogen to  fib r in  ( i. e, the fin a l stage of the 
coagulation pathway) w ith in  the blood vessels. As a thrombus 
(or m icrothrom bus) has a defin ite  h isto log ica l s tructu re  composed 
of p late lets and leucocytes, as w e ll as insoluble fib r in , i t  is  
appreciated that many in te r-re la te d  factors, besides coagulation, 
are involved in  its  development.
I f  in travascu la r coagulation is  defined as activa tion of the 
fin a l stage of the coagulation pathway, it  is  possible to  c lass ify  
in travascu la r coagulation in to  several types. Local throm bosis 
w ill obviously involve the form ation of insoluble fib r in  w ith in  the 
vascular compartment, but there are other fo rm s of in travascu lar 
coagulation in  which m icro th rom bi fo rm  in  sm all blood vessels and 
it  may also be possible fo r a degree of conversion of fibrinogen 
in to soluble fib r in  to  occur w ithout insoluble fib r in  deposition. The 
fo llow ing c lass ifica tion  of in travascu lar coagulation is  therefore
used in  th is  thesis: -
Types of In travascu lar Coagulation (adapted from  F le tcher and 
A lk ja e rs ig , 1973)
(1) H ypercoagulability
(2) Loca l throm bosis
(3) Local in travascu lar coagulation
(4) D issem inated Intravascular coagulation
(1) H ypercoagulability (synonyms: hypercoagulable state, throm botic 
tendency and p re -th rom botic  state).
This te rm  describes a c lin ic a l state in  which the patient is  at 
increased r is k  of developing one of the other fo rm s of in travascu lar 
coagulation in  which insoluble fib r in  deposition occurs (i. e, 2, 3 or 
4), although actual th rom bi or m icro throm bi are not present at th is  
stage. Hypercoagulability may be associated w ith  an increased 
leve l of coagulation facto rs in  the blood (N ilsson, 1974a) o r w ith  
the presence of activated coagulation factors in  the blood (e. g. 
soluble fib rin o g e n -fib rin  complexes; G raeff, von Hugo and H afte r,
1975), but precise de fin ition  is  lacking* Indeed the existence of a 
pure hypercoagulable state is  by no means generally accepted. It 
may be that a degree of insoluble fib r in  deposition is  always present 
in  such patients (e. g* hypercoagulability and lo ca l throm bosis 
occurring together in  the same patient),
(2) Loca l throm bosis
This te rm  describes the development of a m acroscopic, 
insoluble fib rin -p la te le t thrombus in  a segment of an a rte ry  o r 
vein. Th is often occurs secondary to  loca l vascu lar disease.
(3) Local in travascu la r coagulation
This te rm  describes the development of m icro th rom b i or 
insoluble fib r in  deposits in  the sm all blood vessels of a single 
organ.
(4) D issem inated in travascu la r coagulation (synonyms: diffuse 
in travascu la r coagulation, often re fe rre d  to as "D . I. C.
This te rm  may be used to describe the development of m ic ro ­
throm bi o r insoluble fib r in  deposits in  the sm a ll blood vessels of 
several organs and in  portions of the vascular tree  uninvolved by 
p rim a ry  disease. This is  therefore a h isto log ica l diagnosis, 
which can usually be made only at post-m ortem  o r occasionally 
on the basis of biopsy m ate ria l obtained from  the liv in g  patient.
I t  is  suggested that the te rm  "h is to log ica l dissem inated in tra ­
vascular coagulation" could be used to  describe th is  condition.
It is  c le a rly  im portant to  make a presum ptive diagnosis 
of dissem inated in travascu la r coagulation in  the liv in g  patient.
This is  usually made on the basis of a va rie ty  of labora to ry tests 
including a low blood p la te le t count and a high serum  fib rino ge n / 
fib r in  degradation product (FD P /fdp) leve l. I t  is  suggested that 
the te rm  "haem atological dissem inated in travascu la r coagulation" 
could be used to describe the condition diagnosed in  th is  way. It 
has to be stressed that there is  no evidence of insoluble fib r in  
deposition in  th is  la tte r group of patients. Other te rm s such as 
"consum ption coagulopathy o r syndrome" and "de fib rina tion  state 
o r syndrom e" have been suggested to describe such a condition 
although, of course, the te rm  "d e fib rina tion " can only be used 
when there is  de fin ite  evidence of a fa ll in  plasma fibrinogen levels 
(see N ilsson, 1974b and M erskey, 1976).
The problem s of nomenclature and diagnosis w ill be discussed 
throughout th is  thesis. Many tests of coagulation, fib rin o ly tic  and 
p la te le t a c tiv ity  have been used in  an attem pt to  diagnose the 
d iffe ren t types of in travascu la r coagulation. Although th is  may 
not be ve ry  d iffic u lt in  the most flo r id  cases of dissem inated 
in travascu la r coagulation, the less severe form s of in travascu lar
coagulation may be d iffic u lt to  detect* In p a rtic u la r, i t  is  
d iffic u lt to  iden tify  patients, who are p a rticu la rly  at r is k  of 
developing serious pathology (e. g. widespread dissem inated 
in travascu la r coagulation) at an ea rly  stage, when some form  
of preventative therapy m ight be attempted.
One m ajor problem  in  th is  area is  lack of knowledge of the 
pathogenesis of the d iffe ren t types of in travascu lar coagulation 
leading to  the development of throm bi o r m ultip le  m icro th rom bi.
It  is  appreciated that there is  a complicated in te raction  of many 
factors including changes in  blood flow  and v isco s ity , damaged 
endothelium, a lte ra tions in  blood p late lets and leucocytes, as 
w e ll as activa tion of the coagulation pathway w ith  conversion of 
soluble fibrinogen f ir s t  in to  soluble and then insoluble fib rin .
A t the same tim e the system of in h ib ito rs , developed as a defense 
mechanism against inappropriate in travascu lar coagulation, has 
to  be overcome. The re la tive  importance of these various factors 
in  d iffe ren t c lin ic a l situations is  poorly understood. I t  is  c lear 
that in travascu la r coagulation w ith  the form ation of fib r in  is  only 
one aspect of th is  problem , yet it  is  the only one which w ill be 
considered in  de ta il in  th is  thesis. I t  is  w orth stressing at the 
outset that other aspects are involved, which may be of equal o r 
greater im portance in  d iffe ren t c lin ica l situations*
The condition studied in  de ta il in  th is  thesis is  the obste trica l 
com plication of pre-eclam psia, in  which it  is  suspected that low 
grade dissem inated in travascu la r coagulation occurs (Chapters V 
and V I). This w ork form s the centra l core of the thesis and led 
to the study of a va rie ty  of other obste trica l (Chapter V II) and non- 
obste trica l conditions (Chapters IV  and V III). The "m ode l" of 
acute de fib rina tion  induced by intravenous ancrod infusion (Chapter
IV ) proved p a rtic u la rly  in te resting.
T his thesis is  concerned w ith  the iden tifica tion  of soluble 
fib rin o g e n -fib rin  complexes in  c lin ica l conditions. I t  is  not 
concerned w ith  the detailed b iochem istry of these complexes but 
only w ith  th e ir possible use as m arkers of in travascu la r coagulation. 
Rome in  v itro  experim ents were, however, perform ed to  help in  
setting up the technique and in  the in te rp re ta tion  of the resu lts 
(Chapter II).
In a p ro ject ca rrie d  out over the same three year period in  
the same laboratory M r. W illia m  Edgar has studied the b io ­
chem istry of soluble fib rin o g e n -fib rin  complexes and soluble 
fib r in  and inevitab ly there was some overlap of in te res t between 
the two pro jects . The resu lts  of a jo in t study in to  the structure  
of soluble complexes form ed by the coagulant enzyme, ancrod, 
both in  v itro  and in  v ivo  w ill be described in  Chapters m . 6 and
IV . 4(c). This Joint study is  im portant and relevant in  that it  
resulted in  an increased understanding of the possible methods 
of soluble complex form ation (Chapter IV . §).
Inevitab ly over the three years since the s ta rt of th is  pro ject 
much has appeared in  the lite ra tu re  which has proved relevant to  it .  
Th is subject is  developing rap id ly  and quite basic aspects of theory, 
methodology and in te rp re ta tion  are being questioned. The 
relevant lite ra tu re  on each c lin ica l condition is  discussed at the 
beginning of the chapter o r section of the chapter dealing w ith  
that condition (e. g. the lite ra tu re  concerning the association between 
pre-eclam psia and in travascu la r coagulation is  discussed in  Chapter
V. 2). The lite ra tu re  concerning the biochem istry of fibrinogen and 
soluble fib rin o g e n -fib rin  complexes is  discussed in  de ta il in  Chapter I, 
w hile  the background lite ra tu re  concerned w ith  agarose gel filtra tio n  
and the plasma fibrinogen chromatography technique w ill be discussed
in  Chapter II. 2 and 3.
The resu lts  obtained w ill be discussed in  de ta il in the 
appropriate cliapter* In the fin a l chapter (Chapter IX ) an 
attem pt w ill be made to  b ring  a ll these resu lts  together in  
order to  make a c r it ic a l assessment of the plasma fibrinogen 
chromatography technique and also to  in te rp re t the resu lts  in  
te rm s of the d iffe ren t types of in travascu lar coagulation.
CHAPTER I
HISTORICAL INTRODUCTION
The subject of soluble fib rin o g e n -fib rin  complexes is  both 
com plicated and con trovers ia l. Many d iffe ren t types of soluble 
complex can be produced in  v itro , but there is  debate as to  th e ir 
presence and significance in  v ivo . Before discussing the 
lite ra tu re  available on the subject, i t  is  necessary to  sum m arise 
what is  known about fibrinogen its e lf, the fib rin o g e n -to -fib rin  
conversion and the pro teo lys is of fibrinogen and fib r in  to  produce 
fib rin o g e n /fib rin  degradation products.
These subjects w ill be discussed in  de ta il in  Chapter 1 .1,
1 .2 and 1.3. F ibrinogen synthesis, d is tribu tion  and degradation 
in  v ivo  w ill then be discussed in  Chapter 1.4. The lite ra tu re  on 
the subject of soluble fib rin o g e n -fib rin  complexes w ill be discussed 
in  Chapter I. S and the techniques cu rren tly  available fo r the 
iden tifica tion  of soluble complexes in  c lin ic a l conditions together 
w ith  the resu lts  of such studies w ill be described in  Chapter 1 .6.
The background lite ra tu re  on the c lin ic a l conditions studied 
in  the thesis w ill be considered at the beginning of the appropriate 
chapter (e. g. the re levant lite ra tu re  on pre-eclam psia w ill be 
discussed in  Chapter ¥ . 1 and V. 2).
1.1(a) F ibrinogen -  H is to rica l Aspects
F ibrinogen is  a p ro te in  of considerable im portance in  norm al 
blood coagulation. M alp ighi (1686) demonstrated that the s truc tu ra l 
basis of blood c lo t was the w hite fib rous m a te ria l, which is  now 
called fib r in . Although the existence of a soluble fib r in  p recursor 
in  plasma was suspected, i t  was not u n til the 19th century that the 
p recu rso r, fibrinogen, was isolated (Denis-De-Com m ercy, 1859;
aHammarsten, 1879). Hammarsten observed that fibrinogen did 
not coagulate spontaneously taut did so rap id ly upon the addition 
of a "th ro m b ic " enzyme. He therefore proposed that fib r in  was 
a specific re su lt of the in te raction  of throm bin and fibrinogen.
M ore recent w ork has shown that the conversion of fibrinogen 
to fib r in  occurs in  several stages (Laki and M om m aerts, 1945;
La k i, 1951 and L a k i, 1953), Throm bin f ir s t  reacts w ith  fibrinogen 
and prepares it  fo r the po lym erisation process which can then occur 
"spontaneously" in a suitable ionic environment. D ire c t evidence 
of the lim ite d  p ro teo ly tic  a c tiv ity  of throm bin on fibrinogen was 
provided when a differences between the N -te rm in a l amino acids 
of bovine fibrinogen and fib r in  was demonstrated (B ailey,
Bette lhe im , Lorand et a l. , 1951).
The extensive w ork, which has been done in  studying th is  
reaction, w ill be discussed in  de ta il in  Chapter 1.2,
1.1(b) Physicochem ical P roperties of F ibrinogen
There is  now considerable evidence that fibrinogen prepared 
from  blood consists of populations of s lig h tly  d iffe ren t molecules 
(Mosesson, 1970; Mosesson, 1974). These can be separated on 
the basis of th e ir so lu b ility , ranging from  a type which precip ita tes 
upon standing in  the cold to  one which is  soluble even in  the presence 
of saturated glycine solutions. The properties of these d iffe ren t 
form s of fibrinogen have been summarised by Mosesson (1970). 
Follow ing the nomencalture introduced by Cohn, Strong, Hughes 
and colleagues (1946), the higher the number assigned to a given 
fibrinogen frac tio n , the higher the overa ll so lu b ility  of that frac tion . 
Therefore F raction  I - l  consists of the low so lu b ility  species which 
is  said to  p rec ip ita te  w ith  cold insoluble globulins. F raction  1-4 
constitutes the bulk of fibrinogen in  plasma and represents the 
species of fibrinogen p u rifie d  by "c la ss ica l" techniques, so called
9"na tive " fibrinogen. F raction  1-8 is  highly soluble and although 
)95% clottatale has a m olecular weight low er than that of the 
F raction  1-4 species. I t  may represent a product of lim ite d  
p ro teo lysis.
Due to  the va rie ty  of species of fibrinogen, estim ations of 
m olecular weight va ry . Mosesson (1970) suggested a m olecular 
weight in  human preparations of 269, ODD fo r F raction  1-8 and 
325,000 fo r F raction  1-4. The generally accepted value fo r 
"na tive " fibrinogen is  340,000 (Murano, 1974).
1.1(c) S tructure
F ibrinogen is  a sym m etrica l molecule w ith  a tw o-fo ld  
axis of sym m etry. There are three chains in  each ha lf­
molecule and, according to  in ternational nom enclature, they 
are known as the A o( , B jg and X chains (repo rt of the 
Nomenclature Subcommittee of the International Committee 
fo r Throm bosis and Haemostasis, Oslo, Norway, 1971). The 
molecule appears to  be a d im er held together by sym m etrica l 
disulphide bonds between the A oC , B |S and QT chains. The 
structu re  of the N -te rm in a l region, the N -te rm in a l disulphide 
knot (N-DSK), has been described in  considerable de ta il 
(Blomback, 1969; Blomback and Blomback, 1972). The 
fibrinopeptides A and B which are released by the action of 
throm bin are located in  th is  region of the molecule (see F igure 
1). Detailed review s of th is  subject have been published by 
Murano (1974) and Blomback, Hogg, Gardlund and colleagues
(1976).
The shape of the molecule is  uncertain. H a ll and Slayter 
(1959) described a trig lo b u la r structure . M ore recent work 
has challenged th is  and a number of d iffe ren t models have been 
suggested. One of the most recent suggests a spherica l p a rtic le
10
22 nm in diam eter folded up around the N -te rm ina l disulphide 
knot (Hudry-C lergeon, M arguerie, Pouit et a l. , 1975). These 
authors suggest that marked conform ational changes occur in 
the molecule under the action of throm bin and due to tem perature, 
pH, ionic strength, solvent nature and prote in concentration.
I. 2. F ib rino ge n -F ib rin  Transform ation
The conversion of soluble fibrinogen into insoluble fib r in  
is  the fin a l reaction in  the coagulation cascade (M acfarlane, 1964; 
M acfarlane, 1976; see F igure 2). This complicated "cascade" 
system of in e rt p recursors and active enzymes has presumably 
evolved to  prevent in travascu la r coagulation occurring 
inappropria te ly. As a fu rth e r safeguard a correspondingly 
complicated system of in h ib ito rs  has also developed.
The com plexity of the cascade system is  increased by the 
rea lisa tion  that even th is  fin a l reaction takes place in  stages.
Two enzymes are im portant in  th is  fin a l reaction -  throm bin 
(F Ila ) and fib rin -s ta b ilis in g  facto r (F X llla ). Throm bin acts by 
converting fibrinogen to fib r in  monomer which is  then capable of 
spontaneous polym erisation. This reaction w ill be considered in 
de ta il in  Chapter I. 2(a). F X llla  acts by introducing strong 
covalent bonds between the units of the fib r in  polym er. Its  
action w ill be considered in  de ta il in  Chapter 1.2(b).
I. 2(a) F ib rino ge n -F ib rin  T ransform ation - Throm bin
The fita rinogen-fib rin  transform ation occurs in a series of 
stages (see detailed discussion Scheraga, 1961). A sim ple 
model of th is  reaction is  shown in  F igure 3 (adapted from  
Laskowski, Rakowitz and Scheraga, 1952). The enzymic step 
induced by throm bin is  lim ite d  to stage i.  Throm bin f ir s t  removes
11
the fibrinopeptide A fragm ents from  the A o< chain of fibrinogen 
by cleaving an a rg iny l-g lyc ine  bond, This reaction proceeds 
rap id ly . The fibrinopeptide B fragm ents are then removed a fte r 
a lag phase during which po lym erisation has already occurred 
(Blomback, 1908). As the fibrinopeptides c a rry  a strong 
electronegative charge th e ir rem oval a lte rs  the e le c tric  charge 
of the molecule and is  also thought to produce a conform ational 
change opening up various polym erisation sites (see Murano,
1974 and its  bibliography).
The process of po lym erisation Is poorly understood (i. e. 
stages i i  and ii i) .  I t  would appear to  involve the form ation of 
weak, reve rs ib le  bonds between the po lym erising un its. These 
are probably hydrogen bonds between ty ro sy l donors and h is tid y l 
acceptors (Sturtevant, Laskowski, Donnelly et a l. , 1955; Endus, 
Ehrenpreis and Scheraga, 1966) although hydrophobic bonding or 
charge neutra lisa tion may also be im portant (Collen, 1971).
A schematic model fo r the po lym erisation of fib r in  monomer 
un its has been described (BlombSck et a l. , 1976; see F igure 4). 
The binding sites A  and A* are located in  the N -te rm in a l disulphide 
knot region of each molecule. The binding s ites a and a* are 
located in  the carboxyterm inal end of each m olecule. The A -A* 
sites requ ire  activa tion by throm bin, w hile the a-a* sites are 
already active in  the molecule as i t  c ircu la tes in  the blood.
The A o r A ’ s ite  in te racts w ith  the a or a* s ite  of a neighbouring 
m olecule. In th is  model a succeeding molecule covers the 
preceding one in  a half-staggered fashion. This produces "end- 
to-end" alignm ent. "S ide -to -s ide " alignm ent occurs at a second 
set of binding sites (B-B* and b-b*) whose existence is  not yet 
confirm ed.
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The conversion of soluble fib r in  polym er to  insoluble fib r in  
(stage i i i )  is  also incom pletely understood. I t  may be that once 
a c r itic a l size is  reached the polym er becomes insoluble. It 
must be stressed that stages i i  and i i i  are reve rs ib le  under 
certa in  conditions (e. g. by a lte rin g  pH), The irre v e rs ib le  
step is  produced by the form ation of covalent bonds induced by 
the action of F X llla ,
1.2(b) F ib rino ge n -F ib rin  T ransform ation -  F ib rin -S tab ilis ing
Factor (F m i l / F XHIa)
In 1923 Barkan and Gaspar demonstrated that the so lu b ility  
of fib r in  could be a lte red by the presence or absence of oxalate in  
the in itia l fibrinogen preparation. La te r i t  was shown that calcium  
ions increased the firm ness of fib r in  c lo t (Mellanby and P ra tt, 1940), 
It was then demonstrated that a "serum  fa c to r" was also required 
fo r the form ation of insoluble fib r in  (Robbins, 1944). This "serum  
fa c to r" was found to  be present in  higher concentrations in  plasma 
and is  now known as fib rin -s ta b ilis in g  factor o r F xni/F X llla .
The reaction involving calcium  ions and F XlOa is  known as cross- 
link ing  and was eventually shown to involve the form ation of covalent 
bonds (see F in lay son, 1974 and its  bibliography).
In 1966 F u lle r and D oo little  showed that the Ê -am ino group of 
lysine took pa rt in  crosslink ing  and they proposed that the cross­
lin k  was Ê ( Y  glutam yl) lys ine . Factor XH I can be activated by a 
number of enzymes including throm bin, tryp s in , papain and F Xa 
(Finlayson, 1974; McDonagh and McDonagh, 1975). Factor X III 
does not appear to  be activated by plasm in o r chym otrypsin and 
is  probably not activated by the most h ighly p u rifie d  preparations 
of the snake venom deriva tives ancrod and R eptilase, although 
cruder preparations may do so (Finlayson, 1974; McDonagh and 
McDonagh, 1975).
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C haracte ris tics of the fib r in  cross link
The C/ and X chains take pa rt in  crosslink ing , the Y  chains 
crosslink ing  m ore rap id ly  than the ^  chains (McKee, M attock and 
H ill, 1970), The ^  chains do not cross link (Chen and D o o little , 
1969). It is  there fore  possible to distinguish between crosslinked 
and non-crosslinked fib r in  by examining the chains present a fte r 
cleavage of disulphide bonds before electrophoresis. (P izzo, 
Schwartz, H ill et a l. , 1972; Gaffney and B rasher, 1973). In 
crosslinked fib rin K  - Y d im ers and OC polym ers and oligom ers 
are found.
The physio logica l significance of fib r in  cross link ing  is  not 
understood, Duckert (1972) suggested that the consequences of 
fib r in  crosslink ing  are increased mechanical strength and e la s tic ity , 
decreased suscep tib ility  to  pro teo lysis and support fo r tissue 
re p a ir.
I t  has frequently been claim ed that cross link ing  increases 
the mechanical strength of fib r in  (e, g, Duckert, Jung and 
Schm erling, 1960), although there is  no difference in  the electron 
m icroscopic appearance of crosslihked and non-crosslinked fib r in  
(Kay and Cuddigan, 1967), The re la tive  resistance to  ly s is  of 
the two form s of fib r in  has been studied using d iffe ren t p ro teo ly tic  
enzymes, activa to rs and experim ental approaches (Finlayson, 1974). 
C rosslinked clo ts appear to be more resistant to  ly s is  induced by 
urokinase (McDonagh, McDonagh and D uckert, 1971) although there 
appears to be no difference in  the susceptib ility  of the two kinds of 
fib r in  to  ly s is  induced by tryp s in  o r plasm in (T y le r, 1972), The 
evidence regarding streptokinase is  conflic ting, T y le r (1972) 
found no d ifference between crosslinked and non-crosslinked fib rin ; 
w h ile  Henderson and Nussbaum (1969) reported that non-crosslinked
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f ib r in  was more rap id ly  lysed. It now seems possible that cross- 
link ing  of the "Y chains does not increase lys is  tim e but that cross- 
linkage of the OCehains does (Schwartz, P izzo, H ill et a l. , 1973),
It appears that crosslinkage may occur in  step w ith  poly­
m erisation ra th e r than occurring at the very end of the fib rinogen- 
to -fib rin  conversion. Finlayson and Aronson (1974) induced 
throm bosis in  the jugu lar vein of the rabbit and showed that even 
in  the ea rlies t clots Y X -d im erisa tion was essentia lly complete 
and a considerable degree of oC polym er had form ed. It is not 
known i f  there is  a species va ria tion  in th is  respect.
It is  recognised that F X llla  can cross link soluble fib rinogen- 
fib r in  complexes (Sasaki, Page and Shainoff, 1966) and even 
fibrinogen its e lf (Kanaide and Shainoff, 1975). This group cla im  
that soluble dissociable (uncrosslinked) fib rin o g e n -fib rin  complexes 
are rap id ly  cleared from  the c ircu la tion  and that crosslinked 
complexes rem ain in  the c ircu la tion  fo r several days (Shainoff 
and Sasaki, 1971),
The a b ility  of F X llla  to  cross link fibrinogen is  c lea rly  an 
im portant observation. In v itro  the in itia l rates of crosslinking 
of fibrinogen varied d ire c tly  w ith  the fibrinogen concentration. A t 
ve ry high concentrations (30 m g /m l) fibrinogen crosslinked more 
rap id ly  than fib r in  (Kanaide and Shainoff, 1975). Experim ents 
using th rom b in -free  F JHÏIa have suggested that the precip ita tion  
of fibrinogen is  required to produce the conform ational change, 
which allows crosslink ing  to occur (Seelich, F u r Ian and Beck,
1976), Presum ably throm bin induces a s im ila r conform ational 
arrangement of the sub-unit chains allow ing cross link ing  to  occur.
The significance of the studies on crosslinking of fibrinogen 
have to be assessed in  v ivo  but could provide a means of soluble
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complex (L e. a molecule la rg e r than fibrinogen but antigenically 
re lated to  it)  production w ithout the in tervention o f throm bin.
It has been suggested that a stable d im er found re g u la rly  in 
patients w ith  renal a llog ra fts  and also in  patients w ith  necrotis ing 
vascu litis  is  form ed in  th is  way (Kanaide, Braun and Shainoff,
1973). A s im ila r d im er has also been found in  two cases of 
Hodgkin’s disease (Shainoff and Sasaki, 1971),
1 .3. F ibrinogen and F ib rin  Degradation Products
These are molecules sm a lle r in  size than fibrinogen produced 
by extensive pro teo lysis of fibrinogen, non-crosslinked fib r in  or 
crosslinked fib r in . Although a number of p ro teo ly tic  enzymes can 
produce such pro teo lys is, it  is  usually assumed that plasm in is  
the enzyme responsible in  v ivo . A great deal is  known about 
fibrinogeno lysis and fib rin o ly s is  in  v itro  and much less about 
these reactions in  v ivo . The in  v itro  w ork w ill be discussed 
f ir s t.
1.3(a) F ibrinogenolysis and F ib rin o lys is  In V itro
In 1934 G arner and T ille tt demonstrated that fibrinogen could 
be fragmented by a streptococcal extract in to  sm a lle r molecules, 
which were no longer clottable by throm bin. In 1945 iSeegers,
N ie ft and Vandenbelt c le a rly  identified two components in  a 
fibrinogen lysate a fte r e lectrophoresis. In 1961 Hussenzweig and 
colleagues using D EAE-cellu lose chromatography identified five  
products (Fragm ents A, B, C, D and E) in  the "te rm in a l fibrinogen 
lysa te ", Fragm ent D made up 50-60% of the to ta l pro te in  in  the 
lysate and Fragm ent E 15-20% (Nussenaweig, Seligmann and G rabar, 
1961; Nussenzweig, Seligmann, Pelmont and G rabar, 1961). During 
the 1960s and 1970s much w ork was done on th is  subject (e, g. 
H a rd e r, Shulman, C a rro ll, 1969; M ills , 1972; H a rd e r, Budzynski,
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James, 1972; P izzo, Schwartz, H ill et a l. , 1972; Budzynski,
H a rde r and Shainoff, 1974). Despite differences in  nomenclature 
some basic p rinc ip les are established. The reaction sequence 
which w ill be described is  based on the w ork and nomenclature of 
H a rd e r’s group.
P lasm in in itia lly  attacks the carboxy-term ina l end of the 
A cA chain (see F igure 5) and early Fragment X  is  produced.
P lasm in next attacks the am ino-term ina l end of the B ^  cham, 
rem oving in  the process the fibrinopeptide B fragm ent, fo rm ing 
Fragment X. The molecule is  then sp lit asym m etrica lly to 
produce Fragment Y and Fragm ent D. F in a lly , Fragm ent Y is 
its e lf sp lit asym m etrica lly into Fragment E and a fu rth e r Fragment 
D. C lea rly , th is  is  an ove r-s im p lifica tion  and in  fact several 
species of Fragm ent X, Y, D and E exist w ith  varying lengths of 
A o< , B ^  and % chains. This model of plasm in digestion of 
fibrinogen suggests that there are two Fragments D and one 
Fragment E contained in  each molecule of fibrinogen. This has, 
however, been challenged (see review  M arguerie, Hudry-C lergeon 
and Suscillon, 1975).
N on-crosslinked fib r in  would seem to be degraded in  a fa ir ly  
s im ila r fashion to  fibrinogen (Gaffney, 1973), However, fib r in  in 
which the ')( chains are crosslinked (as Y -Y dim ers) w ill be degraded 
d ire c tly  to  Fragm ent D -d im er and Fragment E (Gaffney, 1973).
It would be helpful to  be able to  d istinguish between the 
degradation products of fibrinogen, non-crosslinked and crosslinked 
fib rin . Despite the fact that fibrinogen and non-crosslinked fib r in  
are degraded in a fa ir ly  s im ila r fashion, there appear to  be 
im m unological differences between th e ir degradation products 
associated w ith  both the D and E regions of the parent molecule.
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These "cleavage associated neoantigene" are thought to  represent 
c ryp tic  sites on the parent molecule which are revealed by plasmin 
digestion (Plow and Edgington, 1973; Edgington, 1075), It is  
claimed that these neoantigens can be used to quantitate the amount 
of degradation product derived from  fibrinogen o r from  non-cross­
linked fib r in  (Edgington, 1975).
It is  possible to d istinguish between deriva tives of cross- 
linked and non-crosslinked fib r in  as only crosslinked fib r in  will 
be degraded to  Fragment D-dimer (Gaffney, 1973),
1.3(b) The P lasm inogen-P lasm in System
The basic fib rin o g e n o ly tic /fib rin o ly tic  pathway is  shown in  
F igure 6. There is  an obvious s im ila rity  w ith  the fin a l stages of 
the coagulation pathway and indeed it  seems probable that the two 
systems have evolved in  p a ra lle l to each other, each w ith  an 
appropriate system of in h ib ito rs  (see review  Chesterman, 1975),
Both systems can be activated by F X lla  (Kaplan and Austen, 1972) 
and by endothelial damage and tissue factor (Todd, 1958), Indeed 
the coagulation, fib rin o ly tic , k a llik re in -k in in  and complement systems 
are a ll closely re la ted (see review s Hatnoff, 1969 and Storm orken,
1975). These in te r-re la tion sh ips  are probably of great importance 
in  disease but are incom pletely understood, one of the problem s 
undoubtedly being that "the  defenses of the body may be dissected 
by the investigator to  su it h is experim ental convenience but that 
in  nature they fo rm  a seamless web" (Ratnoff, 1969),
It is  usually assumed that the plasm inogen-plasm in system 
plays an im portant ro le  in  the rem oval of pathological fib r in . The 
re ticu lo -endo the lia l system may also be of considerable importance 
in this respect. There may be a complex in te r-re la tio n sh ip  
between the two systems (see Chapter I. 5(e) ). Although 
plasm in is  lik e ly  to be im portant other fib rin o g e n o ly tic /
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fib rin o ly tic  enzymes may be involved e, g. red c e ll p ro teo ly tic  
enzymes, cathepsins or peptidases (Johnson and M erskey, 1971),
I t  is  Im portant to  rea lise  that there may be differences in 
the plasm inogen-plasm in reaction depending on the means of 
plasminogen activation. In a recent series of publications 
Gurewich, Lipinski and colleagues (see below) have studied 
"n a tu ra lly  occurring plasminogen activa to r" and compared 
th e ir resu lts  with those obtained w ith  activa tor prepared fo r 
therapeutic use (1. e, streptokinase and urokinase), which had 
been used in the earlier w ork on th is  reaction. N atura l 
plasminogen activa to r was obtained in  blood samples collected 
a fte r venous occlusion (Lipinski, Nowak and Gurewich, 1974), 
immediately a fte r death (Gurewich, Nowak, L ip inska et a l. ,
1974) and a fte r strenuous physical exercise (Gurewich, L ip inska 
and L ip in sk i, 1974).
It was shown that soluble fibrinogen, soluble fib r in  monomer 
complexes and soluble fib r in  degradation products are resistant to 
na tu ra lly  induced fib rin o ly tic  a c tiv ity . In contrast there was rapid 
lys is  of insoluble fib r in , protam ine sulphate precip ita ted fibrinogen 
and protam ine sulphate and ethanol induced gels of fib r in  monomer. 
F u rthe r w ork on cadaver-derived vascular plasminogen activa tor 
suggested that th is  is  because activa i or -  in h ib ito r complexes are 
form ed which can only dissociate on the surface of insoluble fib r in  
o r precip ita ted fibrinogen (Gurewich, Hyde, L ip in sk i, 1975). 
Equivalent effective concentrations of streptokinase or urokinase- 
activated plasm in caused extensive fibrinogenolysis. I f  th is  w ork 
is  confirm ed it  would appear that soluble fibrinogen and its  soluble 
deriva tives have to pass through an insoluble phase before they can 
be lysed by plasm in induced by natura l plasminogen activa to r.
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I. 3(c) F ib rin o g e n o lys is /F ib rin o lys is  M V ivo
W hile it  is  generally accepted that fib rin o ly s is  occurs 
in  v ivo , fibrinogenolysis in v ivo  is  at present a very con troversia l 
issue. F ib rin o lys is  w ill be considered f ir s t .  It is  not yet 
established how plasminogen activa to r, plasminogen and fib r in  
come in to contact in v ivo . Any model that is  proposed must 
include the separation of the active enzymes from  inh ib ito rs .
A lk ja e rs ig , F le tcher and Sherry (1959) suggested that as 
fib r in  po lym erises, plasminogen is  adsorbed p re fe re n tia lly  onto 
the fib r in  and is  available in large quantities w ith in  a thrombus 
or fib r in  deposit, com paratively free of antiplasm ins. When 
activa tor enters the c ircu la tion  it  diffuses into the c lo t converting 
plasminogen to  plasm in in  s itu . Ambrus and M arkus (1960) 
suggested that plasm in is  bound in  a plasm in-antip lasm in complex, 
which is  reve rs ib le , and which dissociates in the presence of the 
p re fe rred  substrate, fib rin . Chesterman, A lling ton  and Sharp 
(1972) have produced evidence that it  is  the activa to r which is  
adsorbed onto the fib r in  and that c ircu la ting  plasminogen is  
converted in to  plasm in w ith in  the thrombus.
F ibrinogenolysis in  v ivo  is  a ra ther con trovers ia l issue. 
Mosesson (1974) suggested that in  the norm al physio logical state 
"fib rinogeno lys is  is  a m ajor catabolic pathway". He based th is  
suggestion on the heterogenity of fibrinogen re la ted pro te in  found 
in  norm al blood. He claim ed that human fibrinogen prepared from  
fresh plasma contains m ore than 20% high so lu b ility  m a te ria l w ith 
degraded A 0< chains. Two m ajor fibrinogen components (higher 
and low er m olecular weight fibrinogen; HMW and LMW fibrinogen 
respective ly) have also been found in  plasma from  healthy subjects 
by L ip inska, L ip in sk i and Gurewich (1974). HMW fibrinogen made
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up about 70% of the to ta l clottable protein.
Mosesson (1974) in terpre ted his findings as showing plasm in 
digestion of fibrinogen in  v ivo  and suggested that OC  ^ m acroglobulin 
fo rm s a complex w ith  plasm in, which is  capable of fibrinogenolysis.
In contrast L ip inska and colleagues (1974) were unable to  demonstrate 
any digestion of fibrinogen by na tu ra lly  activated fib rin(ogen)o lysis. 
They fe lt some other mechanism was involved. The extensive w ork 
on na tu ra lly  occurring plasminogen activa tor by th is  group already 
described (Chapter 1.3(b) ) would tend to support th is  view. I f  
soluble fibrinogen is  resistan t to  naturally activated plasm in it  is  
d iffic u lt to see how fibrinogenolysis can occur in  v ivo  w ithout the 
in troduction of a therapeutic plasminogen activa to r. The only 
way fibrinogen could be catabolised by plasm in would be by 
conversion in to insoluble fib r in .
This could occur in  a low -grade fashion as a physio logical 
defense mechanism. In 1956 A strup suggested that there was a 
dynamic equ ilib rium  between coagulation, with f ib r in  constantly 
being la id  down to  seal defects in  endothelium and fib rin o lys is  
rem oving such deposits after they had served th e ir haemostatic 
function. In favour of th is  are the findings of sm all amounts of 
measurable fib rin o g e n -fib rin  related antigen (FE-antigen) in  sera 
from normal subjects (M erskey, Lalezari and Johnson, 1968) and 
low concentrations of fibrinopeptide A in  norm al plasma (Nossel,
1976). It is  possible that these changes are occurring  in v itro  
despite attem pts taken to prevent this* A study of ^^^I-labe lled  
fibrinogen has suggested the form ation of both c ryo p ro fib rin  and 
early  degradation product in the healthy rabb it (Sherman, 1972).
This would also be in  keeping w ith  A strup ’s theory of continual 
low-grade coagulation and fibrinolysis in the healthy anim al 
(Astrup, 1956).
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The re la tive  im portance of fib rin o lys is  and fib rinogeno lysis 
in  v ivo  c le a rly  requ ires fu rth e r elucidation. This subject is , 
however, of considerable im portance in  the form ation of the 
d iffe ren t types of soluble complexes (Chapter IV . 4).
1.4 F ibrinogen Synthesis, D is tribu tion  and Degradation In V ivo 
This com plicated subject was reviewed by Reeve and Franks 
(1974). A summary of th is  review  is  shown as a com partm ental 
model in  F igure 7. The "fib rinogen core system " represents the 
norm al m etabolic pathway, as seen by these authors. The 
rem aining pathways are thought to operate m ainly during 
pathological states. Much of th is  theory rem ains highly 
speculative. Ind ividual pathways are discussed in  de ta il else­
where in  th is  thesis. I t  is  useful, however, to  look b rie fly  at 
an ove ra ll view of fibrinogen m etabolism .
1.4(a) N orm al M etabolic Pathways
Fibrinogen is  m ainly synthesized in  the liv e r  (M ille r and 
Bale, 1954) and like  album in appears to  be secreted d ire c tly  into 
the blood stream  and only to  a sm all extent in to  the hepatic lymph 
(Eosenoer and R othschild, 1970; Reeve and Franks, 1974). The 
factors regulating fibrinogen synthesis and secretion are not yet 
com pletely understood, althougli it  is  appreciated that there may 
be rap id fluctuations in  the synthetic ra te (Atencio, Jo iner and 
Reeve, 1969). F ibrinogen is  one of the plasma pro te ins that 
shows an "acute phase response". Follow ing surg ica l traum a, 
the in jection  of endotoxin o r acute infections, plasma fibrinogen 
shows a ris e  in  concentration to  at least tw ice the in it ia l leve l, 
over a period of 24 to  72 hours depending on the species of 
anim al studied (see review  Reeve and Franks, 1974).
When fibrinogen enters the blood stream , it  is  im m ediately 
exposed to  the potentia l dangers of pro teo lysis by enzymes such
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as throm bin, plasm in and possibly tryp s in  and elastase (Reeve 
and Franks, 1974). To prevent e ither generalised in travascu lar 
coagulation or generalised fibrinogenolysis a complicated system 
of enzyme precursors and inh ib ito rs  has developed (Chapter 1.2 
and I. 3), The p o ss ib ility  that throm bin and plasm in may act on 
fibrinogen in the healthy anim al has already been discussed 
(Chapter I. 3 (c)). This question rem ains unresolved at present, 
although Reeve and Franks (1974) conclude that it  is  probable that 
such pathways play "a  m in im al ro le  in  norm al fibrinogen 
m etabolism ".
A part from  attack by c ircu la ting  enzymes fibrinogen is  
exposed to  two other fates. It may pass through permeable 
vessels to  enter the in te rs titia l flu ids  or i t  may pass to  a 
catabolic breakdown site. In te rs titia l fibrinogen is  m ainly 
d istribu ted  in  the sm all volume rapid flow in te rs titia l flu ids  
of the v isce ra , which possess cap illa ry  beds of high perm eability 
and which contribute to  70% of thoracic duct lymph flow  (Reeve 
and Franks, 1974). In general^knowledge of in te rs titia l flu id  
fibrinogen and its  deriva tives is  to ta lly  lacking.
The second fate of c ircu la ting  fibrinogen is  catabolism .
When ca re fu lly  prepared labelled fibrinogen is  in jected into the 
c ircu la tion  of man or experim ental animals there is  rap id rem oval 
of the 1 or 2% which has been altered in a good preparation (Reeve 
and Franks, 1974). There is  evidence that the a ltered pro te in  is  
rap id ly  taken up by the reticu loendothelia l ce lls  (e. g. the Kupffer 
ce lls) and rap id ly  catabolised by them (Barnhart and Noonan, 1973). 
A fte r th is  phase catabolism  proceeds at a regu lar ra te  w ithout any 
great delay between the tim e the labelled fibrinogen destined fo r 
catabolism  leaves the c ircu la tion  and the tim e the catabolic 
products -  labelled low m olecular weight degradation products 
and free  label (usually iodide) - enter the c ircu la tion  (Atencio,
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B ailey and Reeve, 1965 and Atencio and Reeve, 1965). Although 
the location o f these catabolic s ites is  unknown, they m ight be in  
the ca p illa ry  endothelium, which is  ric h  in  plasminogen activa to r, 
o r in  the synovium (Reeve and Franks, 1974). I f  significant 
pinocytosis of drops of plasma occurred, the plasminogen which 
tends to  be associated w ith  fibrinogen m ight be activated, leading 
to fibrinogen digestion by plasm in w ith in  the pinocytotic vesicles 
(Reeve and Franks, 1974). The subject of fib rino ge no lys is / 
fib rin o ly s is  in  v ivo  is  discussed in  Chapter 1.3(c).
1.4(b) Pathophysiology of the F ibrinogen System
The pathways involved include a ll those outw ith the "fib rinogen 
core system " in  F igure 7.
Throm bin Pathway (see also Chapter 1.2(a) ).
D issem inated in travascu la r coagulation w ith  m icro th rom b i 
in  the kidney, liv e r , lung and spleen can be produced by throm bin 
infusion in  experim ental anim als (M argaretten, Csavossy and 
McKay, 1967). The subject of experim ental dissem inated in tra ­
vascular coagulation w ill foe discussed in  de ta il in  Chapter I. 5(c) 
w ith  p a rticu la r reference to soluble fib rin o g e n -fib rin  complexes. 
Dissem inated in travascu la r coagulation w ith  reference to the 
obste trica l condition of pre-eclam psia w ill be discussed in  de ta il 
in  Chapter V.
P lasm in Pathway (see also Chapter 1.3(b) and 3(c) )
As has already been discussed plasminogen is  converted into 
plasm in in  v itro  by many d iffe ren t activa tors (e .g . streptokinase, 
urokinase, and various tissue activa tors including that produced 
by vascular endothelial ce lls ). Studies using labelled plasminogen 
in  dogs have shown the appearance of labelled plasm in in  v ivo  a fte r
24
giving streptokinase, urokinase or typhoid vaccine and the 
prolonged release of plasm in a fte r venous in ju ry  (Takeda,
1972). The catabolic ra te  of plasm in appears to  be about 
1,2 plasma poo ls/day (Takeda, 1972), but the mechanisms 
con tro lling  the amount of c ircu la ting  plasm in are unknown 
(Reeve and Franks, 1974). Indeed present knowledge in  th is  
fie ld  is  very incom plete. The re la tive  contribution of the 
reticu loendothelia l system and the fib rin o ly tic  pathways in 
the rem oval o f fibrinogen and its  deriva tives in  pathological 
states also rem ains to  be established.
I. 5. Soluble F ib rinogen-F ib rin  Complexes
F ibrinogen, the effects of throm bin, F X llla  and plasm in 
on fibrinogen and fin a lly  fibrinogen m etabolism  have each been 
considered in  de ta il because of th e ir importance to  the subject 
of soluble fib rin o g e n -fib rin  complexes. The lite ra tu re  on th is  
subject w ill be discussed under four headings:
I. 5. Soluble F ib r inogen-F ib r in  Complexes
(a) H is to rica l and theore tica l aspects
(b) In v itro  experim ents
(c) A n im al experim ents
(d) B io log ica l properties
I. 5(a) H is to rica l and Theoretica l Aspects
A soluble fib rin o g e n -fib rin  complex can be defined as a 
d im er or polym er containing antigenic m ate ria l which reacts 
w ith  specific fibrinogen antiserum , or which in  some other way 
(e, g. c lo ts on addition of throm bin o r reacts w ith  staphylococcal 
clum ping facto r) can be shown to  be closely re la ted to  fibrinogen. 
These complexes probably represent some fo rm  of fib rinogen- 
fib r in  in term ediate, the existence of which was apparently
26
suggested by Hammarsten in  1876. In 1955 Donnelly, Laskowski, 
Motley and colleagues also suggested the existence of such an 
interm ediate -  a soluble complex of fibrinogen and fib r in  
monomer. The w ork of Shainoff and Page (I960; 1962) on 
"c ry o p ro fib rin " gave fu rth e r support to th is  suggestion# 
"C ryo p ro fib rin " was found in  high concentrations in  the blood 
of endotoxin treated rabb its . C ryopro fib rin  contained 30% 
less fibrinopeptide A than fibrinogen, but had the same 
concentration of fibrinopeptide B . It was suggested that 
libe ra tion  of fibrinopeptides by throm bin unmasks previously 
unavailable po lym erisation sites containing ty ro sy l residues, 
w hile the h is tid y l residues are norm ally unmasked in  fibrinogen. 
The h is tid y l residues of fibrinogen and fib r in  monomer therefore 
compete to  fo rm  hydrogen bonds w ith  the unmasked ty ro sy l 
residues on the newly form ed fib r in  monomer. F ibrinogen 
molecules by combining w ith  fib r in  monomer block fu rthe r 
po lym erisation and so in  the presence of high concentrations 
of fibrinogen, fib r in  monomer could be prevented from  form ing 
fib r in  (c. f. the po lym erisation scheme described in  Chapter 
1.2(a) and F igure B).
The o rig in a l idea that soluble complexes could only be 
composed of un its  of fib r in  monomer and fibrinogen was shown 
to  be an ove r-s im p lifica tion . L ip in sk i, W egrzynowicz, Budzynski 
and colleagues (1967) using a rad io isotopic labe lling  technique 
claim ed that both ea rly  and the la te  fibrinogen degradation 
products could be incorporated in to soluble complexes. Theor­
e tica lly  there fore  many d iffe ren t form s of soluble complex m ight 
exist, d iffe rin g  in  th e ir phyBiochemical p roperties. W egrzynowicz, 
Kopec and L a ta llo  (1971) c lassified  soluble complexes in to  three 
types, shown in  Table 1. Only d im ers are shown in  th is  scheme
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but c le a rly  polym ers could also be form ed in  many cases and 
mixed fo rm s e, g, x . F; X - f^ -F ; o r y -f-D  could also occur. 
L a ta llo  (1975) has demonstrated the various types of soluble 
complex in  diagram atic fo rm  (see F igure 8) basing his 
scheme on a system of hydrogen bonding. Collen (1971) 
challenged the idea that complexes are form ed by hydrogen 
bonding. He demonstrated that the application of hydro­
static pressure had an im m ediately depolym erising effect on 
in term edia te ly polym erised o r clotted solutions. Th is effect 
was com pletely reve rs ib le . He concluded that po lym erisation 
was accompanied by a volume increase suggesting some fo rm  of 
hydrophobic bonding or charge neutra lisation. W hatever fo rm  
of bonding is  involved, the bonds appear to  be ra the r weak and 
are dependent on pH, tem perature, ionic strength and 
concentration (La ta llo , 1975), These environm ental factors 
can lead to problem s in  iso la ting and studying soluble complexes. 
I t  is  there fore  theo re tica lly  possible that many form s of 
soluble complex exist. A ttem pts have been made to  demonstrate 
th e ir existence in  a va rie ty  of in  v itro  experim ents.
I. 5(b) In V itro  Experim ents
Bang and Chang (1974) reviewed the lite ra tu re  on th is  
subject and suggested s ix  mechanisms fo r the form ation of 
soluble complexes in  v itro .
Type A: (1) The d ire c t action of throm bin on 
fibrinogen.
(2) The in te raction of fib r in  monomer 
and fibrinogen, in  the absence of 
throm bin.
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Type B: (3) The in te raction of fib r in  monomer 
and fibrinogen Fragments X , Y ,
D and E#
(4) The pro teo lysis of fibrinogen by 
plasm in.
(5) The ly s is  of fib r in  (fib rin  Fragm ents 
X, y, d and e).
Type C: (6) C ross-link ing  mediated by F XîHa of 
fib r in  monomer and fibrinogen o r, 
a lte rna tive ly , through cro ss-lin k in g  
of fibrinogen not exposed to  throm bin.
These s ix  mechanisms can be grouped in to  three main 
types (A, B and C): complexes produced by the action of 
throm bin alone (mechanisms 1 and 2); complexes incorporating 
plasm in deriva tives of fibrinogen and fib r in  (mechanisms 3, 4 
and §) and complexes form ed through tlie  action of F XZIIa 
(mechanism 6).
Type A: Soluble Complexes Produced by the A ction of Throm bin 
Alone (Mechanisms 1 and 2)
(1) By the d ire c t action of throm bin on fibrinogen
This reaction has already been discussed in  de ta il in 
Chapter 1.2(a) -  see F igure 5. The soluble fib r in  polym er 
in  stage ( ii)  of th is  reaction is  the sim plest fo rm  of soluble 
complex. W ork from  many laboratories using a va rie ty  of 
teclm iques has confirm ed the existence of th is  fo rm  of soluble 
complex. Smith and Bang (1972) showed that prolonged 
incubation of fibrinogen w ith  low concentrations of throm bin 
converted alm ost a ll the fibrinogen into soluble complexes 
before v is ib le  gelation took place.
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I t  is  not certa in  whether the component un its  of such 
complexes consist solely of fib r in  monomer un its o r whether 
fibrinogen units may also be involved# Von Hugo, H afte r, 
Stemberger and colleagues (1975) studied soluble complexes 
produced by incubation of fibrinogen w ith  throm bin by 
adsorption chromatography. The complexes dissociated 
in  a ra tio  of 1:1 in to a component adsorbed by cyanogen 
brom ide activated fibrinogen sepharose (L e, fib r in  monomer) 
and a component that was not adsorbed (i. e, fibrinogen). Under 
the conditions of th e ir experim ents,fibrinogen would seem to be 
incorporated in to  th is  fo rm  of soluble complex. Such complexes 
may also contain a cold insoluble globulin, as w e ll as un its of 
fibrinogen re lated pro te in  (Bang and Chang, 1974).
(2) Soluble complexes produced by the in te raction  of fib r in
monomer and fibrinogen, in  the absence of throm bin
I t  could be argued that these complexes are ve ry  s im ila r, 
i f  not iden tica l, to  those form ed by incubation of fibrinogen w ith  
throm bin. Bang and Chang (1974), however, deal w ith  tliis  
mechanism separately. I t  may be that varia tions in  the re la tive  
concentrations of fib r in  monomer and fibrinogen are im portant 
w h ile  the continuing action of throm bin on fibrinogen m ight also 
be very im portant. Complexes form ed by the in te raction  of 
fib r in  monomer and fibrinogen w ithout continuing throm bin action 
correspond closely to  the "c ry o p ro fib rin " of Shainoff and Page. 
L a te r studies from  th is  group (Sasaki, Page and Shainoff, 1966) 
showed that the complex form ed by m ixing fibrinogen and fib r in  
monomer could be stab ilised by the addition of F X llla .
Jakobson, Ly  and K ie ru lf (1974) prepared complexes by
125incubating I  labelled fibrinogen and unlabelled fib r in  monomer.
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separating the complexes by gel exclusion chromatography.
The fact that fib r in  monomer w ill adsorb on inso lub ilised 
fibrinogen fixed to  cyanogen brom ide activated sepharose 
suggests that some fo rn i of in te raction between fibrinogen 
and fib r in  monomer occurs under these conditions (Heene 
and M atthias, 1973),
I t  has, however, been suggested that in tact fibrinogen 
does not incorporate in to complexes. Smith and Bang (1972) 
using N -te rm in a l analysis were unable to  show the presence of 
fibrinogen in  soluble complexes form ed in  a m ixtu re  of fibrinogen 
and fib r in  monomer. Using gel exclusion chromatography Smith 
and C ra ft (1974) fa iled  to  demonstrate complex form ation between
*1 O K 1 O K
I  labelled fibrinogen and unlabelled fib r in  monomer; and I  
labelled fib r in  monomer and unlabelled fibrinogen.
These apparently con flic ting  resu lts  are d iffic u lt to  explain 
but may be due to  d iffe rin g  experim ental conditions. The ro le  of 
F X llla  in  th is  context may be im portant.
Type B: Soluble Complexes Incorporating P lasm in D eriva tives 
of F ibrinogen and F ib rin  (Mechanisms 3, 4 and 5)
The lite ra tu re  on th is  subject provides severa l con flic ting  
resu lts  concerning which deriva tives can take p a rt in  complex 
form ation. As th is  thesis is  concerned w ith  the iden tifica tion  
of soluble complexes in  various c lin ic a l conditions, ra the r than 
the actual component units th is  lite ra tu re  w ill not be discussed in  
great de ta il.
Since the in it ia l stages of plasm in digestion re su lt only in 
the sp littin g  o ff of "m a rg in a l" parts of fibrinogen and do not 
involve gross s tru c tu ra l changes, these deriva tives can be 
considered as analogues of fibrinogen and, a fte r exposure to
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throm bin, fib r in  monomer (La ta llo , 1975). Thus m in im a lly  
degraded Fibrinogen X  behaves s im ila rly  to F ibrinogen (F) 
and m in im a lly  degraded fib r in  k behaves s im ila rly  to  fib r in  
monomer (f; fj^). Therefore the form s of complex already 
discussed involving F , f  and f^  should also be able to  be 
form ed by X  and x. In th is  connection, it  is  in te resting  that 
m in im a lly  degraded fib r in  x  can fo rm  a fib r in - lik e  network 
indistinguishable by electron m icroscopy from  th rom bin- 
induced fib r in  (N iew iarow ski, Stewart and M arder, 1970).
The three mechanisms suggested by Bang and Chang 
(1974) fo r the form ation of soluble complexes containing 
degradation products w ill now be discussed in  tu rn .
(3) The in te raction  of fib r in  monomer and fibrinogen
Fragm ents X, ¥ , D and E
The o rig in a l w ork of L ip in sk i and colleagues (1967)
suggested that fibrinogen X , Y , D and E could a ll complex
w ith  fib r in  monomer. Kudryk, Reuterby and Blomback (1973)
showed that approxim ately 50% fibrinogen D was capable of
complexing w ith  fib r in  monomer im m obilised on cyanogen
brom ide activated sepharose. F ibrinogen E did not complex
under these conditions. M atthias, Heine and K onradi (1973)
showed that fibrinogen X  and Y had greater a ffin ity  fo r
inso lub ilised fib r in  monomer than fibrinogen D.
In contrast the w ork of Smith and Bang (1972) and
subsequent w ork from  th is  group (summarised Bang and Chang,
1251974) fa iled  to  show incorporation of I  labelled fibrinogen D 
and E in to  soluble complexes, using gel exclusion chrom ato­
graphy. D iffe ren t experim ental conditions may again be 
responsible fo r these con flic ting  resu lts .
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(4) The pro teo lys is of fibrinogen by plasm in
I t  is  generally accepted that fibrinogen X  w ill only fo rm  
complexes i f  some fib r in  deriva tive  is  present (Bang and Chang, 
1974), There is  only one published report suggesting that 
plasm in digestion of fibrinogen can re su lt in  polym er form ation, 
which was demonstrated by u ltracen trifuga tion  (F le tcher, 
A lk ja e rs ig , F isher et a l. , 1966).
It  was suggested that plasm in m ight cleave arg ine-g lycine 
bonds, including those susceptible to throm bin, in  a random 
fashion re leasing the fibrinopeptides, and allow ing complex 
form ation. This hypothesis rem ains speculative as it  has not 
been confirm ed by subsequent experim ents (Bang and Chang,
1974).
(5) The ly s is  of fib r in  (fib rin  x , y, d and e)
Bang, Hansen, Smith and colleagues (1973) stated that 
fib r in  degradation products can be shown to  pa rtic ipa te  in  three 
types of soluble complex in  v itro :
(a) low m olecular weight complexes form ed when fib r in  
d and e are incubated w ith  fibrinogen and throm bin.
(b) high m olecular weight complexes apparently resu lting  
from  reaggregation of components of an early  f ib r in  digest (fib rin  
x ). These complexes may be involved in  the phenomenon of 
"paracoagulation" (see Chapter 1.6(a) ).
(c) d im ers form ed when fib r in  % and y are incubated w ith  
fibrinogen in  the absence of throm bin.
Type C: (6) Soluble complexes a ris in g  from  crosslink ing
I t  is  recognised that F XIHa can cross link soluble fibrinogen-
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fibrin complexes (Sasaki, Page and Shainoff, 1966) (see Chapter 
1.2(b) ). L y , Kierulf, Jakobson and Gravem (1974) added F 
X llla  to  complexes produced by incubating fibrinogen w ith  
throm bin. N -te rm in a l analysis suggested that in  the oligom ers 
form ed le ss  than 30% of the component un its were fibrinogen 
m olecules. They subsequently showed X " T  crosslink ing  but 
no CX chain crosslink ing  in  the oligom ers and that F X llla  could 
cross link fibrinogen to fo rm  a fibrinogen d im er (Ly, K ie ru lf 
and Jakobsen, 1974; see also Chapter Î, 2(b) ). Approxim ately 
equal amounts of X  T "  T d im er were present suggesting 
that one of the two X cha ins of each fibrinogen molecule was 
in te rcrosslinked (Ly, K ie ru lf and Jakobsen, 1974),
F X llla  can therefore cross link existing complexes and 
even fo rm  complexes. This provides a mechanism fo r the 
form ation of soluble complexes w ithout the action of throm bin, 
although, of course, throm bin m ight w e ll act as the activa tor 
of F X III (F inlayson, 1974). The importance of th is  in  v ivo  
rem ains to  be established*
It is  obvious that considerable in form ation is  available 
concerning the form ation of soluble complexes in  v itro . Despite 
con flic ting  resu lts  over certa in  deta ils the im portant point is  that 
stressed by L a ta llo  (1975) -  "T here  exists no data indicating that 
under "physio log ica l" conditions of pH, tem perature and ionic 
strength in tact fibrinogen o r any of its  plasm ic de riva tives, 
which have not been exposed to  throm bin or FSF (F X llla ), are 
able to  associate and fo rm  soluble polym ers o r complexes.
Hence, it  could foe concluded that the rem oval of at least one 
of the fibrinopeptides is  a p re requ is ite  condition fo r the 
form ation of any complexes between fibrinogen derived 
m olecules".
3 3
3ùa th e ir most recent w ork on th is  subject L a ta llo , M a ttle r, 
Bang and colleagues (1976) suggest that under very ca re fu lly  
contro lled experim ental conditions soluble complexes form ed 
in  v itro  have only "tw o identifiab le  components, f ib r in  monomer 
and clo ttable f  ragm ent x  monomer, although incorporation of 
native fibrinogen and Fragm ent X  unreacted by throm bin into 
soluble fib r in  complexes cannot be excluded"*
I. 5(c) Soluble F ib rin o g e n -F ib rin  Complexes -  In V ivo 
Experim ental W ork
The basic aim s of such experim ents are:
(1) To find out how soluble complexes are metabolised 
in  v ivo .
(2) To co rre la te  the presence of soluble complexes in  
plasma w ith  de fin ite  in travascu lar pathology (e. g. 
deep venous throm bosis o r disseminated in tra ­
vascular coagulation).
1. M etabolism  of Soluble Complexes In V ivo
T h is can be studied by the use of rad ioactive isotopes. In
a series of experim ents Sherman, Earw ig and Lee (1975) showed
that ^^^ I labelled fibrinogen had a h a lf- life  of 52 hours, when
125injected in to  rabb its . When I  labelled fib r in , consisting of 
a m ixture  of complexed and uncomplexed un its , was injected a 
h a lf- life  of 10 hours was recorded. It there fore  appeared that 
soluble fib r in  was metabolised more rap id ly than fibrinogen.
When uncrosslinked soluble fib rin o g e n -fib rin  complexes,
131 125composed of I  labelled fibrinogen and I  labelled fib r in ,
125were injected a h a lf- life  of 12 hours was found fo r the I
131fib r in  and 15 hours fo r the I  fibrinogen. The complexes 
were apparently stable in  v ivo , as they could be demonstrated 
by gel filtra tio n  in  blood samples taken from  the rabb its .
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Sherman and colleagues (1975) also demonstrated that
crosslinked soluble fib rin o g e n *fib rin  complexes were handled
in  a s im ila r way to  non-crosslinked complexes. In  th is  respect
th e ir resu lts  d iffe red  from  those of Shainoff and Sasaki (1971)
who found that crosslinked complexes remained in  the c ircu la tion
longer than non-crosslinked ones.
Soluble complexes consisting of early (m in im a lly  degraded)
fib r in  degradation products also disappeared rap id ly  from  the
c ircu la tion  when in jected in to  rabb its , w ith  a h a lf- life  of 5 hours,
high concentrations appearing in  the spleen (Bang and Chang, 1974).
I t  the re fore  appears that soluble fib r in  m a te ria l w ith in  the
c ircu la tio n  can be identified  by the body's defense mechanisms
and removed m ore rap id ly  than fibrinogen. F ibrinogen
incorporated in to a complex w ith  fib r in  w ill foe eatabolised
m ore rap id ly  than uncomplexed fibrinogen, G urewich, W etmore,
125Nowak and colleagues (1974) showed that I  labelled fib r in  
monomer was progressive ly and rap id ly  deposited in  the kidney, 
liv e r , lungs and spleen. The concentration of ra d io activ ity  per 
gram  tissue was greatest in  the spleen.
The probable im portance of the reticu loendothelia l system 
in  rem oving c ircu la tin g  soluble fib r in  m ate ria l was f ir s t  stressed 
by Lee (1962). He demonstrated that, w h ile  intravenous in jections 
of endotoxin o r infusion of throm bin rabbits did in itia te  a degree of 
in travascu la r coagulation in  some of the anim als, they do not 
usually re su lt in  massive fib r in  deposition. However, i f  the 
re ticu loendothelia l system is  blocked by T horo trast, throm bin 
infusion w ill produce the c lassica l features of the generalised 
Shwartzman reaction (GSR) w ith  massive insoluble fib r in  
deposition. (The generalised Shwartzman reaction is  
produced in  the experim ental anim al, c lass ica lly  by two
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appropriate ly spaced in jections of endotoxin. It re su lts  in  the 
development of b ila te ra l renal co rtica l necrosis and bleeding. 
These features are a ttributed to  widespread in travascu lar 
coagulation).
Follow ing h is observations Lee (1962) suggested that "In  
the generalised Shwartzman reaction, the f ir s t  intravenous dose 
of endotoxin in itia te s  in travascu la r conversion of fibrinogen to  
fib r in , but th is  is  then qu ickly cleared from  the c ircu la tio n  by 
the reticu loendothelia l system. Subsequently, at a tim e when 
the a c tiv ity  of the reticu loendothelia l system is  much depressed, 
a second in jection of endotoxin again activates in travascu la r 
coagulation, but now fib r in  aggregates pe rs is t and accumulate 
in  the c ircu la tio n  and are progressive ly deposited in  the te rm in a l 
vascular bed".
The idea of a two stage reaction in  the GSR w ith  f ir s t  the 
form ation of soluble fib rin o g e n -fib rin  complexes and th e ir 
subsequent p rec ip ita tion  as insoluble fib r in , is  now w idely 
accepted. Follow ing a single in jection of endotoxin in  the 
rabb it, soluble complexes can be demonstrated by the ethanol 
gelation test and the se ria l d ilu tion  protam ine sulphate test 
(see Chapter I. 6(a) ), a peak concentration occurring  6 hours a fte r 
in jection , although a t th is  tim e no h isto log ica l changes can be 
found in  the kidney (Szczepanski and Lucer, 1975). This 
"p repa ra tive " in jection  presum ably overloads the defense 
mechanisms (possibly in  the reticu loendothelia l system) fo r the 
rem oval of soluble complexes. Therefore a second (provocative) 
in jection of endotoxin resu lts  not only in  an increase in  soluble 
complex concentration a fte r 3-6 hours, but also in  p rec ip ita tion  
of insoluble fib r in  w ith in  the kidney reaching a maximum at 6 
hours (Szczepanski and Lucer, 1975).
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The causes of p rec ip ita tion  of soluble fib rin o g e n -fib rin  
complexes (or soluble fib rin ) in  the second stage of th is  reaction 
are uncerta in. Th is stage, un like the actual form ation of 
soluble complexes, cannot be prevented by heparin (M u lle r- 
Berghaus and Hocke, 1972; L ip in sk i, Gurewich, Nowak et a l. , 
1974). The action of throm bin is  therefore un like ly  to  be 
necessary at the p rec ip ita tion  stage. Various non-enzym ic 
mechanisms have been suggested e. g. through basic proteins 
(L ip in sk i, W egrzynowicz, Budzynski et a l. , 1967) which could 
be released from  pla te le ts o r leucocytes. These mechanisms 
would have obvious s im ila ritie s  to  the paracoagulation reaction 
in  v itro  (see Chapter 1,6(a) ). P la te le ts and leucocytes m ight 
also play a ro le  in  the actual form ation of soluble complexes 
through the generation of throm bin.
The im portance of leucocytes and p late lets in  the 
development of endotoxin induced in travascu lar coagulation 
rem ains uncerta in. Although e a rlie r w ork suggested that 
thrombocytopenia (induced by p la te le t antiserum ) prevented 
m ic ro -c lo t form ation in  the GSR (M argaretten and McKay, 1969), 
L ip in sk i and Gurewich (1976b) showed that thrombocytopenia 
(induced by neuram inidase) did not prevent throm bin form ation 
demonstrated by soluble complex production fo llow ing endotoxin 
in jection . M uUer-Berghaus and K ram er (1976) m oreover found 
that thrombocytopenia (induced by plate let antiserum ) did not 
prevent the p rec ip ita tion  of soluble complexes o r soluble fib r in  
by endotoxin. It is  therefore possible that p la te le ts are not 
required fo r e ither o f the two reactions in  endotoxin induced 
in travascu la r coagulation. (D ifferent methods of inducing 
thrombocytopenia w ith  varying success may foe responsible 
fo r con flic ting  resu lts ). D ipyridam ole, however, seems to
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125protect against insoluble fib r in  deposition in  I  f ib r in  monomer 
infused rabb its  (L ip in sk i, Gurewich and Nowak et a l . , 1974), 
although i t  is  possible that some other action, besides that of an 
antip ia te le t agent is  involved.
The evidence link in g  leucocytes w ith  the development of
endotoxin-induced in travascu lar coagulation is  ra th e r stronger.
I t  was o rig in a lly  shown by Thomas and Good (1952) that severe
leucopenia prevented the development of m ic ro -c lo ts  in  the .
It has been shown that leucopenia protects against the form ation
of soluble complexes fo llow ing endotoxin in jection (L ip in sk i and
125Gurewich, 1976b) and also against the deposition of infused I 
labelled fib r in  monomer (Gurewich, W etmore, Nowak et a l. ,
1974), M uller-B erghaus and Eckhardt (1975), however, showed 
that leucopenia did not pro tect against the p rec ip ita tion  of soluble 
complexes (produced by in it ia l ancrod infusion) by endotoxin.
A fu rth e r study, however, did show that the granulocyte count 
before the second in jection  of endotoxin (but a fte r the f irs t)  was 
s ign ifican tly  re la ted to  the subsequent development of m ic ro -c lo ts  
(M uller-B erghaus, Bohn and Hobel, 1976). The evidence fo r 
leucocytes being involved in  the p recip ita tion  step is  therefore 
ra the r confusing but they may be required fo r the in it ia l 
elaboration of throm bin by the release of procoagulant m ateria l.
It  may be the monocytes which are m ainly responsible fo r 
endotoxin-induced procoagulant release from  leucocytes (R ivers, 
Hathaway and Weston, 1975).
A review  of th is  subject by M uller-B erghaus, Eckhardt and 
K ram er (1976) suggests that ne ither p late lets nor leucocytes are 
p a rtic u la rly  im portant in  the p rec ip ita tion  a n d /o r po lym erisation 
of soluble fib r in  by endotoxin in  v ivo . Instead the im portance of 
stim ulation of 0(-adrenerg ic receptor sites in  the p rec ip ita tion  of
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soluble complexes (soluble fib rin ) is  stressed, an observation 
o rig in a lly  made by th is  group in  ancrod treated rabb its 
(M uller-Berghaus and Mann, 1973)i
Other facto rs such as endothelial ce lls  m ight be involved 
in  a process of pinocytosis resu lting  in p rec ip ita tion  of soluble 
complexes, although evidence fo r such pathways is  at present 
lacking. The degree to  which sm all changes in pH, ionic 
concentration and stasis contribute to  p rec ip ita tion  of soluble 
complexes also is  unknown.
2. C o rre la tion  Between Presence of Soluble F ibrinogen- 
F ib rin  Complexes in  Plasma and D efin ite  In travascular 
Pathology
It is  c lear from  the previous discussion that soluble 
complexes may be present in the blood w ithout insoluble fib r in  
deposition ( i. e. fo llow ing the preparative in jection  of endotoxin 
in  the GSR). It cannot therefore be concluded that the presence 
of high concentrations of soluble complexes necessarily im p lies 
the presence of thrombus o r m icro tlirom b i.
I f  a bolus in jection  of throm bin is  given intravenously to 
rabb its , throm bin sensitive, h ighly aggregated, soluble complexes 
(demonstrated by agarose gel filtra tio n ) can be found in  plasma at 
1, 2, 4, 6, 8 and 10 minutes a fte r in jection. Rapid clearance of 
these complexes must occur, as they cannot be demonstrated a fte r 
10 m inutes (Bang, Hansen, Smith et a l. , 1973).
Chang, W ilson and F renke l (1974) studied three experim ental 
models in  dogs:
(1) th rom b i form ed by stasis
(2) in jection of homologous serum as a source of 
activated c lo tting  factors
(3) combined infusion of homologous serum  and stasis 
throm bosis
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Soluble complexes were demonstrated by agarose gel filtra tio n  
and by the s e ria l d ilu tion  protam ine sulphate test (see Chapter 
L 6(a) ). S e ria l studies demonstrated that loca l throm bosis 
in  the absence of c ircu la ting  activated c lo tting  facto rs did not 
produce s ign ifican t amounts of soluble complexes. The 
in jection of serum  in  the absence of stasis throm bosis resulted 
in  only occasional and transien t increases in  c ircu la tin g  soluble 
complexes. The infusion of serum  together w ith  the form ation 
of stasis throm bosis consistently gave rise  to  substantial and 
sustained concentrations of soluble complexes.
The experim ental design in  re la tion  to  the localised 
throm bosis could be c ritic is e d , as the authors adm itted. During 
the f ir s t  30 m inutes two clamps were applied on e ither side of 
the developing throm bus, so that it  was not in contact w ith  
c ircu la ting  blood. Subsequently p a rtia lly  stenosing liga tu res 
were applied and the clamps removed. This allowed contact 
between the thrombus and the c ircu la ting  blood but growth of the 
thrombus at th is  point m ight have been lim ite d . Complete 
rem oval of the liga tu res allowed em bolisation to  occur to  the 
lung. A t th is  point s ign ifican t elevations of soluble complex 
concentration w ere noted on the se ria l d ilu tion  protam ine 
sulphate test. This could re fle c t propagation of the embolus 
w ith in  the pulm onary vasculature or the release of ea rly  fib r in  
degradation products due to  fib rin o ly s is . The resu lts  do, 
however, suggest that p re -ex is ting  localised deep venous 
throm bosis m ight not be associated w ith  g reatly increased 
soluble complex concentration.
Homologous serum  contains F DCa; F Xa and F XIa 
(Deykin, Chun, Lopez et a l. , 1966), The throm bus-inducing 
capacity of injected serum w ill therefore depend on the content
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of these activated factors and how quickly they are removed* 
Traces of throm bin w ill probably be produced. In jection of 
homologous serum  therefore may m im ic a "hypercoagulable" 
state -  defined as the presence of activated c lo ttin g  factors 
w ith in  the c ircu la tion . Combining th is  w ith  loca lised 
throm bosis seems to  lead to  h ig ii concentrations of soluble 
complex (Chang et a l, , 1974), These authors suggest that 
pe rs isten tly  increased levels of soluble complexes requ ire  
a system ic " hypercoagulable state" together w ith  "an 
am plify ing system fo r throm bin generation" in  a loca l area 
of stasis. This combination allows the continued bu ild-up 
of soluble complexes in  su ffic ien t quantities to  surpass the 
clearance capacity of the reticu loendothelia l system.
In a d iffe ren tly  designed set of experim ents Donati^
B erton i, Mussoni and colleagues (1976) induced m acroscopic 
liv e r  throm bosis and "a  laboratory p ictu re  of dissem inated 
in travascu lar coagulation" in  ra ts  by f ir s t  feeding them on a 
high fa t d ie t fo r 10 weeks, followed by a single in jection  of 
endotoxin (Group I), Two other groups of ra ts  received 
only one stim ulus (Group n  were fed a high fa t d ie t fo r 10 
weeks and Group I I I  were given a single in jection  of endotoxin).
In neither of these groups did macroscopic throm bosis occur, 
although the ra ts  rece iv ing an in jection of endotoxin (Group m ) 
showed "la b o ra to ry  signs of moderate dissem inated in travascu lar 
coagulation". A ll three groups showed increased soluble 
complex concentrations compared w ith an untreated contro l 
group. The resu lts  were calculated in  term s of the percentage 
concentration of fib rinogen-like  m ate ria l eluted before the 
fibrinogen peak and were: -
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Group I  55 -  17%
Group I I  34 i  14%
Group I I I  17 i  4%
Therefore in  these experim ents also the combination of 
"hypercoagulab ility" and actual throm bosis gave the highest 
soluble complex concentration, but "hypercoagulab ility" alone 
was also associated w ith  ra ised levels. The differences 
between Groups n  and I I I  are ra the r in te resting  * especially 
the ra the r high values obtained by feeding a fa t-r ic h  d ie t (Group 
II).
W hile considerable caution needs to  be exercised in  extra ­
polating these anim al models to  the human situation, these studies 
are c le a rly  im portant in attem pting to in te rp re t the resu lts  to  be 
described in  th is  thesis. C lea rly  an established loca l throm bosis 
may not foe associated w ith  increased soluble complex concentrations, 
but d iffe ren t fo rm s of "hypercoagulab ility" appear to  re su lt in  
ra ised leve ls. The combination of loca l thrombus (or m ic ro - 
throm bosis) and "hypercoagulab ility" appears to  be the most 
potent method of inducing sustained increased soluble complex 
levels. These circum stances are p a rticu la rly  lik e ly  to occur in  
association w ith  dissem inated in travascu lar coagulation. The 
anim al experim ents already discussed in which the GSR is  induced 
show that soluble complexes are present in  such circum stances 
(e. g. Szczepanski and Lucer, 1975).
I. 5(d). B io log ica l P roperties of Soluble F ib rino ge n -F ib rin  Complexes 
Soluble complexes may play a pa rt in  the form ation of insoluble 
fib r in  deposits by p rec ip ita tion  (Chapter I. 5(c) ). A part from  th is  
very lit t le  is  known about th e ir b io log ica l p roperties.
The throm bin se n s itiv ity  of one fo rm  of soluble complex has 
been studied. Soluble complexes were prepared from  throm bin-
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treated plasma or p u rifie d  fibrinogen. The p u rifie d  soluble 
complexes showed a s ign ifican tly  greater sen s itiv ity  to throm bin 
i.  e. they clotted s ign ifican tly  m ore rap id ly  than fibrinogen over 
a wide range of throm bin concentration (Bang and Chang, 1974; 
Hansen, Bang, Barton et a l. , 1975). It was also noted that 
soluble complexes substantia lly shortened the throm bin c lo tting  
tim e of normal plasma and enhanced the resistance of plasma 
to  heparin action in  v itro . Soluble complexes containing Intact 
(fib rin o g e n /fib rin  monomer) are reported to  aggregate 
p la te le ts (Kopec, W egrznowicz, Budzynski et a l . , 1908;
L a rrie u , 1971) as does po lym erising fib r in  (N iew iarow ski, 
Regoeezi, Stewart et a l.,  1972). Soluble complexes containing 
degradation products only aggregate p late lets i f  low concentrations 
of degradation products are present (Kopec et a l. , 1968; L a rrie u ,
1971).
Blood and plasma viscosity may also be alte red by the 
presence of soluble complexes. In a recent study by Jacob, 
F le tcher and A lk ja e rs ig  (reported by F letcher and A lk ja e rs ig ,
1975) plasma v iscosity  at low shear rates was shown to be 
s ign ifican tly  and positive ly  corre la ted w ith  percentage of soluble 
complexes of high m olecular weight. The approxim ate ra tio  of 
rheolog ical a c tiv ity  of soluble complex: uncomplexed fibrinogen: 
fibrinogen: Fragm ent X was 10:5:1.
B la ttle r, Straub and Peyer (1974) studied blood v iscosity  
in  human volunteers treated w ith  the defibrinating agent Defibrase 
(see Chapter IV ). They found that i f  blood v isco s ity  measure­
ments were made at 22^0 a sign ificant increase in  blood v iscosity  
was noted in  the Defibrase treated group compared w ith  a contro l 
group. However, if  blood v iscosity  measurements were 
perform ed at 87^C no difference between the two groups could
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be noted. These authors therefore  suggest that soluble 
complexes are not present at 37*^ C and thus do not influence 
blood v iscos ity . (They did not, however, c a rry  out agarose 
gel filtra tio n  at 37^C to  confirm  this hypothesis).
It is  therefore necessary to  await fu rthe r w ork in  tliis  
fie ld  (p a rticu la rly  at 37°C) before accepting that soluble 
complexes w ill increase blood o r plasma v iscosity  in  v ivo .
I f  it  could be confirm ed that they do have th is  effect, soluble 
complexes could reduce the blood flow  to  an organ o r tissue, 
producing ischaem ia or even in fa rc tion , w ithout the p rec ip ita tion  
of insoluble fib r in . Th is could be of p a rticu la r relevance in  
a rte ria l disease.
I. 6{g)Soluble F ib rino ge n -F ib rin  Complexes -  Techniques
Available fo r th e ir Identifica tion and Assessment in
C lin ica l Conditions
Soluble complexes or soluble fib r in  can be identified  by a 
va rie ty  of techniques, some of which have already been mentioned. 
These can be classified: -
(1) Paracoagulation or Gelation Tests -
(i) ethanol gelation test (EGT)
( ii)  protam ine sulphate tests e. g. s e ria l 
d ilu tion  protam ine sulphate test
( iii)  cryofibrinogen
(2) N -te rm in a l analysis of a m odified Cohn F raction  
I  of plasma
(3) ^^C labelled glycine ethyl ester incorporation 
in to  soluble complexes
(4) A ffin ity  o r adsorption chromatography
(5) Agarose gel filtra tio n  o r plasma fibrinogen 
chromatography
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(6) The measurement of fitarinopeptide A hi 
plasma. (This is  an in d irec t measure­
ment of fibrinogen to fib r in  conversion).
None of these tests are en tire ly  sa tis facto ry. Whatever 
technique is  used utm ost care must be taken in  blood collection 
to prevent in  v itro  throm bin action,
(1) Paracoagulation o r Gelation Tests
"Paracoagulation" re fe rs  to  the puzzling phenomenon where­
by a digestion m ixture  from  insoluble fib r in  can once again be 
converted into an insoluble gel or c lo t by various non-enzymatic 
means, but not by the enzyme throm bin (Derechin, 1965). Para­
coagulation can be induced by among other methods the addition of 
protam ine sulphate, p la te le t facto r 4, d ilu tion  w ith  d is tille d  w ater, 
staphylococcal clum ping factor and cooling to  4^C (see review  in 
N iew iarow ski and L ip in sk i, 1970).
Paracoagulation may be associated w ith  the presence of 
soluble complexes containing non-clottable fib rin o g e n -fib rin  
degradation products as w e ll as fib r in  monomer un its  (L ip in sk i, 
W egrzynowicz, Budzynski et a l, , 1967). The paracoagulating 
agent may act by causing dissociation of these complexes into 
th e ir component un its  and thereby allow ing the fib r in  monomer 
un its to po lym erise in to insoluble fib r in  (L ip in sk i et a l, , 1967; 
N iew iarow ski and L ip in sk i, 1970). E a rly  f ib r in  x  un its  could 
presum ably po lym erise in  a s im ila r way, as it  has been shown 
that both protam ine sulphate and ethanol can produce "an 
extensive netw ork" on addition to  ea rly  fib r in  x , which is  
indistinguishable on electron m icroscopy from  that produced 
by the action of throm bin on fibrinogen (N iew iarow ski, Stewart 
and M arder, 1970).
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This explanation of paracoagulation has been c ritic is e d  
by La ta llo , Mattler, Bang and colleagues (1976), who cla im  
that soluble complexes do not contain non-clottable degradation 
products. Ind ividual fractions of a throm bin-treated early  
fibrinogen digestion m ixture  were isolated by agarose gel 
filtra tio n  and then treated w ith  protam ine sulphate at 37°C.
M ore than 90% of the pro te in  in  the soluble complex fractions 
was precip ita ted by the protam ine sulphate, w h ile  less than 
10% of the p ro te in  in  the degradation product fractions was 
precip ita ted (La ta llo  et a l, , 1976). Thus it  may be that 
protam ine sulphate acts d ire c tly  on soluble complexes to  
allow  po lym erisation, w ithout f ir s t  inducing dissociation of 
the complexes. A charge neutra lisa tion effect may be 
involved.
W hatever the mechanism involved paracoagulation 
would seem to  re fle c t the presence of soluble complexes o r 
soluble fib r in  in  a plasma sample.
(i) Ethanol Gelation Test (EGT)
This Is thought to  give positive results when soluble 
complexes containing fibrin monomer units are present. In 
a series of in v itro  experim ents perform ed to  evaluate the 
significance of a positive EGT fresh plasma was incubated 
w ith  throm bin, the subsequent addition of ethanol at 20^C 
yie ld ing a gel (IC ierulf, 1973). When th is  gel was examined 
by u ltracen trifuga tion  a film  was produced containing fibrinogen- 
fib r in  deriva tives. Th is m a te ria l was 95% clottable and was 
shown by polyacrylam ide gel electrophoresis in  sodium dodeeyl 
sulphate (8D8) to  contain deriva tives w ith  a m olecular weight 
greater than the parent molecule (i. e. soluble complexes).
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O ligom ers w ith  m olecular weight of 700,000 (dim ers); 1,000,000 
(tr im e rs); 1,300,000 (tetram ers) etc. were demonstrated. If 
c itra te  was used as an anticoagulant in  preparing the plasma 
dim ers could be found in  th is  m ate ria l suggesting the action of 
F X llla . (If EDTA was used as anticoagulant, ^  d im ers 
could not be demonstrated).
K ie ru lf (1874) then studied c itra ted  plasmas from  6 patients 
w ith  a positive  ethanol gelation test using the same techniques. 
N -te rm in a l analysis showed that a ll the fib rin o g e n -fib rin  film s  
contained N -te rm in a l glycine, the amount being sm a lle r when 
the plasma fibrinogen concentration was high. Polyacrylam ide 
electrophoresis showed varying amounts of high m olecular 
weight fibrinogen deriva tives ( i. e. soluble complexes) and these 
contained ^  - i f  d im ers. He therefore suggested that throm bin 
and F X lüa  were involved in  the production of soluble complexes 
in these cases. He also suggested that since the amount of N - 
te rm in a l glycine and fibrinogen derived oligom ers was sm alle r 
in  samples from  patients w ith  a ra ised plasma fibrinogen, " i t  
appears ju s tifie d  to  place a greater emphasis on a positive  
ethanol gelation test in  the presence of a norm al o r sub-norm al 
fibrinogen leve l, than when the plasma fibrinogen leve l is  
elevated".
C onflicting resu lts  have been published regarding the use­
fulness of the EGT in  c lin ic a l conditions. To illu s tra te  th is  two 
studies w ill be described in some deta il. K ie ru lf and Godal (1971) 
studied a la rge number of unselected patients. 11.4% demonstrated 
a positive EGT. In th is  group there was a s ta tis tica lly  s ign ificant 
number of patients w ith  m alignant disease, pneumonia, pulmonary 
em bolism , a rte ria l and venous throm bosis. A con tro l population 
of 275 healthy subjects were also studied. None of these showed 
a positive  EGT.
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In contrast Hedner and N ilsson (1972) found the EGT much 
less useful. They studied a group of 305 patients w ith  malignant 
disease, post-operative com plications, sepsis, m u ltip le  frac tu res, 
liv e r disease, pregnancy and various blood d isorders. An overa ll 
incidence of 10% positive tests was recorded but only 5 out of 17 
patients exh ib iting a ll the c lass ica l c lin ica l and laboratory signs 
of dissem inated in travascu lar coagulation (D. I. C. ) had positive 
tests. Other series have also produced ra the r con flic ting  
resu lts  (see review  Bang and Chang, 1974).
( ii)  Protam ine Sulphate Test
T h is test is  thought to be sensitive to  the presence of early 
fib r in  x m a te ria l, as w e ll as fib r in  monomer, A good co rre la tion  
has been found between the resu lts  of the s e ria l d ilu tion  protam ine 
sulphate test and the soluble complex concentration using agarose 
gel filtra tio n  (Gurewich and L ip in sk i, 1976). The study examined 
plasma samples fro m  throm bin and endotoxin treated rabb its , as 
w e ll as samples from  patients w ith  suspected in travascu lar 
coagulation.
As w ith  the EGT c lin ica l studies using protam ine sulphate 
have produced con flic ting  resu lts . Most series repo rt a high 
incidence of positive  tests in  patients w ith  dissem inated in tra - 
vascular coagulation (Seaman, 1970; N iew iarow ski and Gurewich, 
1971; Gurewich and Hutchison, 1971), The incidence of positive 
tests in  deep venous throm bosis va ries in  d iffe ren t series. 
Gurewich, Hume and P a trick  (1973) found an incidence of 86% 
positive tests in  sym ptomatic deep venous throm bosis patients 
w ith  positive  venograms. The incidence fe ll to  24% in  asymptom­
a tic  patients w ith  positive Venograms and to  11% in  patients w ith  
negative venograms. Seaman (1970) however detected only 2 
positive tests in  16 deep venous throm bosis patients, w hile 
Bang and Chang (1974) found 1 positive test in  38 deep venous
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throm bosis patients.
A s ign ifican t incidence of positive tests has also been 
found in  pulm onary throm boem bolism  (Gurewich and Hutchison,
1971; Gurewich, Hume and P a trick , 1973), in  acute a rte ria l 
throm boem bolism  (Gurewich and Hutchison, 1971), in  
disseminated malignant disease (Palester«Chlebowczyk, 
Strzyzewska, Sitkoweki et a l. , 1971; Gurewich and Hutchison,
1971) in  renal disease (Palester-Chlefoowczyk et a l . , 1971) and 
in  systemic hypertension, in  which there appeared to  be a 
co rre la tion  between the serial dilution protamine sulphate 
t itre  and the value of the systo lic  blood pressure (âo la - 
Sleczek and Bzczepaniec, 1974).
Jn contrast Hedner and Nilsson (1972) only found 1 positive 
re su lt out of 305 samples tested. This was a case of disseminated 
in travascu lar coagulation but 15 other s im ila r cases gave negative 
tests. I t  is  probable that the type of protam ine sulphate is  very 
im portant in  th is  technique.
In the few studies in  which the EGT and s e ria l d ilu tion  
protam ine sulphate tests have both been used a poor corre la tion  
has been observed (Musumeci, 1971; Hedner and Nilsson, 1972). 
This may p a rtly  be explained on the basis of in  v itro  experim ents 
which suggest that the EGT is  sensitive m ainly to  soluble 
complexes containing fib r in  monomer, w hile the protam ine 
sulphate test is  sensitive also to  soluble complexes form ed 
from  lysing fib r in  (Konttinen, Kemppainen and Turunen, 1972; 
Gurewich, L ip in sk i and L ip inska, 1973). The con flic ting  resu lts  
may also be due to  the d iffe ren t assay conditions used by diffe ren t 
groups (see review  Bang and Chang, 1974). The EGT appears to 
be sensitive to  pH, being more specific at a m ore alkaline pH. The 
EGT may also produce a false positive resu lt at very high fibrinogen
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leve ls. The protam ine sulphate test appears to  be sensitive 
to  the amount and preparation of protam ine sulphate added, 
the pH, tem perature and fibrinogen concentration. The 
optim al conditions fo r maximum sens itiv ity  and spe c ific ity  
of these two tests has not been established but they have the 
undoubted advantage of being rap id and sim ple to  pe rfo rm ,
( iii)  C ryofibrinogen
The appearance of increased levels of co ld -p recip itab le  
fibrinogen (called "cryo fib rinogen") was f ir s t  reported by K o rs t 
and IC ratochvil (1955) in  a patient w ith  m ig ra to ry throm bophlebitis 
associated w ith  bronchia l carcinom a. McKee, K a lb fle isch  and 
B ird  (1963) detected abnorm ally high leve ls of cryofibrinogen in  
28 out of 665 patients but not in  135 healthy con tro l subjects.
This abnorm ality was associated w ith  malignancy, collagen 
disease o r throm boem bolism . P indyck, Lichtm an and Kohl 
(1970) noted an incidence of cryofibrinogen of 26% in  women 
taking the o ra l contraceptive therapy but also found an incidence 
of 12% in  women w ith  in tra u te rine  contraceptive devices and 8% 
in  healthy, norm al women.
Sm all series and case reports  have also shown cryofibrinogen 
to be associated w ith  carcinom a, D .I, C ,, severe acute o r chronic 
infections and m ajor throm bo-ocelusive disease (see review  Bang 
and Chang, 1974), C ryofibrinogen has also been found in  
association w ith  pre-eclam psia (W ardle and Menon, 1969;
Howie, P rentice and M cN icol, 1971).
C ryofibrinogen may be re lated to the presence of soluble 
fib rin o g e n -fib rin  complexes -  in  p a rticu la r a d im er (A lk jae rs ig , 
Roy and F le tcher, 1973) and possibly also a polym er (Kazama 
and Abe, 1976).
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Although th is  is  also a re la tive ly  sim ple test and 
h is to ric a lly  the f ir s t  test fo r "so lub le fib r in "  to  be introduced, 
it  has not been evaluated fu lly  in screening fo r in travascu la r 
coagulation in a la rge series nor has it  been corre la ted  w ith
the other available tests.
2. N -Terminal Analysis of a Modified Coim F raction  I  of .
Plasma
The removal of the fibrinopeptide fragments fro m  fibrinogen 
by throm bin exposes previously masked glycine residues on the H - 
terminal end of the fibrin monomer thus formed. Jh this test 
plasma is  treated w ith  ethanol in the cold. A fibrinogen fraction 
of greater than 90% clottability can then be harvested. A 
comparison of the N-terminal glycine of the to ta l precip itated 
frac tio n , the clottable proteins and the clo t liq u o r can then be 
perform ed, allow ing quantification of the N -te rm in a l glycine in 
clottable soluble complexes (Kierulf and Abidgaard, 1971).
In a small series studied by this technique (K ie ru lf and 
Godal, 1971) N -te rm in a l glycine was demonstrated in  la rge 
amounts in  samples fro m  10 patients with positive  EGT and 
signs of in travascu la r coagulation and fibrinolysis. In addition, 
some patients showed increased amounts of several other N - 
te rm in a l groups suggesting that plasm in or other protease as 
w e ll as thrombin had been involved in  the form ation of these 
soluble complexes. The technical com plexity of th is  technique 
would seem to  prevent its  widespread use.
(8) -Labelled G lycine E thyl E ster Incorporation into
Soluble Complexes
This is  also a technica lly d iffic u lt technique and therefore
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14few reports  have been published on its  use. When C -labelled
glycine ethyl ester is  incubated w ith  throm bin-a lte red fibrinogen
(i. e. soluble complexes) in  the presence of F XHXa and calcium ,
14enzymic incorporation of C -labelled glycine ethyl ester occurs. 
The incorporation in to  fibrinogen or fibrinogen degradation 
products is  m in im al (K isker and Rush, 1971). Th is test was 
found to provide useful in form ation fo r the diagnosis and treatm ent 
of two patients w ith  meningococcal septicaem ia, two patients w ith  
Rocky Mountain spotted fever and three patients in  whom therapeutic 
abortions induced by the in trau te rine  in jection of hypertonic saline 
produced D, I, C. (proven by laboratory changes). Increased levels 
of soluble fib r in  have also been detected in  women taking oestrogen- 
progestogen therapy using th is  technique (P ilgeram , E lliso n  and 
von dem Bussche, 1074).
(4) A ffin ity  o r Adsorption Chromatography
In th is  technique inso lub ilised fibrinogen is  prepared by 
chem ical fixa tio n  of pu rifie d  fibrinogen to  cyanogen brom ide 
activated agarose o r sepharose (Heene and M atthias, 1973). 
Throm bin incubated plasma containing EGT positive m ate ria l 
(i. e. soluble complexes containing fib r in  monomer) revealed 
absorption of a fibrinogen deriva tive  which could subsequently 
be eluted at pH 4 .1 . The amount of m a te ria l which adsorbed 
corre la ted s ign ifican tly  w ith  the quantitative EGT and was there­
fo re  presumed to  consist of fib r in  monomer.
Raised leve ls of soluble fib r in  have been found using th is  
technique in  samples from  patients w ith disseminated in travascu lar 
coagulation, acute m yocardial in fa rc tion  and carcinom a (M atthias, 
R einicke, Heene et a l. , 1975). I t  was claim ed that a ra ised leve l 
of soluble fib r in  was present before abnorm alities developed in the
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ethanol gelation test o r in  analysis of plasma coagulation factors.
( §) Agarose G e l F iltra tio n  /  Plasma F ibrinogen Chromatography 
(Gel Exclusion Chromatography, Column Chromatography)
In th is  technique plasma is  separated by filtra tio n  through 
large pore agarose gels and the eluant fractions are analysed fo r 
fibrinogen re la ted pro te in . The ra te at which an individual 
p ro te in  flow s through the column is  proportiona l to  its  m olecular 
size and in  p a rticu la r the ind iv idua l m olecular Stokes rad ius.
The p rinc ip les governing ana lytica l gel filtra tio n  have been fu lly  
discussed by W inzor (1969) -  see also Chapter II.
Soluble complexes w ill be eluted in advance of norm al 
fibrinogen using th is  system, w hile  fib rin o g e n -fib rin  degradation 
products are eluted a fte r the parent molecule, F le tcher, 
A lk ja e rs ig  and th e ir colleagues have developed th is  technique 
(F le tcher, A lk ja e rs ig , O 'B rien  et a l, , 1970) and using a computer 
program m e based on chromatographic plate theory analysis are 
able to  a rriv e  at a sem i-quantita tive estim ate of the re la tive  
content of soluble complex, fibrinogen and degradation products 
in  poorly resolved chrom atographic patterns (A lk jae rs ig , Hoy 
and F le tcher, 1973),
Th is group have extensive experience of applying th is  
teclmique to  studying c lin ic a l conditions associated w ith  hyper­
coagulability o r throm bosis.
Deep Venous Throm bosis (D .V .T .)
In a collaborative study F letcher and colleagues studied
plasma samples from  patients pa rtic ipa ting  in  a B ritis h  M edical
125Research Council t r ia l of I  fibrinogen scanning in  the detection 
of post-operative deep venous throm bosis (F le tcher and A lk jae rs ig ,
1972). The fibrinogen scan and ciirom atography resu lts  corre la ted
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w e ll. Out of a to ta l of 101 patients complete agreement of both
positive and negative findings fo r the two methods was found in
72 patients -  both assays were negative (1. e, norm al) in 31 cases
and positive  (i. e* abnorm al) in  41 cases. In 22 patients abnorm al
chromatography resu lts  were detected in  patients w ith  norm al
fibrinogen scans. In 15 of these cases abnorm al resu lts  were
present p re -ope ra tive ly , using the chromatography technique.
(F ibrinogen scans were not perform ed p re -opera tive ly). The
authors suggest that the abnorm al pre*operative re su lts  were
associated w ith  underlying pathology, such as carcinom a of lung,
and point out that the fib r in  deposits or thrombus m ight have been
present in  some site  other than the leg veins. They also suggest
that the chromatography technique may be more sensitive than
the scan technique in  detecting sm all fib r in  deposits. However,
7 patients had norm al chromatography resu lts  and abnorm al 
125I  fibrinogen scans, A representative series of chromatography 
resu lts  fo r one patient are shown in  F igure 9. Th is is  an 
in te resting  study which does suggest that plasma fibrinogen 
chromatography m ight be useful in  the early detection of deep 
venous throm bosis,
Hansen, Bang, K im  and G lover (reported in  Bang and 
Chang, 1974) have ca rried  out a s im ila r study in  the detection 
of post-operative D .V .T . These authors used venography to  
make a diagnosis ra th e r than fibrinogen scans. They studied 
38 patients, 12 developed venographic evidence of D, V. T. post­
operative and a ll 12 showed abnorm al chromatography resu lts , 
although only 1 patient developed c lin ica l signs of D. V. T . which 
was la te r com plicated by pulmonary em bolism . 18 patients had 
negative venograms and norm al chromatography re su lts . 8 
patients had norm al venograms and abnormal chromatography 
resu lts . Out o f the 20 patients w ith  abnormal chromatography
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resu lts  post-operative ly 7 were abnormal p re -opera tive ly .
Th is rep o rt has the advantage of confirm ing the diagnosis 
of D. V. T. by venography. The resu lts  are fa ir ly  s im ila r to 
those of F le tch e r's  group. The usefulness of the chromatography 
technique is , however, lim ite d  in  that i t  fa ils  to loca lise  the s ite  
of the throm bus and also (ra the r m ore im portan tly) there is  an 
inevitable delay in  obtaining the re su lt, even using the m odifications 
described by A lk ja e rs ig  and colleagues (1973).
Qestrogen-Progestogen (O ral Contraceptive) Therapy
A lk ja e rs ig  and colleagues have shown abnorm al plasma 
fibrinogen chromatography resu lts  in  women taking oestrogen- 
progestogen therapy (A lk jae rs ig , F le tcher and B ur stein, 1971 
and 1975). In  the more recent repo rt the re su lts  on 1,350 
samples from  193 women were reported. Abnorm al plasma 
fibrinogen chromatography resu lts  were found in  27% of women 
taking the oestrogen-progestogen therapy and in  6% of norm al 
contro l women. The authors suggested that these resu lts  showed 
that women taking oestrogen-progestogen therapy develop "c lin ic a lly  
s ilen t throm botic lesions" w ith  a four to five -fo ld  greater frequency 
than in  con tro l subjects. They concluded that "these women are at 
a four to  five -fo ld  greater r is k  of developing c lin ic a lly  overt disease, 
a r is k  fac to r in  line  w ith  that derived by epidem iologic study".
Asbeck, Bebber and van de Loo (1974) have published 
resu lts  on a group of 7 healthy women studied before and during 
a 4-12 week period of combined oestrogen-progestogen therapy.
They demonstrated increased amounts of soluble complexes (dim ers) 
representing about 5-6% of the to ta l amount of the fibrinogen peak 
using the mean resu lts  fo r the whole group. S im ila r resu lts  have 
been obtained by G raeff, von Hugo and H a lter (1976).
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It  is  therefore probable that increased concentrations of 
soluble complexes are present in  plasma from  women taking 
oestrogen-progestogen therapy. The significance of th is  in  
te rm s of actual throm botic disease rem ains unknown.
C erebral Vascular Accidents due to  C erebral Throm bosis
In an in it ia l study soluble complexes were demonstrated 
in  31 out of 43 patients w ith  cerebra l throm bosis (Brooks, Davis 
and Devivo, 1970). 7 patients had norm al findings and 5 patients
showed evidence of ea rly  clottable fib rin o g e n -fib rin  degradation 
products. 13 of the patients were treated w ith  urokinase. I t  
was fe lt that fibrinogen chromatography helped in  assessing the 
effects of th is  therapy and also in  assessing the prognosis in  th rom ­
botic strokes.
Subsequently se ria l studies on 20 patients w ith  acute cerebra l 
throm bosis were reported (A lk jae rs ig , Laursten and F le tcher,
1972). 49% of the to ta l plasma samples showed evidence of
c ircu la tin g  soluble complexes. These patients also showed 
s ign ifican tly  depressed levels of antithrom bin H I, plasminogen, 
oC -1 -a n titryps in  and o<-2-m acroglobulin. The suggestion 
was made that a "hypercoagulable state" fo llow s acute throm botic 
stroke in  a high proportion of patients.
Acute M yocard ia l In fa rction
In studies of blood samples obtained fo llow ing the onset of 
signs and symptoms of acute m yocardial in fa rc tion , F le tcher and 
A lk ja e rs ig  (1973) found that approxim ately 50% of patients had 
increased levels of soluble complexes which tended to  fa ll towards 
norm al leve ls over the next 2-3 days. A fu rth e r 30% had increased 
leve ls of soluble complexes, which persisted unchanged fo r as long 
as 10 days, w hile  in  20% no abnorm alities were found.
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Colman, Anaya-Galindo, Shattil and colleagues (1975) 
examined 21 patients undergoing coronary arte riography fo r 
evaluation of chest pain using the agarose gel filtra tio n  technique. 
16 patients had one o r more coronary a rte rie s  occluded by more 
than 80% and 5 patients had no angiographic abnorm alities. The 
two groups were comparable fo r age, to ta l and low density lip o ­
p ro te in , cholestero l and trig ly ce rid e . There was a s trik in g  
increase in  soluble complex concentration measured by th e ir 
technique in  the patients w ith  abnormal a rte riog ram s (23.3 -
3 .5(s. E. M^%; norm al 4 .6 -  1.3%) compared to  patients w ithout 
angiographic abnorm alities (10,9 -  1.5%). A lso  the concentration 
of soluble complex showed a good co rre la tion  (r  = 0.49; p (0.005) 
w ith  the degree of angiographic abnorm ality. They suggest that 
th is  technique could provide "a  useful non-invasive screening 
test fo r assessing the extent of coronary a rte ry  occlusion".
Increased soluble complex concentrations have been found 
in  many other m edical conditions including acute g lom erulonephritis 
(F le tcher and A lk ja e rs ig , 1973), sickle  ce ll c rise s  (Chaplin, 
A lk ja e rs ig  and F le tcher, 1974), type I I  hyperlipoproteinaem ia 
(Carvalho, Colman and Lees, 1974), throm boangitis obliterans 
(Kazama and Abe, 1976), dissem inated in travascu la r coagulation 
due to  a va rie ty  of causes (Kazama and Abe, 1976), chronic 
active hepatitis (Coccheri, G asbarrin i, P a lare t et a l. , 1976) 
and during Defibrase therapy (Asbeck, Lecher, M a rtin  et a l. ,
1975).
Soluble complexes have also been identified  in  increased 
concentrations in  obste trica l and gynaecological conditions. In 
one study H afte r, Schneebauer, Tafel and colleagues (1975) studied 
67 healthy prim iparous and m ultiparous women (6-40 weeks 
gestation). The amount of soluble complex (expressed as a
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percentage of the to ta l fibrinogen-re la ted pro te in ) increased from  
2, 6 « 0.4% (mean -  S. D* ) in  ea rly  pregnancy to  4 .9  -  1.3% at 40 
weeks. Additional increases occurred during labour. Chain 
analysis of the soluble complexes showed decreased amounts of 
oC chain "ind ica ting  plasm in a c tiv ity ", ^  " K d im ers were not 
observed (i, e. F X llla  had not crosslinked fibrinogen to  produce 
these complexes, nor had it  crosslinked throm bin-produced 
complexes). This group have also shown a ris e  in  the early 
puerperium  to 6.3 -  1.2%, w ith  a concentration of 3.3 -  1. 3% 
three months a fte r de live ry (G raeff, Wiedmann, von Hugo 
et a l. , 1976).
Increased soluble complex concentrations have also been 
found in  association w ith  septic abortion and advanced carcinom as 
of the male and female genital tra c t (G raeff, von Hugo and H after, 
1976). M arkedly increased concentrations of soluble complex 
have also been observed in  single case reports  in  eclampsia 
(G raeff and von Hugo, 1972); abruptio placentae (V erm ylen,
Donati and V erstrae te , 1971; G raeff and von Hugo, 1974) and 
retained dead foetus syndrome treated w ith  Eeptilase (Hafter 
and G raeff, 1975). In addition th is  group have found increased 
soluble complex concentrations in  cord blood from  asphyxiated 
neonates (G raeff, von Hugo and H after, 1973) and in  endotoxic 
shock (G raeff, von Hugo and H afte r, 1976).
Only in  cases, in  which flo r id  "dissem inated in travascu lar 
coagulation" was lik e ly  to  have been present were Y  - ^  d im ers 
found in  the soluble complex m a te ria l indicating in te rm olecu lar 
covalent bonding by F XHla (G raeff, von Hugo, H a fte r, 1975 and
1976). These authors suggest that Y ' Y  d im er is  only found 
once insoluble fib r in  has been la id  down and that i f  no Y  ” Y  d im er 
is  present the co rre c t diagnosis is  "hypercoagulab ility".
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(6) The Ind irec t Measurement of Soluble F ib rin  by a Specific 
Assay fo r F ibrinopeptide A
Plasm a leve ls of fibrinopeptide A can be accurate ly measured 
by a specific  radioimmunoassay (Nossel, Younger, W ilner et a l. ,
1971; Nossel, 1976). Plasma samples from  100 healthy volunteers 
gave a mean leve l of 0. 6 p m o le s /m l, w ith  a range of 0 .1 -1 .5  pm oles/ 
m l (Nossel, 1976), G rossly elevated levels ()7 p m o le s /m l) were 
found in  patients w ith  acute pulm onary em bolism , acute throm bo­
ph leb itis  o r acute dissem inated in travascu lar coagulation (Nossel,
1976). M oderately elevated levels (1. 5-7 pm o le s /m l) were found 
in  patients w ith  acute infections (septicaem ia, lobar pneumonia and 
c e llu litis ), in  carcinom atosis w ithout c lin ic a lly  evident throm bosis, 
system ic lupus erythem atosus, renal transplant re jec tio n  and ao rtic  
aneurysm (Nossel, 1976).
Other groups have reported ra ised plasma fibrinopeptide A 
leve ls in  deep venous throm bosis, dissem inated in travascu la r 
coagulation and hypertonic saline-induced abortion (G e rrits ,
F lie r  and van der M eer, 1974), and also during ancrod therapy 
and in  re tin a l vascular occlusion (Budzyfiski and M arder, 1975), 
P o ten tia lly  th is  would seem a useful technique fo r identify ing 
in travascu lar coagulation. I t  is  possible, however, that the very 
short h a lf- life  of fibrinopeptide A in  plasma (3 m ins; Nossel,
Canfield and B u tle r, 1973) m ight prove a problem .
1.6(b) Soluble F ib rin o g e n -F ib rin  Complexes - A Summary
It is  c lear that the lite ra tu re  on th is  subject is  extensive.
In some areas apparently con flic ting  resu lts  have been published.
In th is  sum m ary the in fo rm ation and conclusions discussed e a rlie r 
are brought together. F o r a fu ll discussion of each topic and 
references the appropriate section should be consulted.
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In v itro  experim ents suggest that soluble complexes can 
foe form ed in  a va rie ty  of ways. F ibrinogen incubated w ith  low 
concentrations of throm bin provides the sim plest model fo r th e ir 
form ation. P lasm in may also act on the component un its of the 
complexes before o r a fte r th e ir formation.. F X llla  may act by 
crosslink ing  soluble complexes» that have already been form ed, 
o r by crosslink ing  in tact fibrinogen to  fo rm  complexes. In th is  
way soluble complexes could be form ed w ithout the action of 
throm bin. The relevance of these observations in  v ivo  rem ains 
to  be established.
There is  good evidence that fib r in  monomer and early 
fib r in  x monomer act as component units of soluble complexes. 
F ibrinogen and early fibrinogen X  may also be incorporated into 
complexes. W hether the la te r degradation products of fibrinogen 
o r fib r in  fo rm  complexes rem ains controversia l.
In v ivo  experim ents have shown that complexes can be 
produced by in jection  or infusion of throm bin, ancrod, D e fib rase / 
B eptilase, endotoxin and the activated coagulation facto rs in  serum. 
The reticu loendothelia l system may be im portant in  the clearance 
of these complexes. ” Over-loading*’ o r blocking the re ticu lo ­
endothelial system could re su lt in  deposition of soluble complexes 
as insoluble fib r in  deposits.
W hile ’ ’hypercoagulability”  can produce transien t increases 
hi soluble complex concentration, the combination of ’ ’hyper­
coagulability”  and insoluble fib r in  deposition appears to  resu lt 
in higher and sustained soluble complex concentration in  in  vivo  
anim al experim ents. Formed thrombus (i. e. not extending or 
rap id ly  lysing) does not give ris e  to high leve ls of soluble complex 
in  one in  v ivo  anim al model, but may under d iffe ren t experim ental 
conditions.
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As most w ork on the iden tifica tion  of soluble complexes is  
perform ed at 20-22^C (room  tem perature) care must be taken in  
re la tin g  the resu lts  obtained to  the in  vivo  situation at 37^C, It  
is  possible that at least some form s of soluble complex (e.g . in  
Defibrase injected human volm iteers) are not present at 37^C.
A va rie ty  of techniques are available fo r the iden tifica tion  
of soluble complexes (or soluble fib rin ) in  c lin ica l conditions. The 
sim p le r tests (e. g. the ethanol gelation test and the protam ine 
sulphate tests) have shown varying resu lts in  d iffe ren t series 
w ith  appreciable numbers of fa lse positive and negative resu lts .
The ethanol gelation test may give fa lse positive resu lts  w ith  high 
fibrinogen leve ls , w h ile  the protam ine sulphate tests are very 
dependent on the type of reagent used. The m ore complicated 
tests (e. g. agarose gel filtra tio n , labelled glycine ethyl ester 
incorporation) are too d iffic u lt and tim e consuming fo r a routine 
c lin ic a l labora tory but provide sensitive techniques fo r research 
use. There is  good evidence re la tin g  abnorm alities in  the agarose 
gel filtra tio n  technique to  c lin ica l in travascu lar coagulation whether 
localised o r d iffuse. However, s ligh tly  increased values are also 
found in  healthy pregnant women and in  women taking oestrogen- 
progestogen therapy. In such eases the problem  may be one of 
"hypercoagulab ility”  ra the r than insoluble fib r in  deposition. The 
assumption that the presence of soluble fib r in  (or complexes) in  
plasma im p lies  insoluble fib r in  deposition cannot be made.
Soluble fib rin o g e n -fib rin  complexes in  plasma do, however, 
suggest the action of throm bin o r F X llla , im plying activation of 
the coagulation pathway. Exam ination of the chain s truc tu re  of 
the complexes may be useful, although such w ork im p lies that 
th is  has not been a lte red in  v itro  a fte r blood sam pling. I f  in tact 
AoC , B ^  and chains are found, the component un its  of the
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complexes must be fibrinogen or fib r in  monomer. Such 
complexes could only be form ed by the action of throm bin (or 
a th ro m b in -like  enzyme e. g. ancrod). I f  reduced amounts of 
in tact o( chain are found some other p ro teo ly tic  enzyme (e. g. 
plasm in) has also been acting besides throm bin. I f  polym ers 
o r K  - % d im ers are found, F X n ia  must have acted on these 
complexes -  and they could have been form ed w ithout the action 
of throm bin. Exam ination of the chain structu re  may, but does 
not necessarily, allow  the conclusion that the complexes have 
derived from  insoluble fib r in  deposits, as they could have been 
form ed by the action of F X llla  on fibrinogen or soluble complexes.
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CHAPTER II
MATERIALS AND METHODS
n , 1 Introduction
In th is  chapter the development of the technique of "plasm a 
fibrinogen chrom atography" w ill be discussed. Plasma fibrinogen 
chromatography is  based on the biochem ical technique of agarose 
gel filtra tio n  (m olecular sieve chromatography or exclusion 
chromatography). Agarose gel filtra tio n  w ill therefore be 
discussed f ir s t  and then its  application to  the study of fibrinogen 
and its  deriva tives by F le tcher, A lk jae rs ig , O’B rie n  and colleagues 
(1970), M odifications introduced by G raeff and von Hugo (1972) 
and other groups w ill next be discussed and fin a lly  the methods 
employed in  setting up the p ro ject described in  th is  thesis.
H, 2 Agarose Gel F iltra tio n  -  H is to rica l and Theoretica l Aspects 
In 1966 Lathe and Huthven suggested that soluble pro te in  
m ixtures m ight be fractionated by passage through columns of 
swollen gel granules, Porath and FlOdin (1959) introduced the 
use of crosslinked dextran as the gel medium and employed the 
te rm  "g e l filtra tio n "  to  describe the technique. The term s 
"m o lecu la r sieve chrom atography" (H jerten and Mosbach, 1962) 
and "exclusion chrom atography" (Pedersen, 1962) have also been 
used.
Gel filtra tio n , lik e  u ltracen trifuga tion , is  a transpo rt process, 
in  which m ig ra tion is  governed la rge ly  by the size of the solute 
(e. g, a pro te in) under investigation. The various m athem atical 
models constructed to  explain the process have been reviewed by 
W inzor (1969), The in teraction of a specific pro te in  and the gel
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is  governed by the m olecular dimensions of the pro te in . 
M athem atically th is  is  expressed as the Stokes* rad ius of the 
pro te in  molecule ( i, e. the radius of the equivalent hydrodynamic 
sphere). No attem pt w ill be made to  discuss the m athem atical 
models in  de ta il, as a non-m athem atical model is  easier to 
understand and provides adequate explanation fo r the application 
of the technique to the study of fibrinogen and its  deriva tives.
The fo llow ing  sim ple, non-m athem atical explanation of gel 
filtra tio n  is  adapted from  that described in  the B iorad Laboratory 
Manual on "G el Chromatography" (1971). The p a rtic le s  of the gel 
m a te ria l have a sponge-like m a trix  s tructure , containing pores of 
controlled dim ensions. The gel is  poured in to  a glass or p lastic  
column under conditions which allow  un iform  packing of the 
pa rtic le s  to  fo rm  "the bed". The sample, consisting of a 
m ixture  of soluble pro te ins, which d iffe r in  m olecular dimensions, 
is  then applied to  the bed surface and allowed to  percolate through 
the bed using a constant flow  of eluant buffer. As elution proceeds, 
molecules which are too la rge to  enter the pores of the gel m a trix  
pass rap id ly  through the bed (in the space surrounding the bed 
pa rtic les) and are eluted in  a single zone near the beginning of the 
elution p ro file  (the void volum e, V^). Sm aller m olecules, which 
are capable of d iffusing into the pores of the m a trix  are retarded 
in  th e ir m igra tion through the bed. The extent of re ta rdation is  
inverse ly corre la ted to  the m olecular dimensions of the prote in . 
Therefore the sm allest molecules are retarded to the greatest 
extent and are the las t to  emerge from  the bed. In the absence 
of other than m olecular sieve effects (e, g, ion exchange), elution 
of a ll sample solutes is  complete when a volume of eluant, 
approxim ately equal to the to ta l bed volume, has passed through
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the bed. When a homogenous solute (e. g. a pure pro te in) is  
studied by agarose gel filtra tio n , under optim al conditions, the 
elution p ro file  w ill be a Gaussian curve.
F igure 10 shows the elution p ro file  fo r a pure pro te in  
analysed by th is  technique. The elution volume (V^) of a pro te in  
is  the volume of eluant bu ffe r, which issues from  the gel bed from  
the tim e penetration begins u n til the pro te in  begins to  appear in  the 
eluant bu ffe r (B iorad Laboratory Manual, 1971). On the elution 
p ro file  th is  volume is  measured as the eluant volume corresponding 
to the ha lf-he ight of the leading side of the peak (method 1). 
A lte rn a tive ly , the leading side of the peak can be extrapolated to 
the base-line (method 2). In the example shown in  F igure 10 the 
of the pro te in  by method 1 is  100 m l and by method 2 is  96 m l. 
The void volume (V^) of a gel filtra tio n  column is  a measure 
of the to ta l space surrounding the p a rtic le s  of the chromatography 
medium packed in  the column. It is  determ ined by measuring the 
elution volume of a solute, which is  excluded from  the pores of the 
gel m a trix , A coloured substance which is  excluded from  the gel 
m a trix  is  best fo r estim ating th is . B lue Dextran 2,000 (Pharmacia 
G .B . L td ., 75 Uxbridge Road, London) has a m olecular w eig lit of
2 X 10 , but is  "po lyd isperse". As the gel used fo r th is  p ro ject
6(Biogel A5 m) has an exclusion lim it of 5 x  10 , B lue Dextran is  
not e n tire ly  satisfacto ry fo r an accurate estim ation of the void 
volume. A t a p ra c tica l le ve l, however, i t  gives a useful value 
and because it  is  coloured allows rap id v isua l checking of the bed 
surface (see Chapter in, 2),
F le tcher and colleagues have applied th is  technique to the 
study of fibrinogen and its  deriva tives. I f  the fib rin o g e n -fib rin  
re lated antigen elution p ro file  does not conform  to  a perfect 
Gaussian curve, th is  is  in terpreted as being caused by the presence
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of soluble complexes o r degradation products (F le tcher et a l. ,
1970). They introduced the te rm  "plasm a fibrinogen chrom ato­
graphy" to  describe th e ir technique*
HE. 3(a) Plasma Fibrinogen Chromatography 
Method of F letcher*s Group
This teclm ique was developed from  e a rlie r w ork based on 
measurements of p ro te in  d iffusion constants by the im m unodiffusion 
method of A lliso n  and Humphrey (I960)* F le tcher and colleagues 
m odified th is  method to  determ ine the m olecular weight of the 
predominant fib rin o g e n -fib rin  deriva tive  in  plasm a. D uring an 
outbreak of heat-stroke in  1967 they studied 4 patients, who 
subsequently died quite unexpectedly from  pulm onary embolism  
(A lk jae rs ig , 1967; F le tcher and A lk jae rs ig , 1975), A fib rinogen- 
fib r in  deriva tive  w ith  a m olecular weight apparently greater than 
fibrinogen as determ ined by its  d iffusion cha racte ris tics  (i. e, a 
soluble fib rin o g e n -fib rin  complex) was found in  high concentrations 
in  the plasma of a ll 4 patients fo r some days p rio r to  death.
This study suggested to  the authors that soluble complexes 
m ight provide valuable in form ation about "c lin ic a lly  s ilen t 
throm bosis" (F le tcher and A lk ja e rs ig , 1975). I t  established 
the fo llow ing im portant p rin c ip le s ;-
(1) the exam ination of plasma ra ther than serum  fo r the 
products of enzymic action on fibrinogen
(2) the iden tifica tion  of these products by the use of 
fibrinogen antiserum
(3) the c lass ifica tion  of these products on a m olecular 
weight basis.
They began to experim ent w ith  the use of agarose gel filtra tio n  
(using B iogel A6 m , obtained from  B iorad Labora tories, 1510750) 
to  separate the fibrinogen deriva tives on a m olecular weight basis.
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They found that th is  method worked w e ll and that they could read ily  
analyse the eluant fractions fo r fib rin o g e n -fib rin  re lated antigen 
using a m odified ra d ia l im m unodiffusion teclinique (M ancini, 
Carbonara and Heremans, 1965).
The theory of soluble complex form ation used by F le tch e r’s 
group is  shown in  F igure 11 and the resu lts  of in  v itro  experiments 
supporting th is  theory are shown in  F igure 12. The soluble 
complexes were produced by m ixing norm al plasma w ith  the 
degradation products of lysed fib r in . As those complexes are 
la rg e r in  m olecular size than fibrinogen they are eluted in  
advance of the norm al fibrinogen peak. This is  reported as 
a ’ ’sh ift to the le ft" . S im ila rly  early fibrinogen degradation 
products are eluted a fte r the parent m olecule. Th is is  reported 
as a "s h ift to the rig h t". In c lin ic a l conditions associated w ith  
"hypercoagu lab ility" o r throm bosis a "s h ift to the le ft"  is  seen, 
w hile the appearance of uncomplexed degradation products due to 
fib rin o ly s is  o r fibrinogenolysis causes a "s h ift to  the r ig h t".
Examples of these patterns found in  samples from  a patient 
w ith  a deep venous throm bosis have already been shown in  F igure 
9. The resu lts  of c lin ic a l series studied by th is  group and others 
have been reviewed in  Chapter 1.6(a),
II. 3(b) M odifications Introduced by Other Groups
G raeff and von Hugo (1972) described several m odifications 
to  th is  basic technique.
(1) F ibrinogen and its  deriva tives were precip ita ted from  
plasma, using ^  -a lanine, by a m odification of the method of 
Straughn and Wagner (1966). The precip ita te  was redissolved 
before agarose gel filtra tio n .
m(2) The same gel medium (Biogel A5 m, mesh size 100-200) 
was used but the packed column height was 80 cms w ith  a diam eter 
of 2. 5 cms. This is  a much la rg e r packed column than that used by 
F le tch e r’s group, Verm ylen, Donati and V erstraete  (1971) had 
also used a la rge column of height 96 cms and diam eter 2,5  cms,
(3) A ttention was paid to  addition of enzyme in h ib ito rs  to 
both the anticoagulant in  which the blood was collected and the 
column bu ffe r, (Presumably th is  was also done by F le tch e r’s 
group, but the methodological details are d iffic u lt to  obtain).
This should prevent in v itro  fibrinogen p ro teo lysis.
(4) Eluant fractions were examined by
(a) op tica l density readings (at 280 nm) fo r 
to ta l p ro te in  concentration
(b) throm bin tim e to  identify fibrinogen
(c) ra d ia l im m unodiffusion using P artigen- 
fibrinogen plates (Behringwerke, OTDP 
0203) fo r fib rin o g e n -fib rin  re la ted antigen 
(FR-antigen).
Using th is  m odified technique G raeff and von Hugo (1972) were 
able to  iden tify  elevated soluble complex levels in  plasma from  a 
patient w ith  eclampsia. Elevated soluble complex leve ls were also 
found fo llow ing in  v itro  ly s is  of insoluble fib r in  (von Hugo and G raeff,
1973) and la te r in  a va rie ty  of c lin ica l conditions (see Chapter 1.6(a)). 
In th e ir la te r studies they have used B iogel A15 m, mesh size 100-200 
from  B iorad Laboratories, 1511040 (G raeff, von Hugo and H after,
1973).
F o r the present p ro ject i t  was decided to adopt the p re lim in a ry  
-alanine p rec ip ita tion  step fo r two reasons. F irs tly , i t  allowed a 
fa r greater concentration of fibrinogen-re la ted p ro te in  to be applied 
to  the gel bed. This meant that higher concentrations were obtained 
in  the eluant frac tions, allow ing easier iden tifica tion  of low soluble
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complex leve ls in  patient samples. Secondly, polyacrylam ide 
gel electrophoresis could foe ca rried  out d ire c tly  on the soluble 
complex fractions, as the amount of contam inating pro te in  was 
greatly reduced.
B iogel A6 m was used as the gel medium fo r the present 
p ro jec t (as recommended by F le tcher’s group) because fibrinogen 
w ith  a m olecular weight of about 340,000 appears in  the m iddle of 
the fractiona tion  range of th is  gel (see Chapter III .  2, F igure 23). 
B iogel A15 m would im prove the separation of the soluble complex 
fractions, but at the expense of the separation of the degradation 
products. It was also decided to  use columns of packed height 
and diam eter (35 x 2. 6 cms), that is  much la rg e r than those used 
by F le tch e r’s group in  order to im prove the reso lu tion of the 
elution p ro file . The mesh size of 200-400 was also selected to 
im prove resolution.
O ptical density, throm bin c lo tting  tim e and ra d ia l immuno­
d iffusion FR-antigen estim ations were perform ed on the eluant 
fractions (cf. G rae ff’ s group). The throm bin c lo tting  tim e test 
had also been proved to be useful in  the iden tifica tion  of soluble 
complexes by Bang, Hansen, Smith and colleagues (1973), It 
was decided to  use the anticoagulant and column bu ffe r suggested 
by G raeff’ s group w ith  some s ligh t m odifications (see Chapter II, 
4(h) ).
Other methods have been used to  iden tify  the fib rin o g e n -fib rin  
re lated m a te ria l in  the eluant fractions. The staphylococcal 
clumping test (SCT) has been claim ed to be be tte r at identifying 
the soluble complex m ate ria l than the rad ia l im m unodiffusion 
method (Asfoeck, Lech le r, M a rtin  et a l. , 1975), The SOT was 
therefore used to obtain a sem i-quantitative estim ate of the 
amount of fib rin o g e n -fib rin  re lated pro te in  in  the ve ry  high
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m olecular weight (void volume) fractions.
II. 4 Methods Used fo r the P ro ject Described in  th is  Thesis 
II. 4(a) C ollection of Blood Samples
Blood was collected by carefu l venepuncture whenever possible 
w ithout venous occlusion. I f  venous occlusion was required the 
tourniquet was applied im m ediately before venepuncture and 
removed once the needle was placed in  the vein. Blood was 
collected in  s te rile , p lastic  syringes and im m ediately divided 
into aliquots fo r preparation of plasma, serum and, in  the ancrod- 
treated patients (Chapter IV), fo r observation of clo t quality.
II. 4(b) Preparation of Plasma Samples
Whole blood was collected into p lastic  tubes containing 
anticoagulant. The anticoagulant m ixture (pH 7. §) contained 
before the addition of blood; -  trisod ium  c itra te  Ô, ISM; N tr is  
(hydroxym ethyl) m ethyl 2 aminoethane sulphonic acid (T. E .S . )
0 .06M; epsilon am inocaproic acid (E. A . G. A . ) 0 .02M; ethylene 
diam ine te tra -a ce tic  acid (E .D . T , A , ) 0 .04M; and apro tin in  
(T ra sy lo l, Bayer Pharm aceuticals L td ., Haywards Heath, Sussex, 
England) 10® iC .I. Ü. / I  (pH adjusted to 7.6 ). In samples from  
patients rece iv ing ancrod therapy 0,2 m l ancrod antiserum  
(snake venom antiserum , Agkistrodon rhodostoma, the L is te r 
Institu te , E ls tree , England) was added to each m illi l it r e  of 
anticoagulant to neutra lise any ancrod in the blood sample.
(The E .D . T . A . was only added to  the anticoagulant m ixture  
in the autumn of 1974, therefore i t  was not present in  the blood 
samples collected from  the ancrod patients, but was present in  
the blood samples fo r a ll subsequent patient w ork).
This anticoagulant mixture is based on that of G raeff and 
von Hugo (1972). Their anticoagulant contained trisod iu m  c itra te .
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T .E .8 . and aprotin in . W hile aprotin in  should d ire c tly  in h ib it 
the action of any plasm in in the blood sample, E .A .C .A .w a s  
also added to  prevent activation of plasminogen. E. D, T. A . 
was included, not only fo r its  anticoagulant effect, but also to 
prevent the crosslinking action of F X îïla .
This anticoagulant m ixture  should therefore have prevented 
any in  v itro  enzymic action, although it  is  im possible com pletely 
to  exclude th is . I t  is  also possible that a degree of in  v itro  
p ro teo lys is might have occurred during the actual process of 
venepuncture (e. g. blood w ith in  the syringe). Adding anticoagulant 
to  the syringe would have reduced th is  p o ss ib ility , but would have 
made it  im possible to prepare serum.
The anticoagulated blood was cooled to  4^C immediately after 
collection. This should also have prevented in v itro  pro teo lysis - 
but m ight, i f  cooling does cause soluble complex form ation 
(B la ttle r, Straub and Peyer, 1974), have actually produced 
complexes. (The paper by B la ttle r and colleagues (1974) was 
not published u n til a fte r th is  p ro ject was started. It was decided 
that even if  the complexes were being form ed by a cooling effect 
in  v itro  they did reflect changes in  v ivo  based on the resu lts  from  
other groups, see Chapter 1.6(a) ), The blood was centrifuged at 
3,000 g fo r 20 m ins. Plasma was separated and subsequently 
handled w ith  s ilicon ised glass-w are.
II. 4(c) P reparation of serum samples
Whole blood was collected in  the containers provided fo r use 
w ith  "W ellcom e F .D .P . K its " (Wellcome Research Laboratories, 
Beckenham, England, HA 14). These contain thrombin, to prom ote 
complete c lo t form ation, and a plasmin inhibitor, to prevent in  vitro 
fibrinogen/ fibrin degradation product formation. In samples 
collected from patients rece iving ancrod therapy, ancrod antiserum
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(0.05 m l) was added. C lotting was allowed to occur at room 
tem perature fo r several hours (usually overnight) and serum 
separated and stored at -20^0.
II. 4(d) C lot Q uality Observation Test
This was only perform ed on samples taken from  the ancrod 
group of patients (Chapter IV ). 1 m l of whole blood was incubated 
in a glass test tube (75 x 10 mm) containing 0.05 m l ancrod an ti­
serum at 37^G fo r 24 hours. The resultant c lo t was graded 1 to 5, 
a "no rm a l c lo t" being graded as 1 and "no c lo t" as 5. The grades, 
2, 3, 4 represented m ild , moderate and severe defects (Beid,
Chan and Thean, 1963).
11.4(e) Plasma Fibrinogen Estim ation
This assay was based on the method of Ratnoff and Menzie 
(1961). This technique measures throm bin clo ttable pro te in  
(i. e. i t  w ill also measure ea rly, clottable Fragm ent X and 
possibly also some form s of soluble complex). I t  was the 
general experience in  the laboratory during the tim e of th is 
p ro ject, that the Ratnoff and Menzie assay gave values low er 
than m ight have been expected. Duplicate estim ations were 
always ca rried  out and if  these were at variance by more than 
20 m g /100 m l the assay was repeated.
Because of doubts as to  the accuracy of th is  assay, plasma 
fibrinogen was estimated in  28 samples from  norm al healthy 
subjects using the ra d ia l im m unodiffusion method (see Chapter
II. 4(j) ) as w e ll as the throm bin clottable pro te in  method. A good 
co rre la tion  was found between the two methods, but the immuno­
log ica l method consistently gave higher values than the throm bin 
clottable method (see F igure 13). I t  is  lik e ly  that some loss of
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f ib r in  occurs during the washing of the glass beads using the 
Ratnoff and Menzie (throm bin clottable protein) method, A 
discrepancy between throm bin clottable and im m unoreactive 
fibrinogen should not, however, occur in  samples from  healthy 
subjects (W olf, F a rre ll and W alton, 1972).
It  has to  be concluded that the throm bin clo ttable pro te in  
method was probably giving values which were consistently "too 
low ", at least compared w ith  the values obtained by the immuno­
log ica l method and which would have been expected from  reference 
to  the w ork of other groups. As re la tive  ra the r than absolute 
values were im portant, i t  was fe lt that the resu lts  obtained by the 
Ratnoff and Menzie method could be accepted. The discrepancy 
in  the plasma fibrinogen levels was not investigated u n til the 
p ro ject had been in  progress fo r more than a year. Some of the 
samples from  the early stages of the p ro ject were unsuitable fo r 
fu rth e r analysis (due to  age and repeated thawing-out caused by 
storage in  a m alfunctioning -20^C freezer). It was therefore 
decided to  continue to  use the Ratnoff and Menzie method fo r the 
sake of consistency.
11.4(f) Serum F ibrinogen-F ib r in  Degradation Product Estim ation 
(Serum F D P /fdp)
This was measured by the tanned red ce ll haemagglutination 
inh ib ition  immunoassay (T .B .C .H .I. I. ) of M erskey, K le in e r and 
Johnson (1906), using pre-packed k its  from  W ellcome Research 
Laboratories (HA14), The resu lt was expressed in  p g /m l w ith  
reference to  a standard fibrinogen preparation. The sens itiv ity , 
defined as the lowest concentration of the standard fibrinogen 
preparation giving a "no agglutination" reaction, was usually
1.25 p g /m l (range 0. 63 -  2. 5 ixg/ml).
The serum  F D P /fdp  leve l was also measured by the staphy­
lococcal clum ping test (SCT) -  see Chapter II. 4(1).
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II. 4(g) jS-alanine P rec ip ita tion  Technique
This was perform ed by the method of G raeff and von Hugo 
(1972), im m ediately fo llow ing separation of the fresh  plasma,
9 m l of plasma was gently m ixed w ith  ^ -alanine (fin a l 
concentration 2 .5  M ) in  an ice-bath (4^C) fo r 30 m inutes. The 
resu lting  precip ita te  was packed by centrifugation at 9,000 g 
fo r 20 m inutes. The supernatant was discarded and the 
prec ip ita te  redissolved in  3 m l column buffer (see below) at 
20°C.
II. 4(h) Agarose Gel F iltra tio n
B iogel A5 m (mesh size 200-400) obtained fro m  B iorad 
Laboratories L im ited , B rom ley, Kent, England (1510750) was 
used as the gel medium. S light varia tions were found in  the 
separation cha racte ris tics  of d iffe ren t batches of th is  gel. 
E ssentia lly there were two types, which w ill subsequently be 
re fe rre d  to  as Batches I  and II. Batch I  was used fo r the in itia l 
p ro ject w ork including in  v itro  experiments and the ancrod-treated 
patient group. Batch I I  was used fo r a ll fu rth e r w ork including a ll 
the obste trica l groups (see Appendix I). Chromatography columns 
2,6 40 cm (K26/40) from  Pharm acia G .B . L im ited , 75 Uxbridge 
Road, London were used. The gel medium was poured in to  the 
column and packed w ith  care to  ensure that the p a rtic le s  settled 
un ifo rm ly  to produce an "even bed". As it  is  d iffic u lt to  reproduce 
the same packed height in  every gel column -  any value from  34- 
35 cms was accepted. (The diam eter of 2 .6  cms rem ained 
constant). Once packed^the column bed was equilib rated over­
night w ith  buffer under standard running conditions. Before use 
the packing was checked using Blue Dextran 2,000 (Pharm acia). 
This was repeated as required to  con firm  that the packing was s t ill
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in  good order, o r to  check fo r a suspected technical fau lt.
The packed gel column was always "washed-out" a fte r 
use w ith  50-100 m l of bu ffe r. The column bu ffe r and gel 
medium were degassed before use, to prevent bubble form ation 
w ith in  the packed gel. Sodium azide (0.015 M) was added to the 
column buffer to prevent bacte ria l contam ination. Although 
some packed columns could be used fo r many pro te in  analyses 
(20-30) it  was found to  be desirable to lim it the number of 
analyses to 10-15 fo r each column. A fte r th is  number of 
analyses it  was found that technical fau lts tended to develop.
Gel not in  use was stored in  buffer containing sodium azide 
(0.015 M) to  prevent bacte ria l growth.
The column elution bu ffe r (pH 7. 6) contained:- t r is  
(hydroxym ethyl) methylamine 0 .05M; sodium chloride 0.115 M; 
trisod ium  c itra te  0.012 M; epsilon am inocaproic acid (E. A. C. A . ) 
0 .05M; ethylene diam ine te trace tic  acid (E. D. T. A , ) 0.02 M; 
aprotin in  (T ra sy lo l, Bayer), 10 K . I. Ü. / I  and sodium azide 
0,015 M. The pH was adjusted (using 0. IM  hydroch loric acid) 
to  7. 6.
This is  based on the column buffer of G raeff and von Hugo 
(1972), E .A .C .A . and E .D . T. A. were added to  tr y  to prevent 
enzymic action on fibrinogen. Chromatography was perform ed 
at room  tem perature (the p o ss ib ility  that cooling from  37°C may 
induce complex form ation is  discussed elsewhere -  Chapter 
Î. 5(d); Chapter IV . 5).
The flow  rate of 20 m l/h o u r was controlled by a constant 
infusion pump and 2. 6 m l fractions were collected. These 
conditions varied s ligh tly  over the three year period of the 
p ro ject and so cum ulative elution volumes were always recorded 
ra ther than sim ply the frac tio n  number, A diagram  of the 
apparatus is  shown in  F igure 14. A ll the equipment apart from
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the column its e lf was supplied from  L .K .B .-P ro d u c te r 
(Box 76, Stockholm-Blomma 1, Sweden),
Constant optica l density (O. D. ) m onitoring (at 280 nm) 
was perform ed using the U vl-co rd  apparatus (spectrophoto­
m eter) and a p rin t-o u t obtained on the pen-recorder. This 
allowed the pro te in  containing fractions to be iden tified  and 
the O. D, of these fractions was confirm ed using a Beckman 
spectrophotom eter,
n , 4(i) Throm bin C lotting Tim e (T. C, T. ) and Throm bin 
C lottable P ro te in  Incubation Test (T, C .P . )
This was estim ated using the method of M cN icol and Douglas 
(1964) w ith  m inor m odifications. The test system consisted o f:- 
0. 2 m l of eluant frac tion ; 0.3 m l of throm bin titra tio n  m ixture 
and 0,1 m l of throm bin (6 u n its /m l. Bovine Throm bin, Parke- 
Davis, 4-2073-1). The throm bin was added la s t and the c lo tting  
tim e recorded fro m  that point. The throm bin titra tio n  m ixture 
contained 6 m l of 0.9% (w /v ) saline, 3 m l of 0.7% (w /v ) calcium  
chloride and 1 m l of 0 .1_M tr is  buffer (pH 7. 5). Duplicate assays 
were perform ed.
When the c lo tting  tim e was in  excess of 3 m inutes, the test 
was discontinued. An identica l test-system  (the throm bin 
clottable pro te in  incubation test o r T . C. P. ) was set up fo r each 
eluant fra c tio n  w ithout m ixing and incubated fo r 24 hours. Any 
evidence of c lo t o r fib r in  strand form ation was regarded as a 
positive test.
In  order to pe rfo rm  s ta tis tica l analysis of the resu lts  two 
ra tio s  were calculated. A ra tio  was used ra the r than a single 
elution volume in  an attem pt to m inim ise the differences between 
d iffe ren t batches of agarose gel medium.
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The ra tio s  were calculated as shown in  F igure  15, using 
the fo llow ing form ulae: -
T .C .P . ra tio  = V g
T .C .T . ra tio  =
The T i C. P. ra tio  proved much the more useful of the two (see 
Chapter ¥ ; 4(c) ) and is  the one considered in  most of the thesis.
II, 4 (j) Radial Im m unodiffusion Technique fo r F lb rino ge n -F lb rin
Related Antigen (FR-Antigen)
The FR-antigen concentration of each p ro te in  containing 
eluant frac tio n  was measured using th is  method, adapted from  
that described by M ancini, Carbonara and Heremans (1905) w ith 
m odifications suggested by W olf and W alton (1965). Agar 3% 
w /v  ("D ifco " Bacto-Agar, D ifco Laboratories, C entral Avenue, 
West M olesey, Surrey, England 0141-02) was dissolved by 
heating in  b a rb ita l-sa lin e  buffer (pH 7.2) which contained:- 
sodium barb it  one 0.02 M; sodium chloride 0.29M ; ethylene 
diam ine te trace tic  acid (disodium salt) 0 ,01M; trisod ium  
c itra te  0.012M; epsilon am inocaproic acid 0. D IM  and sodium 
azide 0.003 M . The pH was adjusted (using 0 .0 1 M hydroch loric 
acid) to  7 .2 .
6 m l aliquots of th is  agar were used. F ibrinogen antiserum  
(Behringwerke-Hoechst Pharm aceuticals, Hounslow, M iddlesex, 
England, ORCH 05) was used at a 1:120 d ilu tion  in  0. 9% w /v  
saline ( i. e, 0.05 m l antiserum  in  5.95 m l saline). This was 
warmed to 56^C. 6 m l of dissolved agar was added to  the 6 m l
dilu ted antiserum , a fte r cooling the agar to 60^0. The antiserum - 
agar m ixture  was then poured in to a p lastic  p e tri dish (8.5 cms 
in  diam eter) placed horizon ta lly  on a leve lling  table and allowed 
to gel. Samples of eluant fractions were applied to  5 p i "ho les"
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punched in the gel and d iffusion continued fo r a m inim um  of 48 
hours at room  tem perature in  a m oist atmosphere. Assays 
were perform ed in  duplicate. C lear rings were obtained by 
staining w ith  0.01% w /v  tannic acid, fo r a few seconds, under 
in d irec t illum ina tion . P lates were calibrated by the use of 
appropriate d ilu tions of P rote in  Standard P rote in  (P .S. P ,, 
Behringwerke-Hoechst Pharm aceuticals, O TFI, 03). Where 
necessary the samples were diluted in  column bu ffe r before 
use.
It  is  known that the area of the rin g  (once d iffusion is  
complete) is  d ire c tly  proportiona l to  the antigenic concentration 
(M ancini et a l. , 1965). Thus (where D is  the diam eter of 
the rin g ) w ill also be d ire c tly  proportional to the antigenic 
concentration. This was confirm ed in  the experim ent shown 
in  F igure 16. A fibrinogen solution of known concentration 
(prepared from  F ibrinogen, Grade L , Kabi Pharm aceuticals 
L td ., Stockholm, Sweden) was diluted to  give concentrations of 
40, 30, 20, 10, 5 and 2. 5 m g /100 m l. These d ilu tions were
then analysed in  duplicate fo r FR-antigen using the m odified
2M ancini technique and D measured. It can be seen that there
2was a very good co rre la tion  between D and the known fibrinogen 
concentration. In th is  way a standard line  could be drawn from  
which the FR-antigen concentration of each eluant frac tio n  could 
be calculated. Two plates were usually set up fo r each gel 
filtra tio n  run (one fo r measuring range of 1-7 m g /100 m l; and 
one fo r m easuring range of 7-20 m g /100 m l). The spacing of 
the holes and the d ilu tion  of the standards d iffe red  between the 
two plates, but not the antiserum  concentrations.
This method did seem to w ork fa ir ly  w e ll. It  is  possible 
that the concentration of FR-antigen in  the soluble complex
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fractions was underestim ated (see Chapter III. 4 and 6). The 
m olecules may have been too la rge to diffuse through the agar 
p rope rly  and the antigenic determ inants may also have been 
altered (W olf and W alton, 1965; W olf, F a rre ll and W alton,
1972).
lL 4 (k ) C alculation of Results from  Antigenic o r O ptical 
Density E lu tion P ro file s
F le tch e r’ s group have developed an elaborate method of 
in te rp re ting  th e ir resu lts  measuring the re la tive  concentrations 
of soluble complex (polym er), fibrinogen and early  degradation 
product ( f irs t deriva tive). They use a computer program  based 
on chrom atographic plate theory analysis (A lk jae rs ig , Roy and 
F le tcher, 1973). Th is enables them to analyse even poorly 
resolved antigenic e lution p ro file s  and so they can use sm all 
columns which allow the analysis to  be perform ed rap id ly . A 
computer p rin t-o u t from  a sample from  a patient w ith  "post­
operative throm bophleb itis" is  shown in  F igure 17.
In order to develop such a computer aided analysis 
considerable experience has to  be obtained w ith  the gel filtra tio n  
technique. Such an analysis would requ ire  a high degree of 
tec lin ica l expertise and precise knowledge of the m olecular 
weights of the d iffe ren t form s of soluble complex. A s im p le r 
method of calculation was required fo r the present p ro ject.
A  much s im p le r, but c le a rly  more Inaccurate method of 
calculating resu lts  has been suggested by G rae ff’ s group (H after, 
Schneebauer, T afe l et a l. , 1975; G raeff, Wiedmann, von Hugo 
et a l. , 1976), They no longer use the ra d ia l im m unodiffusion 
technique fo r the estim ation of FR-antigen and now re ly  on optical 
density e lution curves. They cla im  that optica l density (OD)
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readings can give an accurate estim ate of the amount of FR- 
antigen in the soluble complex range (excluding the void volume 
peak, in  which contaminant proteins are present) -  provided 
the in it ia l j§ -alanine p rec ip ita tion  step is  included. The O. D. 
is  measured at 325 nm and subtracted from  the value at 280 nm,
A representative example of such an elution p ro file  is  shown in 
F igure 18. The percentage of soluble complexes in  re la tio n  to 
the to ta l fibrinogen content was determ ined using the fo rm u la :-
soluble complex _ A 
concentration % A + B
This type of method was adapted fo r th is  present p ro ject, 
but FR -antigenic curves were used because they were fe lt to be 
more accurate than O. D. curves, because of the presence of 
contam inating prote ins even in  a |S -alanine p rec ip ita te . In 
addition much of the w ork to  be described in  th is  thesis had 
already been perform ed before th is  method of calculating resu lts  
was f ir s t  published (July 1975). The use of O .D . curves would, 
however, greatly reduce the amount of w ork involved in  the 
technique and m ight w e ll be w orth evaluating in  the fu ture .
The method used fo r the present pro ject is  shown in  F igure 
19. The soluble complex concentration (area m) was calculated 
according to  the form ula: -
soluble complex
concentration % = — - x  100
to ta l FR antigen m -i- n + p
S im ila rly  the degradation product concentration, m ainly fibrinogen 
Fragment X  o r fib r in  Fragm ent x (area p), is  calculated according 
to  the form ula; «
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degradation product
concentration % = — ^  100
to ta l FR-antigen m + n + p
C learly  th is  method is  only, at best, sem i-quantita tive but it
was found extrem ely useful in  separating d iffe ren t patient
groups*
I t  was also fe lt that the elution volume at which FR - 
antigen could f ir s t  be identified , using the ra d ia l immuno­
d iffusion technique, m ight also be helpful because of s ligh t 
va ria tion  between d iffe ren t packed gel columns the FR-antigen 
ra tio  was calculated as shown in  F igure 20,
FR-antigen _ a
ra tio  "  b
n . 4(1) The Staphylococcal Clumping Test (S. C. T . )
This was perform ed according to  the test-tube method 
(N iew iarow ski and L ip in sk i, 1970; Hawiger, N iew iarow ski, 
Gurewich et a l. , 1970), C erta in stra ins of staphylococcal 
aureus produce staphylococcal clumping facto r. These 
staphylococci w ill "c lum p" in  the presence of fibrinogen, 
fib r in  monomer and early but not la te degradation products.
The mechanism of staphylococcal clumping may consist of 
paracoagulation occurring at the surface of the b a cte ria l w a ll.
The bacteria may be connected by bridges form ed of precip ited 
fibrinogen and its  deriva tives (N iew iarowski and L ip in sk i, 1970), 
The method is  shown diagram atica lly in  F igure 21.
Doubling d ilu tions were perform ed and the re su lt expressed in  
term s of the lowest d ilu tion  giving a c le a rly  positive  clumping 
reaction. This d ilu tion  was in  tu rn  expressed as the negative 
logarithm  to the base 2 ( i.e . 1 /1  0,5; |  1 .0 ; i  2 etc).
Staphylococcal clumping facto r was obtained from  Sigma London
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Chemical Co. L td ., Kingston-upon-Thames, Surrey, England 
(850-10). The sen s itiv ity  of the method, defined as the lowest 
concentration of a standard fibrinogen preparation giving a 
positive reaction was 1.8 -  3, 6 jitg /m l. Th is is  s lig h tly  
d iffe ren t from  the reported values of 0. 38 -  1.5 p g /m l 
(Hawiger et a l . , 1970),
A fte r some experience w ith  th is  technique it  was decided 
that it  was useful as a "screening te s t" fo r fib rin o g e n -fib rin  
re lated p ro te in  in  the void volume fractions of the column eluate. 
As it  was im possible to  use a "standard" soluble complex 
preparation to  quantitate the amount of m ate ria l present, the 
resu lt was expressed in  te rm s of the lowest d ilu tion  g iving a 
c le a rly  positive clum ping reaction. M inor batch to  batch 
va ria tion  in  sen s itiv ity  probably did occur, but th is  was 
accepted. In the present p ro ject it  was found that the SCT 
was less sensitive than the T .R .C .H .I.I. in  m easuring serum 
fib rin o g e n -fib rin  degradation product levels (see Chapter V. 4(b)).
n . 4(m) S ta tis tica l Methods
Three s ta tis tica l techniques were used fo r evaluating the 
resu lts : -
(i) a rithm etic  mean and standard deviation 
(ungrouped data)
( ii)  " t" -s ta tis tic s  fo r significance difference in  mean
( ii i)  lin e a r regression analysis
These were calculated using the Wang Model 600 Program m able 
C alcu lator. P robab ility  leve ls were determ ined using "S c ien tific  
Tables. Documenta Geigy" edited by Diem and Lentner (1970).
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CHAPTER m
PRODUCTION OF SOLUBLE FIBRINOGEN-FIBRIN 
COMPLEXES m VITRO BY A VARIETY OF 
PROTEOLYTIC ENZYMES
HI. 1 Introduction
These in  v itro  experim ents were ca rried  out to  evaluate 
the technique of plasma fibrinogen chromatography, set up as 
described in  Chapter II. 4. The fo llow ing points required to 
be v e rifie d :-
(i) that the technique did separate solutes on a 
m olecular weight basis
( ii)  that the elution position of fibrinogen rem ained 
constant fo r a p a rticu la r column system
( iii)  that soluble complexes and fib rin o g e n /fib rin  
degradation products could be separated (at 
least p a rtia lly ) from  fibrinogen using the gel 
filtra tio n  technique
(iv) that the -alanine prec ip ita tion  step did not 
a lte r the elution characte ris tics of fibrinogen 
and that i t  precip ita ted soluble complexes and 
fib rin o g e n -fib rin  degradation products.
The background lite ra tu re  has already been discussed in  Chapters 
I  and n .
HI. 2 The E ffect of M olecular Weight of the E lu tion Volume
of Solutes
In th is  set of experim ents a number of p u rifie d  standards
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were analysed by the gel filtra tio n  tecim ique. The same gel 
column was used throughout (Column D2, Batch in  gel). The 
d iffe ren t solutes, th e ir m olecular weights and elution volumes 
(Vg), measured by method 1 (see Chapter n . 2) are shown in 
Table 2. The elution curves (optical density at 280 nm) fo r 
four of these solutes are shown in F igure 22. The elution 
volume (Y^) measured by method 1 is  plotted against the 
logarithm  to the base 10 of the m olecular weight fo r a given 
solute in  F igure 23.
It  can be seen that there is  a good negative co rre la tion  
between and the logarithm  to  the base 10 of the m olecular 
weight (r  = -0 .862). I t  can also be seen from  F igure  23 that 
fibrinogen (M .W . 340,000) is  eluted near the centre of the 
fractiona tion range of B iogel A5 m, confirm ing that th is  is  a
good gel medium fo r separating fibrinogen from  deriva tives of
6m olecular weight ) 1 x 10 (soluble complexes) to  ( 83,000 
(Fragm ent D).
Using th is  p a rticu la r gel column the of fibrinogen was 
105 m l. The of fibrinogen was found to vary w ith  d iffe ren t 
gel column system s. W hile m inor varia tions in  height of the 
packed gel columns occurred, the most im portant factor 
appeared to  be the batch of agarose gel. This subject is  
discussed in  de ta il in  Appendix I.
D uring the in it ia l four months of the p ro je c t a packed gel 
column of 2.5 cms diam eter and 40.0 cms height was used 
(to ta l bed volume % 196 m l). Thereafter a packed gel column 
of 2.6  cms diam eter and 35.0 cms height was used (to ta l bed 
volume = 186 m l). The resu lts  obtained during the in itia l 
stages of the p ro ject therefore varied s lig litly  from  those obtained 
la te r on. This was not im portant as these in it ia l resu lts  fo rm  a
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separate group, which w ill now be discussed. This column 
system was labelled Column A1 (Batch I  gel) to  distinguish 
it  from  subsequent column systems,
H I, 3 Comparison of of F ibrinogen w ith  Samples of 
P u rifie d  F ibrinogen, Plasma and a 6 ^alanine 
P rec ip ita te  of Plasma ^
P u rifie d  fibrinogen (Kabi, Grade L ) was analysed using the 
Column A1 (Batch I  gel) system. A representative resu lt is  shown 
in  F igure 24. I t  was obvious from  comparison of the to ta l p ro te in  
( i.e . O .D , trace) and the FR-antigen p ro file  that contaminant 
proteins were present. Th is was consistently found and was in  
keeping w ith  the c lo tta b ility  of 90% reported by the m anufacturers. 
The FR-antigen p ro file  corresponded to  a Gaussian curve and there 
was complete identity w ith  the T .C .T , curve. The of fibrinogen 
fo r th is  packed gel column was 96 m l, A sample of norm al plasma 
analysed under iden tica l conditions is  also shown in  F igure 24, The 
FR-antigenic and T . C. T. p ro file s  overlapped as before and appeared 
at an iden tica l position. The fact that fibrinogen was present at 
th is  position was confirm ed by comparing plasma and serum from  
the same blood sample (see F igure 25). The high concentrations 
of other plasma pro te ins besides fibrinogen was c le a rly  apparent 
from  th is  experim ent.
The effects of introducing the p re lim in a ry  -alanine 
p rec ip ita tion  step is  illu s tra te d  in  F igure 26, A sample of plasma 
from  a healthy volunteer, a jS -alanine p rec ip ita te  of plasma from  
the same donor and the supernatant from  th is  preparation are 
shown. The p rec ip ita tion  step c le a rly  did not a lte r the elution 
cha racte ris tics  of the fibrinogen m ate ria l and it  g rea tly  reduced 
the amount of non-fibrinogen protein . No FH-antigen was found 
in the supernatant. The of fibrinogen was v ir tu a lly  identica l
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in  samples of p u rifie d  fibrinogen, plasma and a -alanine 
p recip ita te  of plasma (Table 3), It can therefore be concluded 
that the of fibrinogen rem ains constant when using the same 
column system and is  not a ltered by the ^  -alanine prec ip ita tion  
step,
III. 4 The Action of Low Concentrations of Throm bin on
F ibrinogen as Demonstrated by Agarose Gel F iltra tio n  
The effect of incubation of fibrinogen w ith  low concentrations 
of throm bin was studied.
Method
25 mg aliquots of fibrinogen (Kabi, Grade L ) were prepared 
and stored at -20^0. F o r each experiment one aliquot (10 m g / 
m l) was incubated w ith  increasing, but nevertheless low 
concentrations of throm bin at 37^C fo r 5 m inutes (see Table 4). 
Heparin was then added in  an attempt to neutra lise the action of 
the throm bin (see Table 4), I t  was appreciated that th is  was 
un like ly  to be ve ry  effective as heparin requ ires antithrom bin 
I I I  (o r heparin cofactor) in  order to neutra lise throm bin. H irud in  
would have been a m ore suitable in h ib ito r, but was not available. 
Insoluble fib r in  did not appear to  fo rm  during the course of these 
experim ents, although the p o ss ib ility  that some insoluble fib r in  
form ation did occur in  the course of gel filtra tio n  cannot be 
excluded. I t  is  now appreciated that prolonged incubation 
(5 i hours) of fibrinogen and low concentrations of throm bin can 
be perform ed w ithout insoluble fib r in  form ation (Bang and Chang,
1974). This would appear to  be the explanation of the lack of 
insoluble fib r in  form ation in  these experim ents, ra the r than any 
neutra lisa tion of the throm bin by heparin. It should be noted 
that the addition of heparin to  fibrinogen did not produce soluble 
complex form ation (see below). Column A1 (Batch I  gel) was 
used.
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Results
The resu lts  of th is  set of experiments are shown in  F igure 
27 (O, D. resu lts ), F igure 28 (T, C, T. resu lts) and F igure 29 
(FR-antigen resu lts ). I t  can be seen that a range of soluble 
complexes was produced fo llow ing throm bin incubation and that 
increased concentrations of throm bin appeared to  produce 
increased concentrations of soluble complex^ The soluble 
complexes were rea d ily  identified  by O. D. traces and by the 
T .C .T . assay* It  appeared that the high m olecular weight 
complex m ate ria l **c lo tted" m ore rap id ly  than an equivalent 
concentration of fibrinogen. Although it  proved possible to 
convert most of the fibrinogen in to soluble complexes w ithout 
insoluble fib r in  fo rm ation before and presumably during the gel 
filtra tio n  stage (see F igure  27h), th is  m ate ria l tended to  "c lo t"  
spontaneously on standing at room  tem perature overnight o r, 
more rap id ly  on cooling to  4^C, It  proved im possible to  
detect th is  m ate ria l using the ra d ia l im m unodiffusion (Mancini) 
technique, as no antigenic m ate ria l at a ll could be identified  in  
tlie  0.2 un it throm bin experim ent (F igure 29h). I t  is  possible 
that complete conversion of fibrinogen to fib r in  monomer had 
occurred in  th is  p a rticu la r experim ent. The ra d ia l immuno­
d iffusion technique is  therefore less suitable than the T . C. T. 
assay fo r detecting these complexes. I t  was therefore decided 
to  pe rfo rm  both assays on a ll p ro te in  containing eluant fractions 
when analysing patient samples. M ore detailed comparisons of 
the T . C. T. and M ancini assays are shown in  F igu re  30.
Conclusions
From  th is  set of experim ents it  was concluded that soluble 
complexes could be produced by the action of low concentrations 
of throm bin and could be p a rtia lly  separated from  fibrinogen by
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the gel filtra tio n  technique. These complexes could be identified
by changes in  the O .D . and the T .C . T. elution curves. The
M ancini technique was not a satisfactory method of identify ing
the very high m olecular weight soluble complexes (polym ers
w ith  V close to V ). e o
III. 5 The A ction of P lasm in on F ibrinogen Demonstrated by 
Agarose G el F iltra tio n
Fibrinogen (Kabi, Grade L ) was incubated w ith  streptokinase 
fo r varying lengths of tim e to activate plasminogen to  plasm in and 
the resu ltan t m ixture  analysed by the gel filtra tio n  technique.
Method
10 m l of fibrinogen (10 m g /m l) was incubated w ith  1,000 
un its of streptokinase (Varidase, Lederle 5-2200) at 37^C. A t 
10, 20, 30, 40 and 120 minutes^a 2 m l sample was removed and 
pipetted in to  sm all p las tic  tubes containing 0,2 mgm of Soybean 
T rypsin  In h ib ito r (Sigma T. 9003) to in h ib it fu rth e r p ro teo lysis. 
Each sample was im m ediately frozen in ethanol-dry ice and 
stored at -20*^C. Samples were then analysed in  tu rn  by the 
gel filtra tio n  technique. Column A1 (Batch I  gel) was used.
Results
The re su lts  of th is  set of experiments are shown in  F igure 
31. Only O .D . traces were obtained, as the aim  of the experiment 
was sim ply to con firm  that fibrinogen degradation products could 
be p a rtia lly  separated from  fibrinogen using gel filtra tio n  (H arder, 
Shulman and C a rro ll, 1969). The resu lts  obtained were s im ila r 
to  those already published by th is  group. The positions of 
fibrinogen and fibrinogen Fragments X, Y , D and E expected 
from  the study of H a rde r and colleagues (1969) are shown in 
F igure  31.
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Conclusion
It was possible to  demonstrate gradual conversion of 
fibrinogen in to  fibrinogen degradation products using the gel 
filtra tio n  technique,
III. 6 The Action of Coagulant and F ib rin o ly tic  Enzymes on
Plasma F ibrinogen -  The S -A lanine P rec ip ita tion
Step
A pool of norm al plasma was collected from  8 healthy male 
donors. The anticoagulant on th is  occasion did not contain 
E. A, C, A , o r apro tin in  as digestion by plasm in was required 
fo r several experim ents. The plasma was divided in to  9 m l 
aliquots and stored u n til required at -20^C.
Ancrod was used instead of throm bin fo r th is  series of 
in  v itro  experim ents as the resu lts  were to  be compared w ith  
those obtained during ancrod infusion in  vivo  (Chapter IV . 4). 
Ancrod (A rv in , B erk Pharm aceuticals L td ., Shalford, Sussex, 
England) is  the th ro m b in -like  defibrinating agent derived from  
the venom of the Malayan p it v ipe r (Agkistrodon o r Ancistrodon 
rhodostoma). A fu ll discussion of its  actions w ill be found in  
Chapter IV . 2. The aim s of th is  set of experim ents w ere :-
(i) to  show that soluble complexes produced in  
plasma could be precip itated w ith  jS -alanine
( ii)  to show that early fibrinogen degradation 
products produced in  plasma could be 
precip ita ted w ith  ^  -alanine
( ill)  to  investigate the effect of combined action of 
coagulant and fib rin o ly tic  enzymes on plasma 
(i. e. ancrod and plasm in respective ly).
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Methods
These are outlined in  Table 5. Incubation of plasma w ith  
enzymes was ca rrie d  out in p lastic  test-tubes in  a 37^C w ater- 
bath* Inh ib ito rs  were added a fte r 1 minute in  the case of ancrod 
and 20 m inutes in  the case of streptokinase. In experim ent c 
the T .C . T. of the incubation m ixture  was prolonged by 7 seconds 
(from  18 to 25 seconds) dem onstrating conversion of fibrinogen 
to early  degradation products. In each case ^  -alanine 
prec ip ita tion  of the fibrinogen related pro te in  was ca rried  out 
as already described (Chapter II. 4(g) ) and gel filtra tio n  perform ed. 
Column B4 (Batch I I  gel) was used.
Results
The O. D. resu lts  are shown in F igure 32, the T . C. T. 
resu lts  in  F igure 33 and the M ancini resu lts  in  F igure 34. The 
overlapping T , C. T. and FB-antigen curves are shown in  F igure 
35. It can be seen that soluble complexes were produced in  
experim ents b and d and probably also in experim ent e. I t  
proved d iffic u lt to  obtain satisfactory data fo r experim ent e as 
very low concentrations of complex were produced. It is  possible 
that a d im er form ed from  the degraded m ate ria l.
As in the set of experim ents described in  Chapter III. 4 the 
O .D. and the T .C .T , curves were good methods of identifying 
the presence of soluble complexes but the ra d ia l im m unodiffusion 
(M ancini) technique seemed to  underestim ate the quantity of 
soluble complex present (especially in  experim ent b).
The s tructu re  of the component un its of the soluble complexes 
was investigated by M r, W illia m  Edgar (U n iversity Department of 
M edicine, Glasgow Royal In firm a ry ) using polyacrylam ide gel 
electrophoresis in  sodium dodecyl sulphate (Weber and Osborn, 1969). 
A fte r cleavage of the disulphide bonds link ing  the chains of the
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component un its using mercaptoethanol, i t  was shown that the 
soluble complexes form ed in  experiment b had in tact C< chain 
and those produced in  experim ents d and e were m arkedly 
deficient in  in tact c< chain, w ith  some samples showing p a rtia l 
loss of in tact 0< -chain.
These experim ents demonstrated;-
(i) that soluble complexes and early fibrinogen 
degradation products form ed in  v itro  can be 
precip ita ted by ^  -alanine and subsequently 
demonstrated by the gel filtra tio n  technique.
( ii)  tha t soluble complexes can contain p a rtia lly  
degraded m ate ria l.
( ii i)  that an early  fibrinogen digest can only fo rm  
soluble complexes a fte r treatm ent w ith  a 
coagulant enzyme.
Soluble Complex Form ation Follow ing the L ys is  of Insoluble 
F ib rin
One fu rth e r experim ent was perform ed to  con firm  that low 
concentrations of soluble complex could be form ed fo llow ing the 
lys is  of insoluble fib r in .
Method
10 m l of plasma was prepared using 0.13 M trisod ium  
c itra te  as anticoagulant. This was cooled to  4*^ C in  an ice - 
bath and 100 un its of throm bin (0.1 m l volume) added (i. e. 9.9 
u n its /m l). As the clo t started to  fo rm  25 un its of p a rtia lly  
p u rifie d  plasm in (Kabi 67233, volume 0.2 m l) was added 
(i, e. 2,4  u n its /m l). The c lo t was then incubated at 37 
and inspected fo r ly s is , which was complete at 45 m inutes. 
Digestion was continued fo r a fu rth e r 10 m inutes and then
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10,000 K . Î.U . (1 m l volume) of aprotin in  was added to  inh ib it 
fu rth e r pro teo lys is (i, e. fin a l concentration 885 I i ,  I. Ü, /m l) . 
The reaction m ixture  was precip itated w ith  ^  -alanine and 
gel filtra tio n  perform ed. Column BIO (Batch I I  gel) was used 
fo r th is  experim ent,
K esults
V ery low concentrations of fibrinogen re la ted p ro te in  were 
recovered (F igure 36), however, the m ixture c le a rly  contained 
soluble complexes and degradation products. The void volume 
fraction  form ed sm all w isps of " f ib r in "  on prolonged incubation 
w ith  throm bin (24 hours). I t  also had a staphylococcal clumping 
test t it re  of ^  8.
I t  can therefore be concluded that low concentrations of 
soluble complex can foe form ed in  an early  insoluble fib r in  lysate. 
S im ila r resu lts  have been reported (von Hugo and G raeff, 1973).
I l l ,  7 Conclusions
These experim ents confirm ed the points outlined in  the 
in troduction to  th is  chapter and confirm ed the va lid ity  of the gel 
filtra tio n  technique fo r the separation of fibrinogen and its  proteo­
ly s is  products.
(i) The technique separated solutes on a m olecular 
weight basis,
( ii)  The V^ of fibrinogen remained a constant fo r a 
p a rticu la r column system. There was some 
va ria tio n  between d iffe ren t packed gel columns 
(see Appendix I),
( ii i)  Soluble complexes and fib rin o g e n /fib rin  degradation 
products were p a rtia lly  separated from  fibrinogen 
using the tecimique.
(iv ) The ^-a lan ine  p rec ip ita tion  step did not a lte r
â -alanine precip ita ted 
soluble complexes and degradation products as
the of fibrinogen.
w e ll as fibrinogen.
The biochem istry and structure  of the soluble complexes 
was not studied in  de ta il, as th is  thesis is  concerned w ith  the 
iden tifica tion  of these complexes in  c lin ica l conditions ra ther 
than th e ir com position. I t  was noted that the action of a 
coagulant enzyme (throm bin o r ancrod) was requ ired fo r the 
production of soluble complexes. Three methods of production 
were dem onstrated:-
(1) the incubation of fibrinogen w ith  low concentrations 
of a coagulant enzyme
(2) the incubation of early  fibrinogen degradation 
products w ith  a coagulant enzyme
(3) the ly s is  of insoluble fib rin .
Only low concentrations were produced by methods 2 and 3.
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CHAPTER rv
SOLUBLE Fm RlNQGEN-FIBRIN COMPLEXES 
DURING THERAPEUTIC DEFIBRINATION 
INDUCED BY ANCROD INFUSION
IV . 1 Introduction
The acute de fib rina tion state induced by infusion of ancrod 
(a p u rifie d  fra c tio n  of venom from  the Malayan P it V iper) provides 
a means of studying fib r in  form ation in  v ivo . I t  m ust, however, 
be remembered that th is  fo rm  of widespread in travascu la r 
coagulation d iffe rs  c lin ic a lly  from  other fo rm s because of its  
apparently benign nature.
It  had already been demonstrated that soluble complexes 
could be produced in  v itro  by incubation of plasma w ith  ancrod 
(Chapter III .  6). It  therefore seemed probable that soluble 
complexes would also fo rm  in  vivo during the in it ia l stages of 
ancrod therapy. W hile the present study was in  progress two 
papers were published showing soluble complex form ation in  vivo 
during treatm ent w ith  Defibrase (Reptilase) a ra the r s im ila r 
de fib rina ting agent also derived from  a snake venom (B la ttle r, 
Straub and Peyer, 1974; Asbeck, Lechler and M a rtin  et a l. ,
1975).
A  group of patients rece iving ancrod (A rv in ) infusion were 
therefore studied to con firm  that the gel filtra tio n  technique could 
iden tify  soluble complexes produced in  v ivo . I t  was hoped also to 
learn  m ore about the form ation and structure  of these soluble 
complexes.
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In order to  evaluate the resu lts  that were obtained it  is  
necessary to f ir s t  discuss what is  known about the actions of 
ancrod in  v itro  and in  v ivo .
IV . 2 The E ffects of Ancrod 
IV . 2(a) H is to rica l Introduction
Since Fontana noted in  1787, that the blood remained flu id  
in anim als that had died fo llow ing the b ite  of certa in  species of 
v ip e r, the re la tion  of snake venoms to coagulation and haemorrhage 
has been studied by many w orkers. Mellanby (1909) suggested that 
v ipe r venom defibrina tion was caused by in  vivo  by conversion of 
fibrinogen to fib r in  which was then removed from  the c ircu la tion .
A part from  loca l pain and swelling patients b itten  by the 
Malayan p it v ipe r (Agkistrodon or Ancistrodon rhodostoma) 
rem ain rem arkably w e ll (Heid, Chan and Thean, 1963; Beid and 
Chan, 1968), Serious haemorrhage does not occur even the 
severest cases despite to ta lly  incoagulable blood. These 
observations suggested that the p u rifie d  coagulant fra c tio n  of 
the snake venom m ight be usehil as an "anticoagulant" in  the 
treatm ent of throm botic disease. This frac tio n  of the venom 
was isolated and studied by Esnouf and Tunnah (1967), The 
approved name of th is  frac tio n  is  "ancrod". I t  is  manufactured 
under the trade name "A rv in " by B erk Pharm aceuticals L td , 
(Shalford, Surrey, England). The te rm  "ancrod" w ill be used 
throughout th is  chapter,
A s im ila r venom deriva tive  "D efibrase" (or "R eptilase"), 
is  manufactured by Pentapharm L td , (Basel, Sw itzerland), It is 
derived from  the venom of Bothrops atrox and is  also used 
therapeutica lly as a de fib rina ting  agent.
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IV . 2(b) The Action of Ancrod on the Coagulation Pathway
Ancrod has a th rom b in -like  action on fibrinogen In v itro  
releasing fibrinopeptide A and two sm all fibrinopeptide fragm ents 
AP and AY from  each A oC chain, but un like throm bin ancrod does 
not release fibrinopeptide B (Holleman and Coen, 1970; Ew art, 
Hatton, Basford et a l. , 1970). It has been suggested that 
rem oval of fibrinopeptide A allows end-to-end polym erisation 
w hile  s ide-to -s ide  o r la te ra l aggregation occurs only when 
fibrinopeptide B is  also removed (Laurent and Blom back, 1958).
Ancrod can cause m ore extensive digestion of the CA chain 
in  v itro  re leasing a single polypeptide (or a group of polypeptide 
fragm ents) w ith  a (to ta l) m olecular weight of 31,000, the rem aining 
portion  of the Oi chain having a m olecular weight of 39,000 (Mattock 
and Esnouf, 1971; Edgar and P rentice , 1978). It is  not known 
whether th is  0< chain digestion occurs hi vivo during therapeutic 
de fib rina tion but a Cohn F raction  Î  preparation of pooled plasma 
from  patients during a course of ancrod therapy did demonstrate 
extensive loss of in tact (X chain (Barlow , Lazer, F in ley et a l, ,
1973). It was suggested that th is  was caused by ancrod its e lf but 
could, of course, also have been caused by other p ro teo ly tic  
enzymes (e, g. p lasm in). I t  is  probable that the concentration of 
ancrod in  the plasma of such patients is  too low to  produce 
extensive oC chain digestion (Gaffney and B rasher, 1974).
It is  possible that com m ercia l preparations of ancrod activate 
other coagulation factors e. g. Factor X III (Mattock and Esnouf,
1971). These additional effects may be due to  im p u ritie s  in  the 
preparation ra th e r than due to the ancrod itse lf.
IV . 2(c) The Action of Ancrod on P latele ts
Ancrod therapy does not appear to  a lte r p la te le t numbers, th e ir 
a b ility  to adhere to  glass o r to  aggregate under the influence of
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adenosine diphosphate (B e ll, P itney, Goodwin, 1968). A la te r 
rep o rt demonstrated a dim inished response to adenosine diphosphate 
induced p la te le t aggregation during the f ir s t  24 hours of therapy 
(P rentice, Hassanein, Turp ie et a l. , 1969). This was attributed 
to  the very high leve ls of fib r in  degradation products at th is  stage 
of therapy and not to  a d ire c t action of ancrod. I t  has been 
confirm ed that the fib r in  degradation products form ed from  
an cro d -fib rin  in  v itro  do in h ib it both the f ir s t  and second phases 
of adenosine diphosphate induced p la te le t aggregation (Kwaan,
Barlow  and Suwanwela, 1978).
IV . 2(d) The A ction of Ancrod on the F ib rin o ly tic  Pathway
In v itro  studies have shown that ancrod does not activate 
plasminogen d ire c tly  o r enhance the activa tor effect of strepto­
kinase on plasminogen, in  addition, ancrod has no d ire c t ly tic  
a c tiv ity  on fib r in  plates and no significant ly tic  effect on 
experim ental th rom bi in  the Chandler tube (Turp ie , P rentice, 
M cN icol et a l. , 1971).
However, when ancrod is  adm inistered to  patients there is  
a rap id  fa ll in  plasma plasminogen concentration (B e ll et a l. ,
1968). There is  also a m in im al, but inconstant increase in  the 
c ircu la ting  leve ls of plasminogen activa tor but c ircu la tin g  plasm in 
cannot be detected (P itney, B e ll and Bolton, 1969). Increased 
tissue fib rin o ly tic  a c tiv ity  in  the lung and liv e r has been observed 
using histochem ical techniques fo llow ing ancrod in jection  in m ice 
(Silberman, P otter and Kwaan, 1971). It has been suggested that 
both plasminogen and activa tor are adsorbed onto the surface of 
fib r in  m ic ro -c lo ts  produced by ancrod w ith  loca l release of 
plasm in causing ly s is  of the fib r in  and the appearance of fib r in  
degradation products (P itney et a l. , 1969).
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The insoluble fib r in  produced by ancrod may be more 
susceptible to  p lasm in induced ly s is  than the insoluble fib r in  
produced by throm bin (Kwaan and Barlow , 1971; Kwaan et a l. ,
1973). The low er m olecular weight fib r in  degradation products 
are produced more rap id ly  from  an crod -fib rin  than throm bin- 
fib r in . The increased susceptib ility  to lys is  was shown not to 
be re la ted to  the fact that the ancrod-^fib rin  was non-crosslinked 
and it  the re fore  was suggested that the lack of s ide-to -s ide  
po lym erisation in  the an crod -fib rin  (due to  the presence of 
fibrinopeptide B) le ft the bonds susceptible to plasm in ly s is  
more read ily  available fo r cleavage (Kwaan et a l. , 1973). h i 
addition ancrod its e lf m ight attack the (X chain i f  present in  high 
enough concentration, although th is  is  un like ly  in  the therapeutic 
situation (Gaffney and B rasher, 1974), The actual s tructure  of 
the fib r in  degradation products form ed during ancrod therapy is  
s im ila r to  those produced by plasm in on fibrinogen (P rentice,
Edgar and M cN icol, 1974).
The relevance of these observations to  fib rin o ly s is  in  patients 
undergoing therapeutic de fibrina tion rem ains to  be assessed. 
F ib rin o lys is  is  presum ably ve ry  im portant in  such patients, as 
anim als treated w ith  E .A .C . A , o r soybean tryp s in  in h ib ito r p r io r 
to  ancrod in jection  show extensive in travascu lar c lo t form ation at 
post-m ortem  (Eegoeczi, Gergely and M cFarlane, 1966) and if  they 
survive long enough develop m icroangiopathic haem olytic anaemia 
(Hubenberg, Begoeczi, B u ll et a l.,  1968),
IV . 2(e) The A ction of Ancrod on the R eticuloendothelia l System
Ancrod also appears to  cause a rapid, pronounced stim ulation 
of the re ticu loendothelia l system in  rabbits (Ashford and Bunn, 1970). 
This appears to  be unrelated to  its  coagulant action on fibrinogen and 
m ight involve another venom deriva tive  besides ancrod. This 
stim ulant effect may involve a d irec t action on phagocytic ce lls
and an effect on co llo ida l pa rtic le s  v ia  serum opsonins. I t  is  
not known whether a s im ila r action occurs in  man tout there may 
be a species va ria tio n  in  th is  respect, as con flic ting  resu lts  
have been published using crude venom in  the dog (Esnouf and 
M arsha ll, 1968),
IV , 2(f) Comparison of Ancrod and Defibrase (Reptilase)
The action of Defibrase (Reptilase) on fibrinogen is  very 
s im ila r to  that of ancrod^in that it  also removes fibrinopeptides 
A , AP and Y but not fibrinopeptide B (Blomback, 1958). It seems 
to have a s im ila r in vivo  action to ancrod in  experim ental anim als 
(Egberg and N ordstrom , 1970) and when adm inistered therapeutica lly 
to human patients (Egberg, 1973). F X III concentrations fa ll during 
Defibrase therapy (Egberg, 1973), and it  would appear that activation 
of F X III is  m ore pronounced than during ancrod therapy.
XV. 2(g) The Action of Ancrod in  Producing Therapeutic D efibrination 
On the basis of studies in  rabbits using crude venom and rad io ­
a c tiv ity  labelled fibrinogen,Begoeczi and colleagues (1966) suggested 
that the venom rap id ly  converted in travascu lar fibrinogen in to 
insoluble fib r in  m ic ro -c lo ts , which tem pora rily  were trapped in  the 
sm alle r vessels of various organs. These m ic ro -c lo ts  were 
demonstrated both by conventional histology and by autoradiography.
It  was thought that they were rap id ly  lysed by the fib rin o ly tic  system. 
It has been generally accepted that a s im ila r sequence of events 
occurs during therapeutic de fibrina tion induced by a slow intravenous 
infusion of ancrod (P itney et a l. , 1969; Prentice et a l. , 1974). The 
slow ra te  of ancrod infusion is  thought to resu lt in the form ation of 
m ic ro -c lo ts  at a ra te , which is  w e ll w ith in  the capacity of the defense 
mechanisms to remove them from  the c ircu la tion .
The re la tive  and interdependent ro les of the reticu loendothelia l 
and fib rin o ly tic  systems in th is  respect are incom pletely understood.
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Local release of plasminogen activa to r from  the vascular endothelium 
would seem to be im portant (P itney et a l, , 1909; S ilberm an et a l, , 
1971), The ease w ith  which ancrod m ic ro -c lo ts  are cleared from  
the c ircu la tion  probably re fle c ts  the in s ta b ility  of f ib r in  which 
re ta ins fibrinopeptide B (Kwaan et a l. , 1973), The lack of a d irec t 
action of ancrod on p late lets and the im paired p la te le t aggregation 
during ancrod therapy may prevent incorporation of p la te le ts into 
fo rm ing m ic ro -c lo ts  contributing to th e ir in s ta b ility  (P rentice et a l. ,
1969).
M ore recently it  has been suggested that, in  the therapeutic 
situation, ancrod does not cause the deposition of insoluble fib r in  
(Gaffney and B rasher, 1974). i t  was instead suggested that the 
fib rin o ly tic  system attacked the fib r in  w hile it  was s t il l in  the 
soluble fo rm . Gaffney and Brasher (1974) produced in d irec t 
evidence to  suggest that ancrod in  therapeutic concentrations 
converts prothrom bin to  throm bin in  v itro  and that the throm bin 
in its  tu rn  activates Factor X llla . These authors have never 
observed D -d im er o r % d im er in  the plasma of patients treated 
w ith  ancrod and they therefore suggested that the fib r in  form ed by 
ancrod is  digested by the fib rin o ly tic  system w hile  it  is  s t ill soluble 
before there is  tim e  fo r crosslink ing  and insoluble fib r in  deposition 
to  occur (F igure 37).
Much of th is  theory rem ains unproven but it  presents an 
in te resting  a lte rna tive  pathway fo r the form ation of fib r in  degradation 
products during ancrod therapy and may have w ider im p lica tions. A 
number of anim al experim ents support th is  theory. Ancrod infusion, 
in  a dose of 1.5 U /K g , does not appear to  generate h is to log ica lly  
demonstrable g lom eru la r m ic ro -c lo ts  in  rabb its (M uller-Berghaus 
and Hocke, 1972). Detailed studies of the m ic ro c ircu la tio n  in  the 
mesentery, in testina l w a ll and th in  abdominal muscles, in  rabb its.
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cats and ra ts  (Hauck, 1975) fa iled  to show any disturbance during 
ancrod infusion in  "therapeutic" doses (2-3 u n its /K g ). Only when 
the dose of ancrod was increased (4-8 U /K g ) did m ic ro -c lo t form ation 
occur.
Therefore it  would seem possible that m ic ro -c lo ts  do not fo rm  
when low doses of ancrod are adm inistered. This would help to 
explain why the acute de fib rina tion state induced by ancrod infusion 
is  so "benign". Whether the m ic ro -c lo ts  fa il to  fo rm  because of 
selective rap id  fib rin o ly s is  of soluble fib r in  (complexes) according 
to Gaffney and Brasher*s theory or because of some other defense 
mechanism (e. g. the re ticu loendothelia l system) rem ains uncertain.
The w ork of Konttinen, L a lla  and Turunen (1973) does suggest that 
the fib rin o ly tic  system has an essentia lly higher a ffin ity  fo r fib r in  
monomer than fibrinogen, Streptokinase was used as the plasminogen 
activa tor in  these experim ents and extrapolation of th e ir conclusions 
to the in  vivo  situation has been c ritic is e d  by L ip in sk i and Gurewich 
(1976a) because of the differences between natura l and a r tif ic ia l 
plasminogen activa tors (see discussion Chapter 1.3(b) ). The w ork 
of Gurewich, L ip in sk i and colleagues is  ce rta in ly  opposed to the rap id 
selective ly s is  of soluble fib r in  suggested by Gaffney and Brasher (1974).
The in itia l stages of defibrination induced by ancrod infusion 
therefore rem ain incom pletely understood. It is  not certa in  whether 
insoluble fib r in  m ic ro -c lo ts  fo rm  in  th is  situation but ^ nevertheless, it  
provides a c lin ic a l model of widespread in travascu lar coagulation 
according to the de fin ition  used fo r th is  thesis. The opportunity 
was there fore  taken to  study 7 such patients using the plasma 
fibrinogen chromatography technique.
IV . 3 Design of C lin ica l Study
The c lin ica l deta ils fo r the seven patients studied are summarised 
in Table 6. There were five  males and two females in  the group w ith
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an age range of 22-72 years, Four patients were suffering from  
established loca l venous throm bosis and three from  severe periphera l 
a rte ria l disease. Ancrod (A rv in , B erk Pharm aceuticals L im ited , 
Shalford, Sussex, England) was adm inistered as a constant in tra ­
venous infusion in  a dose of 2 u n its /K g  body w e ig h t/12 hours. No 
anticoagulant or fib rin o ly tic  agent was given during the period of 
study. Blood samples were coUected from  a ll patients before 
s ta rting  treatm ent and a fte r 6 and 24 hours ancrod infusion. In 
some cases additional blood samples were collected. Columns B1 
(Batch I  gel), B2 (Batch I  gel) and B3 (Batch I  gel) were used fo r 
th is  study.
rv , 4 Results
IV . 4(a) C lot Q uality Observation Test (Chapter IL  4 (d ))
In a ll of the patients the pre-treatm ent samples were norm al 
(Grade 1 c lo t). A fte r 0 hours ancrod infusion the c lo t remained 
Grade 1 o r 2. A fte r 24 hours infusion the blood was com pletely 
incoagulable (Grade 5).
IV . 4(b) Plasma F ibrinogen and Serum F D P /fdp  leve ls
The plasma fibrinogen levels fe ll sharply fo llow ing the s ta rt 
of ancrod infusion (Table 7). S ignificantly low er leve ls were found 
a fte r 6 hours therapy. A fte r 24 hours therapy the assay recorded 
v irtu a lly  zero leve ls. There was, however, a degree of individual 
va ria tio n  in  the ra te  at which the patients reached very low fibrinogen 
leve ls e. g. Patients 3 and 7 were alm ost com pletely "de fib rina ted" 
a fte r 6 hours therapy.
The serum F D P /fdp  leve ls, as measured by both the tanned 
red ce ll haemagglutination inh ib ition  immunoassay (Table 8a) and the 
staphylococcal clum ping test (Table 8b), showed a highly significant 
ris e  6 hours a fte r the s ta rt of ancrod infusion. There was no 
sign ifican t difference in  the resu lts  recorded a fte r 6 and 24 hours 
ancrod therapy. There was a highly s ign ificant positive co rre la tion
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(r = 0.964; 2 c<<0.001) between the two methods fo r measuring
serum FDP /  fdp.
IV .4 (c) Plasma F ibrinogen Chromatography
The optical density tracings fo r a typ ica l patient (W. McG.
No. 7) are shown in  F igure 38. It can be seen that as the amount 
of pro te in  in  the elution position of fibrinogen decreased there was 
a corresponding increase in  p ro te in  in  the elution position of soluble 
complexes. I t  was necessary, however, to con firm  that th is  m ate ria l 
was fib rinogen-re la ted .
The FK -antigen elution p ro file s  from  two typ ica l patients are 
shown in  F igure 39a and b. I t  can be seen that a fte r 6 hours ancrod 
infusion a range of soluble complexes and degradation products had 
form ed. A fte r 24 hours ancrod infusion very lit t le  fib rinogen-re la ted  
pro te in  remained but soluble complexes and degradation products were 
s t ill present*
Overlapping T .C .T . and FR-antigen curves fo r two fu rth e r 
patients a fte r 8 hours treatm ent are shown in  F igure 40. The 
fractions showing c lo t form ation a fte r 24 hours incubation w ith  
throm bin (T, C. P. ) are also indicated. It can be seen that, as in 
the in  v itro  experim ents, the soluble complexes w ill c lo t w ith  throm bin 
(Chapter HI. 4 and 8) although the very short tim es observed in v itro  
were not found in  v ivo . A double peak was invariab ly noted in  the 
T .C .T . curve. A fte r 24 hours ancrod infusion no fib rinogen-re la ted  
pro te in  w ith  a recordable T. C. T. was identified.
I t  is  probable that the ra d ia l im m unodiffusion (M ancini) 
technique underestim ated the amount of soluble complex present to 
some extent, but com parison w ith  the O. D. traces suggested that 
th is  was less marked than in  the case of the in  v itro  experim ents 
(Chapter I II .  4 and 8). The FR-antigen concentration on the void 
volume (Vq) frac tions in  samples from  4 patients measured by the 
ra d ia l im m unodiffusion (M ancini) technique and by the SCT t itre
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(Chapter IL  4(1) ) are shown in  Tables 9a and b. There was a 
s ign ifican t positive co rre la tion  (r  ”  0.804; 2 o( (0,01) between 
the resu lts  measured by the two methods. I t  can be seen that 
the FR-antigen concentration, measured by both methods rose 
s ign ifican tly  a fte r 6 hours ancrod infusion, but that there was 
no sign ifican t difference between the 6 and 24 hour values. It 
w ill also be noticed that one patient (No. 8) had a high p re ­
treatm ent value.
Areas m , n and p (Chapter II.  4(k) ) were measured in  
samples from  5 patients. (The rem aining two patients were 
studied ve ry  ea rly  in  the p ro ject and the separation was not good 
enough fo r analysis). It can be seen from  Tables 10, 11 and 12 
that, a fte r 8 hours ancrod infusion, there were sign ifican t 
increases in  area m and area p values and a s ign ifican t decrease 
in  area n values. There were no significant differences between 
the 0 and 24 hour measurements. This was because percentage 
ra the r than absolute values were used fo r, c le a rly , the absolute 
values had fa llen  a fte r 24 hours treatm ent (see F igure 39). There 
was a degree of ind ividual va ria tion  in  the pattern of changes found 
in  the five  patients. Th is becomes more obvious on looking at the 
scatter of resu lts  fo r areas m and p shown in  F igures 41 and 42.
The FR-antigen ra tio  (Chapter II.4 (k )), the T .C .P . ra tio  
(Chapter I I .4 ( i) ) and the T .C . T . ra tio  (Chapter I I .4 ( i) ) were also 
calculated and the resu lts  are shown in  Tables 13, 14 and 15 
respective ly. The FR -antigen ra tio  fe ll s ign ifican tly  a fte r 8 
hours ancrod infusion, but there was no sign ificant d ifference 
between the 6 and 24 hour resu lts  (Table 13). The T .C ,P . ra tio  
did not a lte r s ign ifican tly  a fte r 6 hours treatm ent (Table 14) but 
the T .C .T . ra tio  did show a highly significant decrease (Table 15). 
(It was not possible to  calculate resu lts  fo r the T . C. P. o r T. C. T.
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ra tio s  on the 24 hour resu lts  as no recordable T .C . T. was found 
in any fractions).
It can therefore be concluded that a range of soluble 
complexes are produced during ancrod infusion. A dditional 
in form ation about these soluble complexes was obtained by 
M r. W illia m  Edgar, who studied th e ir component un its using 
polyacrylam ide gel electrophoresis in  sodium dodecyl sulphate 
(see F igures 43 and 44). The component units had a m olecular 
weight s lig h tly  less than that of fibrinogen, s im ila r to  a m in im a lly  
degraded early fibrinogen Fragm ent X  or fib r in  Fragm ent x 
(F igure 43), A fte r reduction of the disulphide bonds w ith  
mercaptoethanol it  was found that the units in  the soluble 
complexes lacked in tact OC chain (F igure 44). These soluble 
complexes were therefore s im ila r to those produced in  v itro  by 
the action of both ancrod and plasm in on the fibrinogen of plasma 
(Chapter III. 6). I t  is  w orth also noting that no o<chain fragm ent 
of m olecular weight 39,000 was identified , suggesting that ancrod 
was not responsible fo r the ^  chain digestion. In addition no 
dim er or c< polym er was found, suggesting that no crosslin lclng by 
F X llla  had occurred.
IV . 6 Discussion
This study demonstrated that ancrod infusion resu lts  in  
the form ation of a range of soluble complexes in  v ivo . These 
complexes were read ily  demonstrated using the plasma fibrinogen 
chromatography technique. This was encouraging, as it  suggested 
that soluble complexes form ed in other c lin ica l conditions m ight also 
be demonstrated using th is  method.
The p o ss ib ility  that these soluble complexes were form ed 
in  v itro  has to be seriously considered. A low concentration of 
ancrod would be present in the blood sample. Throm bin or plasm in
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m ight also have been form ed due to activation of precursors at 
the tim e of blood sam pling. Inh ib ito ry concentrations of ancrod 
antiserum , S, A. C. A . and apro tin in  were added w ith  the an ti­
coagulant used in  preparing the plasma, but these may not have 
neutralised active enzyme im m ediately fo r even a delay of a few 
seconds m ight have been suffic ient to allow some enzyme action 
in  v itro .
It is  also possible that cooling from  was responsible 
fo r the soluble complex form ation as suggested by B la ttle r and 
colleagues (1974) w ith  reference to soluble complexes form ed 
during Defibrase therapy. It is  true , however, that soluble 
complexes were not found in  high concentrations in  plasma 
samples from  norm al individuals (Chapter V. 4(c) ). In the 
in v itro  experim ents soluble complexes were only form ed 
fo llow ing the action of a coagulant enzyme (Chapter III. 7).
These observations would suggest that the presence of soluble 
complexes in  plasma does re fle c t the action of a coagulant enzyme 
in  conversion of fibrinogen to  soluble fib r in  monomer. Whether 
th is  soluble fib r in  monomer takes pa rt in  soluble complex production 
in  vivo  at 37^C rem ains unproven, but it  is  c le a rly  im portant to 
appreciate that it  may not do so.
Soluble complexes deficient in in tact o( chain could theore tica lly  
be produced in  a number of ways:
(i) D igestion of chain by ancrod its e lf
High concentrations of ancrod progressive ly attack the 
chain of fibrinogen in  v itro  (Mattock and Esnouff, 1971; Edgar and 
P rentice, 1973), however, the concentrations of ancrod required to  
produce th is  digestion are much higher than those lik e ly  to be 
present therapeutica lly (Gaffney and B rasher, 1974). In addition, 
i f  ancrod were responsible fo r the o( chain digestion the cx chain 
fragm ent of M . W. 39,000 should be present (Edgar and P rentice,
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1973) and th is  was not identified in  the present study.
It  would therefore  seem more probable that the o( chain 
digestion was caused by some other p ro teo lytic  enzyme. In view 
of the marked plasminogen depletion which occurs during the early 
stages of ancrod infusion (P itney et a l. , 1969) it  seemed lik e ly  that 
plasm in was responsible fo r the o( chain loss,
( ii)  D igestion of the o ( chain by plasm in
The method of plasminogen activation during ancrod therapy 
is  unknown. W liile  plasm in w ill attack fibrinogen, soluble fib r in  
monomer and insoluble fib r in  in v itro , i t  is  uncerta in whether it  
w ill also attack a ll these substrates in  vivo (see discussion on 
fibrinogenoly s is /fib r in o ly s is  in  v ivo , Chapter 1.3(c) ). The 
component un its in  the soluble complexes were s im ila r to  early 
fib rinogen Fragm ent X  or fib r in  Fragment x . Presum ably at 
least some of the un its lacked fibrinopeptide A (due to ancrod 
action) or they would not have been able to fo rm  complexes.
E arly  fib r in  Fragm ent x could be form ed in such circum stances 
by:
(a) the action of ancrod on early fibrinogen Fragment X, 
which was form ed by the action of plasm in on fibrinogen,
(b) the action of plasm in on Insoluble fib r in  m ic ro -c lo ts , 
which were form ed by the action of ancrod on fibrinogen,
(c) the action of plasm in on soluble fib r in  monomer (e ither 
uncomplexed o r complexed), which was formed by the action of 
ancrod on fibrinogen.
The early fib r in  Fragment x could then c ircu la te  in  complex 
fo rm  u n til fu rth e r digestion by plasm in destroyed the rem aining 
po lym erisation sites (which must be on the ^  chain). The complex 
would then break up into uncomplexed fib r in  degradation products 
(F igure 45).
The resu lts  of the experim ents described in  th is  chapter 
cannot d istinguish between these pathways. A ll three pathways 
can be shown to  operate in  v itro  (Chapter ICI. 6). Although (a)
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and (b) only caused sm all amounts of soluble complex in  these 
in  v itro  experim ents it  is  possible that in  vivo w ith  a constant 
supply of native fibrinogen, th is  would enter the complexes and 
m ight increase th e ir concentration (F letcher and AHqaersig,
1072).
%V. 0 Conclusions
It can be concluded that the gel filtra tio n  technique (set up 
as described in Chapter II, 4) w ill demonstrate soluble complexes 
in  plasma samples from  patients in  whom in travascu lar coagulation 
was induced by ancrod infusion. These soluble complexes m ight 
not be present in  v ivo  but appear to re fle c t enzymic action by a 
coagulant enzyme. Steps were taken to  try  to  prevent any in v itro  
enzymic action alüiough th is  cannot be completely excluded.
The soluble complexes, which were form ed, could have 
derived from  e ither soluble or insoluble non-crosslinked fib rin .
They certa in ly  could have form ed w ithout the production of insoluble 
m ic ro -c lo ts  according to the theory of Gaffney and B rasher (1974).
It is  not yet certa in  whether F X III activation occurs during ancrod 
therapy and, I f  i t  does, whether F X llla  w ill only cross link  insoluble 
fib r in  as suggested by these authors. If these suppositions are 
co rre c t, the resu lts  described in th is  chapter would be in  favour 
of th e ir theory that m ic ro -c lo ts  do not form  during therapeutic 
ancrod infusion. The theory rem ains highly speculative.
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CHAPTER V
SOLUBLE FIBBINOGEN-FIBRIN COMPLEXES IN 
NORMAL PREGNANCY AND PRE-ECLAMPSIA
V, 1 Introduction
The cen tra l a im  of the fibrinogen chromatography pro ject 
was to  study plasma samples from  women w ith  pre-eclam psia and 
th is  work w ill be described in  the next two chapters. It  has been 
suggested that in travascu la r coagulation plays a p a rt in  the patho­
genesis of pre-eclam psia and the background lite ra tu re  in  support 
of th is  idea w ill be reviewed in  the f ir s t  pa rt of th is  chapter (V. 2),
In the second pa rt of th is  chapter (V. 3 and 4) the in itia l study in  the 
present p ro ject w ill be described. In th is  study plasma samples 
from  10 pre -eclam ptic patients are compared w ith  those from  10 
age, p a rity  and gestation matched norm al pregnant women and 10 
age matched non-pregnant women.
P re-eclam psia is  a useful c lin ica l model because patients 
can be followed through th e ir illness to  the phase of recovery during 
the puerperium . The resu lts  of sequential studies in  s ix p re ­
eclam ptic patients w ill be discussed in  de ta il in  Chapter V I. 2.
In Chapter V II. 2 the plasma fibrinogen chromatography 
findings in  norm al pregnancy w ill be presented in  more de ta il. The 
resu lts  from  samples from  patients suffering from  conditions closely 
related to  pre-eclam psia w ill also be described. These related
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conditions include in trau te rine  growth re ta rdation (Chapter V II, 3), 
essential hypertension in  pregnancy (Chapter V II. 4) and also 
chronic rena l disease in  pregnancy (Chapter V II. 5). Conclusions 
from  the obste trica l studies and from  a fu rth e r study in  women 
taking oestrogen-containing o ra l contraceptive therapy (Chapter 
VIH. 2) w ill be discussed together in  Chapter IX*
pre -ec lam psia  is  an in te resting obste trica l syndrome, 
which, although it  has engaged the attention of research w orkers 
w ith  w idely varying in te rests fo r many years, nevertheless 
rem ains a "disease of theories" of unknown p rim a ry  aetiology 
(Jeffcoate, 1966). Confusion surrounds even the nomenclature 
and de fin ition  of th is  syndrome. The old te rm  "toxaem ia of 
pregnancy" was c ritic is e d  by Strauss (1939) as "a  diagnostic 
waste basket" and the same c ritic is m  could probably be raised 
to  the use of the te rm  "pre-eclam psia" today.
H ippocrates in  the 5th century B .C . noted that "drow siness, 
fits  and coma" were of serious prognostic im portance in  a pregnant 
woman, but the actual te rm  "eclam psia" was f ir s t  introduced by 
Varandeus in  1619. It is  derived from  the Greek word fo r a 
"fla sh " because many such patients complain of seeing "flash ing  
lig h ts " before the onset of a seizure. In 1843 Lever reported 
that p ro te inuria  was present in  patients w ith  eclam psia and th is  
led to  the recognition of a "p re -ec lam ptic  sta te".
I t  was believed fo r many years that the placenta manufactured 
a specific tox in , which was responsible fo r both pre-eclam psia and 
eclampsia (Holland, 1909) and th is  concept led to  the use of the 
te rm s "toxaem ia of pregnancy" o r "p re -ec lam ptic  toxaemia 
(P. E. T . )", A toxin  has never been discovered, so it  is  
preferab le to  use the te rm  "p re-eclam psia" to  describe a 
c lin ic a l state which can po ten tia lly  progress to  eclam psia.
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A precise , generally acceptable de fin ition  of pre-eclam psia 
has not yet been reached and d iffe ren t c lin ica l c r ite r ia  have been 
used (Campbell, 1976). The main features of th is  syndrome are 
system ic hypertension, p ro te inuria  and oedema, which develop 
during pregnancy and resolve fo llow ing de livery. The differences 
in  de fin ition  lie  in  the degree of abnorm ality required to  make a 
diagnosis. Oedema is  d iffic u lt to quantitate and is , in  any case, 
present in  40% of norm al pregnant women (Thomson, Hytten and 
B illew icjs, 1967). The diagnosis of pre-eclam psia is  usually 
made, therefore , on the basis of sustained hypertension and 
p ro te inuria  developing during the second ha lf of pregnancy (Page, 
1972).
An e d ito ria l in  The Lancet (1975) suggested the use of the 
te rm  "hypertensive disease of pregnancy" to  avoid the "la rg e ly  
semantic debate over whether a patient is  "toxaem ic" o r not.
Such a group, which would include patients w ith  p re -ex is ting  
hypertension and chronic renal disease, would be even more 
heterogenous than that included under the te rm  "p re -ec lam psia ".
In the present p ro ject pre-eclam psia was defined as the 
development of a d iasto lic  blood pressure of greater than 90 mm 
of m ercury, on at least two occasions separated by 24 hours, and 
pro te inuria  in  excess of 0. 5 g /24  hours. A ll the patients were 
normotensive and did not have detectable p ro te inuria  at th e ir f ir s t  
ante-natal v is it (at 10-14 weeks gestation). The signs developed 
a fte r the 24th week of pregnancy and resolved fo llow ing de livery 
(although in  some cases th is  took several months). These patients 
would a ll conform  to the de fin ition  of "severe pre -eclam psia" as 
outlined in  the B ritis h  P erina ta l M o rta lity  Survey (B u tle r and 
Bonham, 1963).
Although many biochem ical and other abnorm alities have 
been demonstrated in  association w ith  pre-eclam psia, it  has not
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yet been possible to  iden tify the p rim a ry  factor (or factors) 
responsible fo r the syndrome. D efinite abnorm alities found 
in  association w ith  pre-eclam psia (in addition to  those 
suggestive of in travascu la r coagulation discussed in  Chapter 
V. 2) include disturbances in  the renin-angiotensin system, in 
the im m unological response to pregnancy and in  carbohydrate 
and pro te in  m etabolism ,
In norm otensive pregnancy ren in values ris e  to  the very 
high leve ls usually associated w ith  a hypertensive response 
(W eir, Brown, F rase r et a l, , 1973). The reason fo r th is  
resistance to  ren in in  norm al pregnancy is  not yet understood. 
Paradoxica lly it  has been shown that plasma ren in , ren in  substrate, 
angiotensin H and aldosterone are a ll decreased in  pre-eclam psia 
fa llin g  towards the non-pregnant values (W eir et a l. , 1973). The 
suggested explanation was that an unknown pressor agent was 
suppressing the renin-angiotensin-aldosterone mechanism and 
resu lting  in  the hypertension found in pre-eclam psia. Th is work 
has not been confirm ed in  a more recent study (Symonds, Broughton 
P ipkin  and Craven, 1975), in  which elevated angiotensin IX levels 
were found in  pre-eclam psia. In th is  study a s ign ifican t positive 
co rre la tion  was established between the d iasto lic  blood pressure 
at the tim e of sample collections and the plasma angiotensin 11 
leve ls. The reasons fo r the discrepancies between these two 
studies are not yet apparent.
Evidence in  favour of an im m unological cause of p re ­
eclampsia has been supported by the dem onstration of immuno­
globulins and complement in  the placental bed (K itz m ille r and 
Benirschke, 1973), renal g lom eru li (Petrucco, Thomson,
Lawrence et a l. , 1974) and hepatic sinusoids (A rias and M ancilla - 
Jimenez, 1976). I t  is  not known, however, whether the deposition 
of immunoglobulins and complement indicates active involvement in
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the pathogenesis of pre-eclam psia, because these prote ins could 
have been passively trapped as p a rt of a separate pathological 
process. A recent study has fa iled  to  show evidence of 
complement activa tion in  the plasma of pre-eclam ptic patients 
(Thomson, Stevenson, Behan et a l. , 1976) and there fore  does 
not support the idea that c ircu la ting  immune complexes are 
involved in  the p rim a ry  aetiology of pre-eclam psia.
A bnorm alities in  carbohydrate m etabolism  w ith  low 
fasting plasma glucose leve ls and low fasting plasma placental 
lactogen leve ls have been found in  association w ith  pre-eclam psia 
(Singh, 1976). Plasm a u ric  acid levels are higher in  pre -eclam ptic 
patients than in  norm al pregnant women, and the ris e  seems to  occur 
usually about 3 weeks before the onset of p ro te inuria  (Eedman,
B e ilin  and Bonnar, 1076). The seromucoid fra c tio n  of m aternal 
serum  glycoproteins is  increased in pre-eclam psia (Good, 1075) 
and th is  may re fle c t "progressive placental de te rio ra tion  w ith 
increasing trophoblastic fragm entation and deportation".
It is  probable that aü these effects are secondary and are 
not re la ted to  the p rim a ry  pathology of the p re -eclam ptic  syndrome. 
The various theories of the pathogenesis of pre-eclam psia need not 
be m utually exclusive. Page (1972) w ith  h is "v ic iou s c irc le  of 
pre-eclam psia and eclam psia" linked many of these findings 
together. I t  should, however, be stressed that pre-eclam psia 
is  a syndrome which may encompass several p rim a ry  disease 
processes. Theobald (1974) warned against the dangers of try in g  
"to  pinpoint one lesion as being the cause of, o r always being 
associated w ith  pre-eclam psia".
Nevertheless the concept of an association between low 
grade dissem inated in travascu la r coagulation and pre-eclam psia 
is  an a ttrac tive  one, because if  in travascu lar coagulation was 
im pa iring  blood flow  to organs such as the placenta, kidney, liv e r
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and b ra in , many of the c lin ica l features of pre-eclam psia would be 
explained. The evidence in  favour of such an association has come 
from  several sources including:»
(a) histology of human pre-eclam psia
(b) anim al experim ents
(c) haematological changes in  human pre-eclam psia.
These w ill be discussed in tu rn  in the next section*
V. 2 The Association between Pre-eclam psia and In travascu lar
Coagulation
This subject has attracted widespread in te rest over the last 
few years. A recent e d ito ria l in  The Lancet (1975) concluded that 
"We cannot yet demote in travascu lar coagulation from  its  p re ­
eminence as an explanation of toxaemia of pregnancy".
V. 2(a) H istology of Human P re-eclam psia
The o rig in a l lin k  between eclampsia and m icrovascu lar 
throm bosis was described by Schmorl in  1893. In 1909 Holland 
stated that "a  widespread throm bosis of cap illa ries  is  a consistent 
feature of fa ta l cases of eclam psia".
The development of safe techniques fo r obtaining biopsy 
m ate ria l and the fa c ilitie s  fo r good electron m icroscopy have 
allowed th is  w ork to be extended to  the study of pre-eclam psia. 
Many reports have now been published on renal biopsy histology 
(including Po liak and N ettles, 1960; P ira n i, P o liak, Lannigan 
et a l, , 1963; Thomson, Paterson, Smart et a l. , 1972). There 
appears to  be a g lom eru lar lesion fa ir ly  typ ica l of pre-eclam psia, 
which includes sw elling of the endothelial and mesangial ce lls  
("endothe liosis"), p la te le t aggregates and the deposition of an 
amorphous fib rin o id  m ate ria l w ith in  the ce lls  and beneath the 
basement membrane* Using immunofluorescence th is  amorphous 
fib rin o id  m a te ria l was shown to  contain fibrinogen o r fibrinogen
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deriva tives (by among others V assa lli, M o rris  and McCluskey,
1963; Petrucco et a l. , 1974).
Deposition of fib rinogen-re la ted pro te in  has also been 
demonstrated by immunofluorescence around the hepatic sinusoids 
in  liv e r biopsy specimens from  pre-eclam ptic patients, but not in  
those from  healthy pregnant controls (A rias and M ancilla-Jim enez, 
1976).
Changes have also been found in  placental histo logy suggesting 
increased fib r in  deposition in  pre-eclam psia. In norm al pregnancy the 
in itim a l endothelium of the sp ira l a rte rie s  is  la rge ly  replaced by 
cytotrophoblast and the e lastic lam ina and smooth muscle of the 
media by an amorphorous m a trix  containing variab le  amounts of 
insoluble fib r in  (Brosens, Robertson and Dixon, 1967; Sheppard 
and Bonnar, 1974a and b).
In pregnancies com plicated by m aternal hypertension a lesion 
described as "acute a therosis" appears (Zeek and A ssa li, 1950; 
de W olf, Robertson and Brosens, 1975). The f ir s t  evidence of 
a rte ria l damage may be "fib rin o id  necrosis" (Dixon and Robertson, 
1958) w hile massive in tra m ura l fib r in  deposition and lum inal 
throm bosis occur in  the la te r stages of the disease process (de 
W olf et a l. , 1975). Sheppard and Bonnar (1976) describe a s im ila r 
lesion w ith  marked increase in  the fib r in  content of the media and 
occlusive atheromatous lesions of the sp ira l a rte rie s  in  pregnancies 
com plicated by placental in fa rc tion  and foetal growth re ta rdation, 
regardless of whether the m other is  hypertensive o r not.
These studies indicate that placental fib r in  deposition occurs 
in  norm al pregnancy. Local in travascu lar coagulation w ith in  the 
placenta is  increased in  pre-eclam psia but is  not specific fo r th is  
condition.
Although no d ire c t h isto log ica l evidence of in travascu la r 
coagulation is  available in  the lungs, perfusion defects have been
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found on lung scans from  pre -eclam ptic patients (The B irm ingham  
Eclam psia Study Group, 1971). C ritic ism s  of th is  paper would 
include the lack of studies in  a norm al pregnancy contro l group 
and the non-specific nature of a perfusion defect in  the absence 
of any in form ation on ventila tion , but nevertheless the finding 
could suggest the occurrence of in travascu lar coagulation w ith  
p la te le t-fib rin  aggregates blocking the pulm onary ca p illa rie s  in 
pre-eclam psia.
In summary, h is to log ica l studies in  pre-eclam psia have 
indicated that fib rinogen-re la ted  m ate ria l (presumably fib rin ) 
is  la id  down in  the renal g lom eru li, the hepatic sinusoids and to 
an increased extent in  the m aternal placental vessels. There is , 
in  addition, presum ptive evidence that a s im ila r process may 
occur in  the pulm onary vasculature. These studies do not, 
however, indicate at what stage in  the pathological process the 
fib r in  is  deposited, nor do they indicate the stim ulus to  in tra ­
vascular coagulation. In an attempt to answer these questions 
anim al experim ents have been undertaken, although it  has been 
d iffic u lt to obtain an en tire ly  sa tisfactory anim al model.
V. 2(b) A nim al Experim ents
In 1909 Englemann and Stade injected placental extracts 
in to pregnant rabb its  and the anim als died w ith  widespread in tra ­
vascular coagulation, which could be prevented by p r io r  an ti­
coagulation w ith  h irud in . Follow ing a s im ila r series of 
experim ents Schneider, (1947; 1951) suggested that in travascu lar 
coagulation was a cause of eclam psia and that throm boplastin 
release from  the placenta m ight be the p rec ip ita ting  fac to r, a 
suggestion also made by Page (1948).
During placental separation or fo llow ing traum a to the 
placenta, "w hite  em boli" enter the m aternal c ircu la tion  in
experim ental anim als and the anim als develop h isto log ica l evidence 
of in travascu lar coagulation (Brown and S talker, 1969), V assa lli, 
Simon and R o u ille r (1963) demonstrated that infusion of throm bo­
p lastin  in  pregnant rabb its produces rena l g lom eru la r changes 
s im ila r to those seen in  human pre-eclam psia.
Throm boplastin release from  the placenta in to  the m aternal 
c ircu la tion  caused by traum a to  the placenta o r m inor episodes of 
abruptio m ight therefore give rise  to  some of the features of p re ­
eclampsia as w e ll as in travascu lar coagulation. In th is  connection 
i t  is  in te resting  that trophoblastic ce lls  have been encountered 
more frequently in  the u terine vein blood of pre-eclam ptic women 
compared w ith  norm al contro ls (Jaam eri, Koivuniem i and Carpen, 
1965) and that the trophoblast has very high throm boplastic a c tiv ity  
(Chargaff, 1945).
O ther anim al models of pre-eclam psia have been used.
W ardle and W right (1973) ca rried  out suture of the placental bed
of pregnant rabb its . The spectrum  of c lin ic a l changes produced
ranged from  abruptio placentae to "toxaem ia" w ith  m ild  hypertension
125and p ro te inu ria . I  fibrinogen studies demonstrated in travascu lar 
coagulation w ith  fib r in  deposition in  the lung, liv e r  and kidney. The 
renal histo logy, however, showed marked tubular degeneration and 
no p ro life ra tiv e  response. It is , therefore , not certa in  that these 
anim als were suffering from  a "p re -ec lam p tic " type of illness .
A rhe lge r, Douglas and Langford (1967) induced hypertension 
and p ro te inu ria  in  u n ila te ra lly  nephrectomised pregnant ra ts  by 
feeding them deoxycorticosterone acetate and a high salt d ie t. The 
rena l h isto logy resembled that of human pre-eclam psia and in 
p a rticu la r the g lom eru li were fille d  w ith  fib r in - lik e  m ate ria l.
McKay, Goldenberg, Kaunitz and colleagues (1967) fed pregnant 
ra ts  a diet low in  tocopherol and containing m olecular d is tilla te s  
of oxidised cod liv e r  o il (lip id  peroxidases). D issem inated in tra -
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vascular coagulation was produced, the ea rlies t changes being 
p la te le t damage and clumping w ith  adhesion to  endothelium in the 
intestine, spleen and placenta. The placenta was the f ir s t  organ 
to be affected. I t  was suggested that p late lets m ig îit act as a 
trig g e r to a process of dissem inated in travascu lar coagulation, but 
it  could be argued that th is  anim al model was ra the r d iffe ren t from  
human pre-eclam psia.
Studies using rad ioactive ly labelled p la te le t aggregates 
infused in to the in fe rio r vena cava of the rabb it have shown that 
they become lodged w ith in  the pulmonary vasculature (W ardle, 1973). 
This find ing would be in  keeping w ith  the perfusion defects detected 
in  lung scans on pre -eclam ptic patients, (see Chapter V. 2(a) ). 
Throm boplastin, however, does cross the pulm onary c ircu la tion  
in  the same experim ental model (W ardle, 1973), A s im ila r process 
may occur in human pre-eclam psia and could re su lt in  the develop­
ment of dissem inated in travascu la r coagulation.
I t  is  debatable how fa r such anim al experim ents re fle c t the 
pathogenesis of human pre-eclam psia. I t  does, however, seem 
possible that throm boplastin release from  the placenta (Schneider, 
1947) may trig g e r changes in  coagulation factors and p la te le ts in  the 
m other's c ircu la tio n  resu lting  in low-grade in travascu lar coagulation. 
P lacental ischaemia or in fa rc tion  could be responsible fo r the 
throm boplastin release, which in  its  tu rn  would cause fu rth e r 
placental ischaemia and in fa rc tion , thus setting up a vicious 
c irc le .
in  th is  context it  may be im portant that pregnant anim als 
are p a rticu la rly  at r is k  of developing the Generalised Shwartzman 
Reaction o r GSR, (For a discussion of the GSR see Chapter I. 5(c) ). 
It  is  known that only one in jection of endotoxin is  required to  produce 
the GSR in  pregnant anim als (Apitz, 1935; B e lle r and G raeff, 1967). 
H isto log ica l studies have drawn attention to the s im ila r ity  between
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human eclampsia and the GSR (McKay, M e rr ill,  W einer et a l. , 
1953), It would therefore  appear that pregnancy its e lf produces 
a state s im ila r to  that produced by the preparative in jection  in  the 
GSR. This "hypercoagulatale state" (see also Chapter V. 2(c)) 
m ight include changes in  the vascular endothelium as w e ll as in  the 
coagulation factors and the p la te le ts, McKay and colleagues in  
th e ir o rig in a l paper (1953) stated, w ith  reference to  eclam psia, 
that "pregnancy prepares the blood vessels" and that "prem ature 
separation of the placenta releases "to x in " from  the necrotic 
decidua in  the c ircu la tion  which amounts to the "provoking”  dose 
in the Shwartzman phenomenon". The evidence from  histology 
in human pre-eclam psia and also from  the va rie ty  of anim al 
experim ental models already discussed, suggests that a s im ila r 
although less dram atic process may occur in  pre-eclam psia 
(Schneider, 1047; Page, 1948). The "to x in " may be throm bo­
p lastin , w hile  placental ischaemia or in fa rction  may foe responsible 
fo r its  release ra the r than actual prem ature separation of the 
placenta.
Valuable as such anim al studies may be in unravellm g the 
complex nature of pre-eclam psia, there are obvious problem s in  
extrapolating the resu lts  that are obtained to the human situation,
V. 2(c) Haematological Changes in  Human P re-eclam psia
(i) M icroangiopathic haem olytic anaemia
In 1908 Zangemeister noted the presence of haemoglobin in  
serum in  5 out of 14 cases of eclampsia. The haem atological 
abnorm ality was investigated fu rth e r in 3 cases of severe p re ­
eclampsia (P ritcha rd , Weisman, Ratnoff et a l . , 1954). A 
haem olytic anaemia was found w ith  blood film  appearances 
s im ila r to  those la te r described in  m icroangiopathic haem olytic 
anaemia (B rain and Hourihane, 1967). This is  now known to foe
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closely re lated to  dissem inated in travascu lar coagulation (Ruben- 
berg, Regoeczi, B u ll et a l. , 1968). M icroangiopathic haem olytic 
anaemia is , however, only present in  severe o r longstanding cases 
of pre-eclam psia, and re fle c ts  flo r id  dissem inated in travascu lar 
coagulation. Several studies have described m ore subtle changes 
suggestive of in travascu lar coagulation by measuring coagulation, 
fib rin o ly tic  and p la te le t function and these w ill be described below.
( ii)  Coagulation system
During norm al pregnancy the levels of many of the blood 
coagulation facto rs ris e  reaching a peak in  the th ird  trim e s te r 
(several repo rts  including Pechet and Alexander, 1961 and N ilsson 
and K u llander, 1967). Bonnar (1976) summarised the current 
lite ra tu re  and stated that increases have been found in  plasma 
fibrinogen leve ls (reaching as high as 400-600 m g /100 m l in  la te 
pregnancy and labour) and in  Factors V II, V III, IX  and X w ith  
dim inished concentrations of Factors X I and X II. A s ligh t 
increase in  the ra tio  of Factor V III related antigen to  Factor V III 
a c tiv ity  (Bouma, Sixma, van M ourik et a l, , 1973; Bonnar, 1976) 
together w ith  s ign ifican tly  ra ised levels of "th rom b in  activated 
Factor V " (Factor Va) have also been found in  norm al pregnancy 
(van Boy en and ten Cate, 1976).
Since the c ircu la ting  blood volume increases in  norm al 
pregnancy by 30-50% many of the coagulation facto rs  double in  
absolute amount compared w ith  the non-pregnant state. These 
changes may have a physio logica l im portance in  assisting the 
pregnant woman to  achieve and m aintain haemostasis during and 
a fte r the th ird  stage of labour. On the other hand, the ve ry  
changes which help to m aintain the in te g rity  of the vascular tree  
may also predispose the pregnant woman to dissem inated in tra ­
vascular coagulation.
Compared w ith  norm al pregnancy concentrations of some
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blood coagulation factors ris e  s t il l fu rth e r in  association w ith 
pre-eclam psia. Howie, P rentice and M cH icol (1971) noted a 
fu rth e r increase in  Factor V IE  ac tiv ity  levels in a group of 
p re-eclam ptic  women compared w ith  a matched pregnant contro l 
group. Reid, F rig o le tto , T u llis  and colleagues (1971) noted a 
shortened Quick prothrom bin tim e in  th e ir group of pre-eclam ptic 
patients suggesting that Factors II, V, V II o r X m ight be elevated. 
They also noted a s trik in g ly  shortened ra tio  fo r s ilicone-to -g iass 
c lo tting  tim es, which was in terpre ted as suggesting the presence 
of Factors X lla  a n d /o r :XIa in  association w ith  pre-eclam psia. In 
contrast, Factor V levels were found to be lower in  hypertensive 
compared w ith  norm otensive pregnant patients (Davidson and 
P h illip s , 1972). A recent study has shown s ign ifican tly  ra ised 
Factor X II leve ls in  pre-eclam psia compared w ith  norm al pregnancy, 
w hile Factors X I and X  were s ligh tly  lower in  the patient group 
(Condie, 1976), The ra tio  of Factor V ÏÏI re lated antigen to  Factor 
V III a c tiv ity  is  increased in  women w ith  pre-eclam psia compared 
w ith  the changes in  norm al pregnancy (Bonnar, 1976).
C onflicting resu lts  have been published com paring the levels 
of plasma fibrinogen in  a group of patients w ith  pre-eclam psia to  
those from  a matched pregnant contro l group. Usually no s ta tis ­
tic a lly  s ign ifican t d ifferences is  found in  plasma fibrinogen levels 
(W ardle and Menon, 1969; Bonnar, M cN icol and Douglas, 1971; 
Howie et a l. , 1971; K itz m ille r, Lang, Yelenosky et a l. , 1974) 
but both higher (D ienst, 1905) and low er levels (B irm ingham  
Eclam psia Study Group, 1971; Dube, Bhattacharya and Dube,
1975) have also been reported.
A number of techniques have been used to  iden tify  abnorm al 
or activated form s of fibrinogen in  pre-eclam psia (see Chapter 
L 6(a)).
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(i) C ryofibrinogen
Increased cryofibrinogen levels have been found in  p re ­
eclampsia compared w ith  norm al pregnancy (McKay and Corey,
1964; W ardle and Menon, 1969; Howie et a l, , 1971). A s im ila r 
abnorm al fo rm  of fibrinogen "heparin precip itab le  cold fib rinogen" 
has also been found to  be increased in  pre-eclam psia (Smith, 1957),
( ii)  Protam ine Sulphate Tests
Increased numbers of positive protam ine sulphate tests have 
been found in pre-eclam psia compared w ith  the numbers found in  
norm al pregnancy (Hyde, Joyce, Gurewich et a l. , 1973; K ita m ille r, 
Lang, Yelenosky et a l. , 1974; Pinango, L ina res, Cova et a l. , 1976).
( iii)  Ethanol Gelation Tests
One study has shown 4 positive ethanol gelation tests out of 
6 samples taken from  2 pre-eclam ptic  patients, but no positive  tests 
were found in  samples from  10 healthy pregnant women (Keid et a l. , 
1971),
(iv) F ibrinogen Series
A t a m ore sophisticated leve l a "fib rinogen se ries" has been 
developed which is  claim ed to  distinguish between predom inant 
coagulation, predom inant fib rin o lys is  and coagulation balanced by 
fib rin o lys is  (Wood, Burnett, Picken et a l. , 1974). Im m unoreactive 
fibrinogen, heat precip itab le  fibrinogen and cryofibrinogen are 
measured. Im m unoreactive fibrinogen measures fib rinogen- 
re lated antigen in  addition to  in tact fibrinogen and is  therefore  usually 
ra ised above the heat precip itab le  fibrinogen leve l during fib rm o lys is , 
but fa lls  below the heat p recip itab le  fibrinogen leve l when throm bin 
action predom inates. In several cases of pre-eclam psia changes 
have been found in  th is  fibrinogen series to  suggest that in travascu lar 
coagulation (i. e, throm bin action) is  associated w ith  de terio ra tion  in  
the pre -eclam ptic state, w hile enhanced fib rin o ly s is  occurs during 
c lin ic a l im provem ent.
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AU these tests fo r abnormal or activated fibrinogen are 
somewhat unsatisfactory (see discussion Chapter 1.6(a) ).
Despite th is  there is  c le a rly  some evidence to  suggest that 
increased throm bin-activated fibrinogen (i. e. soluble fib r in  
monomer) is  present in  pre-eclam psia compared w ith  norm al 
pregnancy.
I t  is  known that soluble fib rin o g e n -fib rin  complex 
concentration demonstrated by fibrinogen chromatography does 
increase in  norm al pregnancy reaching a peak concentration at 
te rm  (H after, Schneebauar, Tafe l et a l. , 1975) and fu rthe r 
increases occur in  the puerperium  (G raeff, Wiedemann, von 
Hugo et a l. , 1976). A  marked increase in  soluble complex 
concentration has been w e ll documented in  a case of eclampsia 
(G raeff and von Hugo, 1972) and also in  two cases of abruptio 
placentae (Verm ylen, Donati and V erstraete, 1971; G raeff and 
von Hugo, 1974). W ardle (1973) found "both high and low 
m olecular deriva tives of fibrinogen are in  the c ircu la tio n  , . .  
in hypertension in  pregnancy" using the plasma fibrinogen 
chromatography technique, but the details of th is  w ork have 
never been published (W ardle, 1976).
h i sum m ary, there fore , the increased concentrations of 
several coagulation facto rs and changes in  fibrinogen suggest that 
the tendency towards hyper coagulability in norm al pregnancy is  
enhanced in  pre-eclam psia.
The coagulation system only re flec ts  one aspect of the 
mechanisms responsible fo r haemostasis and the changes in  the 
fib rin o ly tic  system and the form ation of fib rin o g e n -fib rin  degrad­
ation products w ill now be discussed.
( iii)  F ib rin o ly tic  system
In norm al pregnancy there is  an increase in  the leve l of
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plasma plasminogen (Bonnar, M cN ieol and Douglas, I960), which 
is  in  step w ith  the ris e  in  plasma fibrinogen (Bonnar, M cN icol and 
Douglas, 1969). Despite th is  the spontaneous fib rin o ly tic  a c tiv ity  
in  the blood is  dim inished (as measured by prolongation of the 
euglobulin ly s is  tim e) in  norm al pregnancy (G illm an, Naidoo and 
Hathorn, 1959; Shaper, Macintosh and Kyobe, I960; Bonnar,
M cN icol and Douglas, 1969). The euglobulin ly s is  tim e rap id ly 
re tu rns to  norm al fo llow ing de live ry (Bonnar, M cN icol and 
Douglas, 1970).
The low leve l of c ircu la ting  plasminogen activa to r, suggested 
by the prolonged euglobulin ly s is  tim e, could be due to dim inished 
activa to r synthesis, to  inh ib ition  of the release of activa tor from  the 
endothelium and also to  c ircu la tin g  inh ib ito rs .
I t  is  known that loca l release of plasminogen activa tor in 
response to venous occlusion is  progressive ly dim inished during
o
pregnancy and is  bare ly detectable at te rm  (Astedt, 1972a), F u rth e r­
more an im paired fib rin o ly tic  response to physical exercise has 
been reported in  la te pregnancy (Woodfield, Cole and Cash, 1968), 
Venous biopsy specimens show dim inished fib rin o ly tic  a c tiv ity  
during pregnancy, although the actual leve l of a c tiv ity  is  much 
higher than that found in  the blodd (Astedt, 1972a). This could 
suggest the presence of an a c tiva t or -  r  elease in h ib itin g  mechanism.
P lacental biopsy specimens have also shown lack of fib rin o ­
ly tic  a c tiv ity  in  the cytotrophoblastic ce lls  lin in g  the sp ira l a rte rie s  
(Sheppard and Bonnar, 1976). This m ight be due to loca l production 
of an activa to r in h ib ito r fo r it  is  also known that the placenta is  r ic h  
in  in h ib ito rs  to  urokinase activation of plasminogen (ICawano,
M orim oto and Uemura, 1968).
Increased inh ib ition  of urokinase by pregnant serum compared 
w ith  non-pregnant serum was demonstrated in  one study (Kawano et a l. ,
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1968) but not confirm ed In fu rth e r studies using serum  (Hedner
O
and Astedt, 1971) o r plasma (Bonnar, M cN icol and Douglas, 1969). 
The differences between batches of urokinase and between urokinase 
and na tu ra lly  produced plasminogen activa tor are c le a rly  im portant 
in  assessing these resu lts  (Chapter L  3(b) ). Although in h ib ito rs  of 
urokinase activa tion of plasminogen may not ris e  during pregnancy, 
i t  should be noted that antip lasm in a c tiv ity  and (X ^  m acroglobulin 
and ^ an titryps in  concentrations do ris e  (Hedner and Astedt, 1971), 
The explanation fo r the in liib itio n  of fib rin o ly s is  in  norm al 
pregnancy is  therefore fa r from  c lear, but it  is  probable that the 
placenta is  im portant, because the depressed fib rin o ly tic  a c tiv ity
o
only re tu rns to  norm al fo llow ing placental de live ry  (Astedt, 1972b).
It  may be that in h ib ito rs  are  produced in  the placenta, which enter 
the m aternal blood and in  some way prevent the release of 
plasminogen activa to r from  endothelial ce lls .
I t  is  probable that fib rin o ly s is  is  only p a rtia lly  inhib ited 
because serum  fib rin o g e n -fib rin  degradation product (FD P /fdp) 
levels ris e  during pregnancy, especially during the th ird  trim e s te r 
(W oodfield, Cole, A llan  et a l. , 1968). Th is ris e  appears to  be 
episodic and may not occur in  a ll women (Hoq, Pepper, P rescott 
et a l. , 1975), There is  a fu rth e r increase in serum  F D P /fdp  
during labour and in  the puerperium  (Bonnar, Davidson, Pidgeon 
et a l. , 1969), which presum ably re flec ts  ly s is  of insoluble fib r in  
form ed at the tim e of placental separation.
The depression of fib rin o ly tic  a c tiv ity , whatever its  cause, 
w ill tend to  aggravate any tendency towards in travascu la r coagulation 
in  pregnancy. Th is may be im portant in re la tio n  to  pre-eclam psia.
In pre-eclam psia low er levels of plasma plasminogen are 
present than in  norm al pregnancy (Bonnar, M cN icol and Douglas,
1971; Howie et a l. , 1971). There is  also an increase in  the leve l 
of in h ib ito r to urokinase in  plasma from  patients w ith  pre-eclam psia
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(Bonnar, M cN icol and Douglas, 1971; Howie et a l, , 1971),
Serum F D P /fdp  levels are higher in  pre -eclam ptic  women 
than in  norm al pregnant contro ls (Bonnar, Davidson and Pidgeon 
et a l. , 1969; Henderson, Pugsley and Thomas, 1970; Howie et a l, , 
1971; Hyde et a l. , 1973; Dube et a l. , 1975) although sequential 
studies suggest that consistently ra ised levels are not always 
present in  pre-eclam psia (Gordon, Katky, Baker et a l, , 1976). 
U rina ry  F D P /fdp  levels are also higher in  pre-eclam ptic  patients 
than in  norm al pregnancy, p a rticu la rly  fo llow ing de live ry  (Howie 
et a l, , 1971).
These resu lts  suggest that although there may be increased 
inh ib ition  of fib rm o lys is  in  pre-eclam psia, th is  is  not complete and 
some lys is  of insoluble fib r in  is  occurring. The resu lts  are 
therefore compatible w ith  a degree of in travascu lar coagulation being 
present in  pre-eclam psia,
(iv) P la te le t count and function
Thrombocytopenia was f ir s t  described in  eclam psia by 
Stahnke in  1922 but it  also occurs in  association w ith  pre-eclam psia 
(Bonnar, M cN icol and Douglas, 1971; Howie et a l. , 1971; 
B irm ingham  Eclam psia Study Group, 1971; Davidson and P h illip s , 
1972; K itz m ille r et a l. , 1974), One recent study has shown a 
co rre la tion  between the reduced m aternal p la te le t count and in tra ­
u terine growth re ta rdation in  pre-eclam psia (T rudinger, 1976), 
Increased p la te le t adhesiveness was described by McKay, 
de Bacalao and 8edlis (1964) in pre-eclam psia compared w ith  
norm al pregnancy. They claim ed that there was a d ire c t re la tio n ­
ship between the severity  of the pre-eclam psia and the "p la te le t 
adhesiveness index” . In contrast to th is  rep o rt, however, other 
studies have suggested that p late lets are less reactive  in  p re ­
eclampsia as compared w ith  norm al pregnancy. Thus there is  
a reduced response to  adenosine diphosphate induced aggregation
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in pre-eclam psia (Howie et a l. , 1971) and p la te le t adhesion and 
aggregation fo llow ing exposure to  connective tissue may also be 
dim inished in some eases of pre-eclam psia (K itz m ille r et a l. ,
1974).
In an on-going study Whigham, Howie, Drummond and 
colleagues (1977) have found that p late lets in  women w ith  severe 
pre-eclam psia are generally less reactive (using a va rie ty  of 
aggregating agents) than platelets from  norm al pregnant women. 
The dim inished maximum ra te  of aggregation was p a rticu la rly  
marked when collagen was used as the aggregating agent. It 
was also found that p la te le t serotonin content was s ign ifican tly  
reduced in  severe pre-eclam psia compared w ith  norm al pregnancy. 
The general loss of p la te le t re a c tiv ity  is  fu rth e r emphasised by the 
observation that p la te le t factor 3 is  reduced in association w ith  
pre-eclam psia (Howie et a l. , 1971).
I t  is  d iffic u lt to in te rp re t these findings at present but they 
are not incom patible w ith  a low grade in travascu lar coagulation in 
which p late lets are being consumed in  the form ation of m ic ro ­
throm bi. In the process some platelets m ight disaggregate from  
these deposits and c ircu la te  in  the blood in a less reactive fo rm .
(v) Summary
Pre-eclam psia is  therefore associated w ith  abnorm alities 
in  a number of tests of coagulation, fib rin o ly tic  and p la te le t 
function, which can be broadly summarised as fo llow s:
(i) Ind irec t evidence of activation of the coagulation 
system,
( ii)  Depression of fib rin o ly tic  a c tiv ity
( iii)  Production of fib rin o g e n -fib rin  degradation products
(iv) Ind irect evidence of activation and consumption of 
p late lets.
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Taken together th is  evidence would favour a degree of in travascu lar 
coagulation, although quite profound changes do occur even in  
norm al pregnancy. It would appear that certa in  trends are 
established in norm al pregnancy, which become accentuated 
in association w ith  pre-eclam psia.
It  seemed that the technique of plasma fibrinogen chromato­
graphy was w e ll suited to  provide fu rth e r and ra th e r more d irec t 
evidence of increased activation of the coagulation system in  p re ­
eclampsia. Accord ingly the study comparing groups of p re ­
eclam ptic, norm al pregnant and norm al non-pregnant women was 
undertaken and is  described in  the next section.
V. 3 Design of C lin ica l Study
Three groups of subjects were studied (see Table 16).
Group I  consisted of 10 patients w ith  a c lin ica l diagnosis of p re ­
eclampsia which was defined as a sustained d iasto lic  blood pressure 
of greater than 90 mm of m ercury and pro te inuria  in  excess of
0. 5 g ra m /24 hours. The signs developed a fter the 24th week of 
pregnancy and resolved fo llow ing de livery (fo r discussion of th is  
de fin ition  see Chapter V. 1). These women were a ll ambulant in ­
patients at e ither the Royal M ate rn ity  Hospital or the Queen 
M other's H ospita l in  Glasgow. Short case sum m aries w ill be 
found in  Appendix n .
Group I I  consisted of 10 healthy pregnant women, who were 
attending the antenatal c lin ic  at the Royal M atern ity  H ospita l in 
Glasgow. They were care fu lly  matched fo r age, p a rity  and length 
of gestation w ith  those subjects in  Group I, I t  proved im possible 
to obtain suitable in -pa tien t norm al pregnant women, as the reason 
fo r adm ission usually made them unsuitable fo r inclusion in  a 
"co n tro l" group. A ll the women in  Groups I  and I I  were rece iving 
iro n  and fo lic  acid, but the pre-eclam ptic patients received a 
va rie ty  of drugs (e. g. antihypertensive agents, sedatives, d iu re tics
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etc. ) not given to the contro l pregnant women. The drug therapy 
fo r each ind ividual p re -eclam ptic patient is  lis te d  in  Appendix II. 
E very norm al pregnant woman recru ited  into the con tro l group 
was reviewed fo llow ing her post-nata l v is it to ensure that no 
obste trica l or other com plication had occurred during pregnancy 
or the puerperium . I f  such a com plication (e. g. hypertension) 
had developed a fte r the tim e of study th is  patient was w ithdrawn 
and another recru ited .
Group H I consisted of 10 healthy non-pregnant women, none 
of whom were taking the o ra l contraceptive " p ill"  o r any other drugs. 
They were matched fo r age w ith  those in  Groups I  and II. They were 
a ll norm otensive and no s ign ifican t p ro te inuria  was found on testing 
a single u rine  specimen w ith  A lbustix  (Ames). A ll subjects in 
Groups I, I I  and H I gave inform ed consent to inclusion in  the study 
which amounted to  the taking of 20 m l (Groups I  and II) o r 30 m l 
(Group IH) of venous blood. (The d iffe ren t volumes were re lated 
to the changes in  haem atocrlt in  norm al pregnancy). The deta ils 
used in matching the three groups are shown in  Table 17. Ten sets 
of three matched subjects were obtained and these were coded into 
Sets 1-10 fo r convenience. Exact matching was im possible but age 
was matched to w ith in  3 years, length of gestation (calculated from  
the pa tien t's  last m enstrual period) to w ith in  2 weeks and p a rity  
was matched exactly in  every Set except Set 9 in  which the patient 
w ith  pre-eclam psia had suffered one more abortion in  the past than 
the contro l pregnant woman. The pre-eclam ptic patient in  Set 8 
had a tw in pregnancy, w hile  the con tro l pregnant woman had a single 
pregnancy. The differences between tw in and single pregnancies 
were investigated separately (Chapter VH. 2). They were found to 
be m in im al and therefore could not have caused the differences in  
resu lts  found in Set 8 (see resu lts  section). S ta tis tica l analysis
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using the " t "  test fa iled  to  show any difference between the groups 
fo r age and between the pregnant groups fo r length of gestation. 
Systolic and d iasto lic  blood pressure measurements fo r a ll three 
groups at the tim e o f blood sam pling are shown in  Tables 18(a) 
and 18(b). The quantitative pro te inuria  resu lts  on the day of 
study fo r the pre-eclam ptic  patients in  Group I  are shown in  
Table 18(c). A ll the patients in  Group I  had some degree of 
oedema of th e ir face and hands (as w e ll as ankles) and a rough 
c lin ica l assessment was made on a scale from  a trace to  .
I t  can be seen that there was a wide spectrum of severity  w ith in  
the pre-eclam ptic  group and th is  w ill be discussed fu rth e r in  
Chapter V I. 3.
The fo llow ing packed agarose gel columns were used fo r 
the w ork described in  the pre-eclam ptic patients (Chapters V and 
V I):-
Columns B5 to B8 (Batch II)
C8 (Batch n )
C9 (Batch II)
D eta ils regarding these packed gel columns can be found in  Appendix
I.
V. 4 Results
(a) Plasma fibrinogen
The plasma fibrinogen leve ls (measured by the Ratnoff and 
Menzie technique) are shown in  Table 19, It can be seen that there 
was a s ign ifican t r is e  associated w ith  norm al pregnancy (Group I I /  
Group III) . Th is would have been expected in view of previous 
published resu lts  (see discussion Chapter V. 2(c) ). There was no 
s ta tis tica lly  s ign ifican t d ifference in  plasma fib rinogen levels 
between the two pregnant groups (Group 1 /Group II), although the 
general trend was towards low er levels in  association w ith  p re ­
eclampsia. Although the lite ra tu re  is  ra the r confusing on th is
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point, th is  re su lt is  in  keeping w ith  previous w ork in  which e ither 
norm al or low plasma fibrinogen leve ls have been found in 
association w ith  pre-eclam psia (see discussion Chapter V. 2(c) ),
(b) Serum F D P /fdp  levels
These were measured by two tecliniques « the tanned red 
ce ll haemagglutination inh ib ition  immunoassay (T .H .C .X i. 1.1. ) 
and the staphylococcal clum ping test (SCT), The resu lts  are 
shown in  Tables 20 and 21.
Using the T .H . C. H. 1.1, it  can be seen that there was a 
sm all, but s ta tis tica lly  s ign ifican t increase in  serum FDP /fd p  
leve ls in  norm al pregnancy, when compared w ith the norm al non­
pregnant contro l group (Group IE/Group III). A fu rth e r sm all, 
s ta tis tica lly  s ign ificant increase in serum FDP /fd p  leve ls was 
found in association w ith  pre-eclam psia when compared w ith  
norm al pregnancy (Group 1 /Group II),
The SCT proved a less sensitive method of measuring 
serum F D P /fdp , as only ha lf of the pre-eclam ptic and none of 
the contro l groups showed a positive  resu lt. There was, however, 
a sign ifican t r is e  in  association w ith  pre-eclam psia (Group 1/
Group II). There was also a s ign ificant positive co rre la tion  fo r 
the paired resu lts  on the samples from  a ll three groups taken 
together using the two d iffe ren t tecliniques (Table 22).
(c) Plasma fibrinogen chromatography
Ten sets of matched resu lts  were obtained. Each set 
contained a sample from  a pre-eclam ptic patient, a matched 
pregnant contro l and a matched non-pregnant contro l. A set 
of matched resu lts  fo r FR-antigen curves is  shown in  F igure 
46, The shape of the antigenic curve was consistently abnormal 
in  association w ith  pre-eclam psia, and suggested soluble complex 
form ation. In addition, antigenic m ateria l (indicated by the arrow )
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seemed to  be eluted much e a rlie r (close to the void volume 
fractions) in  pre-eclam psia compared w ith  norm al pregnancy.
F urther examples of elution curves in  pre -eclam ptic  patients 
can be found in  F igures 49-51 (Chapter V I),
The resu lts  were examined in  a number of d iffe ren t ways 
in  order to  obtain the maximum amount of in fo rm a tion :-
(i) FK-antigen ra tio
( ii)  8CT T itre  of the V ^ fractions
( iii)  T , G. P, ra tio
(iv) T .C .T . ra tio
(v) A reas m , u and p
This is  a measurement of the elution volume at which 
fib rin o g e n -fib rin  re la ted (F K -) antigen could f ir s t  be detected.
A ra tio  was used ra th e r than the actual elution volume to  m in im ise 
the m inor d ifferences between the packed gel colum ns. The resu lts  
are shown in  Table 23. I t  can be seen that the ra tio  was consistently 
low er in  association w ith  pre-eclam psia, ind icating that the antigenic 
m a te ria l was eluted e a rlie r than in  norm al pregnancy close to  the void 
volume. The difference between the resu lts  in  pre-eclam psia and 
norm al pregnancy was highly s ign ifican t. There was also a 
s ign ificant difference between the resu lts from  the pregnant and 
non-pregnant norm al con tro l groups.
The low er FR-antigen ra tio s  found in  some of these samples 
could have been associated w ith  a corresponding ris e  in  plasma 
fibrinogen leve ls , there fore  the paired resu lts  were studied using 
the technique of lin e a r regression analysis (Table 24), The only 
s ign ifican t co rre la tion  was found when the resu lts  fo r Groups I I  and 
I I I  were considered together. This was negative and only reached 
borderline  leve ls of significance (2p (0.05). I t  may therefore be
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suggested that the higher fibrinogen levels in  norm al pregnancy 
resulted in  the FE-antigen m a te ria l being eluted from  the packed 
column at a s lig h tly  e a rlie r volume. This c le a rly  did not happen 
in  the samples from  the pre-eclam ptic  patients (Group I) because 
in  these samples antigenic m ate ria l appeared close to  the void 
volume, regardless of the fibrinogen level.
It was already known that the M ancini technique was not 
ideal fo r m easuring the amount of antigen in  the fractions close 
to the void volume (see Chapter III, 4 and III. 6), the re fo re , the 
SCT titre  was determ ined fo r these fractions.
( ii)  SCT t itre  of fractions (Chapter II. 4(1) )
Several fractions close to  the void volume were tested. The 
highest concentration of fib rinogen-re la ted m a te ria l measured was 
used fo r s ta tis tica l analysis. This was, in fact, usually one or 
two fractions la te r than the crest of the to ta l p ro te in  peak as 
determ ined by the optica l density elution curve. The resu lts  are 
shown in  Table 25. The sm all batch varia tions in  the sens itiv ity  
of the staphylococci were not taken into account. I t  can be seen 
that norm al pregnancy was associated w ith  a positive test in  5 out 
of 10 cases. The difference between the norm al pregnant and the 
non»pregnant con tro l groups only reached borderline  significance 
(2p (0.05) and th is  could possibly have been due to  a degree of 
batch va ria tion . The difference between the pre -eclam ptic  group 
and norm al pregnant con tro l groups was, however, highly 
s ign ifican t and it  seems improbable that th is  could be explained 
in  term s of batch va ria tio n .
The resu lts  fo r FE-antigen concentration fo r the same 
fractions (close to  the void volume) measured by the ra d ia l immuno­
diffusion (M ancini) technique are shown in Table 26. The co rre la tion  
between the two techniques fo r measuring FH-antigen was calculated
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by line a r regression analysis and the resu lts  are shown in Table 
27. A s ign ifican t positive co rre la tion  was obtained when the data 
from  a ll three groups was considered together (although as 
antigen was recorded using the ra d ia l im m unodiffusion technique 
in Groups I I  and I I I  no co rre la tion  could be expected w ith in  these 
groups).
( iii)  T. C. P. ra tio  (Chapter II. 4 (i) )
This is  a measurement of the ea rlies t elution volume at 
which " f ib r in "  c lo t or strands could be produced fo llow ing incubation 
w ith  throm bin. A ra tio  was used to try  to m in im ise the va ria tion  
between d iffe ren t packed gel columns. The resu lts  are shown in  
Table 28. A much low er ra tio  was consistently seen in  association 
w ith  pre-eclam psia indicating that m ate ria l which w ill produce " f ib r in "  
c lo t o r strands was present close to the void volume in  these samples. 
The difference in resu lts  between the pre-eclam ptic and norm al 
pregnant contro l groups was again highly s ign ificant. The difference 
In resu lts  between the pregnant and non-pregnant con tro l groups also 
reached s ta tis tica l significance.
It is  possible that a higher fibrinogen leve l could have resulted 
m a low er T. C. P. ra tio , however, as can be seen fro m  Table 29 th is  
did not seem to be the case. The only sign ifican t co rre la tion  found 
using th is  data was positive (Group I  data alone) and th is  only reached 
a borderline leve l of significance (2 oC (0.05). Th is presum ably 
re fle c ts  the tendency fo r plasma fibrinogen levels to fa ll s ligh tly  
w hile  the T . C. P. ra tio  is  also low er in  pre-eclam psia. The two 
changes m ight not be d ire c tly  re lated.
There was, however, a s ign ifican t positive co rre la tion  
between the resu lts  of the FR«antigen and T. C, P. ra tio s  when the 
paired data fro m  a ll three groups was considered together (Table 
30). This m ight have been expected as both measure the f ir s t  
e lution volume at which fibrinogen-re la ted m ate ria l could be detected.
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The resu lts  fo r the FB-antigen ra tio , the SCT t itre  at 
and the T . C. P. ra tio  a ll suggested that fib rinogen-re la ted  pro te in  
was present in  the very early  void volume fractions in  association 
w ith pro-eclam psia. In a ll three tests there was a s ta tis tica lly  
s ign ifican t d ifference between the resu lts  found in  pre-eclam psia 
and norm al pregnancy. This m ate ria l is  lik e ly  to  represent 
polym er of ve ry high m olecular weight (see Chapter III, 2).
(iv) X, C. T . ra tio  (Chapter 11.4(i) )
This is  a measurement of the ea rliest elution volume at 
which a T. C. T. of less than 3 m inutes was recorded. A ra tio  was 
used to m m im ise m inor differences between the packed gel columns. 
The resu lts  are shown in  Table 31. i t  can be seen that there was a 
trend towards low er values in  association w ith  pre-eclam psia, but 
that th is  fa iled  to reach s ta tis tica l significance. The low er values 
found in  norm al pregnancy compared w ith  the non-pregnant contro l 
group did, however, reach s ta tis tica l significance (2p (0,02). This 
ra tio , there fore , did not produce as good a separation between the 
d iffe ren t groups as the T. C. P. ra tio  did and w ill the re fore  not be 
considered fu rth e r.
(v) Areas m, n and p. (Chapter III, 4(k) )
Measurements of these areas are related to changes in  the 
shape of the FE-antigen p ro file . A rea m w ill la rge ly  re fle c t the 
form ation of d im ers and area p the form ation of early  degradation 
products.
A rea m (Table 32 and F igure 47)
There was a consistent increase in area m in  association 
w ith  pre-eclam psia compared w ith  norm al pregnancy and th is  
difference was h ighly s ign ifican t (2p (0.001). There was also a 
s ign ifican t increase in  area m, when the resu lts  obtained in 
norm al pregnancy were compared w ith  those from  the non­
pregnant contro l group.
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The co rre la tion  between changes in area m and plasma 
fibrinogen levels is  considered in Table 33, When the resu lts  of 
Groups Ï Ï  and I I I  were considered together a s ign ifican t positive 
co rre la tion  was found. It may therefore be that the ris e  in  area 
m levels in  norm al pregnancy is  associated w ith the higher 
fibrinogen leve ls. Th is is  not the case fo r the pre-eclam ptic 
samples, because when the Group I  samples were considered a 
s ign ificant negative co rre la tion  was found (which s t il l applied to 
the re su lt when the Group I  and I I  data were considered together). 
The negative co rre la tion  in  the Group I  data presum ably re fle c ts  
the tendency fo r plasma fibrinogen levels to fa ll s lig h tly  and area 
m levels to rise  in  pre-eclam psia but these changes may not foe 
d ire c tly  related.
The co rre la tion  between changes in  area m and serum 
FOP /fd p  levels is  shown in  Table 34. There was a significant 
positive co rre la tion  when the data from  Groups I I  and H I and 
Groups I, I I  and I I I  were considered together but not in  any of the 
groups taken separately. It is  most like ly  that both area m and 
the serum FO P /fdp levels ris e  independently in association w ith  
pregnancy and pre-eclam psia, but there m ight foe a true  association 
(e. g. serum F D P /fdp  m ight be derived from  soluble complexes in  
area m).
A rea p (Table 35 and F igure 48)
Although area p tended to  be s lig litly  higher in  norm al 
pregnancy than in  the non-pregnant contro l women the trend did 
not reach s ta tis tica l significance. Area p also tended to  be 
increased in  pre-eclam psia compared w ith  norm al pregnancy and 
th is  trend reached borderline  s ta tis tica l significance (2p (0.05).
The co rre la tion  between area p and plasma fibrinogen levels 
is  considered in  Table 36, The only significant co rre la tion  was 
found when the Group H data was considered separately. In th is
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a negative co rre la tion  was found which jus t reached significance 
leve ls (2 (0. 05). This was most probably due to chance.
The co rre la tion  between area p and serum F D P /fdp  leve ls 
is  considered in  Table 37, I t  can be seen that it  was only when the 
resu lts  from  Groups I, II and III were considered together that a 
s ign ificant positive co rre la tion  was found (2 c< (0,05), This may 
sim ply have been due to chance or both values m ight rise  
independently in  association w ith  pregnancy and pre-eclam psia. 
There may, however, be a true  association fo r it  would not be 
unreasonable to  imagine that serum FD P /fdp levels are derived 
from  the early clottable degradation products found in  area p.
There was no sign ifican t co rre la tion  between values fo r 
area m and area except when the data from  Groups I, I I  and III  
were considered together in  which case a positive co rre la tion  of 
borderline  significance (2 oC (0,05) was found (Table 38). It is  
most lücely that both values increase independently in  pregnancy 
and pre-eclam psia, but there could be a degree of true  association 
(e. g, area p could be derived from  area m).
Area n (Table 39)
The changes in  area n obviously m irro re d  the changes in 
areas m and p. The pre -eclam ptic  group had much low er values 
than the norm al pregnant group (2p (0,001), Area n was also 
s ign ifican tly  low er in  association w ith  norm al pregnancy compared 
w ith  the non-pregnant contro l group (2p (0,005),
There was no sign ifican t co rre la tion  between area n and 
plasma fibrinogen leve ls (Table 40), w hile  the co rre la tion  between 
area n and serum F D P /fdp  levels only reached significance when the 
data from  a ll three groups was considered together (Table 41). In 
th is  case a s ign ifican t negative corre la tion  was found (2 c< (0.01),
It is  probable that the two values are not d ire c tly  re lated, but change 
Independently in  pregnancy and pre-eclam psia.
137
(v i) Summary
This ca re fu lly  matched study using plasma fibrinogen 
chromatography demonstrated several differences between a 
group of p re -eclam ptic  patients and a norm al pregnant contro l 
group. There w ere also sm all differences between the norm al 
pregnant and the norm al non-pregnant groups. These resu lts  
are sum m arised in  Table 42, together w ith  the plasma fibrinogen 
and serum  F D P /fdp  leve ls. For many of these resu lts  there 
appears to  be a spectrum  of abnorm ality extending from  the non­
pregnant contro l group, through norm al pregnancy, in to  the p re ­
eclam ptic group.
Thus the FH-antigen ra tio , the SCT t itre  at and the 
T . C. P. ra tio  a ll suggest that a polym er containing fibrinogen 
re lated p ro te in  is  present in  samples from  patients w ith  p re ­
eclampsia. The SCT t itre  suggests that low er concentrations 
of th is  po lym er may also be present in  norm al pregnancy (at 
least in  some cases). The area m resu lts  suggest that a d im er 
containing FR -antigen is  present in  association w ith  p re ­
eclampsia in  higher concentrations than in  norm al pregnancy, 
although the concentration appears to ris e  even in  association 
w ith  norm al pregnancy.
It has to be accepted that there may be an appreciable e rro r 
in  some of the resu lts , p a rticu la rly  in  the calculation of areas m, n 
and p. A sm all e rro r in  estim ating the FR-antigen concentration in 
any frac tio n  of the main antigenic peak w ill produce an appreciably 
la rg e r change in  the area m or p concentrations. Th is must be
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remembered in  assessing the resu lts . There may also have been 
a degree of subjective bias in  the calculation of these resu lts , as it  
was not possible to  ca rry  out the study "b lin d ". Ideally the blood 
samples should have been collected and coded by someone outwith 
the laboratory and the code not broken u n til the end of the study; 
but only one person was involved in  organising the study, co llecting 
the blood samples, perform ing the gel filtra tio n  and laboratory 
w ork and in  calculating the resu lts .
Sequential studies in  several pre-eclam ptic patients w ill be 
considered in  the next chapter (VI. 2). An attem pt w ill also be 
made to  determ ine whether there is  any co rre la tion  between the 
laboratory resu lts  and the patient’s c lin ica l condition (Chapter 
V I. 3). The significance of the resu lts  in  pre-eclam psia and 
norm al pregnancy in  re la tio n  to  in travascu lar coagulation w ill 
be discussed in  de ta il in  the fin a l chapter (Chapter IX ).
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CHAPTER V I
SOLUBLE FIBRINOGEN-FIBRIN COMPLEXES IN
PRE-ECLAMPSIA -  SEQUENTIAL STUDIES
VI. 1 Introduction
The study described in  Chapter V demonstrated sign ifican t 
differences between samples fro m  patients w ith  pre-eclam psia and 
norm al pregnant women using the teclinique of plasma fibrinogen 
chromatography. In the present chapter sequential data from  six 
of the pre -eclam ptic  women w ill be described and discussed in 
de ta il (Chapter V I. 2). This study followed the evolution of the 
plasma fibrinogen chromatography changes during the ante-natal 
period and re lated them to changes in  the c lin ica l p ic tu re . The 
study was continued into the phase of c lin ica l recovery fo llow ing 
de live ry. The fin a l samples were taken at the post-nata l v is it 
(approxim ately s ix  weeks a fte r de livery) at which tim e  alm ost 
complete c lin ic a l recovery had occurred.
F o r the purpose of these studies area m and SCT t itre  at V^ 
were considered to  represent soluble complexes and as such to 
re fle c t coagulation a c tiv ity  (see Chapter III. 4 and 6). F ibrinogen- 
re lated m a te ria l e luting close to  the void volume and identified  by 
the SCT must be incorporated in to a polym er of high m olecular 
weight (see Chapter H I. 2). The fib rinogen-re la ted m a te ria l 
identified in  area m has a low er m olecular weight and must be 
incorporated in to  an oligom er (probably a d im er). In contrast
140
the serum F D P /fdp  and area p resu lts  were considered to  re fle c t 
fita rin o g e n o ly tic /fib rin o ly tic  a c tiv ity  (see Chapter HI, 5 and 6).
These resu lts , together w ith  the plasma fibrinogen leve ls, 
were considered in  re la tion  to  the d iasto lic  blood pressure and 
quantitative p ro te inu ria  resu lts  obtained on the day of study.
These resu lts  can be evaluated in  d iffe ren t ways. In the 
f ir s t  pa rt of the chapter the resu lts  w ill be described and discussed 
in  de ta il from  the point of view of the individual patient. The 
resu lts  can, however, also be studied in  d iffe ren t groups, using 
s ta tis tica l analysis to  see whether there is  any re la tionsh ip  between 
the laboratory findings and the c lin ic a l p ic tu re  and outcome of 
pregnancy. These studies w ill be described and discussed in  the 
second pa rt of the chapter (V I. 3). The resu lts  were grouped in  
the fo llow ing ways fo r these s ta tis tica l analyses:-
(i) A ll the resu lts  from  samples taken ante-nata lly 
from  the pre-eclam ptic  patients were used,
( ii)  Only the resu lts  from  samples from  p re ­
eclam ptic patients taken closest to  de live ry or 
in trau te rine  death were used. (Samples 
taken w hile the patient was in  labour were not 
included). Th is group was selected as 
probably representing the samples at the 
tim e the patient was most c r itic a lly  i l l  ante- 
nata lly.
( ii i)  The calculations perform ed using groups (i) and
( ii)  were repeated including the resu lts  from  the 
norm al pregnant women studied in Group H 
(Chapter V).
The features of pre-eclam psia used in  th is  analysis were: -
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(a) A "c lin ic a l index" based on the d iasto lic  blood 
pressure and quantitative p ro te inuria  resu lts  
on the day of study (Howie, Pur die, Begg et a l* ,
1976).
(b) Foetal surviva l*
(c) P ercentile  b irth  weight.
(Lubchenco, Hansman, D ressie r et a l* , 1963).
F inally^the resu lts  used fo r Group I  in  Chapter V were compared 
w ith  those cu rre n tly  available from  35 samples taken fro m  p re ­
eclam ptic patients, in  order to see i f  there were any differences 
between the sm a lle r, selected group and th is  la rg e r group (Chapter 
V I. 4).
V I. 2 Sequential Studies on Six P re-E clam ptic  Patients
The sequential fibrinogen chromatography resu lts  fo r three 
pre -eclam ptic women (Patients 3, 7 and 9) are shown in  F igures 
49, 50 and 51. I t  can be seen that many of these samples appear 
qua lita tive ly  abnorm al, although it  is  d iffic u lt to fo llow  the changes 
in  any but a ve ry  general way. It is  s im p le r to  use the sem i- 
quantitative measurements of areas m and p and the SCT t it re  at 
V^ in  th is  respect. Therefore in  th is  section, in  which the sequential 
data from  s ix  pre -eclam ptic women w ill be discussed in  de ta il, these 
sem i-quantita tive measurements w ill be used.
h i each case a short c lin ic a l summary w ill be followed by a 
discussion of the changes in  plasma fibrinogen leve ls , soluble 
complexes (area m representing oligom ers and SCT t it re  at V^ 
representing polym ers) and fib rin o g e n /fib rin  degradation products 
(area p and serum  F D P /fdp  leve ls).
(i) Patient 3 (M. H. ) F igures 49 and 52.
Th is e lde rly  p rim ig rav ida  developed pre-eclam psia at 26-27 
weeks gestation. Over the next two weeks she developed gross
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pro te inuria  and sustained severe hypertension. E lective  Caesarean 
section v/as perform ed at 29 weeks. The baby was born a live  but 
developed severe R esp ira tory D istress Syndrome (as a com plication 
of extreme p rem atu rity ) and died 31 hours a fte r b irth , The 
patient recovered gradually fo llow ing de live ry , although she was 
s t il l m ild ly  hypertensive at her post-nata l v is it. She was norm o- 
tensive when reviewed by the renal physicians and the diagnosis of 
pre-eclam psia was accepted (see summary Appendix H),
I t  can foe seen that as the patientas c lin ic a l condition deteriorated 
the plasma fibrinogen leve l fe ll to below norm al leve ls. As th is  
happened both area m and the SCT t itre  at rose, w hile  area p 
and the serum F D P /fdp  levels fe ll. Before de live ry , however, 
both area p and the serum  F D P /fdp  levels had rise n  above the 
norm al range. Follow ing de live ry the plasma fibrinogen leve l 
rose w hile  area m and SCT t it re  at started to  fa ll. The area p 
and serum  F D P /fdp  levels peaked fo llow ing de live ry  and then fe ll.
A t the post-nata l v is it the laboratory resu lts  were w ith in  the range 
found in  the norm al non-pregnant contro l group (Group III, Chapter 
V) apart from  s lig h tly  ra ised area p and serum F D P /fdp  levels.
Comment
This patient was an example of steadily de te rio ra ting  severe 
pre-eclam psia. The increasing p ro te inuria  was m irro re d  by the 
pattern of increasing coagulation (as measured by area m and SCT 
titre  at V^), w h ile  fib rin o ly s is  (area p and serum  F D P /fdp  levels), 
remained e ither low or only s lig h tly  increased. A fte r de live ry, 
there was a surge of fib rin o ly tic  a c tiv ity  and a decrease in 
coagulation a c tiv ity .
( ii)  Patient 5 (J. T . ) F igure 53
This patient developed hypertension and p ro te in u ria  at 24-25 
weeks gestation. Her condition gradually deteriorated w ith  in tra ­
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uterine death occurring  at about 28 weeks. She was delivered at 
29 weeks and gradually recovered, She was s t il l s lig h tly  hyper­
tensive at her post-nata l v is it but was norm otensive when reviewed 
by the renal physicians. They concluded that the diagnosis of p re ­
eclampsia had been co rre c t (see summary Appendix II).
Plasma fibrinogen leve ls were low ante-natally but not below 
the norm al range. A rea m leve ls were consistently above the 
norm al range, but fe ll s lig h tly  fo llow ing in trau te rine  death, (No 
*SCT t itre  at values are available on th is  patient). The area p 
and serum  F D P /fdp  leve ls were raised above norm al but both fe ll 
around the tim e  of in trau te rine  death.
Follow ing de live ry  the plasma fibrinogen le ve l rose, but area 
m did not, w hile both area p and the serum F D P /fdp  leve ls peaked 
sharply. A t the post-nata l v is it the plasma fibrinogen, serum F D P / 
fdp and plasma fibrinogen chromatography resu lts  were w ith in  the 
range found in the non-pregnant contro l group, apart fro m  a s lig h tly  
ra ised area m leve l.
Comment
In th is  patient, as in  the previous one, the developing pattern 
of pre-eclam psia was associated w ith  increasing coagulation a c tiv ity  
(area m) and d im in ishing fib rin o ly tic  a c tiv ity  (area p and serum 
F D P /fdp  leve ls). It was in te resting  to  note that coagulant a c tiv ity  
fe ll a fte r foe ta l death but that the post-nata l surge of fib rin o ly tic  
a c tiv ity  was not evident u n til a fte r placental de live ry . This would 
be in  keeping w ith  the hypothesis that a placental fac to r is  responsible 
fo r in liib itio n  of fib rin o ly tic  a c tiv ity  i^ee  Chapter V. 2(c) ),
( ii i)  Patient 7 (M, M . ) F igures 50 and 54
This patient was in  some ways one of the least severely affected 
of those studied sequentially. She developed hypertension and
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pro te inuria  at 35 weeks gestation, but her hypertension was only 
m oderately severe and the p ro te inu ria  only gradually increased.
The baby was s lig h tly  prem ature and dysmature at b irth . The 
patient made a good recovery fo llow ing de live ry. Her blood 
pressure had returned to  norm al and pro te inuria  disappeared by 
the tim e of her post-nata l v is it.
The plasma fibrinogen leve ls were norm al ante-nata lly.
Both area m and the SCT t itre  at were ra ised above norm al, 
although in  the case of area m the leve l was only s lig litly  above 
the norm al range. The serum  F D P /fdp  leve ls were norm al but 
area p rose towards the tim e of de live ry. Follow ing de live ry the 
plasma fibrinogen le ve l rose s lig h tly . Area m also rose s lig litly , 
but the SCT t itre  at fe ll. The serum  F D P /fdp  and area p levels 
peaked fo llow ing de live ry . The laboratory findings at the post­
natal v is it were w ith in  the norm al range found in  norm al non­
pregnant women, except fo r a s lig h tly  raised serum  F D P /fdp  
leve l.
Comment
Th is patient again followed the pattern noted in  the two previous 
cases. D e te rio ra ting  c lin ic a l pre-eclam psia was associated w ith  
increased coagulant a c tiv ity  (area m and SCT at V^) and low o r only 
s lig h tly  increased fib rin o ly tic  a c tiv ity  (area p and serum  F D P /fdp).
A surge of fib rin o ly tic  a c tiv ity  was again noted a fte r de live ry  w ith  a 
re tu rn  to  fa ir ly  norm al resu lts  s ix  weeks a fte r d e live ry .
(iv) Patient 9 (A. McN. ) F igures 61 and 55
This patient is  in te resting  in  that she developed hypertension 
2-S weeks before she developed pro te inuria  (i. e, pre-eclam psia 
according to the de fin ition  used fo r th is  thesis). She was a m u lti- 
parous patient w ith  a past obste tric h is to ry  of two ante-partum  
haemorrhages due to  abruptio placentae. A t no tim e , however, 
had she been noted to  be hypertensive before the pregnancy under
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study. She was delivered by elective Caesarean section at 35 weeks 
gestation* The baby was thought to be both prem ature and dys­
m ature at b irth , but therea fte r progressed w ell* The patient 
continued to  have m ild , fluctuating hypertension fo r some months 
fo llow ing delivery* This was controlled w ith  a low dose of 
propranolo l. I t  is  there fore  possible that there was a degree of 
underlying essential hypertension in  th is  case, which had not become 
m anifest u n til the pregnancy under study (see sum m ary Appendix II).
Over the period of study (from  30-35 weeks gestation) the 
plasma fibrinogen leve l progressive ly fe ll, reaching below norm al 
sho rtly  before de live ry . Area m was consistently ra ised throughout 
the ante-natal period and tended to  ris e , w hile the SCT t itre  at V 
was raised above norm al in  3 out of the 6 ante-natal samples. The 
serum  F D P /fdp  levels were ra ised s ligh tly  above norm al in the 
e a rlie r samples but fe ll during the period of c lin ic a l de terio ra tion. 
A rea p rose to  above the norm al range in  the e a rlie r samples but fe ll 
to  w ith in  the norm al range in  the samples closest to  de live ry. 
Im m ediately fo llow ing de live ry the plasma fibrinogen leve l remained 
low and area m and SCT t itre  at remained high, w hile the area p 
and serum  F D P /fdp  levels peaked. A ll the labora to ry measurements 
had returned to w ith in  the norm al non-pregnant range by the tim e of 
the post-nata l v is it, apart from  a raised serum F D P /fdp  leve l.
Comment
This patient was most in te resting  in  that she was studied 
sequentially before the onset of p ro te inuria . In the early  resu lts  
when she had e ither m ild  pre-eclam psia or essential hypertension, 
there was evidence of only s lig h tly  increased coagulant a c tiv ity  
(area m). In addition there was some evidence of increased 
fib rin o ly tic  a c tiv ity  (serum  F D P /fdp  and area p). As the 
p ro te inuria  developed and deteriorated, both facto rs of coagulant 
a c tiv ity  showed high levels w hile  fib rin o ly tic  a c tiv ity  dim inished before
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delivery (area p and serum F D P /fdp). A fte r de live ry , coagulant 
a c tiv ity  fe ll and fib rin o ly tic  a c tiv ity  peaked as in  the previous 
patients.
(v) Patient 10 (D, F . ) F igure 56
This patient is  in te resting  in  that she had gross p ro te inu ria  
from  28 weeks gestation u n til de livery at 32 weeks. Her hypertension 
fluctuated but never reached high leve ls. The baby grew w e ll and, 
although s lig h tly  prem ature at b irth , progressed sa tis fa c to rily  the re­
a fte r. M arked p ro te inuria  occurred post «partum. S ignificant 
p ro te in u ria  was s t i l l  present at the post-nata l v is it. This disappeared 
by 3 months post-partum . F u ll renal investigation was ca rried  out and 
the diagnosis of pre-eclam psia was accepted by the rena l physicians 
(see sum m ary, Appendix II).
The plasma fibrinogen leve ls were consistently low in  th is  
patient and fe ll below the norm al range from  29 weeks onwards. The 
area m leve ls were always above norm al but were only s ligh tly  raised 
between 29 and 31 weeks. The SCT t it re  at was raised above the 
norm al range in  3 out of the 5 ante-natal samples. The serum F D P / 
fdp levels tended to ris e  towards de live ry, w hile area p levels were 
high in  the three samples taken closest to de live ry. Follow ing 
de livery there was a ris e  in  the plasma fibrinogen le ve l, while area m 
and the SCT t it re  at remained high, only gradually re tu rn ing  to the 
norm al values found at the post-nata l v is it. The serum F D P /fdp  
leve l peaked fo llow ing de livery w hile area p rem ained high. These 
measurements also gradually returned to w ith in  the norm al non­
pregnant range by the post-nata l v is it.
Comment
This patient was unusual in  that she had high leve ls of pro te in ­
u ria  fo r several weeks and despite th is , did not su ffe r eclampsia or 
foetal loss. Her fibrinogen chromatography changes also d iffe red
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from  the previous cases. Coagulant a c tiv ity  (area m and SCT at 
V^) was only s lig h tly  increased, w hile fib rin o ly tic  a c tiv ity  (area p 
and serum  F D P /fdp ) appeared to increase in  the la te r ante-natal 
samples. This pattern of "com pensatory" fib rin o ly tic  a c tiv ity  
may have been a fac to r in  enabling the pregnancy to continue 
despite the adverse c lin ic a l features. A fte r de live ry , the 
fib rin o ly tic  surge seen in  the previous cases was re flected by 
the serum  F D P /fdp  leve ls, but not by area p.
(v i) Patient 1 (M .C . ) F igure 57
This patient is  considered last because ve ry  lit t le  ante-natal 
data is  available on her. She is  w orth discussing, however, because 
she was the only patient in  the group to  develop eclam psia. She 
developed hypertension and gross pro te inuria  at 25-26 weeks gestation 
and th is  necessitated de live ry w ith in  a few days. She was induced by 
prostaglandin infusion and developed eclampsia during labour. The 
baby was s tillb o rn . The patient gradually recovered post-partum , 
although she was s t il l m ild ly  hypertensive at her post-nata l v is it, 
only becoming norm otensive 3 months post-partum . The renal 
physicians agreed that the diagnosis of pre-eclam psia w ith  in tra ­
partum  eclampsia was co rre c t (see summary. Appendix II).
Only two samples were studied on th is  patient ante-nata lly,
(The second sample was taken at the tim e of induction). In both 
samples the plasma fibrinogen levels were norm al. A rea m was 
m arkedly ra ised on both occasions, but the SCT t it re  at was 
norm al in  the f ir s t  sample. A rea p was norm al in  the f ir s t  sample, 
but had fa llen  to  below the norm al range in the second sample although 
the serum  F D P /fdp  leve l was s lig h tly  raised in  both samples. In the 
sample taken 2 days a fte r de live ry there was v irtu a lly  no change in 
plasma fibrinogen o r area m leve ls, although the SCT t itre  a t had 
fa llen  s lig h tly . S im ila rly  the area p and serum F D P /fdp  leve ls 
remained unchanged. It may be that in  th is  patient fib rin o ly tic
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a c tiv ity  was slower to  re tu rn  to  norm al because of the severity  of 
her illn e ss . I t  is  recognised that th is  may happen in  patients w ith 
severe pre-eclam psia /eclam psia  (Bonnar, M cN icol and Douglas, 
1971), A part from  a ra ised serum  F D P /fdp  leve l a ll the resu lts  
had returned to  w ith in  the norm al non-pregnant range by the tim e 
of the post-nata l v is it.
Comment
This patient had a ve ry  short but acute c lin ic a l course.
Coagulant a c tiv ity  was increased in  both ante-natal samples, as 
measured by area m , and appeared to be increasing, as measured 
by SCT t itre  a t V^. F ib rin o ly tic  a c tiv ity , although s ligh t increased 
as measured by serum  F D P /fdp  leve ls, was low and indeed fa llin g  
as measured by area p. The post-nata l increase in  fib rin o ly tic  
a c tiv ity  observed in  the other patients was not seen. Th is may have 
been due to  an unusually marked degree of in liib itio n  of fib rin o lys is  
and m ight have been observed had a sample been taken s lig h tly  la te r 
in  the puerperium .
It had been noted in  passing that some of the laboratory tests 
were s t il l s lig h tly  abnorm al at the tim e of the post-nata l v is it, when 
they were compared w ith  the range of values found in  the norm al non­
pregnant contro l women in  Group I I I  (Chapter V ). None of these 
differences, however, reached s ta tis tica l significance when the 
resu lts  in  the two groups were compared (Table 43).
Comment on the Sequential Studies
The fo llow ing observations can be made: -
(a) Plasma fibrinogen levels
These tended to  fa ll as the patient became c lin ic a lly  less w e ll 
(see Patients 3, 9 and 10). The reason fo r th is  is  uncerta in. Possible 
explanations m ight be dim inished hepatic synthesis of fibrinogen, 
increased "consum ption" of fibrinogen in  form ing fib r in  o r possibly
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increased renal loss. None of the patients had p a rtic u la rly  high 
fibrinogen leve ls at any point ante-nata lly. The leve l of plasma 
fibrinogen rose fo llow ing de live ry  (see Patients 3, 5, 7, 9 and 10) 
and always returned to low er values (s im ila r to  the non-pregnant 
state) at the post-nata l v is it.
(b) Serum F D P /fdp  levels
These tended to  be s lig h tly  ra ised ante-natally although they 
fluctuated considerably, A fa ll in  the serum F D P /fdp  leve ls to 
"n o rm a l" accompanied c lin ic a l de terio ra tion in  three cases (Patients 
3, 5 and 9). The serum F D P /fdp  leve l was never ra ised above 
"n o rm a l" in  Patient 7. A fte r de live ry the leve l of serum  F D P /fdp  
tended to  ris e  (see Patients 3, 6, 7, 9 and 10) but had fa llen  again 
by post-nata l v is it. The values in  Patient 1 were constant through­
out the study.
(c) SCT t it re  at (polym er)
This tended to be ra ised in  the ante-natal samples although 
some fluctuation occurred. The highest values were not necessarily 
associated w ith  the most seriously i l l  patients. A r is in g  value was 
associated w ith  c lin ic a l de terio ra tion  in  three cases (Patients 1, 3 
and 5). The values tended to  fa ll post-nata lly (Patients 1, 3, 7 and 
9). Patient 10 was the only case to  have a recordable SCT t itre  at 
in  the post-nata l v is it sample but she was also the only patient 
w ith  s ign ifican t p ro te inu ria  at the post-nata l v is it.
(d) A rea m (dim er)
Raised leve ls were found in  a ll the ante-natal samples. A 
r is in g  area m leve l appeared to  accompany c lin ic a l de te rio ra tion  in 
Patients 3, 5 and 9 and possib ly also Patient 7. In Patient 1 (who 
became eclam ptic) high leve ls of area m were found. A rea m fe ll 
fo llow ing de live ry in  Patients 3, 9 and 10, Low values were found
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at the post-nata l v is it.
(e) Area p (early degradation products)
Considerable fluctuation was noted in  area p values. A rea p 
tended to  fa ll during phases o f c lin ic a l de terio ra tion  in  some cases 
(Patients 1, 3, 5 and 9). B is ing  area p values accompanied periods 
of d im in ishing p ro te inu ria  in  two cases (Patients 3 and 10). The 
sequential changes in  area p and serum F D P /fdp  values were broadly 
s im ila r in  four cases ante-natally (Patients 3, 5, 9 and 10). A rea p 
tended to  increase post-partum  (Patients 3, 5, 7 and 9) but thereafter 
fe ll to  low levels by the post-nata l v is it,
h i summary it  m ight be suggested that worsening of the c lin ic a l 
p ic tu re  in  pre-eclam psia is  associated w ith: -
(a) a fa llin g  plasma fibrinogen leve l
(b) a fa llin g  serum  F D P /fdp  leve l
(c) a ris in g  area m
(d) a fa llin g  area p
Because of the sm all numbers, fu rth e r w ork would be required 
to  establish whether these observations are in  fact reproducible , but 
the present study does suggest that a pattern of increased coagulation 
and dim inished fib rin o ly tic  a c tiv ity  is  associated w ith  de terio ra ting  
pre-eclam psia.
S e ria l studies in  norm al pregnant women have not as yet been 
perform ed; but s e ria l studies in  two patients considered to  be "a t 
r is k "  of developing pre-eclam psia, but who, in  fact, had uncomplicated 
pregnancies can be found in  Appendix H I.
V I. 3 Relationship of the C lin ica l P ic tu re  and the Outcome of
Pregnancy to  the Plasma F ibrinogen Chromatography
and Other Laboratory Results
h i order to  determ ine whether any such re la tionsh ip  could be 
proven s ta tis tic a lly , the re su lts  were examined in  te rm s of the c lin ic a l 
index at the tim e of blood sam pling, foeta l outcome and percentile  b irth
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weight. These w ill be discussed in tu rn .
(a) C lin ica l Index
The "c lin ic a l index" (Howie et a l. , 1976) is  based on the 
d iasto lic  blood pressure and quantitative p ro te inu ria  resu lts  and 
is  calculated according to  the fo rm u la :-
= 0. 542 X j  + 12.917 log^ (1 + Xg) -  13. 374
where = increase in  d iasto lic  blood pressure (mmHg)
compared w ith  reading ea rly  in  pregnancy
Xg -  p ro te inuria  (g /24 hours)
(The authors arranged th is  equation so that a ll the c lin ic a lly  norm al 
patients in  th e ir study had negative indices, w h ile  positive indices 
were only found in  the pre-eclam ptic patients).
The c lin ic a l index was calculated fo r the day (o r days) when 
blood samples were studied from  a ll the pre -ec lam ptic  and norm al 
pregnant women included in  Groups I  and II, Chapter V (Table 44).
As would be expected a ll the norm al pregnant women had negative 
indices, but negative indices were also found in  resu lts  from  p re ­
eclam ptic Patient 9 in  the early samples (1-3) before the onset of 
p ro te inuria  and in  p re -eclam ptic Patient 4 (sample 2) a fte r in tra ­
u terine death had occurred and the pro te inuria  disappeared.
The c lin ic a l indices were compared w ith  measurements
o f:-
(i) area m
(ii)  SCT t it re  at
( ii i)  area p
(iv ) serum  FDP /  fdp
There was no sign ifican t co rre la tion  using lin e a r regression analysis 
between the paired c lin ica l index and chromatography findings when 
a ll the ante-natal resu lts  were examined (Table 45a). No sign ificant
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corre la tion  emerged when the resu lts  from  the sample closest to 
de live ry (or in trau te rine  death) were examined (Table 45b).
When the re su lts  from  4 patients in  whom the necessary 
in form ation was available fo r 3 o r m ore ante-natal samples was 
examined (Table 45c) some sign ifican t corre la tions d id emerge.
These resu lts  confirm ed s ta tis tica lly  the im pressions already 
gained in  these patients (Chapter V I, 2). These re la tionsh ips 
became m ore obvious when a single c lin ic a l index incorpora ting 
both blood pressure and p ro te inuria  resu lts  was used (see also 
F igures 58a-d).
It is  also w orth noting that although v irtu a lly  no s ign ifican t 
co rre la tion  existed when the pre-eclam ptic data was considered alone, 
i f  the resu lts  from  the 10 norm al pregnant women (Group II, Chapter 
V) were also included sign ifican t positive corre la tions emerged using 
a ll fou r labora tory resu lts  (Tables 46d and e). This was p a rticu la rly  
true  when the las t samples taken before de live ry  in  in trau te rine  death 
in  the pre-eclam ptic  patients were considered together w ith  the norm al 
pregnant resu lts  (Table 45e). Presum ably at th is  point in  tim e the 
patients w ith  pre-eclam psia were most severely affected.
In view of the differences between pre-eclam psia and norm al 
pregnancy already demonstrated in  Chapter V. 4 these resu lts  are 
perhaps not su rp ris in g , but it  is  most in te resting that i f  the c lin ic a l 
index is  used to  fo llow  a spectrum  of c lin ica l severity there appears 
to  be a re la ted spectrum  of severity in  the laboratory resu lts . I t  is  
im portant to  s tress, however, that w ith in  the pre -eclam ptic group of 
resu lts  v irtu a lly  no corre la tions were apparent except in  some 
ind ividual patients,
(b) Foetal Survival
The ante-natal resu lts  were considered in  te rm s of foeta l 
su rv iva l. They were divided in to  two groups -  " liv e  babies" and 
"pe rin a ta l deaths", a perina ta l death being defined as a s t ill-b ir th  
o r death w ith in  the f ir s t  week of life  (Donald, 1969a). As can be
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seen from  Table 46a Patients 1, 3, 6, 6 and 8 a ll suffered "p e rin a ta l 
deaths" according to  th is  de fin ition . The rem aining pre-eclam ptic 
patients and the norm al pregnant women (Table 46b) a ll had " liv e  
babies".
As shown in  Table 47a when a ll the ante-natal pre-eclam ptic 
resu lts  were examined there was no significant difference in  area m, 
SCT t itre  at area p and the serum F D P /fdp  leve ls. In addition 
when only the resu lts  from  the last sample taken before de live ry (or 
in trau te rine  death) were considered no sign ificant d ifference emerged 
(Table 47b). Th is was perhaps not su rp ris ing  as foe ta l su rv iva l w ill 
be affected by so many factors (e. g. the tim e  in te rva l between 
diagnosis and de live ry , see Table 46a).
Not su rp ris in g ly  the inclusion of the resu lts  from  the norm al 
pregnant women produced bette r separation between the two groups, 
p a rticu la rly  when the resu lts  taken closest to  de live ry  or in trau te rine  
death were used (Tables 47c and d). I t  is  w orth noting that area m 
was s ign ifican tly  higher in  the pre-eclam ptic patients, who la te r 
suffered pe rina ta l deaths, but that there was no difference in  the area 
p resu lts  between the two groups. This m ight suggest that coagulation 
a c tiv ity  was p a rtic u la rly  marked in  those patients who la te r suffered 
perina ta l deaths.
(c) P ercentile  B irth  Weight
The percen tile  b irth  weight of the babies born to  the pre-eclam ptic 
and norm al pregnant women (Tables 46a and b) was calculated in  term s 
of sex and gestational age using the Lubchenco charts (Lubchenco et a l. , 
1963; see also Chapter V II. 3). The resu lts  fro m  the ante-natal period 
were divided into two groups: -  those in  which the percentile  b irth  
weight of the baby was below the tenth percentile  ( i, e, those from  p re ­
eclam ptic Patients 4, 7, 8 and 10) and those in  which i t  was above the 
tenth percentile  ( i.e . those from  pre-eclam ptic Patients 1, 2, 3, 6 and 
9) and those from  a ll of the norm al pregnant women.
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As can be seen from  Table 48a there was no sign ifican t difference 
between the re su lts  from  the two groups when a ll the resu lts  from  the 
pre-eclam ptic  patients were considered. No sign ifican t difference 
emerged when only the resu lts  from  the las t sample taken before 
de live ry (or in trau te rine  death) were considered (Table 48b). Again 
it  is  probably not su rp ris in g  that no corre la tion  was observed as 
several factors are lik e ly  to be involved in  leading to  in trau te rine  
growth re ta rdation in  these patients (e* g. duration of pre-eclam ptic 
illness which varied  considerably -  see Table 46a.
When the resu lts  from  the norm al pregnant women were included 
s ta tis tica lly  s ign ifican t differences were only found w ith  the area p 
resu lts , which were higher in  the pregnancies resu lting  in  babies 
below the 10th percentile  in  b irth  weight (Tables 48c and d). W hile 
th is  could have occurred by chance (2p (0.02 in  both analyses) i t  is  an 
in te resting  observation, which m ight indicate increased breakdown of 
insoluble fib r in  in  these patients. (In trauterine growth re ta rdation in  
non-hypertensive pregnancies w ill be considered in  Chapter V II. 3).
V I. 4 T ota l P re-eclam ptic  Data
A t the tim e of preparing th is  chapter a fu rth e r 5 patients w ith  
pre-eclam psia have been studied. The resu lts  are not presented in  
de ta il as they are s im ila r to those already described. Therefore 
the resu lts  from  35 samples from  15 pre-eclam ptic women are now 
available together w ith  the resu lts  from  14 norm al pregnant women 
(to be described in  Chapter V II. 2).
When the resu lts  of these la rg e r but unmatched groups are 
compared (Table 49) the differences are s im ila r to those found in  
Groups I  and I I  in  Chapter V (see Table 42). I t  is  also w orth noting 
that there were in  fact no sign ifican t differences between the sm all 
selected group of 10 resu lts  (Group X, Chapter V) and the to ta l group 
of 35 resu lts  (Table 50).
V I. 5 Summary
When the re su lts  in  Chapters V and V I are considered as a
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whole there is  good evidence th a t:-
(i) a sm all, hut de fin ite  increase in  soluble complex concentration 
occurs in  association w ith  norm al pregnancy compared w ith  the non­
pregnant state
( ii)  a marked increase in  soluble complex concentration occurs 
in  association w ith  pre-eclam psia compared w ith  norm al pregnancy.
These resu lts  would suggest that in  norm al pregnancy there is  
e ither increased production of soluble complexes or dim inished 
clearance of these complexes or possibly both. Th is tendency (or 
tendencies) would seem to be increased in  samples from  women who 
have developed pre-eclam psia.
The actual soluble complex concentration in  the pre-eclam ptic 
patients did not co rre la te  w ith  the c lin ica l severity  of the condition 
as assessed by the "c lin ic a l index" of Howie and colleagues (1976).
If, however, there is  considered to be a spectrum of c lin ic a l severity 
extending from  norm al pregnancy to severe pre-eclam psia (Howie et 
a l. , 1976) a good positive  co rre la tion  can be demonstrated between the 
chromatography findings and the c lin ic a l index. Th is was p a rticu la rly  
true  of the soluble complex measurements (area m and SCT t itre  at
V -
The soluble complex levels did not help to  d istinguish which of 
the pre -eclam ptic pregnancies would resu lt in  pe rina ta l deaths or 
babies w ith  evidence of in trau te rine  growth re ta rdation. This was 
not su rp ris in g  because the foeta l outcome w ill depend on many factors 
including the gestational age at the tim e of onset of the pre -eclam ptic 
symptoms, the management and the duration of the illne ss .
The resu lts  from  Chapters V and V I, together w ith  the resu lts  
obtahied in  the obste trica l conditions studied in  Chapter V II w ill be 
discussed fu rth e r in  Chapter IX , in  which conclusions from  the work 
described in  the en tire  thesis w ill be considered.
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CHAPTER V II
SOLUBLE FIBRm OGEN-FIBRIN COMPLEXES IN 
OBSTETRICAL CONDITIONS C LIN IC ALLY 
RELATED TO PRE-ECLAMPSIA
V II. 1 Introduction
The resu lts  described in  Chapters V and V I showed a sm all, 
but s ign ifican t increase in  soluble fib rin o g e n -fib rin  complex 
concentration in  plasma samples from  healthy pregnant women 
and in  addition a fu rth e r marked increase in  samples from  women 
w ith  pre-eclam psia. In order to  assess these resu lts  more fu lly , 
fu rth e r studies were perform ed in  obste trica l patients w ith: -
(1) apparently uncomplicated single and tw in  pregnancies 
(Chapter VH. 2)
(2) pregnancies com plicated by in trau te rine  growth 
re ta rdation (Chapter VH. 3)
(3) essential hypertension diagnosed before the s ta rt 
of pregnancy (Chapter V II. 4)
(4) chronic rena l disease diagnosed before the s ta rt 
of pregnancy (Chapter V II. 5)
These groups w ill be discussed in  tu rn . The relevant back­
ground lite ra tu re  and the design of each study w ill be described 
f ir s t  followed by the resu lts  that were obtained.
The fo llow ing packed agarose columns were used fo r the 
work described in  th is  chapter: -
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Columns B5 (Batch H)
B5 to  BIO (Batch II)
C5 to  CIO (Batch II).
D eta ils regarding these packed columns can be found in  Appendix I,
VH. 2 Apparently Uncomplicated Single and Tw in Pregnancies
To investigate fu rth e r the increase in  soluble complex concentration 
in norm al pregnancy 21 apparently norm al pregnant women were studied 
(6 w ith  tw in pregnancies) and the resu lts  assessed in  term s of the 
development of com plications (e. g. hypertension), differences between 
single and tw in  pregnancies and the gestational age at the tim e of study. 
The resu lts  in  the tw in  compared w ith  the single pregnancies were of 
p a rticu la r in te res t, because it  is  thought that there is  a higher incidence 
of pre-eclam psia in  tw in  pregnancies (Donald, 1909b),
To be included in  these groups a ll the women had to  be norm o­
tensive and lack p ro te inu ria . There was nothing in  th e ir past m edical 
o r obste trica l h is to ry  to  suggest that any of these women would develop 
hypertension o r pre-eclam psia during the pregnancy under study.
The c lin ic a l de ta ils fo r the single and tw in  pregnancy groups are 
shown in  Tables 51 and 52. The gestational age ranged from  24 to  39 
weeks. Patients 15, 20 and 21 developed hypertension durmg the ante­
natal period and so are placed separately at the foot of the tables.
Patient 15 developed hypertension (B, P. 150/105) at 36 weeks gestation, 
but th is  settled a fte r adm ission to  hospital and bed re s t (B .P , 130/80). 
She never developed p ro te inuria  but had "s ig n ifica n t" fa c ia l and d ig ita l 
oedema. Patient 20 developed hypertension (B. P. 135/90) at 36 weeks 
gestation and la te r developed p ro te inuria  and eclam psia post-partum . 
Patient 21 developed hypertension (B .P . 140/90) at 37 weeks gestation 
but never developed pro te inu ria . Therefore none of these patients 
would have been included under the de fin ition  of "p re -ec lam psia" used 
in  th is  thesis. Patients 16 and 21 m ight be considered to  have had a
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less severe fo rm  of the syndrome, w hile  Patient 20 had post­
partum  eclam psia. Patients 1-14 and 16-19 had uncomplicated 
pregnancies, (Several of these patients were included in  Group 
n . Chapter V ).
The resu lts  of th is  study are  shown in  Tables 53 and 54.
The patients who developed hypertension were not included in  
the s ta tis tica l analysis of the resu lts , but i t  should be noted 
that none of the three patients had very abnormal resu lts . This 
would not encourage the idea that th is  technique would be able 
to  p red ic t which patients would develop hypertension la te r in  
pregnancy, but a much la rg e r study would be requ ired to 
con firm  th is ,
Wîien the resu lts  in  the 14 single and 4 tw in  pregnancies in  
which no com plications developed were compared, areas m and p 
and the SCT t itre  at tended to  be s ligh tly  higher in  the tw ins 
group, w h ile  area n and the FR-antigen and T. C. P. ra tio  tended 
to  be s lig h tly  low er. Only the differences in  the T. C. P, ra tio , 
however, reached s ta tis tica l significance (Table 55), W ith 
la rg e r numbers in  the tw ins group the levels of significance m ight 
have im proved, p a rtic u la rly  fo r the area m resu lts  which only 
ju s t fa iled  to  reach significance.
I t  has, however, to be concluded from  th is  study w ith  sm all 
numbers of patients that there were only m inor d ifferences 
between the two groups. S lightly higher values fo r areas m and 
p and SCT t itre  at and low er values of area n, FR-antigen 
ra tio  and T .C .P . ra tio  would, nevertheless, have to  be accepted 
as "n o rm a l" in  tw in  pregnancies.
There was no sign ifican t co rre la tion  between the gestational 
age (x) and area m (y). The equation calculated by lin e a r regression 
analysis was y ~ 6.340 -  0.060 x  using the data from  the 14 
uncomplicated single pregnancies (T  = -0 .266, 2 o<s )0 .1). I f  the
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data from  the 4 uncomplicated tw in pregnancies was also included 
the equation became y = 7,522 -  0.088 x  ( ^  = -0 .320, 2 cx )0 .1).
A gradual increase in  soluble complex concentration (using a 
measurement s im ila r to area m) to  a maximum of 4 ,9  * 1.3% at 
te rm  has been reported (H after, Schneebauer, Tafe l et a l. , 1975).
It  may be that in  the present series insu ffic ien t numbers of 
patients have been examined, especially in  early pregnancy, to 
show a s ign ifican t positive  co rre la tion . I t  m ight also be necessary 
to examine the same patient s e ria lly  through pregnancy in  order to  
demonstrate a corre la tion .
F rom  th is  study it  can be concluded that: -
(i) the soluble complex concentration was not ra ised in  
patients, who subsequently developed hypertension, 
i f  they were c lin ic a lly  norm al at the tim e  of study
( ii)  the trend towards increased soluble complex 
concentration demonstrated in  norm al single 
pregnancies was s lig h tly  increased in  norm al 
tw in  pregnancies
( iii)  fo r th is  sm a ll series there was no co rre la tion  
between soluble complex concentration and 
gestational age.
V II. 3 In trau te rine  Growth Retardation
In trau te rine  growth re ta rdation (dysm aturity, placental 
insuffic iency, ” sm a ll"fo r-d a tes”  o r "lig h t-fo r-d a te s ” ) is  an 
im portant obste trica l com plication, which may be associated w ith  
loca l i n travascu lar coagulation w ith in  the placental c ircu la tion  (see 
below).
There is  a com plicated in te r-re la tio n sh ip  between p re ­
eclam psia, hypertension in  pregnancy and in trau te rine  growth 
re tardation. P re-eclam psia may be accompanied by in tra ­
u terine growth re ta rdation (Donald, 1969c) and indeed several 
of the babies born to  the m others studied in  Group I  (Chapter V)
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were suffe ring  from  in trau te rine  growth re ta rdation at b irth  
(see Chapter V I. 3).
Increased fib r in  deposition is  a feature of placental histology 
in  in trau te rine  growth re tardation cases (when compared w ith  
placental histology from  uncomplicated pregnancies) and ^ is  
seems to be independent of whether the mother is  hypertensive 
o r not (Bonnar, Redman and Sheppard, 1976; Sheppard and 
Bonnar, 1976).
A  va rie ty  of coagulation^ fib rin o ly tic  and p la te le t function 
tests have been used to  study blood samples from  patients w ith  
in trau te rine  growth re tardation. One rep o rt has shown increased 
levels of plasma Factor V and fibrinogen in  patients w ith  in tra ­
u terine growth re ta rdation compared w ith  norm al pregnant women 
(E lder and M yatt, 1976). In contrast another re p o rt has shown 
no difference in  plasma Factors V and VIH  or fibrinogen in  patients 
w ith  in trau te rine  growth re ta rdation compared w ith  norm al pregnant 
women (Howie, P rentice  and M cN icol, 1971),
There is  lit t le  evidence of a ltered system ic fib rin o ly s is  in  
patients w ith  in trau te rine  growth retardation. Howie and colleagues 
(1971) found norm al euglobulin ly s is  tim es, norm al urokinase 
sen s itiv ity  tests, norm al plasma plasminogen leve ls and norm al 
antip lasm in leve ls in  a group of these patients. C onflicting resu lts  
have been published regarding serum  F D P /fdp  leve ls . These have 
been found to  be w ith in  norm al lim its  (Howie et a l. , 1971), ra ised in  
a sm all percentage of patients (Gordon, Hatky, Sola et a l. , 1975) 
and low er than norm al (E lder and M yatt, 1976) in  d iffe ren t series. 
P lacental extracts, however, from  pregnancies com plicated by 
in trau te rine  growth re ta rdation exhib it greater inh ib ition  of u ro ­
kinase induced fib rin o ly s is  using the fib r in  plate technique, than 
placental extracts from  norm al pregnancies (E lder and M yatt,
1976).
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P la te le t counts are norm al in  in trau te rine  growth re tardation 
patients (Howie et a l. , 1971; E lder and M yatt, 1976). P la te le t 
factor 3, p la te le t adhesiveness and adenosine diphosphate induced 
aggregation are a ll norm al in  these patients, however, p la te le t 
disaggregation appears to  be reduced (Howie et a l. , 1971).
When a ll th is  evidence is  considered together i t  would not 
favour the occurrence of dissem inated in travascu la r coagulation 
in  these patients. An increased degree of loca l i n travascular 
coagulation w ith in  the placenta m ight, however, be present in  these 
patients, although th is  does not seem to  produce marked changes 
in  the pe riphera l m aternal blood. The technique of plasma 
fibrinogen chromatography seemed p a rticu la rly  suitable to  study 
these patients. In addition, it  seemed im portant to  determ ine 
any differences between the in trau te rine  growth re ta rda tion  and 
pre-eclam ptic  patients. It was d iffic u lt to know to what extent 
the findings in  the pre -eclam ptic  patients sim ply re flected  loca l 
in travascu la r coagulation w ith in  the placenta.
A group of 10 patients in  whom the diagnosis of in trau te rine  
growth re ta rda tion  was suspected on c lin ica l grounds were therefore 
studied. A fte r de live ry  th is  to ta l group was divided in to  a sub­
group in  whom the diagnosis of in trau te rine  growth re ta rdation 
was confirm ed (5) and a sub-group in  whom it  was not (5). The 
diagnosis was confirm ed i f  the baby's b irth  weight was below the 
10th percentile  fo r the appropriate sex and gestational age using 
the Lubchenco charts (Lubchenco, Hansman, D ress ie r et a l. ,
1963). The c lin ic a l de ta ils are given in  Table 56. A ll the 
patients were norm otensive and none had sign ifican t protem uria 
at the tim e of study and none of the patients subsequently developed 
pre-eclam psia. Patient 9 did, however, develop m ild  fluctuating 
hypertension (B. P. 140/90) at 37 weeks gestation. In 5 patients
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(1, 2, 6, 8 and 9) the diagnosis of in trau te rine  growth re ta rdation 
was confirm ed at b irth . In one case (Patient 2) the baby’s b irth  
weight was greater than 2,5 Kg (i. e. not ’’low b irth  weight”  by 
some de fin itions, Hutchison, 1969). Nevertheless the baby’s 
b irth  weight was below the 10th percentile  on the appropriate 
Lubchenco chart and there fore  the baby was suffe ring  from  in tra ­
u terine growth re ta rdation according to  de fin ition  used fo r th is  
present study.
The resu lts  of plasma fibrinogen and serum F D P /fdp  
estim ations fo r the to ta l group (10 patients) are shown in  Table 
57. These are s p lit in to  the diagnosis confirm ed (5 patients) and 
not confirm ed (5 patients) sub-groups in  Table 58. The plasma 
fibrinogen chromatography resu lts  fo r the to ta l group are shown 
in  Table 59. These are s p lit in to the two sub-groups in  Table 
60.
S ta tis tica l analysis on the data from  the two sub-groups is  
shown in  Table 61. The gestational age did not d iffe r s ign ifican tly  
between the two sub-groups. The plasma fibrinogen leve l appeared 
to be s ign ifican tly  higher in  the sub-group in  which the diagnosis was 
confirm ed, and w hile  th is  may sim ply be due to  chance (2p (0.02) 
s im ila r resu lts  have been published by E lder and M yatt (1976).
There was no sign ifican t difference in  the serum F D P /fdp  leve ls. 
This is  in  keeping w ith  the resu lts  from  a much la rg e r series 
using a radioimmunoassay (Gordon et a l. , 1975) although lower 
than norm al serum  F D P /fdp  levels in  these m others have also 
been reported (E lder and M yatt, 1976). Area m was s ign ifican tly  
higher in  the sub-group in  which the diagnosis was confirm ed 
(2p (0.01) w hile area p was also s ign ifican tly  increased in  th is  
sub-group (2p (0.05). There was no sign ificant difference in  the 
SCT t it re  at o r in  the FR-antigen or T .C .P . ra tio s .
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Significant differences in  areas m, n and p are also found 
when the data from  the 5 patients in  whom the diagnosis was 
confirm ed was compared w ith  that from  the 14 norm al pregnancies 
described e a rlie r in  th is  chapter (Table 62). There were no 
sign ifican t differences when the data from  the 5 patients in whom 
the diagnosis was confirm ed were compared w ith  that from  the 
14 norm al pregnancies (Table 63).
It would therefore seem that increased soluble complex 
concentrations, as measured by area m (i. e. o ligom ers, probably 
m ainly d im ers) and early  fib rinogen/ fib r in  degradation products, 
as measured by area p, are present in  plasma samples from  
patients in  whom the diagnosis of in trau te rine  growth re ta rdation 
is  subsequently confirm ed on grounds of b irth  weight. The numbers 
are , however, ve ry  sm all. Subjective bias was un like ly  as the 
resu lts  were calculated before the diagnosis was confirm ed or 
refuted. The resu lts  would suggest increased form ation or 
dim inished clearance of soluble complexes (or both) in  in tra ­
uterine growth re ta rdation patients compared w ith  norm al pregnant 
patients. In addition there may e ither be an increase in  fibrinogen- 
o ly s is /fib rin o ly s is  in  the in trau te rine  growth re ta rda tion  patients or 
dim inished clearance of the early  degradation products (or both).
The resu lts  in  the 5 patients w ith  confirm ed in trau te rine  
growth re ta rdation were compared w ith  those from  the 10 samples 
from  10 pre-eclam ptic  patients (Group I, Chapter V) and the resu lts  
of th is  s ta tis tica l analysis are shown in  Table 64. There was no 
difference in  the plasma fibrinogen levels between the two groups. 
There were, however, higher values fo r area m and SCT t itre  at 
and low er values fo r the FR-antigen and T .C .P . ra tio s  in  the 
pre -eclam ptic patients. These findings would suggest higher levels 
of soluble complexes (both oligom ers and polym ers) in  samples from
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the pre -eclam ptic patients. There was no sign ifican t d ifference, 
however, in the area p resu lts , although the serum FDP /fd p  levels 
were s ign ifican tly  higher in  the pre-eclam ptic patients. These 
findings could suggest comparable o r only s lig h tly  increased 
fib rin o g e n o lys is /fib rin o lys is  in  the pre-eclam ptic patients.
C lea rly  the resu lts  in  the in trau te rine  growth re ta rdation 
patients show some overlap w ith  the resu lts  in  p re -eclam ptic 
patients, but the marked abnorm alities found in  many of the p re ­
eclam ptic patients are not seen in  the in trau te rine  growth re tardation 
patients.
Since the number of confirm ed in trau te rine  growth re tardation 
patients was so sm all^care must be taken not to  make unwarranted 
conclusions from  these resu lts . It has, however, been shown that 
there are s ign ifican t differences in  the plasma fibrinogen chrom ato­
graphy resu lts , p a rtic u la rly  w ith  respect to the soluble complexes 
measured in  area m between;-
(i) Patients w ith  suspected in trau te rine  growth 
re ta rda tion  in  whom the diagnosis is  confirm ed 
and those in  whom it  is  not,
( ii)  Patients w ith  confirm ed in trau te rine  growth 
re ta rda tion  and a group of norm al pregnant 
subjects.
( iii)  Patients w ith  confirm ed in trau te rine  growth 
re ta rdation and patients w ith  pre-eclam psia.
In contrast there was significant d ifference between the 
patients w ith  suspected in trau te rine  growth re ta rda tion  in  whom the 
diagnosis was not confirm ed and a group of norm al pregnant subjects.
These resu lts  would be in  keeping w ith  the h is to log ica l evidence 
that increased in travascu la r coagulation occurs w ith in  the placenta 
in  pregnancies com plicated by in trau te rine  growth re ta rdation 
(Bonnar, Redman and Sheppard, 1975). The higher soluble 
complex concentration in  association w ith  pre-eclam psia m ight
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suggest that in  pre-eclam psia the in travascu lar coagulation occurs 
not only w ith in  the placental c ircu la tion , but is  more widespread 
throughout the m aternal c irc u la tio n ..
V II.#  Essentia l Hypertension in  Pregnancy
It was decided to  study a group of patients in  whom essential 
hypertension had been diagnosed before the s ta rt of pregnancy, 
because i t  was im portant to establish whether or not the abnorm alities 
found in  the pre -eclam ptic patients reflected changes inva riab ly  
present in  hypertensive, pregnant women. A previous study had 
fa iled to  show any difference in  coagulation, fib rin o ly tic  o r p la te le t 
tests between pregnant women w ith  essential hypertension and 
norm al pregnant subjects (Howie et a l. , 1971). I t  was necessary, 
however, to see whether there was any difference in  plasma fibrinogen 
chromatography resu lts  between these groups.
To qua lify fo r inclusion in  th is  group the pregnant woman had 
to  have been fu lly  investigated fo r hypertension before the s ta rt of 
pregnancy and a ll causes of secondary hypertension excluded (Table 
65). Patient 5 had a m inor degree of renal a rte ry  stenosis, which 
was not thought to  be of any c lin ic a l significance. Each patient had 
defin ite  hypertension on the day of study, but none of the patients 
subsequently developed worsening hypertension or p ro te inu ria  
suggesting the onset of superimposed pre-eclam psia. As it  
proved ra the r d iffic u lt to  find patients who fu lfille d  a ll these 
c r ite r ia  only 5 patients are considered in  th is  section.
The c lin ic a l deta ils are shown in  Table 65. The plasma 
fibrinogen chrom atography, plasma fibrinogen and serum  F D P /fdp  
resu lts  are shown in  Table 66. The s ta tis tica l analysis comparing 
the resu lts  in  essential hypertension w ith  those in  norm al pregnancy 
are shown in  Table 67. It can be seen that there is  some difference 
in  gestational age between the two groups (lower in  the essential
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hypertensive group 2p (0.05), I t  proved so d iffic u lt to  find 
suitable patients, that th is  had to  be accepted. A part from  
th is  and the obvious higher blood pressure readings in  the 
essential hypertension group, no other s ta tis tica lly  s ign ifican t 
difference was found.
When the resu lts  in  the essential hypertensive group were 
compared w ith  those found in  the 10 samples from  the 10 p re ­
eclam ptic patients (Group I, Chapter V) there was no difference 
in  e ither systo lic o r d iasto lic  blood pressure readings between 
the two groups, nor was there any difference in  plasma fibrinogen 
leve ls (Table 68), A rea m and SCT t itre  at V^, however, were 
both s ign ifican tly  higher, w h ile  the FR-antigen and T .C .P . ra tio s  
were s ign ifican tly  low er in  the pre-eclam ptic group. The soluble 
complex levels (both oligom ers and polym ers) were therefore 
higher in  the pre -eclam ptic patients. Area p leve ls were not 
s ign ifican tly  d iffe ren t between the groups, although the serum 
F D P /fdp  leve ls were s ign ifican tly  higher in  the pre -eclam ptic 
patients. It would there fore  seem possible that fib rino ge no lys is / 
fib rin o ly s is  was comparable o r only s lig h tly  increased in  the p re ­
eclam ptic patients.
F rom  these resu lts  i t  can be concluded that: -
(i) there was no increased concentration of soluble 
complexes in  pregnancies in  which the m other 
suffered from  essential hypertension, compared 
w ith  pregnancies in  which the mother was norm o­
tensive
(ii)  there was a defin ite  increase in  soluble complex 
concentration in  pregnancies com plicated by p re ­
eclam psia, compared w ith  pregnancies in  which 
the mother suffered from  essential hypertension 
w ith  comparable systo lic and d iasto lic  blood 
pressure levels.
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V II. 5 Chronic Renal Disease in  Pregnancy
F in a lly  a group of pregnant patients, in  whom chronic renal 
disease had been documented before the s ta rt of pregnancy were 
studied. It is  recognised that many cases diagnosed as ’’p re ­
eclam psia”  during pregnancy w ill demonstrate s ign ifican t renal 
pathology post-na ta lly . Bedford and T aylo r (1972) found an 
incidence of 38% rena l pathology (demonstrated by intravenous 
pyelography ca rrie d  out post-na ta lly) in  100 women ’ ’w ith  moderate, 
severe o r recu rren t pre-eclam psia” . 8 out of the 10 patients 
described in  Group I  (Chapter V) were re fe rre d  fo r renal 
investigation (including intravenous pyelography) post-na ta lly .
In a ll 8 cases no rena l abnorm ality was found. It  was therefore 
concluded that in  at least 8 out of the 10 patients in  Group I  no 
sign ifican t rena l disease was present, but it  was im portant to 
establish the chromatography findings in  patients w ith  a combination 
of chronic rena l disease and pregnancy.
It  is  d iffic u lt to conduct a study in  chronic rena l disease 
patients during pregnancy because, since hypertension and p ro te in ­
u ria  are often present throughout pregnancy, i t  is  v irtu a lly  
im possible to  decide whether pre-eclam psia has developed in  
addition to  the background renal disease. The aim  of the present 
study was therefore  to  see whether the combination of chronic 
renal disease and pregnancy inevitably produced abnorm alities in  
the plasma fibrinogen chromatography resu lts .
To qualify fo r inclusion in  th is  group the woman had to  have 
been fu lly  investigated before the s ta rt of pregnancy and a defin ite  
diagnosis of chronic rena l disease made. As each of the 5 patients 
studied had e ither hypertension, p ro te inuria  or both throughout most 
of the pregnancy it  was not possible to  make o r exclude a c lin ic a l 
diagnosis of superimposed pre-eclam psia.
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The c lin ic a l de ta ils are shown in  Table 69. 4 out of the 5
patients were known to  have chronic pyelonephritis w h ile  the 
rem aining patient had system ic lupus erythematosus w ith  renal 
involvem ent. The plasma fibrinogen chromatography, plasma 
fibrinogen and serum  F D P /fdp  resu lts  are shown in  Table 70. The 
resu lts  are compared w ith  the group of 14 norm al single pregnancies 
in  Table 71, Only the blood pressure, serum F D P /fdp  and FR - 
antigen and T . C, P. ra tio  resu lts  d iffe red s ign ifican tly .
The resu lts  in  the chronic rena l disease patients were then 
compared w ith  those from  the 10 pre-eclam ptic patients in  Group I, 
Chapter V (Table 72), The blood pressure readings were comparable 
in  the two groups, as were the plasma fibrinogen leve ls. A rea m 
and the SCT t it re  at were s ign ifican tly  higher, w h ile  the FR- 
antigen and T , C. P. ra tio s  were s ign ifican tly  low er in  the p re ­
eclam ptic patients. These findings suggest higher soluble complex 
levels (both oligom ers and polym ers) in  the pre -eclam ptic  patients. 
The area p and serum  F D P /fdp  resu lts  were s im ila r in  the two 
groups suggesting comparable fib rin o g e n o lys is /fib rin o lys is .
Th is study suggests that the combination of chronic renal 
disease and pregnancy does not necessarily produce marked 
abnorm alities in  the plasma fibrinogen chromatography resu lts .
The FR-antigen and T. C. P. ra tio s  did tend to  be s lig h tly  lower 
in  the chronic renal disease patients compared w ith  norm al 
pregnant women, suggesting increased polym er in  the rena l disease 
patients, but th is  was the only s ign ifican t d ifference. The resu lts  
in  the chronic rena l disease patients were m arkedly d iffe ren t from  
those found in  the pre-eclam ptic  group, suggesting a much higher 
soluble complex concentration in  the pre-eclam ptic patients. One 
additional in te resting  observation was the ra ised serum  F D P /fdp  
levels found in  the chronic renal disease patients compared w ith  
norm al pregnancy. The leve ls were s im ila r to those found in  p re ­
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eclampsia. The ra ised levels in  the chronic rena l disease patients 
may re fle c t the dim inished clearance of the low m olecular weight 
fragm ents (D /d  and E /e ) in  patients w ith  loss of functioning renal 
tissue (A tsushi, R utherford, Wochner et a l. , 1976) ra th e r than 
increased production.
It would, however, be in co rre c t to conclude that increased 
soluble complex leve ls (as measured by area m) cannot be found 
in pregnant women w ith  chronic renal disease. Patient 5 was 
followed s e ria lly , the resu lts  selected fo r s ta tis tica l analysis 
were from  the f ir s t  blood sample taken. In F igure 59 the 
resu lts  of area m and p measurements are shown together w ith  
the c lin ica l index on the day of study (see Chapter V I. 3 fo r 
form ula). It can be seen that area m was m arkedly increased 
in  the three samples taken closest to  de live ry. The ris e  in area 
m did accompany a phase of c lin ica l de terio ra tion , but since both 
hypertension and p ro te in u ria  were present throughout pregnancy, 
it  is  im possible to know whether th is  indicated the development of 
superimposed pre-eclam psia. In addition area p levels were 
s ligh tly  ra ised above norm al pregnant values in  4 out of the 5 
ante-natal samples. The b irth  weight of the baby was above the 
10th percentile  and he was in good condition at b irth . It is  
therefore un like ly  that the baby was seriously affected by the 
pre -eclam ptic process if  present.
F rom  the resu lts  in  th is  series of chronic rena l disease 
patients i t  can be concluded that: -
(1) the plasma fibrinogen chromatography resu lts  may be 
w ith in  the norm al lim its  fo r pregnancy in  pregnant women w ith 
defin ite  chronic renal disease, apart from  a possible increase in  
polym er levels (FR-antigen and T .C .P . ra tio s ). In p a rticu la r 
the quantitative measurements (area m and SCT t itre  at V^) were 
norm al in  the chronic renal disease patients studied.
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( ii)  Serum F D P /fdp  leve ls tend to be increased in  pregnant 
chronic rena l disease patients compared w ith  norm al pregnancy.
V II* 6 Summary
The studies described in  th is  chapter have shown that there 
may be a trend towards s lig h tly  higher soluble complex concentration 
in  tw in  as compared w ith  single pregnancies. I t  was not possible, 
however, to  demonstrate a co rre la tion  between soluble complex 
concentration and gestational age.
In trau te rine  growth re ta rdation  was accompanied by a 
sign ifican t increase in  soluble complex concentration, when 
compared w ith  that occurring  in  cases where the diagnosis was 
suspected, but not confirm ed and also when compared w ith  norm al 
pregnancy. The increases found in  in trau te rine  growth re tardation 
were not as marked, as those already demonstrated in  pre-eclam psia. 
There would there fore  seem to be a difference between pre-eclam psia 
and in trau te rine  growth re ta rdation. This may re su lt from  the 
in travascu la r coagulation being lim ite d  to the placental vasculature 
in  the in trau te rine  growth re tardation patients and being more 
widespread throughout the m aternal c ircu la tion  in  pre-eclam psia.
The combination of essential hypertension and pregnancy did 
not appear to  be associated w ith  a s ign ificant increase in  soluble 
complex concentration. I t  is  therefore un like ly  that the increased 
soluble complex concentration found in  the pre -eclam ptic  patients 
was sim ply secondary to the hypertension. F in a lly , i t  was shown 
that the combination of chronic rena l disease and pregnancy did not 
necessarily lead to  the increases in  soluble complex leve ls found in  
the p re -eclam ptic  patients.
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CHAPTER v m
SOLUBLE FIBRINQGEN-FIBRIiSr COMPLEXES IN 
ASSOCIATION WITH OESTROGEN-CONTAmEviG 
ORAL CONTRACEPTIVE DRUGS
V III. 1 Introduction
Women rece iv ing oestrogen-containing o ra l contraceptive 
drugs suffer fro m  an increased incidence of throm bo-em bolic 
episodes (Royal College of General P rac titio ne rs , 1967; Inman 
and Vessey, 1968; Vessey and D o ll, 1968; C ollaborative Group 
fo r the Study of Stroke in  Young Women, 1973 etc. ). Such women, 
therefore , m ight be regarded as suffering from  a ’’hypercoagulable”  
state, at least in  the epidem iological sense.
In h is recent review  a rtic le  on the subject of oestrogens and 
blood coagulation, von Kaulla (1976) pointed out that the acceleration 
of blood c lo tting  by oestrogens was w e ll known before the tim e that 
o ra l contraceptive drugs were introduced. He quotes the observation 
by B ablik (1935) that ’ ’the investigations of various authors indicate 
that c lo tting  is  strongly promoted by fo llic u la r hormone” .
The studies described in  th is  chapter used the technique of 
plasma fibrinogen chromatography to  investigate th is  ’ ’hypercoagulable”  
state, because of the possible s im ila rity  to the ’’hypercoagulable”  state 
occurring in  norm al pregnancy (Chapter VHI. 2), In addition.^a group 
of women diagnosed as su ffe ring  from  ” p ill-re la te d  hypertension”  
were studied, because of the possible s im ila r ity  of th is  condition 
to  ’ ’pregnancy-related hypertension”  or pre-eclam psia (Chapter 
VHI. 3).
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A short account of the relevant lite ra tu re  on each subject 
w ill be discussed f ir s t ,  followed by the design of the study and the 
resu lts  that were obtained.
V III. 2 Healthy (Norm otensive) Women Taking Oestrogen-  
Containing O ra l Contraceptive Drugs
There are several reasons fo r suggesting that women taking 
such drugs su ffe r from  a ’’hypercoagulable”  state. The epidemio­
lo g ica l evidence already mentioned has shown an increased incidence 
of venous throm bo-em bolisra and cerebra l throm bosis o r ischaemia 
in  these women. These women may also suffer from  a ’ ’hyper­
coagulable”  stage in  the haematological sense (many papers including 
Howie, M allinson, P rentice et a l . , 1070).
The a lte ra tions in  the components of the coagulation and 
fib rin o ly tic  systems together w ith  changes in p la te le t function have 
been summarised by von Kaulla (1076):-
(1) Coagulation system:
Increases in  plasma fibrinogen, prothrom bin and Factors V , 
V II, V III, IX  and X  have been demonstrated.
(2) F ib rin o ly tic  system:
Increases in  plasma plasminogen, antiplasm in and decreased 
plasminogen activa to r in  the venous w a ll have been found.
(8) P la te le t function:
Increased p la te le t aggregability has also been demonstrated.
In  addition to  these changes von Kaulla mentions dim inished an ti­
throm bin I I I  a c tiv ity  and increased ’’soluble fib r in ” .
Abnorm al o r activated fo rm s of fibrinogen have been detected 
in  these women as cryofibrinogen (Pindyck, Lichtm an and Kohl,
1970), as plasma soluble fib rin o g e n -fib rin  complexes (A lk jae rs ig , 
F le tcher and B ur ste in, 1970; Astaeck, Bebber and van de Loo,
1974; A lk ja e rs ig , F le tcher and B ur stein, 1975) and as soluble
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f ib r in  (P ilgeram , E lliso n  and von dem Bussche, 1974).
There is  con flic ting  evidence regarding the production of 
soluble complexes and soluble fib r in  by incubation o f fibrinogen 
w ith  oestrogens in  v itro . The o rig in a l w ork suggested that th is  
did occur (P ilgeram  and von dem Bussche, 1974; P ilgeram  and 
von dem Bussche, 1975) but these cla im s have not been supported 
by other studies (Gaulton and D o o little , 1975; Stem berger, H after, 
G ra e ffe ta l., 1976).
The present in  vivo  study was undertaken w ith  two main aim s. 
F irs tly , to  tr y  to con firm  the resu lts  of previous studies and 
secondly, to  compare the resu lts  w ith  those found in  norm al 
pregnancy. Such a com parison is  c le a rly  of in te rest in  helping 
to  unravel the problem  of re la tin g  the plasma fibrinogen chrom ato­
graphy resu lts  to  the d iffe ren t fo rm s of in travascu la r coagulation.
Study and Results
Ten healthy, norm otensive women were studied. They a ll 
had taken a fo rm  of oestrogen-containing o ra l contraceptive drugs 
fo r a m inim um  of 3 months. The actual preparation varied  but 
each contained 50 m icrogram s of e ither e th inyl-oestrad io l or 
m estranol. As the numbers were sm all no attem pt was made to  
compare d iffe ren t preparations. Each woman was taking the drug 
on the day of study. The packed gel columns used fo r th is  study 
w ere ;-
Columns C5 and C6 (Batch II)
B5 and B7 (Batch H).
(D etails regarding these packed columns can be found in  Appendix I).
The resu lts  obtained are shown in  Tables 73 and 74, They were 
f ir s t  compared w ith  the resu lts  from  a group of norm otensive, non­
pregnant women who were not taking oestrogen-containing drugs 
(i. e. Group HI in  Chapter V). The resu lts  of the s ta tis tica l analysis
are shown in Table 75. It can be seen that only one re su lt (area 
m) d iffe red s ign ifican tly  between the two groups. This would 
suggest increased soluble complex concentration of the oligom er 
type. I£ the upper lim it of norm al fo r area m in  the non-pregnant 
women not taking oestrogen-containing drugs is  taken as 3. 5% 
(mean 2 S. D. ) 8 out of the 10 women taking such preparations 
had values fo r area m above th is . These resu lts  are broadly 
speaking in  agreement w ith  those of A lk ja e rs ig  and colleagues 
(1975) and Asbeck and colleagues (1974) although the method of 
calculation of the soluble complex concentration is  d iffe re n t. In 
p a rticu la r, the resu lts  resem ble those of Asbeck and colleagues 
(1974), who c la im  to have demonstrated the appearance of a 
dim er in  plasma samples from  women taking oestrogen-containing 
o ra l contraceptive therapy by comparing resu lts  before and 
during treatm ent.
The resu lts  in  the women taking the oestrogen-containing 
drugs were then compared w ith  those found in  norm al single 
pregnancies ( i. e. the 14 patients in  Chapter V II. 2). The resu lts  
of the s ta tis tica l analysis are shown in  Table 76. The plasma 
fibrinogen leve ls were s ign ifican tly  higher in  the pregnant women 
compared w ith  those taking oestrogen-containing drugs. The 
SCT t itre  at V^ was s ign ifican tly  higher in  the pregnant patients 
and the FR-antigen and T .C .P . ra tio s  s ign ifican tly  low er.
These resu lts  suggest that there is  a higher concentration 
of polym er in  the pregnant patients, than in those taking the 
oestrogen-containing drugs. There was, however, no 
difference between the two groups in  measurements of area m 
and th is  would suggest that the concentration of d im er is  s im ila r. 
Although the pregnant patients tended to have higher leve ls of 
area p (early  degradation product) th is  fa iled  to  reach s ta tis tica l 
significance^although the serum  F D P /fdp  levels were s ign ifican tly
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higher in  the pregnant group.
The resu lts  fro m  th is  study can be sum m arised:-
(i) There are increased soluble complex leve ls (o ligom ers, 
probably d im ers) in  the plasma samples from  women taking 
oestrogen-containing o ra l contraceptive drugs, compared w ith
a con tro l group of women not taking these drugs,
( ii)  Although there appears to be no s ign ifican t d ifference 
between the soluble complex concentrations of the o lig o m e r/d im e r 
type between samples fro m  healthy women taking oestrogen- 
containing drugs and norm al pregnant women, there is  an increase 
in  polym er concentration in  pregnancy.
( ii i)  Plasm a fibrinogen and serum  F D P /fdp  leve ls were 
both s ign ifican tly  higher in  norm al p re ^a n cy  than in  women taking 
oestrogen-containing drugs but there was no difference in  plasma 
fibrinogen and serum  F D P /fdp  levels between women taking 
oestrogen-containing o ra l contraceptive therapy and those who 
did not.
V III, 3 Hypertensive Women Taking Oestrogen-Containing O ra l
Contraceptive Therapy
One com plication of long -te rm  o ra l contraceptive therapy is  
an increase in  the blood pressure. In  a controlled prospective 
study sign ifican t increases in  both mean systo lic and d ias to lic  
blood pressure were found a fte r 4 years treatm ent, the blood 
pressure re tu rn ing  to  p re -trea tm en t levels w ith in  three months 
of discontinuing therapy (W eir, B riggs, Mack et a l. , 1974). A 
sm all percentage of women (5-7%) actually become hypertensive 
(B .P . ) 140/90) w h ile  taking these drugs (Spellacy and B irk , 1972), 
I t  has been suggested that a h is to ry  of pre-eclam psia may be a p re ­
disposing facto r in  such cases (Spellacy and B irk , 1972), I t  is  
known that th is  "p ill-re la te d  hypertension" may be reve rs ib le  on
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discontinuing treatm ent (W eir, T ree and McElwee, 1973),
The concept of a defin ite  diagnostic syndrome of " p il l-  
re lated hypertension" has been strengthened by the dem onstration 
of abnorm alities of the periphera l renal vessels in  these patients 
by angiography and histology (Boyd, Burden and A ber, 1975), The 
vessels may show irre g u la r narrow ing, beading and increased 
to rtuo s ity  but no evidence of m icro throm bi. M icro th rom b i were 
only found in  patients, who had remained hypertensive a fte r 
pregnancies com plicated by pre-eclam psia and were taking 
oestrogen-containing o ra l contraceptive drugs o r in  patients 
developing acute o lig u ric  rena l fa ilu re  w hile  taking these drugs.
Study and R esults
F ive patients in  whom the diagnosis of "p ill-re la te d  hypertension" 
had been made were examined. They had a ll been taking oestrogen- 
containing o ra l contraceptive therapy fo r several years (range - 
9 years). In each case the woman had been known to  be norm o­
tensive before s ta rting  therapy and system ic hypertension had 
developed w hile taking therapy. Each patient had been re fe rre d  
by the F am ily  Planning Association to  D r. H, W eir (Gartnavel 
General H ospita l, Glasgow), who made the diagnosis on the basis 
o f:-
(i) sustained hypertension developing w h ile  taking 
the drug
( ii)  no other obvious cause of secondary hypertension.
The p o ss ib ility  that essential hypertension had developed quite 
fo rtu ito u s ly  w h ile  the patient was on therapy c le a rly  existed.
A ll five  patients had sign ifican t hypertension on the day of 
study and 4 out of the 5 had taken oestrogen w ith in  the previous 24 
hours. The rem aining patient had taken the la s t tab let of a three 
week course, two days before the tim e of blood sam pling. The
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other c lin ic a l de ta ils are shown in  Table 77.
A ll 5 patients discontinued therapy sho rtly  a fte r they had been 
studied. On review  three months la te r 3 out of the 5 patients showed 
a de fin ite  fa ll in  blood pressure (Patients 3, 4 and 5). One patient 
showed worsening of hypertension and was started on antihypertensive 
therapy (Patient 1), w h ile  the rem aining patient (2) showed a 
fluctuating pattern of blood pressure readings, s im ila r to those 
found before stopping therapy. Three out of the five  patients may 
therefore have had "re v e rs ib le " hypertension.
The fo llow ing packed agarose columns were used fo r th is  study: -  
Column BIO (II)
Column CIO (II)
Column C12 (II)
Column C13 (II)
(Details regard ing these packed columns can be found in  Appendix I).
The resu lts  obtained in  th is  group of patients are shown in 
Tables 77 and 78. The s ta tis tica l analysis com paring the resu lts  
w ith  those obtained in the norm otensive women taking oestrogen- 
containing o ra l contraceptive drugs is  shown in  Table 79, The 
hypertensive group were s ign ifican tly  older and th is  presumably 
re fle c ts  the increased incidence of hypertension w ith  increasing 
age. The hypertensive women also had s ign ifican tly  higher plasma 
fibrinogen and serum  F D P /fdp  levels. The only s ign ifican t 
differences in  the chromatography resu lts  were higher SCT titre s  
at and low er FH-antigen ra tio s  in  the hypertensive group. These 
findings suggest increased polym er, but not increased d im er in  the 
hypertensive patients.
The findings in  th is  study can be summarised: -
(i) Soluble complex concentration as measured by area m 
(i, e. o ligom er or d im er) does not d iffe r s ign ifican tly  between a 
group of hypertensive and a group of norm otensive women taking
oestrogen-containing o ra l contraceptive drugs.
( ii)  Increased levels of polym er as measured by SCT t itre  
at V q and the FR-antigen ra tio  may, however, be present in  the 
hypertensive women, but the re la tive  importance of polym er as 
compared to  o ligom er (d im er) is  not yet understood,
( ii i)  Plasma fibrinogen and serum F D P /fdp  leve ls were 
both higher in  the hypertensive patients,
V III. 4 Summary
The two studies described in  th is  chapter have shown a 
s ign ifican t increase in  soluble complex of oligom er (d im er) type 
in  plasma samples taken from  women receiving oestrogen- 
containing o ra l contraceptive therapy. It is  im possible to  say 
whether th is  is  due to  pure "hypercoagulab ility" o r whether some 
degree of insoluble fib r in  deposition has occurred.
This tendency would seem to  be increased, at least in  the 
form ation of po lym ers, in  samples from  women who have become 
hypertensive w hile taking these drugs, but again the re la tionsh ip 
of th is  observation to insoluble fib r in  deposition requ ires fu rth e r 
c la rifica tio n .
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CHAPTER IX  
CONCLUSION
DC. 1 Introduction
In th is  thesis the biochem istry of fibrinogen has been 
discussed in  de ta il w ith  p a rticu la r reference to the form ation of 
soluble fib rin o g e n -fib rin  complexes (Chapter I). To allow  
iden tifica tion  of these soluble complexes the technique of plasma 
fibrinogen chromatography was set up (as described in  Chapter II) 
and the methodology checked in  a series of in  v itro  experim ents 
(Chapter III)  and in  studies of the in  vivo acute de fibrina tion state 
induced by intravenous ancrod infusion (Chapter IV ).
Samples from  norm al pregnant women and patients w ith  
pre-eclam psia were then studied (Chapters V and VI) and the 
resu lts  compared w ith  those found in  several obste trica l conditions 
re la ted to  pre-eclam psia (Chapter V II) and w ith  those found in  
norm otensive and hypertensive women taking oestrogen-containing 
o ra l contraceptive therapy (Chapter V III).
D iscussion of the w ork in  th is  thesis can be considered 
under two main headings, the f ir s t  dealing w ith  an assessment of 
the technique its e lf and the second w ith  the significance of the 
resu lts  as evidence of in travascu la r coagulation,
IX . 2 An Assessment of the Technique of Plasma F ibrinogen 
Chromatography
The fo llow ing questions have to be answered: -  
(a) What conclusions can be drawn from  the 
various measurements obtained using the 
plasma fibrinogen chromatography technique?
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How do these measurements re la te  to each 
other and to  the plasma fibrinogen and serum  
F D P /fdp  resu lts?
(fo) What p ra c tica l problem s are associated w ith  
the plasma fibrinogen chromatography 
technique?
(c) What m odifications could be introduced to 
im prove the technique?
(d) Is the plasma fibrinogen chromatography 
technique ever lik e ly  to  be useful in  the 
c lin ic a l diagnosis and management of patients 
o r does i t  solely have a ro le  at a research 
level?
These questions w ill be discussed in  tu rn  beginning w ith  a summary 
of the re su lts ,
IX . 2(a) Summary of the Results in  th is  Thesis
There are  two main types of abnorm ality found using plasma 
fibrinogen chromatography -  the f ir s t  indicating the presence of 
soluble fib rin o g e n -fib rin  complexes and tîie second indicating the 
presence of ea rly  fib rin o g e n -fib rin  degradation products: -
(1) The presence of increased soluble complex leve ls in  a 
patient group is  suggested, when compared w ith  an appropriate 
contro l group, there a re ;-
(i) increased SCT titre s  at
( ii)  low er FR-antigen and T .C .P . ra tio s
( iii)  increased amounts of FR-antigen in  area .
A rea m probably iden tifies  oligom ers (m ainly d im ers), w hile the 
SCT t it re  a t iden tifies polym ers of high m olecular weight.
The ra tio s  give an indication of the m olecular w e ig lit of fibrinogen 
re lated m a te ria l f ir s t  eluted fro m  the packed gel column.
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(2) The presence of increased ea rly  fib rin o g e n -fib rin  
degradation product concentration in  a patient group is  suggested 
by find ing increased amounts of FR-antigen in  area p when the 
resu lts  are compared w ith  those from  an appropriate contro l 
group.
A summary of the resu lts  (mean -  1 S. D. ) is  shown in  
Table 80. The resu lts  from  a group of patients w ith  established 
loca l venous throm bosis (Appendix IV) are also included fo r 
comparison. The scatter of resu lts  fo r area m, the SCT t itre  
at V^ and area p are shown in  F igures 60, 61 and 62 respective ly.
(i) Plasma fibrinogen levels (Table 80)
Plasma fibrinogen levels rose in  association w ith  norm al 
pregnancy. S lightly low er than norm al values were found in  the 
to ta l p re -eclam ptic  group, but the ind ividual resu lts  were not 
helpful in  d istinguishing pre-eclam ptic patients,
( ii)  A rea m (Table 80 and F igure 60)
Although th is  was at best only a sem i-quantita tive method 
of m easuring the soluble complex concentration in  a sample, it  
proved useful in  d istinguishing between the d iffe ren t c lin ic a l groups 
studied. Increased levels of area m were found in association w ith  
norm al pregnancy and oestrogen-containing o ra l contraceptive therapy, 
when compared w ith  appropriate contro l subjects, h i the obste trica l 
patients a fu rth e r increase was found in  association w ith  in trau te rine  
growth re ta rdation  and pre-eclam psia, but not in  samples from  
patients w ith  essential hypertension. Increased leve ls were found 
a fte r 6 hours of intravenous ancrod infusion.
A rea m was inevitab ly affected by quite sm all e rro rs  in  the 
ra d ia l im m unodiffusion (M ancini) technique, p a rtic u la rly  in  the dim er 
m olecular weight range. Such e rro rs  were lia b le  to  lead to  an over­
estim ation of the amount of antigen in  area m. In addition, as shown 
in Chapter III,  the ra d ia l im m unodiffusion assay was not a good method
182
of measuring the amount of polym er present, which was lik e ly  to 
have been underestim ated. It is  possible that these two sources 
of e rro r compensated fo r each other to some extent, but i t  is  s t ill 
lik e ly  that area m was overestim ated in  some cases.
Area m was less lik e ly  to  have been affected by changes 
in  the separation cha racte ris tics of the agarose gel medium than 
the ra tio  tests. It was also less lik e ly  to have been affected by 
changes in  the sen s itiv ity  of the assay than the FR -antigen ra tio  
o r the SCT t itre . O vera ll i t  proved the best test fo r d istinguishing 
between the d iffe ren t groups,
( iii)  SCT t itre  at (Table 80 and F igure 61)
There was considerable overlap in  tiie  resu lts  obtained in 
the d iffe ren t groups. P a rticu la rly  high titre s  were found in  samples 
from  patients w ith  pre-eclam psia and a fte r 6 hours of intravenous 
ancrod therapy. No positive tests were recorded in  samples from  
a group of 10 healthy contro l women but the other groups showed 
considerable overlap. One problem  was alm ost ce rta in ly  va ria tion  
in  the se n s itiv ity  of d iffe ren t batches of staphylococcal clumping 
facto r. Incorporation of a standard fibrinogen solution in to the te s t- 
system would have helped avoid th is  problem , but would also have 
lim ite d  the number of other tests which could have been perform ed 
on each batch. The test was also affected by the inevitable 
inaccuracy in  perfo rm ing a doubling d ilu tion  technique and 
d iffic u lty  in  determ ining the end-point. The SCT t itre  at 
was used as a test fo r soluble complexes of high m olecular weight 
(1. e. polym ers). I t  was be tte r than the ra tios  in  th is  respect, 
because it  achieved a degree of quantitation.
(iv) FH-antigen and T .C .P . ra tio s  (Table 80)
Despite a degree of overlap these tests proved useful in  
d istinguishing between the d iffe ren t groups. A low ra tio  identified
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the presence of po lym er, but gave no indication as to amount.
The ra tio s  tended to  fa ll in  association w ith  norm al pregnancy 
but not w ith  oestrogen-containing o ra l contraceptive therapy.
Low ra tio s  were found in  association w ith pre-eclam psia and 
a fte r 6 hours intravenous ancrod therapy. The ra tio  tests 
were inevitably affected by the p a rticu la r batch of gel medium,
(v) A rea p (Table 80 and F igure 62)
This was the only test used to  iden tify ea rly  fibrinogen- 
fib r in  degradation products and there was considerable overlap 
in  the range of values between the groups. H igher values were 
found in some patients w ith  in trau te rine  growth re ta rdation and 
pre-eclam psia compared w ith  pregnant contro l subjects, w hile 
very high values were found a fte r 6 hours intravenous ancrod 
infusion.
M ost of the d ifficu ltie s  associated w ith  the measurement 
of area m also applied to area p. In p a rticu la r overestim ation of 
area p was lik e ly  to be caused by the " tra ilin g  e ffect" found w ith 
several technical fau lts (e. g. non-uniform  cross-sectiona l bed 
resistance). Such fau lts could usually be detected by examination 
of the O. D. traces and the sample discarded, but m inor degrees 
probably escaped detection.
(v i) Serum F D P /fdp  levels (Table 80 and F igure 63)
Serum F D P /fdp  levels rose s ligh tly  in  association w ith 
norm al pregnancy. They tended to increase fu rth e r in  association 
w ith  pre-eclam psia, but ind ividual resu lts  were not p a rticu la rly  
he lpfu l in  d istinguishing the pre-eclam ptic patients.
The Question as to  how these individual measurements 
re la te  to  each other has already been considered (Chapter V. 4).
A much la rg e r number of samples were included in  the linear 
regression analysis resu lts  shown in  Table 81. Although there
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was a wide scatter in  the resu lts , several s ign ifican t corre la tions 
were found.
The d iffe ren t methods of detecting and m easuring soluble 
complexes showed sign ifican t degrees of association, as m ight 
have been expected (e* g. SCT t itre  at and FR-antigen ra tio )* 
These resu lts  would suggest that oligom ers and polym ers tend 
to  be increased in  the same conditions.
There was, however, no significant co rre la tion  between 
area m or area p and the plasma fibrinogen leve ls. I t  is  therefore 
un like ly  that changes in  plasma fibrinogen leve ls affected the resu lts  
(except perhaps in  norm al pregnancy, see Chapter V. 4),
The serum F D P /fdp  and area p resu lts  gave a co rre la tion  
coefficient of 0.198, which reached a borderline leve l of significance 
(2 o ( (0.05) because of the large numbers involved, but the degree 
of co rre la tion  was obviously not close. Although both assays 
measure degradation products the serum F D P /fdp  assay w ill 
only measure non-c lo ttab le  degradation products, w hile  most of 
the m ate ria l in  area p is  probably clottable. There was no 
sign ifican t co rre la tion  between the serum FDP /fd p  and area m 
resu lts .
It should be noted also that there was a s ign ifican t degree 
of co rre la tion  between area m and area p measurements. This 
could sim ply re fle c t a tendency fo r both to  be increased in  the 
same samples, but m ight also indicate that the one is  derived in 
some way from  the other*
Despite the broad co rre la tion  between the measurements 
used to  assess the chromatography resu lts , the separation between 
the four main groups studied (i. e. the non-pregnant con tro l group, 
Group III, Chapter V, 4; the pregnant contro l group. Chapter V II. 2; 
the to ta l pre-eclam ptic group, Chapter V I. 4 and the normotensive 
women taking oestrogen-containing o ra l contraceptive therapy or 
the " p ill" ,  Chapter V III. 2) could be improved by considering more
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than one measurement. This was p a rticu la rly  true  when 
measurements of area m (oligom er) and the FR-antigen ra tio  
(polym er) were considered fo r the same sample (F igure 64a and 
b). It  can be seen that there is  a progression towards increasing 
abnorm ality s ta rtin g  w ith  the samples from  the norm al non­
pregnant women and extending through those from  women taking 
oestrogen-containing o ra l contraceptive drugs and norm al pregnant 
women, to those from  pre -eclam ptic patients. There c le a rly  
m ight be some advantage in  using two of the resu lts  from  a single 
sample in  th is  way.
It m ight also be possible to determ ine whether the predominant 
abnorm ality in  a plasma sample was one of increased coagulation, 
increased fib rin o ly s is / fib rinogeno lysis or a balanced increase in  
coagulation and fib rin o ly s is  /  f ib r  inogenoly s is by using the measure­
ments of area m and area p to  re fle c t coagulation and fib r in o ly s is / 
fib rinogenolysis respective ly. In F igure 65 the graph is  divided 
in  ha lf by the lin e  indicating balanced coagulation and fib r in o ly s is / 
fibrinogenolysis (area m = area p). When an ind iv idua l sample 
is  plotted on th is  graph i f  i t  lie s  above th is  d iv id ing line  the 
predominant abnorm ality is  coagulation. S im ila rly , i f  the point 
lie s  below the d iv id ing lin e  the predominant abnorm ality is  
fib rin o ly s is /fib rin o g e n o ly s is , I t  is  also obvious that the fu rth e r 
a point lie s  from  ssero, the greater is  the degree of abnorm ality.
As would be expected when the fou r main groups are 
examined in  th is  way (F igure 66 a-b) the pre -eclam ptic patients 
show the most marked degree of abnorm ality. I t  is  in te resting 
that 26 out of the 35 samples from  the pre-eclam ptic  patients, 
w hile  only 5 out of the 14 samples from  the pregnant contro ls and 
3 out of the 10 samples from  the non-pregnant contro ls lie  above 
the d iv id ing lin e . These observations stress the fact that the
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predominant abnorm ality in  pre-eclam psia appears to be increased 
coagulation ra the r than fib rin o ly s is / fib rinogeno lysis, w hile  in  
samples from  contro l subjects in  which only m inor abnorm alities 
are p resen t^fib rino lys is /fib rinogeno lys is  is  s lig h tly  m ore marked 
than coagulation. In the samples fro m  women taking oestrogen- 
containing o ra l contraceptive therapy ? out of the 10 samples lie  
above the lin e , suggesting ra the r more marked coagulation than 
fib rin o lys is /fib rin o g e n o lys is  in  these subjects.
DC. 2(b) Problem s w ith  the Plasma Fibrinogen Chromatography 
Technique
Some of these have been discussed at various stages through­
out th is  thesis. It has to be stressed that the technique is  laborious 
and tim e consuming. Only one sample can conveniently be handled 
each day when only one set of fractionation equipment is  available.
I f  blood samples are analysed im m ediately a fte r co llection , 
inevitab ly much evening and weekend w ork is  required . This is  
especially true when studying samples from  acutely i l l  patients.
The agarose gel columns are prone to  develop m inor and 
m ajor fau lts some of which (e. g. clogging of the bed support) may 
not be read ily  recognised u n til the filtra tio n  experim ent is  complete. 
M eticulous attention to  de ta il is  required at every stage, when 
om itted th is  usually leads to  the sample having to  be discarded.
On average 2 out of every 10 samples studied fo r the pro jects 
described in  th is  thesis had to be discarded, because of problem s 
w ith  separation at the gel filtra tio n  stage or w ith  the ra d ia l immuno­
d iffusion assay of the eluant fractions. It is  possible that some 
samples were included in  th is  thesis in  which m inor technical fau lts 
were not detected.
DC. 2(c) M odifications which could be Introduced to  Im prove the 
Plasma Fibrinogen Chromatography Teclinique
The technique as described in  Chapter II could probably be
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s im p lifie d  in  several ways w ithout too much loss of in form ation.
The ^  -alanine prec ip ita tion  step could be om itted and th is  
would also have the advantage of reducing the volume of blood 
required fo r the technique (only 2 m l of plasma would be needed 
instead of 9 m l). T im e would be saved (approxim ately 1 hour) 
and the sample could be applied to  the agarose column w ith in  30 
m inutes of venesection in  most cases.
The disadvantage would foe the presence of higher 
concentrations of the other plasma proteins. O ptica l density 
traces would therefore be of even less value and polyacrylam ide 
gel electrophoresis w ithout fu rth e r pu rifica tion  would be im possible.
In the analysis of the eluant fractions the ra d ia l immuno­
diffusion (Maneini) assay m ight be suffic ient on its  own. Areas m 
and p and the FH-antigen ra tio  could a ll be calculated. Although 
the SCT t itre  at T . C. F . ra tio  and abnorm alities in  the T. C. T . 
curve add some fu rth e r useful in form ation, they could probably be 
om itted.
An a lte rna tive  way of obtaining resu lts  m ore rap id ly  has 
been described by G raeff and colleagues (H after, Bchneebauer,
Tafel et a l. , 1975). The j§ -alanine p rec ip ita tion  step is  s t ill 
included, but the analysis of the eluant fractions is  lim ite d  to  
optical density measurements at 325 and 280 nm. The f ir s t  
measurement is  subtracted from  the second to  obtain an estim ate 
of the amount of FK-antigen present. G raeff and colleagues c la im  
to  find th is  method quite satisfactory,
DC. 2(d) C lin ica l Applications of the Plasma Fibrinogen Chromatography 
Technique
The tim e  delay in  obtaining resu lts  w ith  th is  technique (about 
3 days) would seem to seriously handicap its  use in  the diagnosis and 
management of throm boem bolic disease and dissem inated in travascu lar
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coagulation, where rap id laboratory tests are essentia l.
F le tcher and colleagues have introduced several m odifications 
to  the technique (e. g. sm all packed gel columns, automated F B - 
antigen analysis and a computerised calculation of resu lts ) which 
in  th e ir hands appear to  produce accurate resu lts  rap id ly  
(A lk jae rs ig , Roy and F le tcher, 1973), These changes would 
requ ire  a m ajor financia l outlay, which would have to  be 
ju s tifie d  by the quality and value of the resu lts  obtained.
Quite apart from  the tim e delay, the d iffic u lty  in  
in te rp re ting  the resu lts  in  te rm s of the type of in travascu la r 
coagulation (see la te r. Chapter IX . 3) would seem to lim it the 
c lin ic a l usefulness of the technique, but it  is  possible that it  
has a ro le  at a research leve l. F le tcher and A lk ja e rs ig  (1973) 
suggest that the technique m ight be p a rticu la rly  usefu l in  
determ ining " in  v ivo  drug e fficacy", but w hile th is  is  possible 
there rem ain problem s over the in te rpre ta tion  of the resu lts . 
D im in ishing soluble fib rin o g e n -fib rin  complex levels could 
indicate th e ir rem oval from  the c ircu la tion  by the re tic u lo - 
endothelium system or some other mechanism w ithout insoluble 
fib r in  deposition, but another explanation would be the p rec ip ita tion  
of the soluble complexes as insoluble fib r in  th rom b i or m ic ro - 
throm bi, The f ir s t  would seem desirable, w h ile  the second would 
not.
The tim e  involved in analysing a single sample is  c le a rly  
a drawback to  bu ild ing up a la rge series of samples on any one group 
of patients. The technique would therefore seem to be of lim ited  
use in  c lin ic a lly  orientated pro jects. I t  m ight seem m ore sensible 
to  put the tim e  and e ffo rt involved in  the plasma fibrinogen chrom ato­
graphy technique in to  a more specific test fo r soluble fib rin . This 
would be p a rtic u la rly  true  if  th is  test could be perform ed more 
rap id ly . A ffin ity  chromatography, although s t il l a somewhat
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laborious technique, does hold prom ise. Other newer tests 
(e, g, using erythrocytes coated w ith  soluble fib r in  monomer 
described by Largo, H e lle r and Straub, 1976) would seem 
w orth Investigating fu rth e r.
DC, 3 The Significance of Abnorm al Plasma F ibrinogen
Chromatography Results
What do these resu lts  (p a rticu la rly  the increased soluble 
complex concentration) mean regarding the d iffe ren t fo rm s of 
in travascu lar coagulation (see Preface)? I t  was confirm ed in  
Chapter H I that soluble complexes could be produced in  v itro  by :-
(1) the incubation of fibrinogen w ith  low concentrations 
of a coagulant enzyme ( i. e. throm bin o r ancrod)
( ii)  the incubation of early fibrinogen degradation products 
w ith  a coagulant enzyme
( iii)  the ly s is  of insoluble fib r in .
It is  probable, though not ce rta in , that s im ila r mechanisms 
operate in  v ivo . The form ation of soluble complexes should therefore 
re fle c t the action of tliro m b in  on fibrinogen w ith  the form ation  of 
fib r in  monomer. Soluble complexes m ight also be produced by 
F jO IIa  crosslink ing  fibrinogen, but th is  would probably also im ply 
a degree of activa tion of the coagulation pathway (see Chapter I. 5(b) ). 
Soluble complexes in  plasma samples should therefore  indicate 
activation of the fin a l stage of the coagulation pathway and to  th is  
extent in travascu la r coagulation.
The fact that soluble complexes are present in  samples 
analysed by agarose gel filtra tio n  at room  tem perature does not 
necessarily mean that they are present in  the blood c ircu la ting  
in  vivo at 37°C. This question has already been discussed in  
Chapter IV . 5. It is  possible that soluble complexes demonstrated 
at room  tem perature composed of units w ith  degraded (X chain 
are not polym erised at 37^C (Edgar, M cK lllop , Howie et a l, , 1976),
although w ork cu rre n tly  in  progress suggests that the situation 
in  re la tio n  to  complex form ation at d iffe ren t tem peratures may 
be even more com plicated than th is .
It must be stressed, however, that these observations 
do not a lte r the basic prem ise that soluble complexes provide 
biochem ical m arkers of in travascu la r coagulation. F o r the 
reasons discussed in  de ta il in  Chapter 1 .5 and 6 i t  s t il l seems 
high ly probable that they do.
What conclusions can be made from  the resu lts  described 
in  Chapters IV -V in ?  The resu lts  themselves have already been 
summarised in  Table 80 and F igures 60-63. How do they re la te  
to  the d iffe ren t fo rm s of in travascu la r coagulation ( i, e, hyper­
coagulability, loca l throm bosis, loca l and dissem inated in tra ­
vascular coagulation, see Preface)? The main conditions 
studied in  th is  thesis w ill be considered separately: -
(i) N orm al Non-Pregnant Women (Group H I, Chapter V . 4)
In th is  group there is  ve ry  lit t le  evidence of in travascu la r 
coagulation. The soluble complex and degradation product 
concentrations in  areas m and p are lik e ly  to  have been over­
estim ated by about 2 percent, because of the " ta ils "  in  the 
Gaussian type elution p ro file  found w ith  a pure p ro te in  are not 
included in  calculating area n. Therefore the amount of soluble 
complex o r degradation product in  area m and area p is  even less 
than is  suggested by the actual values. A m inor degree of 
fib rin o g e n o lys is /fib rin o lys is  is  suggested by the low leve ls of 
serum  F D P /fdp  and the tendency fo r area p values to  exceed 
area m values.
( ii)  Norm otensive Women taking Oestrogen-Containing O ra l
Contraceptive Therapy (Chapter VIH. 2)
In th is  group there is  some evidence of increased coagulation 
as evidenced by increased o ligom er/ dim er concentration (area m
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resu lts ), but there is  no evidence of increased fib rino ge no lys is / 
fib rin o ly s is  compared w ith  a non-pregnant contro l group. These 
findings may re fle c t pure hypercoagulability, although oestrogens 
m ight be able to  a lte r fibrinogen metabolism  producing soluble 
complexes w ithout activation of the coagulation pathway. There 
is , however, lit t le  experim ental evidence to  support th is  second 
suggestion.
( iii)  N orm al Pregnant Women (Chapters V. 4 and V II. 2)
In th is  group there is  evidence to  suggest increased 
coagulation (area m and SCT t itre  at V^ resu lts) and possibly 
increased fib rin o ly s is  (serum F D P /fdp  resu lts) compared w ith  
the non-pregnant con tro l group. These resu lts  could suggest pure 
hypercoagulability but m ight also re fle c t a degree of loca l in tra ­
vascular coagulation w ith in  the m aternal side of the placental 
vasculature.
(iv) In trau te rine  Growth Retardation Patients (Chapter V II. 3)
In th is  group of patients there was evidence of increased 
coagulation (area m resu lts) and increased fib rin o g e n o lys is / 
fib rin o ly s is  (area p resu lts ) compared w ith  the norm al pregnant 
women. These findings could re fle c t increased loca l in tra ­
vascular coagulation w ith in  the placenta in  the in tra u te rine  growth 
re tardation patients.
(v) Essentia l Hypertension in  Pregnancy (Chapter V II. 4)
No differences were found between th is  group of patients 
and the norm al pregnant con tro l group. There would therefore 
seem to be no difference in  the extent of in travascu la r coagulation 
between the two groups ( i.e . hypercoagulability a n d /o r loca l in tra ­
vascular coagulation in  the placenta).
(v i) P re-eclam psia (Chapters V and V I)
In these patients there is  evidence to  suggest increased
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coagulation (area m and SCT t itre  at resu lts) and increased 
fib rin o g e n o lys is /fib rin o lys is  (area p and serum  FDP /  fdp resu lts) 
compared w ith  the norm al pregnant contro l group. The resu lts  
are m ore m arkedly abnormal than those found in  the other 
obste trica l groups and could re fle c t widespread low -grade 
dissem inated in travascu lar coagulation.
(v ii) Intravenous Ancrod Infusion (Chapter IV)
In th is  c lin ic a l situation, in  which a contro lled dose of a 
coagulant enzyme is  infused in to  the c ircu la tion , there is  evidence 
of both increased coagulation (area m and SCT t itre  at V ^ resu lts) 
and increased fib rinogeno lys is/ fib rin o lys is  (area p and serum 
F D P /fdp  resu lts ). The resu lts  in  pre-eclam psia and ancrod 
therapy d iffe r most m arkedly in  the considerable evidence fo r 
fib rinogeno lys is/ fib rin o ly s is  found in  the ancrod patients. It 
may be that the difference between the two conditions lie s  in  the 
capacity of the fib rin o ly tic  system to rap id ly  lyse m ic ro -c lo ts  in  
the ancrod patients, a capacity which is  inhib ited (or p a rtia lly  
inhibited) in  patients w ith  pre-eclam psia. As i t  is  possible that 
insoluble fib r in  m ic ro -c lo ts  may not fo rm  during ancrod therapy, 
i t  is  im possible to  determ ine whether ancrod in fusion is  an 
example of gross hypercoagulability or widespread dissem inated 
in travascu la r coagulation. It is  certa in , however, that ancrod 
infusion is  a good example of acute defibrination,
(v iii)  Loca l Throm bosis
This condition has not been studied in  de ta il in  th is  thesis, 
but abnorm alities have been detected in  plasma samples from  
several patients w ith  venographic evidence of loca l throm bosis 
(see Table 80 and Appendix IV ). Although defin ite  and highly 
s ign ifican t abnorm alities are present in  plasma samples from  
these patients, the m arkedly abnormal soluble complex resu lts  
(area m and SCT t itre  at V^) seen in  the ancrod and pre-eclam ptic
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patients were not found in  the loca l throm bosis patients.
W hile it  is , of course, not com pletely possible to exclude 
the presence of lo ca l throm bosis in  tlie  obste trica l and other groups 
studied in  Chapters V -V IÏÎ, the m arkedly abnormal resu lts  found in 
pre-eclam psia are most un like ly  to  have been associated sim ply 
w ith  loca l throm bosis. I t  is  also not possible to  be certa in  that 
the loca l throm bosis patients were not in  addition suffering from  
some other fo rm  of in travascu la r coagulation (e. g. 2 of the 6 
patients studied had m alignant disease w ith  secondary spread and 
m ight have had a degree of unsuspected low-grade disseminated 
in travascu la r coagulation).
W hile i t  is  possible to  in te rp re t the resu lts  in  th is  thesis 
as examples of hypercoagulability, loca l throm bosis, lo ca l and 
dissem inated in travascu lar coagulation, a ll that has re a lly  been 
shown is  a difference in  the degree of abnorm ality and it  is  only 
possible to  speculate as to how such abnorm alities re la te  to  under­
ly ing  types of in travascu la r coagulation {F igure 67). I t  must be 
appreciated that although soluble fib rin o g e n -fib rin  complexes 
probably represent reaction products of the lim ite d  pro teo lysis 
of fibrinogen by throm bin, th e ir presence does not indicate the 
s ite  or sites at which th is  reaction occurs, whether insoluble 
fib r in  has been deposited and if  it  has been, whether it  is  in  the
fo rm  of a single thrombus or m ultip le  m icro th rom bi,
IX . 4 F ina l Comments and Aspects fo r F urthe r Investigation
P re-eclam psia obviously involves the com plicated in te r­
action of many facto rs (Chapter V. 1 and 2). Page (1972) has 
produced the "v ic iou s  c irc le " theory of pre-eclam psia and eclampsia 
which has been s lig h tly  m odified to  include the conditions studied in  
th is  thesis in  F igure 68, There are c lea rly  several points of entry 
in to th is  c irc le  and although highly speculative it  does explain many
of the c lin ic a l and biochem ical features of pre-eclam psia including 
the presence of soluble fib rin o g e n -fib rin  complexes.
As a w orking hypothesis the occurrence of low -grade 
dissem inated in travascu lar coagulation in  pre-eclam psia is  
a ttrac tive . Whether involved in  the p rim a ry  aetiology of the 
syndrome or occurring  as a secondary com plication to  an unknown 
p rim a ry  pathology, dissem inated in travascu lar coagulation explains 
many of the signs and symptoms found in  pre -eclam ptic patients.
The confusion over term inology in  the fie ld  of in travascu la r 
coagulation has been discussed elsewhere (see Preface). I t  was 
suggested that there is  a need fo r a te rm , such as "haem atological 
dissem inated in travascu lar coagulation", to apply to  circum stances 
in  which the presum ptive diagnosis of disseminated in travascu lar 
coagulation is  based sim ply on the resu lts  of blood tests and other 
investigations, w ithout h is to log ica l evidence of insoluble fib r in  
deposition in  several organs. Where such evidence is  available 
another te rm , such as "h is to lo g ica l disseminated in travascu la r 
coagulation" could be used.
The evidence cu rre n tly  available in  the lite ra tu re  (Chapter 
V. 2) and that produced in  the o rig in a l w ork in  th is  thesis strongly 
supports an association between "haem atological dissem inated 
in travascu lar coagulation" and pre-eclam psia. There is , of 
course, also evidence of insoluble fib r in  deposition w ith in  the 
kidney, liv e r  and placenta of patients w ith  severe pre-eclam psia. 
Thus h is to log ica l disseminated in travascu lar coagulation may also 
be present in  th is  syndrome.
I f  dissem inated in travascu la r coagulation is  present in 
these patients, there is  the p o ss ib ility  that i t  m ight prove amenable 
to some fo rm  of treatm ent. I t  is  possible that although conventional 
anticoagulant and an ti-p la te le t therapy (heparin and dipyridam ole) 
may not be helpfu l in  patients w ith  established severe pre-eclam psia
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(Howie, P rentice and Forbes, 1975), such therapy m ight be more 
useful i f  started e a rlie r in  the c lin ic a l course of the syndrome.
This m ight be p a rtic u la rly  true  i f  therapy were started "p rophy- 
la c tic a lly " in  "h ig h -ris k " patients (see Appendix III) . W hile it  
m ight w e ll be w orth  attem pting such a study, there also rem ains 
the p o ss ib ility  that newly developed drugs m ight prove more useful 
in  th is  c lin ic a l s ituation and should therefore be evaluated. The 
plasma fibrinogen chromatography technique m ight have a ro le  to  
play in  the labora tory assessment of such studies.
A lthougii i t  is  probable that in  due course the plasma 
fibrinogen chromatography technique w ill be replaced by more 
specific , rap id techniques fo r identify ing and m easuring soluble 
fib r in , i t  has played a useful research ro le  in  con tribu ting to the 
study of in travascu la r coagulation.
To those sceptical about the technique it  should be pointed 
out that when perform ed ca re fu lly , abnormal resu lts  are only found 
in  patients in  whom there is  some other good reason to  suspect a 
degree of in travascu lar coagulation. There is  also at present no 
other single technique which w ill demonstrate the presence of soluble 
complexes and uncomplexed early  fib rin o g e n -fib rin  degradation 
products and d istinguish between the two.
In travascu lar coagulation in  a va rie ty  of disease processes 
rem ains an im portant cause of m orb id ity  and m o rta lity  in  many 
branches of medicine. The study of soluble fib rin o g e n -fib rin  
interm ediates (whether as soluble complexes o r as soluble fib rin ) 
may w e ll have a ro le  to play in  the improved c lin ic a l diagnosis and 
management of the d iffe ren t va rie tie s  of in travascu la r coagulation. 
The need is  fo r a rap id , specific and sensitive test fo r the detection 
of these interm ediates.
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Appendix I
V aria tions in  the V of F ibrinogen in  the Column 
Systems used throughout th is  Thesis
It proved im possible to obtain exact iden tity  of the elution 
p ro file s  of p u rifie d  fibrinogen o r norm al plasma using d iffe ren t 
packed gel column systems and indeed some va ria tio n  occurred 
even using the same column system on d iffe ren t occasions. A 
short-hand method of identify ing each packed gel column was 
devised: -
(1) Each empty column apparatus was iden tified  using a 
capita l le tte r (e. g. Column A , B, C, etc. ).
(2) Each packed gel column was identified using an A rab ic 
num eral fo llow ing the le tte r fo r the p a rticu la r column apparatus 
(e.g. Column A l,  B2, e tc .).
Column A had an in te rna l diam eter of 2 ,5  cms w hile 
Columns B , G and D each had an in te rna l diam eter of 2. 6 cms.
The packed height proved im possible to  reproduce exactly.
Every attem pt was made to ensure a packed height of 34-35 cms 
but i t  was found that some va ria tio n  in  height occurred even in  the 
same packed gel column run under apparently standardised 
conditions. B iogel A5m is  provided as swollen p a rtic le s  and 
therefore a d ry weight cannot be obtained to help in  standardisation.
(3) Each batch of gel was recorded as a Roman num eral
(e. g. I, H etc. ) and placed in  brackets a fte r the Column le tte r and 
number (e.g . Column A l (I), Column 05 (II) etc. ), I t  became 
obvious that the batch of gel was very im portant in  determ ining 
the elution cha racte ris tics  of fibrinogen and other pro te ins.
Several ja rs  of gel from  the same batch were therefore purchased
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at the same tim e to  ensure continuity. The best separation 
was always obtained w ith  previously unused gel. A fte r being 
used fo r several packed gel column systems the number of fractured  
and fine gel spheres greatly increased. (This could be checked 
m icroscop ica lly). There was a corresponding decrease in  the 
quality of the separation obtained and so that p a rticu la r quantity 
of gel was discarded.
The and of fibrinogen fo r the packed gel columns used 
in  th is  thesis is  shown in  Table 82 (a-c). Any obviously abnormal 
elution p ro file s  were excluded from  these calculations as it  proved 
ve ry  d iffic u lt to calculate the of fibrinogen i f  a pronounced 
shoulder was present on the ascending lim b  of the peak. The 
of fibrinogen remained reasonably constant fo r each packed gel 
column system.
In order to  p roperly  standardise each column system several 
samples of pu rifie d  fibrinogen or plasma from  a norm al individual 
should have been analysed before attem pting to analyse patient 
samples. Ideally analysis of each patient sample should be 
followed by analysis of a sample from  an appropriate contro l 
subject. Th is proved im practicable in  the present p ro ject because 
of the d iffic u lty  in  obtaining patient samples at regu la r tim e in te rva ls . 
Only four o r five  samples could be analysed in  a norm al w orking week 
and in  addition a ll the samples were analysed w ithout storage on the 
day of co llection . Long periods of tim e passed in  which few or no 
patient samples were available, p a rticu la rly  in  the pre-eclam psia 
study. Therefore when patient samples were available as many as 
possible were studied and the rem aining tim e was used to analyse 
samples from  norm al contro ls.
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Appendix I I  
Case Summaries
A. P re-eclam ptic  patients
No: 1 (M .C .)
Age: 16 years 
Past m edical h isto ry: 
Past obste tric h isto ry; 
Pregnancy studied;
Occupation: H a ird resser 
No serious illness 
Para 0 -i- ^
1975
Gestation
(weeks)
B .P .
(mmHg)
P ro te inu ria  
(g /24  hrs)
F irs t v is it to  O .P .: 12 120/75 None
F irs t hospita l v is it: 20 130/90 None
Progress: Adm itted - 25-26 140/90 10.5
26-27 160/110 12.5
D elivery:
Induction;
Means of d e live ry : 
Baby:
B irth  weight: 
Placenta:
O ra l iro n , fo lic  acid and vitam ins. Sodium 
amylobarbitone 200 mg o ra lly  b, d. Sodium 
amylobarbitone 250 mg in tra -m uscu la rly  as 
required.
The patientas condition rap id ly  deteriorated 
making term ination of pregnancy necessary, 
26-27 weeks gestation.
Prostaglandin infusion. Eclam ptic f it  in  
labour.
Assisted breech de live ry .
S tillbo rn  female 
1.11 Kg.
0. 25 Kg.
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Post m ortem  on baby:
CN8:
R8:
GIT:
Summary:
P lacental pathology:
Summary:
Puerperlum :
P ost-natal v is it:
Renal U nit fo llow -up:
M arked external b ru is ing  of buttocks and 
low er lim bs.
B ila te ra l te n to ria l tea r. Sm all subdural 
and subarachnoid haemorrhages,
Subpleural haemorrhages.
Hepatic tea r, subcapsular haemorrhages.
(i) In tra -partum  asphyxia (follow ing 
m aternal eclam ptic f it) ,
( ii)  Extrem e p rem atu rity .
(It was d iffic u lt to  determ ine how many of the 
changes had occurred a fte r foeta l death).
Two large areas of in fa rc tion  (one old and 
one recent) occupying m ore than ha lf of the 
placenta. Large area of recent re tro - 
placental c lo t and haemorrhage. H istology 
showed extensive necrosis of the decidua 
capsular is  and decidua basalis w ith  extensive 
fib r in  deposition in  the m aternal vessels and 
p e riv illo u s  fib rin .
P lacental in fa rction ,
A bruptio placentae.
Compatible w ith  pre-eclam psia.
Remained very i l l  fo r several days w ith  gradual 
im provem ent in  B .P , and lessening of p ro te in ­
u ria .
W ell although B .P . s t il l 130/100 mmHg (125/ 
90 mmHg) and a trace of p ro te inuria  at G week 
v is it.
F u lly  investigated* IVP and a ll other renal 
investigations norm al, B .P . gradually 
settled (normotensive by 3 months post-
2üO
partum ) and pro te inuria  disappeared. 
Diagnosis of pre-eclam psia w ith  eclam ptic 
seizure during labour would seem to have 
been co rre c t.
No; 2 (E .S .)
Age: 18 years Occupation:: Student
Past m edical h is to ry: No serious illnesses
Past obste tric h isto ry: Para 0 +
Pregnancy studied: 1974
Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
F irs t v is it to G. P. : 12 110/70 None
F irs t hospital v is it: 26 130/90 None
Progress: Adm itted - 34 160/110 5.6
35 160/110 6,4
Drug therapy: O ra l iro n . fo lic  acid and v itam ins. i
D e livery:
Induction:
Means of de live ry : 
Baby:
B irth  weight: 
Placenta:
Baby*s condition at 
b irth  and progress:
Summary:
Sodium
amylobarbitone 200 mg o ra lly  nocte.
The patient’s condition deteriorated making 
de livery necessary.
35 weeks gestation
Forew ater amniotomy and Syntocinon infusion 
K ie lland ’s forceps 
L ive  female 
3.07 Kg,
0. 83 Kg,
Baby in  satisfactory condition at b irth . 
Subsequently progressed w e ll apart from  
b ila te ra l con junctiv itis .
Baby was w e ll grown fo r gestation (F75-90) 
and in  good condition.
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Placental pathology:
Comment:
Post-nata l v is it:
Renal U nit fo llow -up :
Gross inspection shov/ed 4 sm all in farcted 
areas. Detailed histo logy not perform ed* 
Compatible w ith  pre-eclam psia.
B .P . rose fo llow ing de live ry  to  178/180 mmHg. 
Treated w ith  H em inevrin and diazoxide. There­
a fte r good recovery.
W ell. B .P . 140/90 mmHg (130/88 mmHg).
No pro te inuria .
Not re fe rre d  but diagnosis of pre-eclam psia 
would seem lik e ly  to  have been co rrect.
No: 3 (M. H. )
Age: 35 years 
Past m edical h is to ry:
Occupation: M edical Secretary 
R ecurrent rec ta l bleeding and abdominal pain 
fo r several years. Le ft-s ided  hem icolectomy 
3 years ago. Diagnosis uncerta in (? purgative 
c o litis , ? u lcera tive  c o litis ).
Fast obstetric h is to ry: Para 0 + ^
Pregnancy studied: 1975
Gestation
(weeks)
B .P .
(mmHg)
P ro te inuria  
(g /24  hrs)
F irs t v is it to G, F . : 10 130/80 None
F irs t hospita l v is it: 11 140/80 None
Progress: Adm itted - 23 150/90 None
B .P . settled, allowed 
home
Readmitted: 27 120/90 0.47
Drug therapy: O ra l iro n  and vitam ins. Sodium am
200 mg o ra lly  t . i .d .  Sodium am ylobarbitone 
250 mg in tra -m uscu la rly  as required. 
Salazopyrin 1 g o ra lly  mane. Betnovate rec ta l 
cream  as required. F redso l suppositories - 
1 suppository nocte. Dulcolax suppositories as 
required.
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D elivery:
Means of de livery: 
Baby:
B irth  weight:
Placenta
Baby’s condition at 
b irth :
Post m ortem  on baby: 
RS:
GIT:
Summary:
P lacental pathology:
Comment:
Puerperium :
Post-natal v is it:
Renal U nit fo llow -up:
29 weeks
E lective  Caesarean section 
L ive  female 
1.00 Kg.
0.25 Kg.
Prem ature baby. Despite intensive care 
died of R espira tory D is tress Syndrome at 
31 hours.
M ain findings -
Hyaline membrane form ation and resorption 
ate lectasis. Focal intrapulm onary 
haemorrhages and p rim a ry  ate lectasis. No 
ba cte ria l in fection noted.
Subcapsular haemorrhages.
(i) Severe re sp ira to ry  d is tress syndrome
( ii)  P rem aturity .
Cord was very oedematous but gross inspection 
of placenta revealed no marked abnorm ality. 
H istology showed that the v i l l i  were sm all and 
spindly fo r th is  degree of p rem atu rity  and that 
there were an excessive number of syncytia l 
knots.
"Ageing" phenomena are compatible w ith  p re ­
eclam psia/p lacenta l insuffic iency.
Gradual im provem ent, on discharge B. P. 140/
90 mmHg.
W ell although s t ill s lig h tly  hypertensive. B .P . 
145/95 mmHg (140/90 mmHg).
F u lly  investigated. B .P . 130/85 mmHg. IVP 
and a ll other renal investigations were norm al. 
Diagnosis of pre-eclam psia seemed fa ir ly  certa in.
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No: 4 (S .S .) 
Age: 23 years
?ast m edical h is to ry:
Past obstetric h is to ry:
(1) 1970
Pregnancy studied;
Drug therapy:
D e livery:
Means of d e live ry : 
Baby:
B irth  weight: 
Placenta:
b irth  and progress:
Occupation: G lerkess 
N octurnal enuresis. Obesity.
Para 1 t  ^
P re-eclam psia w ith  an in trau te rine  death at 
28 weeks, Norm otensive 3 months a fte r 
de live ry.
1974
Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
F irs t v is it to  G. P. : 12 130/80 None
F irs t hospita l v is it: 17 150/90 None
22 145/90 None
32 145/90 None
35 150/90 1.9
36 150/95 3.1
O ral iro n , fo lic  acid and v itam ins. Sodium 
am ylobarbitone 200 mg o ra lly  b. d. Sodium 
am ylobarbitone 250 mg in tra -m uscu la rly  as 
required.
The patient’s condition gradually deteriorated.
I t  was decided to de live r by Caesarean section 
at 36-37 weeks*
37 weeks gestation^
E lective  Caesarean section.
L ive  dysmature and prem ature male*
2.25 Kg.
0. 60 Kg.
Baby was m ild ly  asphyxiated at b irth . Despite 
the development of hypoglycaemic attacks and 
R esp ira tory D is tress Syndrome he subsequently 
started to gain weight and was discharged home 
in  good condition.
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Placental pathology;
Puerperium : 
P ost-natal visit; 
Renal U nit fo llow -up:
Ho: 5 (J .T .)
Age: 29 years 
Past m edical h is to ry: 
Past obstetric history:
(1) 1974
Pregnancy studied;
Several sm all areas of in fa rc tion . Mo 
histology available.
Uneventful recovery.
W ell, (B .P . 148/80 mmHg),
F u lly  investigated, IVP and a ll other rena l 
investigations were norm al. Diagnosis of 
pre-eclam psia seemed fa ir ly  certa in .
Occupation: C lerkess
No serious illnesses 
1Para 0 -j*
Spontaneous abortion at 10 weeks 
1974
Gestation B .P . P rote inu ria
(weeks) (mmHg) (g /24h rs)
F irs t v is it to  G. P. : 13 130/80 None
F irs t hospita l v is it: 18 120/90 None
Progress: Admitted - 24 4" 145/95
26 150/100 3.1
28 150/110 6.7
Drug therapy: O ra l iro n , fo lic  acid and v itam ins, i
D elivery:
Induction:
Means of d e live ry : 
Baby:
Sodium
am ylobarbitone 200 mg o ra lly  nocte. M ethyl 
dopa 280 mg o ra lly  q. i.  d. Sodium am ylo­
barbitone 250 mg in tra -m u scu la rly  as required. 
The patient’s condition showed progressive 
de terio ra tion , h itrau te rine  death occurred
28 weeks.
29 weeks gestation.
Prostaglandin infusion -  in trau te rine  death. 
Spontaneous vertex de live ry  
S tillbo rn  female.
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B irth  weight; 
Placenta:
Post m ortem  on baby:
Summary:
P lacental pathology;
Puerperium : 
Post-nata l v is it:
R enal U nit fo llow -up:
0.81 Kg,
0* 17 Kg.
Degree of m aceration suggested death some 
tim e before de livery. (Foetal heart las t 
heard about 1 week before induction). No 
gross congenital abnorm ality.
In trau te rine  death about 1 week before de live ry. 
Macerated w ith  old blood c lo t and several areas 
of old in fa rction . The usual coarse pattern of 
a lternating pink and white areas associated w ith 
an in trau te rine  death. H istology showed patchy, 
squamous change w ith  sm all v i l l i  and sm all 
fresh and old haemorrhages in  the decidua 
capsularis. M aternal vessels showed 
fib rin o id  in  w a lls.
Remained s lig h tly  hypertensive (B, P. 140/96 
mmHg) w ith some p ro te inu ria  u n til discharge. 
B .P . 130/90 mmHg (130/85 mmHg). Trace 
of pro te in .
F u lly  investigated. (B .P . 125/80 mmHg).
IVP and a ll other renal investigations were 
norm al. Diagnosis of pre-eclam psia seemed 
fa ir ly  certa in . (F urthe r pregnancy in  1975 
in  which she did not develop pre-eclam psia).
No: 6 (M .M cL).
Age: 21 years 
Past m edical h is to ry: 
Past obste tric h istory:
(1) 1972
Occupation: M achin ist
Obesity
Para 1 + ^
? u rin a ry  tra c t in fection
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Pregnancy studied: 1974
Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24 hrs)
F irs t v is it to  G .P . : 24 120/70 -
F irs t hospita l v is it: 28 130/70 None
Progress: Adm itted - 29+ 130/80 +++
30 130/90 5.0
30+ 125/85 4"
Drug therapy: O ra l iro n . fo lic  acid and vitam ins.
D elivery:
Induction:
Means of d e live ry : 
Baby;
B irth  weight:
Placenta:
Post m ortem  on baby:
Comment:
P lacental pathology:
The patient’s condition rap id ly  deteriorated.
It  is  possible that in trau te rine  death occurred 
shortly  a fte r adm ission (29-30 weeks).
30 weeks gestation.
Prostaglandin infusion.
Breech extraction.
S tillbo rn  male.
0.950 Kg.
0.220 Kg.
Degree of m aceration and autolysis suggested 
death some tim e before de live ry . (Foetal 
heart last heard about 3 days before de live ry). 
No gross congenital abnorm ality.
In trau te rine  death about 3 days before de livery. 
M u ltip le  re trop lacenta l haematomata re lated to 
areas of red and white in fa rc tion . 60% of the 
placenta showed pathological change.
H istology showed sm all v i l l i  w ith  excessive 
p e riv illo u s  fib r in  and syncytia l knots. M aternal 
vessels showed excessive fib rin o id  in  w a lls 
w ith  frequent complete occlusion. Foetal 
a rte rie s  showed enda rte ritis .
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Puerperium ; 
Post-natal v is it ;
Renal U nit fo llow -up:
Good recovery.
W ell. (B .P . 120/75 mmHg and no 
p ro te inuria ).
F u lly  investigated. IVP and a ll other renal 
investigations were norm al. Diagnosis of 
pre-eclam psia seemed fa ir ly  certa in . 
(F urther pregnancy in  1976 in  which she 
did not develop pre-eclam psia).
No: 7 (M. M. )
Age: 27 years Occupation: Housewife
Past m edical h is to ry: No serious illnesses
Past obste tric h is to ry: Para 0 +
Pregnancy studied: 1975
Gestation
(weeks)
B .P .
(mmHg)
P ro te inu ria  
(g /24  hrs)
F irs t v is it to  G .P .: — -
F irs t hospita l v is it: 9 110/60 None
Progress: Adm itted - 35+ 130/104 1.8
36 130/95 3.1
36+ 160/96 2.2
Drug therapy:
D elivery:
Induction:
Means of de livery:
Baby:
B irth  weight:
O ra l iro n , fo lic  acid and v itam ins. Sodium 
am ylobarbitone 200 mg o ra lly  b. d.
The patient’ s condition gradually deteriorated 
and she was induced at 37 weeks gestation.
37 weeks gestation
Forew ater amniotomy and Syntocinon infusion. 
K ie lland ’s forceps; manual rem oval of 
placenta.
L ive  fem ale.
2.17 Kg.
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Placental weight:
Baby’s condition at 
b irth  and progress:
P lacental pathology:
Summary:
Puerperium : 
P ost-natal v is it: 
Renal U nit fo llow -up:
0.48 Kg.
Baby was m ild ly  asphyxiated at b irth .
She was thought to be both dysmature and 
prem ature (assessed as 36 weeks). She 
did not, however, develop any serious 
com plications and developed w e ll.
There were several areas of old in fa rc tion  
and blood c lo t. H istology showed p e riv illo u s  
fib r in  and syncytia l knots in  excess. Foetal 
vessels showed e n d a rte ritis . M aternal 
vessels showed excessive fib rin o id  deposition 
and one large m aternal vessel was com pletely 
occluded.
D efin ite  placental insuffic iency, compatible 
w ith  pre-eclam psia.
Good recovery.
W ell. B .P . 110/64 mmHg. No pro te inuria . 
Not re fe rre d  but diagnosis of pre-eclam psia 
seemed fa ir ly  certa in  despite th is .
(Subsequent pregnancy in  1976 in  which the 
patient did not develop pre-eclam psia).
No: 8 (M .D .)
Age; 23 years Occupation: Secretary
Past m edical h is to ry: No serious illnesses
Past obstetric h is to ry: Para 0 4
Pregnancy studied: 1975
TWINS Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
F irs t v is it to  G. P. : 10 120/75 None
F irs t hospita l v is it: 22+ 130/90 None
Progress: Adm itted - 34 165/90 3.15
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Drug therapy: O ra l iro n , fo lic  acid and v itam ins. Sodium
amylobarbitone 200 mg o ra lly  nocte. Sodium 
am ylobarbitone 250 mg in tra -m u scu la rly  as 
required. Methyldopa 250 mg o ra lly  t. i.  d. 
Rapid de terio ra tion w ith  fa llin g  u rin a ry  o e s trio l 
levels. One week a fte r adm ission only one 
foeta l heart heard and so patient induced.
D elivery: 34 weeks gestation
Induction: Forew ater amniotomy and Syntocinon infusion
(1) Assisted breech de live ry
(2) Breech extraction
(1) S tillbo rn  male
(2) S tillbo rn  male
(1) 1.24 Kg.
(2) 1.00 Kg.
________  0.35 Kg.
Post m ortem  on babies: Exact sequence of events d iffic u lt to  determ ine.
C lin ica lly  one foetal heart was thought to 
disappear some hours before induction.
Second foetal heart disappeared during labour. 
Twin (1): Signs of in tra -pa rtu m  asphyxia. No 
gross congenital abnorm ality*
Twin (2): Macerated infant* Foetal vascular 
thrombosis* No gross congenital abnorm ality.
Summary: Tw in (1) died of in tra -pa rtu m  asphyxia.
Tw in (2) in trau te rine  death some tim e before 
induction.
P lacental pathology: D iam niotic, monochorionic placenta* No
abnorm al c ircu la tion  demonstrated* M aternal 
vessels showed marked "a th e ro s is " w ith  
fib rin o id  in  vessel w a ll and fib r in  in  lumen
Means of de livery:
Babies:
B irth  weights;
Placenta:
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Puerperium ; 
Post-nata l v is it: 
Renal U n it fo llow -up:
No. 9 (A .M cN)
Age: 24 years 
Past m edical h is to ry: 
Fast obste tric h is to ry:
(1) 1969
(2) 1970
(3) 1971
(4) 1972
of veins and sinusoids. No obvious area 
of in fa rction . A lm ost a ll of la rge vein 
on foetal surface (Tw in 2) was occluded 
w ith  antemortem throm bus. H istology 
compatible w ith  pre-eclam psia.
G radually settled.
W ell. B .F . 140/100 mmHg (120/85 mmHg). 
Not followed up but IVP was norm al. (B. P. 
120/80 mmHg). D iagnosis of pre-eclam psia 
seemed fa ir ly  certa in.
Occupation; Housewife 
No serious illnesses 
Para 2 i ^
Ante-partum  haemorrhage 28 weeks anen- 
cephalic.
Ante-partum  haemorrhage 32 weeks. L ive  
fem ale.
Spontaneous abortion 6 weeks.
Spontaneous abortion 12 weeks.
Never hypertensive.
Pregnancy studied: 1975
Gestation B .F . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
F irs t v is it to G .P .: 10 125/80 None
F irs t hospita l v is it: 16 145/85 None
Progress: 30 120/90 None
32 146/110 0.75
33 160/110 0.62
34 158/110 1.7
211
Drug therapy:
D elivery:
Means of d e live ry : 
Baby:
B irth  weight: 
Placenta;
Baby's condition at 
b ir th  and progress:
P lacental pathology: 
Puerperium : 
Post-natal v is it :
Renal U nit fo llow -up:
O ra l iro n , fo lic  acid and vitam ins. Sodium 
am ylobarbitone 200 mg o ra lly  nocte. Sodium 
am ylobarbitone 250 mg in tra -m uscu la rly  as 
required, Methyldopa 200 mg o ra lly  t. i. d. 
Gradual de terio ra tion in  condition w ith  
development of p ro te inuria .
35 weeks gestation.
E lective Caesarean section 
L ive  female 
2.16 Kg.
0.44 Kg.
Baby was m ild ly  asphyxiated at b irth . She 
was thought to be both prem ature and dysmature. 
No serious com plications but required several 
weeks in  hospita l. Thereafter good progress.
No deta ils available.
Hypertension and p ro te inu ria  gradually settled. 
W ell although s t ill hypertensive -  B .F . 160/
100 mmHg (145/90 mmHg).
S till s lig h tly  hypertensive at f ir s t  v is it 130/100 
mmHg. ÎVP and other rena l investigations were 
a ll norm al although B . P. rem ained s ligh tly  
ra ised u n til treated w ith  a low dose of propranolol. 
I t  is  possible that there may be underlying 
essential hypertension, but the diagnosis of p re - 
eclampsia can probably be accepted.
No: 10 (D .F . )
Age; 22 years 
Past m edical h is to ry:
Occupation: Shop assistant and housewife. 
No serious illnesses.
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Past obstetric h is to ry : Para 0 4-
Pregnancy studied: 1974
0
Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
F irs t v is it to G. P. : 12 110/70 None
F irs t hospita l v is it; 18 110/70 None
Progress: 28 186/100 11.5
30 140/100 7.0
32 120/100 6.0
D elivery:
Means of d e live ry ; 
Baby:
B irth  weight: 
Placenta;
Baby's condition at 
b irth  and progress:
P lacental pathology;
Summary:
Puerperium :
O ra l iro n , fo lic  acid and v itam ins. Sodium 
am ylobarbitone 200 mg o ra lly  t. i.  d. M ethyl­
dopa 260 mg o ra lly  t. i,  d , , la te r increased to  
500 mg o ra lly  t .  i,  d. (at 30 weeks).
Despite marked p ro te inu ria  the patient 
remained su rp ris in g ly  w e ll. It was possible 
to  continue pregnancy u n til 32 weeks.
32 weeks gestation.
E lective Caesarean section.
L ive  male.
1. 60 Kg.
0.33 Kg,
Prem ature baby in  good condition. Thereafter 
made good progress.
F ib rino id  in  m aternal vessel w a lls. Spindly 
v i l l i  and excessive numbers of syncytia l knots. 
Compatible w ith placental insuffic iency and p re ­
eclampsia*
3 days post-partum  p ro te inu ria  —) 13.1 g /2 4  h rs 
but thereafter settled. When discharged home
B. P. 130/85 mmHg and a trace of p ro te inuria .
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P ost-nata l v is it:
Benal U nit fo llow -up:
W ell. (B .P . 120/85 mmHg and a trace of 
p ro te inuria ).
F u lly  investigated. B. P. 110/75 mmHg. 
Quantitative p ro te inuria  = 0, 65 g /2 4  hrs. 
G radually disappeared over next 3 months. 
WP and other renal investigations a ll norm al. 
Diagnosis of pre-eclam psia seemed fa ir ly  
certa in .
B , High r is k  of pre-eclam psia 
A n ti-th rom botic  treatm ent
Ho: 11 (R .8 .)
Age: 31 years 
Past m edical h is to ry: 
Fast obste tric h is to ry:
(1) 1970
(2) 1972
Pregnancy studied:
F irs t v is it to  G. P. : 
F irs t hospita l v is it:
Occupation: Housewife 
No serious illnesses 
Para 2 -h ^
Severe pre-eclam psia at 25 weeks, required 
term ination of pregnancy at 28 weeks. B. P. 
fe ll to norm al 2 months a fte r de livery.
Severe pre-eclam psia at 25 weeks resu lting  in  
an in trau te rine  death at 28 weeks. B .P . fe ll 
to norm al 2 months a fte r de live ry.
Investigated at W estern In firm a ry  B .P . U n it:-  
renal function and I¥P  norm al.
1974
Gestation
(weeks)
8
11
B .F .
(mmHg)
130/80
125/80
P ro te inu ria  
(g /24  hrs)
None
None
Threatened abortion
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Progress;
Therapy:
D e livery:
Means of d e live ry : 
Baby;
B irth  weight: 
Placenta;
Baby's condition at 
b irth  and progress:
Puerperium : 
Post-nata l v is it:
Gestation B .P . P ro te inu ria
(weeks) (mmHg) (g /24  hrs)
20 110/60 None
24 115/00 None
28 115/60 None
32 120/60 None
34 120/65 None
36 120/80 None
38 130/85 None
W ell throughout pregnancy. Steady g
of baby. N orm al oestrio ls .
O ra l iro n , fo lic  acid and vitam ins.
Heparin 5,000 units subcutaneously b. d.
(5 out of 7 days/week).
A sp irin  600 mg o ra lly  t. i.  d.
D ipyridam ole lOO mg o ra lly  t. i.  d. The an ti­
throm botic drugs were discontinued a few days 
before de livery,
38 weeks.
E lective Caesarean section 
L ive  male,
2. 58 Kg (FlO -25)
0. 520 Kg (no details about pathology)
Good condition at b irth , rem ained w e ll w ith  
satisfacto ry weight gain.
Good recovery.
W ell. (B .P . 120/70 mmHg).
No: 12 (J .W .)
Age: 29 years 
Past m edical h is to ry;
Occupation: Housewife 
No serious illnesses
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Past obste tric h is to ry:
(1) 1974
(2) 1974
Pregnancy studied:
Para 2 4 ^
(January) Severe pre-eclam psia at 30 weeks 
resu lting  in  an in trau te rine  death at 32 weeks, 
(November) Severe pre-eclam psia at 30 weeks, 
c lin ic a lly  ” sm all-fo r-da tes '* resu lting  in  an 
in trau te rine  death at 30 weeks.
1978
Gestation
(weeks)
B .P .
(mmHg)
P ro te inu ria  
(g /24  hrs)
F irs t v is it to  G. P. ; 8 118/75 None
F irs t hospita l v is it: 18 120/75 None
Diagnosed as tw in 
pregnancy.
Progress: Adm itted - 24 120/70 None
30 115/70 None
32 120/70 None
34 120/80 None
36 120/80 None
Drug therapy;
D elivery:
Means of d e live ry : 
Babies;
Threatened prem ature labour at 30 weeks. 
Babies appeared to  grow w e ll.
O ra l iro n  and fo lic  acid. D ipyridam ole 100 mg 
o ra lly  q. i.  d. A sp irin  650 mg o ra lly  q. i.  d. 
started at 28 weeks and continued u n til 36 weeks 
(discontinued tem p ora rily  at 30 weeks when 
threatened prem ature labour. This was 
treated w ith IV  salbutam ol),
36 weeks
E lective  Caesarean section
(1) L ive  female
(2) L ive  female
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B irth  weights: 
Placenta;
Babies condition at 
b irth  and progress:
Puerperium : 
Post-nata l v is it:
(1) 2.22 Kg. (P 10-25)
(2) 2.31 Kg* (P 10-25)
1.05 Kg*
No deta ils about pathology.
Tw in (1): P rem ature baby. Required 
resuscitation a fte r de live ry . La te r developed 
m ild  jaundice. 3 weeks a fte r b irth  started to  
gain weight and progress w e ll.
Tw in (2): P rem ature baby. In better 
condition than tw in at b irth . A lso developed 
m ild  jaundice but otherw ise progressed w e ll. 
Good recovery. B .P . 125/80 mmHg.
W ell. (No B .P . recorded in  notes).
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Appendix HI
Two Pregnant Patients Considered at 
" H igh -R isk" of Developing P re-Eclam psia
These patients are presented as examples of s e ria l studies 
perform ed during the ante-natal period on patients who did not 
develop pre-eclam psia. In view of th e ir past obste tric  h is to ry  
i t  m ight have been expected that each of these patients would 
develop hypertensive com plications during the pregnancy under 
study. Both received a fo rm  of anti-tin*om botic therapy, but it  
would c le a rly  be im possible to  re la te  the good c lin ic a l outcome 
in  each case to th is  treatm ent. (Detailed case sum m aries on 
each patient can be found in  Appendix II).
(i) Patient 11 (H,S. ) F igure 69.
This patient had had two previous pregnancies both of which 
had been com plicated by fu lm inating pre-eclam psia. In both cases 
the baby had died. She was in  hospital fo r most of th is , her th ird , 
pregnancy. She was f ir s t  studied at 20 weeks gestation and there­
a fte r followed se ria lly  throughout pregnancy. She received low - 
dose subcutaneous heparin, A sp irin  and dipyridam ole as an ti­
throm botic therapy in  the dosage shown in  the summary (Appendix 
II).
She did not develop any of the c lin ica l features of pre-eclam psia. 
She was delivered by elective Caesarean section at 38 weeks. The 
baby was in  good condition at b irth  and progressed sa tis fa c to rily  
therea fte r. The pa tien t's post-partum  progress was uncomplicated.
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The plasma fibrinogen levels were norm al (the "lo w " value 
at 20 weeks gestation is  only low compared w ith  the range in  
norm al th ird  trim e s te r pregnancies shown in  the chart and the 
"h igh " value ju s t before de live ry  is  not unreasonable fo r a patient 
close to te rm ). Area m was consistently w ith in  the norm al range. 
The SCT t itre  at only rose to  above the norm al range in  the 
sample taken ju s t before Caesarean section, but titre s  as high as 
th is  have been found in  ind ividual norm al pregnancies (see Table 
53). These resu lts  would not suggest increased coagulation 
a c tiv ity  in  th is  patient. Area p levels were ra ised in  3 out of the 
5 ante-natal samples. This could suggest increased fibrinogen- 
oly s is /fib r in o ly s is  o r dim inished clearance of ea rly  degradation 
products (or both). The serum F D P /fdp  leve ls were, however, 
only ra ised in  the sample taken jus t before de live ry and values as 
high as th is  have been found in  norm al pregnancy (see Table 53).
The laboratory resu lts  were therefore la rge ly  w ith in  the 
"n o rm a l" range fo r la te r pregnancy (24-39 weeks) as based on the 
resu lts  in 14 norm al pregnant women (Table 53) and as such were 
compatible w ith  the c lin ic a l p ic tu re .
( ii)  Patient 12 (J .W .) F igure 70.
This was a s im ila r case, the patient having had two previous 
pregnancies w ith  fu lm inating pre-eclam psia and in trau te rine  death. 
She had the additional com plication on th is  occasion of a tw in  
pregnancy. She was f ir s t  studied at 28 weeks. She received 
A sp irin  and dipyridam ole from  about 29 weeks u n til de live ry at 
37 weeks in  the dosage shown in the summary (Appendix 11). This 
therapy was discontinued b rie fly  at 31 weeks when she threatened 
to go in to prem ature labour. She was delivered by elective 
Caesarean section at 36 weeks. Both babies were prem ature and 
both developed m ild  neonatal jaundice. Apart from  th is , th e ir
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condition sho rtly  a fte r b irth  and subsequent progress was 
satisfactory*
The plasma fibrinogen levels were norm al throughout 
the period of study* Area m and the BCT t itre  at were 
only ra ised fo llow ing the episode of threatened prem ature 
labour. Possibly both the laboratory and c lin ic a l p ic tu re  
at that stage re flected a sm all abruptio placenta, but unfortunately 
the placenta was not examined fo r th is  a fte r de live ry . Area p 
was s lig h tly  ra ised in  4 out of 7 ante-natal samples studied. 
Although the true  significance of th is  is  uncerta in, i t  is  w orth 
noting that s lig h tly  ra ised levels of area p were also found in 
the previous patient (Patient 11). It may be that increased 
fib rin o g e n o lys is /fib rin o lys is  was present w ith  o r w ithout 
dim inished clearance of ea rly  degradation products in  both 
patients and th is  m ight have contributed to the good c lin ica l 
outcome. The serum F D P /fdp  levels were, however, not 
increased and so the ra ised area p levels may not be of any 
re a l significance.
Comment on the "H igh -R isk" Patients
It would be im possible to  assess the effect of the an ti­
throm botic therapy on the c lin ic a l course of these patients.
It  seems most lik e ly  that neither were destined to  develop p re ­
eclampsia in  the pregnancy studied, but c le a rly  th is  question 
cannot at present be answered. These sequential studies do, 
however, demonstrate that essentia lly norm al soluble complex 
levels were present in  two patients who did not develop p re ­
eclam psia. The only abnormal area m resu lt occurred in  
Patient 12 fo llow ing an episode of prem ature labour and it  is  
possible that a sm all abruptio placenta was responsible fo r both 
the c lin ica l and labora tory p ic tu re .
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APPENDIX IV 
LOCAL VENOUS THROMBOSIS
Six patients w ith  loca l venous throm bosis were studied.
The c lin ic a l diagnosis was confirm ed in  each case by venography. 
The c lin ica l de ta ils are shown in  Table 83, Two patients (Nos.
1 and 5) had m etastatic carcinom a. None were hypertensive^
The resu lts  obtained on samples from  these patients are shown 
in  Table 84. A wide range of resu lts  were obtained, but th is  is  
not su rp ris in g  in  view of the wide va ria tion  in  c lin ic a l p ic tu re .
Compared w ith  the resu lts  from  the norm al healthy contro l 
subjects (Group III ,  Chapter V) the resu lts  from  the deep vein 
throm bosis patients showed several s ign ifican t d ifferences (Table 
85) although it  must be stressed that these groups were not matched 
(e. g. fo r age and sex).
These resu lts  would suggest that there may be ;-
(i) an increase in  soluble complex concentration -  
both oligom er /  d im er (area m) and polym er 
(SCT t itre  at V^, FR-antigen and T .C . P. ra tio s), 
in  plasma samples from  loca l venous throm bosis 
patients
( ii)  an increased concentration of ea rly  clo ttable 
degradation product (area p) and non-clottable 
degradation product (serum FD P /fdp) concentration 
in  samples from  loca l venous throm bosis patients.
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ABSTRACT Seven patients were studied during defibrination pro­
duced by ancrod infusion. In every case soluble
complexes composed of material antigenically related 
to fibrinogen were demonstrated, using agarose gel 
filtration, after six hours ancrod infusion. Poly­
acrylamide gel electrophoresis in sodium dodecyl 
sulphate showed that the soluble complexes were largely 
composed of units with a molecular weight less than 
fibrinogen similar to a minimally degraded product, 
early Fragment X. Polyacrylamide gel electrophoresis 
in sodium dodecyl sulphate and mercaptoethanol showed 
that the component units of the soluble complexes were 
markedly deficient in intact AoC chain when compared 
with the uncomplexed material. It is suggested that 
> preferential digestion of fibrin may occur while it is
■ still in the soluble form.
INTRODUCTION
Soluble complexes of material antigenically related to 
fibrinogen have been demonstrated in the circulation in a number 
of pathological conditions associated with "hypercoagulability" 
or thrombosis (1). In vitro studies have shown that different 
forms of soluble complexes can be produced (2,3,4,5). Little is 
known, however, concerning the structure, formation and break­
down of soluble complexes in vivo.
Soluble complexes can be demonstrated experimentally
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following thrombin infusion in rabbits (4). The therapeutic 
use of thrombin-like snake venoms as defibrinating agents could,
therefore, provide a useful model of soluble complex production
in man. Soluble fibrin, demonstrated by the ethanol gelation 
test and N-terminal amino acid analysis, has been found in the 
plasma of patients treated with Defibrase, the defibrinating 
agent from the venom of Bothrops atrox (5). Soluble complexes, 
demonstrated by agarose gel filtration, have also been found in 
the plasma of these patients (7). Ancrod is another defibrinat­
ing enzyme derived from the venom of the Malayan pit viper
(Agkistrodon rhodostoma). In vitro ancrod resembles thrombin 
in removing fibrinopeptide A from fibrinogen but differs in 
failing to remove fibrinopeptide B (8). We extend here our 
preliminary observations (9) on a group of seven patients treat­
ed therapeutically with ancrod. Soluble complexes were isolat­
ed from plasma in concentrations suitable for the study of the 
molecular weight and the chains of their component units.
PATIENTS, MATERIALS AND METHODS
Seven patients were studied. Four suffered from deep 
venous thrombosis and three from severe peripheral arterial 
disease. There were five males and two females with an age 
range of 22 to 72 years. Neither female was taking oral contia- 
ceptives. Ancrod (Arvin, Berk Pharmaceuticals Limited, Shal- 
ford, Sussex, England) was administered as an intravenous infus­
ion in a dose of 2 units/Kg body weight/12 hours. No anticoag­
ulant or fibrinolytic agent was given during the period of study. 
Blood samples were collected before treatment and after 5 and 24 
hours of ancrod infusion. Control samples were obtained from 
healthy volunteers with a comparable age range.
Collection of Samples: Blood was collected by careful venepunc­
ture with minimal venous occlusion. Each sample was divided 
into aliquots for preparation of plasma, serum and observation 
of clot quality.
Plasma: Whole blood was collected in anticoagulant in the pro­
portion of 9 parts blood to 1 part anticoagulant mixture 
(pH 7.5). This contained (before addition of blood) trisodium 
citrate O.13M; N tris (hydroxymethyl) methyl 2-aminoethane 
sulphonic acid 0.06M; epsilon aminocaproic acid (E.A.C.A.)O.02M 
and aprotinin (Trasylol, Bayer Pharmaceuticals Limited, Haywards 
Heath, Sussex, England) 10^ K.I.U./l. 0.2 ml. ancrod antiserum
(snake venom antiserum Agkistrodon rhodostoma. The Lister Insti­
tute, Elstree, England) was added to each millilitre of anti­
coagulant to neutralise any ancrod in the blood sample. The 
blood was collected in plastic syringes and containers and 
handled with siliconised glassware. Plasma was prepared by 
centrifugation at 3,000 g to 20 minutes.
Serum: Whole blood was collected in containers provided for use
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with 'Wellcome F.D.P, kits' (Wellcome Research Laboratories, 
Beckenham, England, HA 14). These contain thrombin and a plas- 
min inhibitor, Ancrod antiserum (0.05 ml) was added. Blood 
was allowed to clot at room temperature for several hours and 
serum separated.
Clot Quality Observation Test: 1 ml of whole blood was incub­
ated in a glass test tube (75 x 10 mm) containing 0.05 ml ancrod 
antiserum at 37°C for 24 hours. The resultant clot was graded 
1 to 5, a normal clot being graded as 1 and no clot as 5, The 
grades 2, 3, 4 represented mild, moderate and severe defects(10),
Plasma Fibrinogen was measured by the method of Ratnoff and 
Menzie (11).
Staphylococcal Clumping Test Titre (S.C,T. Titre) was performed 
by the method of Hawiger et al, (12), Staphylococcal clumping 
factor was obtained from Sigma London Chemical Company Limited, 
Kingston-upon-Thames, Surrey, England (850-10).
Serum Fibrinogen-Fibrin Degradation Products (serum F.D.P,) 
estimation was performed using the Tanned Red Cell Haemagglut- 
ination Inhibition Immunoassay (13) using pre-packed kits 
(Wellcome Research Laboratories, HA 14),
p-alanine precipitate of fresh plasma was prepared by the meth­
od of Graeff et al. (14) and gel filtration performed immediate­
ly,
6% Agarose Gel Filtration: An adaptation of the method of
Fletcher ejb al. (1) was employed using Biogel A-5m mesh size 
200-400 (Bio-rad Laboratories Limited, Bromley, Kent, England, 
1510750) with columns of packed height of 35 cms and diameter 
2.5 cm. Void volume as measured by Blue Dextran 2,000 
(Pharmacia G.B. Limited, 75, Uxbridge Road, London,) was 60 ml. 
Elution buffer (pH 7.6) contained Tris (hydroxymethyl) methyl- 
amine 0.05M; O.lM HCl 384 ml/1; NaCl 0.115M; trisodium cit­
rate 0.012M; E.A.C.A. 0.05M; aprotinin (Trasylol) lO^ K.I,U./1. 
The flow rate of 25 ml/hour was controlled by a constant infus­
ion pump and 2.5 ml fractions of eluant were collected.
Fibrinogen-Fibrin related Antigen (FR-antigen) was estimated in 
the eluant fractions using a radial immunodiffusion technique 
(15). Agar, 3% W/V ('Difco' Bacto-Agar, Difco Laboratories, 
Detroit, Michigan, U.S.A. 0.141-02) was dissolved in barbital- 
saline buffer (pH 7.2) which contained sodium barbitone 0.02M; 
sodium chloride 0.29M; O.lM HCl 161 ml/1; ethylenediamine- 
tetracetic acid disodium salt O.OlM; trisodium citrate 0.012M; 
E.A.C.A. O.OlM; sodium azide 0.003M. Fibrinogen antiserum 
(Behringwerke - Hoechst Pharmaceuticals, Hounslow, Middlesex, 
England, ORCH 05) was used at a 1:120 dilution in 0.9% W/V 
saline. 6 ml. of dissolved agar was mixed with 5 ml diluted 
antiserum at 56^C and then poured into a plastic petri dish
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(8.5 cm in diameter) and allowed to gel. Samples of 5 ul were 
applied to this gel and diffusion continued for 48 hours at room 
temperature in a moist atmosphere. Clear rings were obtained 
by staining with 1% W/V tannic acid for 3 minutes. Plates were 
calibrated by use of appropriate dilutions of Protein Standard 
Plasma (Behringwerke - Hoechst Pharmaceuticals OTFl 03). Where 
necessary samples were diluted with column elution buffer before 
assay.
Thrombin Clotting Time (T.C.T.) was performed according to the 
method described by McNicol e^ al. (15) and Thrombin Clottable
Protein (T.C.P.) was demonstrated using the same system except 
that it was incubated without mixing at 37°C and examined for 
clot formation after 1 and 24 hours.
Polyacrylamide Gel Electrophoresis in the presence of sodium 
dodecyl sulphate (S.D.S.) was performed according to the method 
of Weber and Osborn (17). Fibrinogen (Kabi, Grade L, AB Kabi, 
Stockholm, Sweden) was used as a standard. Fragments X, Y and 
D were prepared by streptokinase-induced lysis of the Kabi 
fibrinogen (IB). Densitometric scans were obtained by scanning 
the gels at 600 nm using a Gilford spectrophotometer.
RESULTS
Clot Quality Observation Test: In all of the patients the pre­
treatment samples produced Grade 1 clot. After 6 hours ancrod 
infusion the clot remained Grade 1 or 2. After 24 hours infus­
ion the blood was completely incoagulable (Grade 5).
Plasma Fibrinogen, Serum F.D.P. and Serum S.C.T. Titre Levels 
are shown in Fig. 1. In every case the plasma fibrinogen fell
PLASMA FIBRINOG EN SERUM F.D.P. SERUM S.C.T. T ITR E
(m g /lO O  m l) (negative  log to base 2 )
400 4,000
300 3.000
200
100 1.000
pre 6 pre 66 24 hra pre 24 h r .
FIG. 1
The mean and standard error of the mean of plasma fibrinogen, 
serum F.D.P. and serum S.C.T. titre estimations on samples 
obtained from 7 patients pre-treatment (pre) and after 6 and 
24 hours ancrod infusion.
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significantly after 5 hours ancrod infusion and after 24 hours 
had reached negligible levels. There was a corresponding sharp 
rise in both the serum F.D.P. and serum S.C.T. titre levels
after 6 hours infusion and this was maintained after 24 hours.
6% Agarose Gel Filtration: The FR-antigen from normal control
plasmas always eluted from the column as a symmetrical curve 
(main peak) with a peak elution volume of 90 ml. A similarly 
shaped curve was obtained from the thrombin clotting times. The
results of a representative control sample are shown in Figure 2.
Agarose gel filtra tio nNorma
20
S’ 100
120 O
20 160
60
Elution volum e (m l)
9030 120
FIG.
6% agarose gel filtration of a beta-alanine precipitate of plas­
ma from a normal control subject. FR-antigen measured by radial 
immunodiffusion techniques and T.C.T. estimations are shown in 
terras of elution volume.
The elution pattern of FR-antigen for samples from two represent­
ative patients are shown in Figure 3(a) and (b). The corres­
ponding T.C.T. curves and range of thrombin clottable protein 
(T.C.P.) performed on the same eluant fractions from samples 
from one patient (J.McK.) are shown in Figure 4. In the pre­
treatment samples the FR-antigen and T.C.T. curves, together 
with the range of thrombin clottable protein corresponded close­
ly to results from normal control subjects. In 5 out of the 7 
cases small shoulders were present on both sides of the FR-anti­
gen main peak, as in the cases shown. These probably represent 
low concentrations of soluble complexes and degradation products, 
compatible with the diagnosis of thrombotic disease.
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FIG. 3(a)
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FIG. 3(b)
Elution of FR-antigen following 6% agarose gel filtration of a 
beta-alanine precipitate of plasma obtained from two represent­
ative patients (W.McG. and J.McK.) pre-treatment and after 6 
and 24 hours ancrod infusion.
After 5 hours of ancrod infusion definite shoulders were 
noted on both sides of the FR-antigen main peak indicating the 
formation of increased quantities of soluble complexes and 
degradation products. The void volume soluble complexes 
clotted much more rapidly than an equivalent concentration of 
fibrinogen and appeared unstable in that they precipitated with­
in a few hours of cooling to 4^C and also on standing at room 
temperature for 24-48 hours. The intermediate zone soluble 
complexes did not clot more readily than fibrinogen and in some 
cases the T.C.T. exceeded 3 minutes. Incubation with thrombin 
for one hour resulted in clot formation in those cases. These 
complexes were more stable and did not tend to precipitate on 
cooling to 4°C or on standing at room temperature for 48 hours.
After 24 hours of ancrod infusion only small quantities of 
PR-Antigen were eluted but followed the pattern of the 6 hour 
sample. No recordable T.C.T. was demonstrated in any patient. 
Small amounts of T.C.P. appeared at the position of the main 
peak after 1 hour incubation. In some samples T.C.P. was also 
present after 24 hours incubation.
In every case a high S.C.T. titre was recorded in the void
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volume fraction of samples obtained from patients receiving 
treatment, e.g., in patient W.McG. the pre-treatment titre was 
zero, rising to 8 at 6 hours and remaining 7 at 24 hours.
j  lyicj^ A g a ro se  g e l filtra t io n
I '
 p r e -  tre a tm e n t  /  \
o) 0 0
6  tiours  
2 4  ho urs
C lo tta b le
p ro te in
2  pre -  t re a tm e n t
6 hours  
2 4  hours
6 0  9 0  120
E lu tio n  v o lu m e  ( m l)
FIG, 4
The upper section shows the T.C.T. curves obtained from the 
eluant fractions following 6% agarose gel filtration of a 
beta-alanine precipitate of plasma obtained from patient J.McK. 
pre-treatment and after 6 and 24 hours ancrod infusion, (The
corresponding FR-antigen curves are shown in Fig. 3b). The
lower section shows changes in the range of thrombin clottable 
protein (after 1 hour's incubation) measured on the same eluant 
fractions.
Polyacrylamide Gel Electrophoresis (P.A.G.E.): The component
units of the soluble complexes found in six hour samples at 
elution volumes 60 ml (void volume) and 80 ml (intermediate 
zone) were studied and compared with the uncomplexed material 
eluting at 90 ml (main peak), the position of standard fibrin­
ogen.
P.A.G.E. in presence of S.D.S. alone: This technique allows
approximate estimation of the. molecular weight (M.W.) of the 
component units of the soluble complexes and uncomplexed mater­
ial. Some variation was noted between patients and so the 
results of two patients illustrating those differences are shown 
in Pig. 5(a). Patient W.McG. is more typical of the group as a 
whole than patient J.McK. The component units consisted largely 
of material with a molecular weight less than fibrinogen similar
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to a minimally degraded product early Fragment X. In addition 
small quantities of protein similar in M.W. to Fragment X, Y 
and D were found in some cases (particularly J.McK.). The main 
peak seems to consist of material ranging in M.W. from fibrino­
gen to Fragment X, Degradation products Y and D were present 
in some cases.
RAC. E lec tro p h o r.s is  In S.D.S. 
Six hour sam pl. 9
P.A.G. E lectrophoresis In S.D .S. and 2 ME. 
Six hour sam ples
W .M cG . J .M c K .
Main peak
Void volume
J . M c K .W. M cG .
Main peak
s
8
X)<
In term ediate  
V zone
Void volume
FIG. 5(a) FIG. 5(b)
Densitometric scans of polyacrylamide gels obtained by electro­
phoresis in (a) sodium dodecyl sulphate (S.D.S.) and (b) sodium 
dodecyl sulphate and mercaptoethanol (S.D.S. and 2 ME) of 
selected fractions from agarose gel filtration of the 5 hour 
samples shown in Fig. 3. The migration position of standard 
fibrinogen (F), its degradation products X, Y and D and its 
chain and are indicated.
P.A.G.E. in presence of S.D.S. and Mercaptoethanol: This allows
estimation of the M.W. of the chains within the component units 
of the soluble complexes and the uncomplexed material. The 
results for the same two patients are shown in Figure 5 (b). In 
all 7 patients the component units of the soluble complexes were 
deficient in intact Ao<chain. The A c h a i n  loss varied in
degree and was complete in the void volume complexes in 2 pat­
ients (see J.McK.). In 6 patients Ac/ chain loss in the uncom­
plexed main peak material was minimal or absent (see W.McG).
In only one patient (J.McK.) was total loss of Ao<chain found.
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DISCUSSION
Soluble complexes have been demonstrated in the plasma of 
patients suffering from a variety of conditions (1, 19, 14, 20,
7). In this present study the formation of a range of soluble 
complexes has been demonstrated during defibrination by ancrod 
infusion. It is unlikely that these soluble complexes were pro­
duced by the continued action of enzymes contained in the blood 
sample, as inhibitory concentrations of ancrod antiserum, E.A.CJ^ . 
and aprotinin were added with the anticoagulant used in prepar­
ing plasma. E.A.C.A. and aprotinin were also present in the 
column elution buffer.
Lack of intact Ao< chain in the component units of the sol­
uble complexes suggests that proteolytic digestion has occurred. 
High concentrations of ancrod progressively attack the Ac/ chain 
of fibrinogen vitro (21,22). A Cohn Fraction I preparation 
of plasma from patients already defibrinated by ancrod and 
receiving continued treatment has been shown to be deficient in 
intact A(X chain (23). While this could be due to digestion of 
the Ac/chain by ancrod itself, the concentration of ancrod like­
ly to be present in the plasma therapeutically is less than that 
required for Aocchain digestion vitro (22). If ancrod were 
responsible for the Ac<chain digestion two Ac/chain fragments 
(M.W, 39,000 and 31,000) should have been present (22). These 
were sought but not found in the present study. The rapid fall 
in plasma plasminogen levels which occurs during initial ancrod 
infusion (24) suggests that plasmin could be responsible for the 
Aocchain digestion of the soluble complexes.
The observation, that the Ac/chain loss was more marked 
in the soluble complexes than in the uncomplexed material,in 6 
out of 7 cases, suggests that preferential proteolysis of the 
soluble complexes may have occurred. It has been claimed that 
soluble fibrin monomer is digested rapidly and selectively by 
plasmin ini vitro in preference to fibrinogen (25). This prefer­
ential digestion may be limited to the early stages of the react­
ion (25) . If this occurred vivo sufficiently rapidly to pre­
vent the formation of insoluble fibrin, soluble complexes defic­
ient in intact Ac/ chain could be formed. There would, there­
fore, be no need to postulate the existence of particulate fibrin 
'micro-clots' (24) during ancrod treatment and the benign nature 
of the acute defibrination state produced could be explained.
Soluble complexes deficient in intact Ac/ chain could also 
be produced by the polymerisation of early degradation products 
of fibrinogen or fibrin (4) or by the lysis of insoluble fibrin 
(5). %n vitro studies have shown that soluble complexes defic­
ient in intact Ac/chain can be produced in plasma and purified 
fibrinogen by the sequential action of ancrod and plasmin regard­
less of which enzyme acts first (unpublished observation). It
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is, therefore, possible that the soluble complexes are produced 
in vivo by more than one route. Other enzymes may be involved.
The equilibrium between soluble complex formation and 
breakdown will depend not only on the rate of ancrod infusion, 
but also on the rate at which the individual is able to generate 
proteolytic enzymes and synthesise fibrinogen in response to the 
challenge. Shifts in this equilibrium might be responsible for 
the variation in the degree of Ac/ chain digestion in our pat­
ients. It is possible that digestion of soluble fibrin monomer 
is so rapid that soluble complexes with intact Ao< chain never 
form within the circulation. In such patients (e.g., J.McK.) 
soluble complexes could be produced by polymerisation of early 
X fragments lacking fibrinopeptide A.
The suggestion that F.D.P. in ancrod treated patients 
may be derived from soluble rather than insoluble fibrin has 
already been made on the basis of studies of the cross-linkage 
of the F.D.P. (26). The preferential digestion of soluble 
fibrin could represent an important pathway for the production 
of F.D.P. jji vivo.
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A  soluble fib rin  complex is a polymer composed o f 
units antigeiiically related to fibrinogen. Such, com­
plexes have been identified in  the plasma o f  patients 
suflfering from  ‘hypercoagulable’ states and throm ­
bosis (Fletcher et a l ,  1970). Their presence is thought 
to indicate activation o f the d o ttin g  mechanisms w ith  
conversion o f prothrom bin to  throm bin w ith in  the 
circulation.
A  throm bin-like snake venom, ancrod (A rv in , 
Twyford Laboratories, H igh Wycombe), is used 
therapeutically as a defibrinating agent. In vitro ancrod 
clots fibrinogen by the removal o f fibrinopeptide A. 
The fib rin  monomer so produced is thought to poly­
merise to form , first, a soluble fib rin  polymer and 
then insoluble fibrin. In vivo ancrod produces defibrin­
ation by the conversion o f fibrinogen to  fib rin  
‘m icro-clots’, which are then removed by a combina­
tion o f fibrinolysis and the activ ity o f the reticulo­
endothelial system (Pitney et al., 1969).
A  group o f 7 patients were studied during the 
in itia l stages o f defibrination by ancrod w ith  a view 
to identifying the soluble complexes formed and 
isolating them in sufficient concentration to allow 
study o f their chain structure. Plasma samples were 
obtained before treatment and after 6 and 24 hours 
ancrod infusion at a rate o f 2 «/Kg./12 hours. Agarose 
gel filtra tion  was used to  separate the soluble com­
plexes from  the uncomplexed fibrinogen related 
material on the basis o f their greater molecular size. 
The concentration o f fibrinogen related antigen 
(FR-antigen) in  protein containing elution fractions 
was measured using a radial immunodiffusion tech­
nique. The results from  a typical patient are shown 
in  Figure 1.
The FR-antigen from  normal control plasmas 
always eluted on the columns as a symmetrical curve 
w ith  a peak at an elution volume o f 90 ml. In the 
pre-treatment sample o f the representative patient 
shown in Figure I, there was a small shoulder on both 
the ascending lim b o f the curve, representing soluble 
complex formation, and on the descending lim b 
indicating the presence o f degradation products o f 
fibrinogen or fibrin. Six hours after starting treatment 
increased quantities o f both soluble complexes and 
degradation products were present. A fte r 24 hours 
treatment very little  FR-antigen remained in  the 
plasma but traces o f soluble complexes were still 
found.
The technique o f polyacylamide gel electrophoresis 
in  sodium dodecyl sulphate (S.D.S.) and mercapto­
ethanol was used to study the chain structure o f the 
fibrinogen related molecules w ith in  the soluble com­
plexes. The results o f the same patient are shown in 
Figure 2. Samples were studied from  the void volume 
fraction (60 m l. elution volume) from  an intermediate 
zone fraction (80 m l. elution volume), and were 
compared w ith  the uncomplexed material present in 
the main peak fraction (90 ml. elution volume).
Before treatment the m ain peak fraction showed 
the three bands o f normal fibrinogen corresponding 
to  its alpha, beta and gamma chains. N o FR-antigen 
was present in the void volume fraction. The in te r­
mediate zone soluble complexes showed a marked 
lack o f intact alpha-chain, when compared w ith  the 
main peak fraction. A fte r 6 hours ancrod treatment 
the soluble complexes in  both the vo id volume and 
intermediate zone fractions showed a sim ilar lack o f  
intact alpha-chain. The m ain peak fraction showed 
the bands o f normal fibrinogen w ith  m in im al loss o f 
intact alpha-chain.
The relative lack o f intact alpha-chain in  the soluble 
complexes suggests that they have undergone prefer­
ential digestion by a proteolytic enzyme, such as 
plasmin. Plasmin in itia lly  attacks the alpha-chain o f  
fibrinogen producing a degradation product known 
as early Fragment X . The soluble complexes consisted 
o f similar units.
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Fig. 1. Agarose gel filtra tion  o f fibrinogen related 
antigen derived from  plasma o f a patient undergoing 
ancrod treatment. Samples obtained pre-treatment 
and after 6 and 24 hours treatment w ith  ancrod.
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Soluble fib rin  monomer may be attacked selectively 
by plasmin in preference to fibrinogen in vitro (K o n tti-  
nen et n/., 1973). I f  this occurs in vivo at a sufficiently 
rapid rate the form ation o f insoluble fib rin  ‘m icro- 
clots’ could be prevented. Instead soluble complexes 
deficient in  intact alpha-chain could be produced. 
Further digestion o f these complexes by plasmin 
would result in  the production o f fib rin  degradation 
products (F.D.P.).
The F.D.P. in  ancrod-treated patients may, there­
fore, be derived from  soluble rather than insoluble 
fibrin. As insoluble ‘m icro-clots’ would not form  
w ith in  the circulation, the benign nature o f the acute 
defibrination state produced by ancrod would be
explained. I t  is possible that the preferential digestion 
o f soluble fib rin  by plasmin represents an im portant 
pathway in the production o f F.D.P. in vivo.
C.R.M.P. is in  receipt o f a Wellcome Research 
Fellowship.
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Possible pathway for formation of fibrin  
degradation products during ancrod therapy
SoLUULE complexes composed of protein antigenicaliy related 
to fibrinogen have been found in the plasma o f patients 
suffering from thrombosis or a hypercoagulable state'. These 
complexes are important as they could provide a sensitive 
method fo r the laboratory diagnosis o f such conditions at a 
very early stage in their development'. L ittle  is known 
concerning the structure, form ation and breakdown of 
soluble complexes in vivo.
Soluble complexes can be produced by an intravenous 
infusion of thrombin in rabbits". A lthough such experiments 
are not possible in man, the use o f throm bin-like snake 
venoms as defibrinating agents could provide a valuable 
alternative. Soluble complexes have been identified in the 
plasma of patients given defibrinating doses of the partially 
purified venom of Bothrops moojeni (Defibrase)".
We have studied seven patients receiving treatment w ith 
ancrod, a defibrinating agent derived from the venom of 
Agkistrodon rhodostoma. In vitro ancrod resembles throm ­
bin in removing fibrinopeptide A  from  fibrinogen but differs 
in fa iling to remove fibrinopeptide B (ref. 4). In vivo ancrod 
infusion is thought to produce rapid defibrination by the 
formation o f insoluble fibrin microclots throughout the c ir­
culation, which are removed by fibrinolysis and reticulo­
endothelial cell activity '.
Ancrod (A rv in , Berk, Shalford, Surrey, U K ) was ad­
ministered intravenously in a dose of 2 U per kg body weight 
per 12 h. Blood samples were taken before starting treat­
ment and after 6 and 24 h therapy. Plasma was obtained 
using triscdium citrate (final concentration 0.013 M ) as anti­
coagulant. Epsilon aminocaproic acid (EAC A ), aprotinin 
and ancrod antiserum were added to prevent any in vitro 
proteolysis. Samples were tested immediately w ithout stor­
age, as freezing and thawing may cause the form ation o f 
soluble complexes'*.
Soluble complexes were separated from uncomplexed 
fibrinogen-related protein by 6% agarose gel filtration 
(Biogel A-5m, BioRad Laboratories, 1510750) o f a /3 alanine 
precipitate of plasma' \  E A C A  and aprotinin were added to 
the elution buffer. Protein-containing eluant fractions were 
analysed fo r fibrinogen-fibrin related antigen (FR-antigen) 
by a radial immunodiffusion technique" using fibrinogen 
antiserum (Behringwerke-Hoechst, ORCH 05). There may 
be changes in the antigenic structure o f the fibrinogen- 
related molecules when incorporated into soluble complexes 
and their diffusion properties may also be altered. This 
method is, therefore, only semiquantitative but changes in 
the distribution of FR-antigen were clearly shown and the 
results correlated well w ith  those obtained by continuous 
absorbance m onitoring at 280 nm.
FR-antigen from  the plasma o f normal control subjects 
eluted from  the column as a symmetrical curve w ith  a peak 
at 90 ml. The results from  a representative patient are shown 
in Fig. 1. Before starting treatment there is an essentially 
normal curve but after 6 h o f ancrod infusion a range of 
soluble complexes were present extending from  the void 
volume (60 m l) to the position of standard fibrinogen. Degra­
dation products o f lower molecular size were also present.
Polyacrylamide gel electrophoresis in sodium dodecyl 
sulphate and mercaptoethanol" was performed to study the 
chain structure o f the component units o f the soluble com­
plexes. Samples were taken from  the complexes present at 
60 and 80 ml and compared w ith the uncomplexed material 
at 90 ml. Where electrophoresis could not be performed
immediately, samples were stored at — 20 °C and tested 
w ithin 24-48 h. The results fo r two patients are shown in 
Fig. 2.
Fibrinogen is composed o f three pairs of polypeptide 
chains (Aa, Bp, ?). In  all seven patients there was marked 
loss o f intact A a  chain in the soluble complex material. In  
six out o f seven patients there was only m inimal loss of 
intact A a  chain in the main peak fraction (see W .McG.). 
The remaining patient (J.M cK .) showed virtual absence of 
intact A a  chain.
Proteolytic enzymes in itia lly  attack the A a  chain of 
fibrinogen. The greater degree o f A a  chain loss in the 
soluble complexes in six out o f seven patients suggests that
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Fig. 1 E lution pattern o f FR-antigen fo llow ing agarose gel 
filtra tion  o f a p alanine precipitate o f plasma obtained from  one
patient (W .M cG .) before starting treatment (----------) and after
6 (---------- ) and 24 h ( #  ) therapy.
preferential proteolytic digestion of the complexes may 
have occurred. As there is marked plasminogen depletion 
during ancrod therapy', plasmin may be responsible fo r this 
proteolysis. Ancrod can produce A a  digestion in vitro'", but 
the concentration o f ancrod required is much greater than 
that present therapeutically.
Soluble complexes deficient in intact A a  chain could be 
produced by the repolymerisation of early degradation 
products" or directly by the lysis of insoluble fibrin". I t  has 
also been suggested that soluble fibrin  monomer is lysed by 
plasmin in preference to fibrinogen in v /fro ", I f  this occur­
red in vivo rapidly enough to prevent the form ation of 
insoluble fibrin, soluble complexes sim ilar to those demon­
strated would be formed. Further digestion by plasmin would 
produce uncomplexed fib rin  degradation products (FDP).
FDP in ancrod-treated patients may, therefore, be derived 
from  soluble rather than insoluble fibrin. A sim ilar sug-
J.M cK .W . M cG .
A a A a
2 Densiiomctric scans o f polyacrylamide gel electro­
phoreses o f selected fractions { a ,  main peak fraction at 90 m l; 
h ,  intermediate zone fraction at 80 m l; c, void volume 
fraction at 60 m l) from agarose gel filtra tion  o f the 6 h 
samples from  two patients fW .M cG . and J.M cK .). The m igra­
tion position o f the Aa, Bfi and y chains o f standard fibrinogen 
are indicated.
gestion has been made based on studies of the cross-linkage 
of the FDP (ref. 12). Microclots would not form within the 
circulation, explaining the benign defibrination state pro­
duced by ancrod infusion. The preferential proteolysis of 
soluble fibrin could represent an important pathway for the 
production of FDP in vivo.
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live cholecystectomy with either a subcostal-oblique or midline 
incision. Informed consent was obtained. There were no com­
plications attributable to the investigations.
K h tt premedication with diazepam (0-15-0*20 mg/kg) and 
droperidol (0*035-0*07 mg/kg) administered intramuscularly 
approximately an hour before the investigation, anmthesia 
was induced with a sleep-dose of thiopentone; Succinylcholihe 
(1*5 mg/kg) was then administered and intubation, using a 
wide-bore, cuffed endotracheal tube, was performed after ven­
tilating the lungs with oxygen. The patient was ventilated 
mechanically by the anecsthetist and anesthesia was main­
tained with fentanyl (0*003 mg/kg). Further doses of fentanyl 
(0*02-0*04 mg) and diazepam (2-4 mg) were given if 
required. During the postoperative course, the patient was 
supervised in an intensive-care unit for 2 to 3 hours before 
returning to the surgical ward.
Arterial blood samples, taken by needle puncture, were 
drawn in 5 ml syringes, the dead-space being filled with 
heparin. The syringes were stored on ice, the blood being ana­
lysed within half an hour after sampling. Oxygen and carbon 
dioxide tensions were determined with standard electrodes (E 
5046, E 5036, Radiometer, Copenhagen), calibrated with 
water-saturated, temperature-regulated gases.
Pulmonary photoscanning was done in half the material, 
using a gamma-camera (Nuclear-Chicago PHD gamma scintil­
lation camera). The patient was given 1*5 mCi of the isotope 
’’mTc ferric hydroxide (Radiochemical Centre, Amersham) in­
travenously into a cubital vein, before scanning, which was 
then performed in three projections— frontal, lateral, and dor­
sal,
The statistical analysis consisted of the calculation of means 
and standard errors. Student’s t-test was used to assess the sig­
nificance of differences between the results, both by testing 
dependent paired data and independent mean values.
Procedure
The patients were randomised into two groups, each con­
taining 24 subjects, with the same distributions of subcostal- 
oblique and midline incisions. The patients in one group 
(heparin group) were given 5000 units of sodium heparin 
(10 000 units/nd, Vitrum, Stockholm) subcutaneously into the 
thigh every 12 hours for 5 days, starting 2-3 hours before op­
eration. The patients in the other group (control group) were 
given 0*5 ml of 0*85% saline at corresponding intervals. 
Arterial blood samples were drawn preoperativcly and daily 
for 4 days during the postoperative period. Preoperativcly and 
on the 3rd or 4th postoperative day, a pulmonary photoscan 
and a plain chest X-ray were obtained in 24 patients— 12 from 
each group.
R esu lts
The mean age in the heparin group was 53 years 
(range 26-70 years) and in the control group 54 years 
(range 30-74 years).
The arterial oxygen tension was the satne in both 
groups preoperatively, and during the 1st postoperative 
day it fell significantly (p<0*001) and to the same extent 
(see accompanying figure). During the 2nd post­
operative day the oxygen tension rose in the heparin 
group to values which no longer differed significantly 
from thé preoperative level. In the control group a sig­
nificant reduction (p<0*01) persisted until the 4th post­
operative day. The oxygen tension was lower in the con­
trol group than in the heparin-treated patients during 
the 2nd and 3rd postoperative days, the difference 
reaching a significant level (p<0*01) oh day 3.
The arterial carljon-dioxide tension did not differ 
between the groups preoperatively (heparin-treated subr 
jccts: 36*2+0*8 mm Hg, mean and s.e.; controls:
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Arterial oxygen tension (PO,) during the perioperative period.
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' of Po, in
31*6±0*8 mm Hg); neither did it vary significantly 
between days, the variation between days amounting to 
less than 2 mm Hg in both groups.
In no patient were there any clinical signs of pulmon­
ary embolism during the postoperative period (no chest 
pain, dyspnoea, cyanosis, haemoptysis). The chest X-ray 
obtained postoperatively was normal in all 24 patients 
examined and the photoscan was normal in 23 of 24 
cases. In 1 patient, belonging to the heparin group, the 
photoscan showed defects of uncertain origin.
D iscussion
A reduced ventilatory capacity and decreased arterial 
oxygen tension are common findings after a high laparo­
tomy. The increased intra-abdominal pressure 
pushes the diaphragm cranially, thereby reducing the 
lung volume and increasing respiratory work. Reflex in­
hibition of the abdominal muscle function may also 
occur." The reduced lung volume promotes airway clo­
sure and Veno-arterial shunting." The postoperative 
pain, sedation, mucus remaining in the airways, and 
persisting bronchial spasm are other factors which 
reduce ventilatory efficiency and increase the incidence 
of atelectasis and infection." Ventilation/perfusion dis­
turbances, including shunting, may develop and reduce 
arterial oxygen tension still further." "
Another cause of hypoxæmia may be micro- 
thromboembolisation in the lung vessels, resulting in 
release of smooth-muscle active substances." Thus 
measures to counteract both microthromboemb olis at ion 
and large pulmonary emboli would appear to reduce the 
incidence or shorten the period of postoperative hypoxæ­
mia. In the present study, heparin-treated patients had 
a shorter period of postoperative hypoxæmia than con­
trols. This difference cannot be ascribed to differences in 
alveolar ventilation since the arterial carbon-dioxide 
tension was substantially the same in the two groups. In 
view of the well-known effects of heparin on coagula­
tion, the most reasonable explanation for the shortened 
hypoxæmia is a reduced incidence of embolisation. Since 
ho convincing evidence of large pulmonary emboli was 
obtained in this study in either group, the heparin 
prophylaxis presumably consisted in counteracting 
microembolisation.
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' The anticoagulant action of heparin is not completely 
understood. Presumably heparin interferes at several 
stages with the coagulation.^  ^Eika et aL^  ^found that as 
little as 0 003-0 01 units of heparin per ml blood pro­
longed thé thrombin-timé. Biggs et al.^  ^and Wessler and 
Y in" have suggested that low levels bf heparin enhance 
the çffect of naturally pccurring inhibitors bf activated 
factor X (anli-Xa). Yin et al.^ ® havé demonstrated that 
heparin together with factor Xa inhibitor forms a 
potent antiplatelet-aggregant.
Considering the results, it appears that low-dose 
heparin treatment may shorten the period of post-, 
operative Jiypoxœmia, probably by counteracting both 
large pulmonary emboli, as shown previously, and 
microthromboembolism.
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S u m m a ry  Significantly increased concentrations 
of soluble fibrinogen/fibrin complexes 
were found in plasma samples from ten normal pregnant 
women when compared with ten non-pregnant age- 
matched controls. In ten women with pre-eclampsia 
mean soluble complex concentration was more than 
three times that in the age, parity, and gestation 
matched pregnant controls. Soluble fibririogen/fibrin 
complexes are also found in the plasma of patients in
various hypercoagulable and thrombotic states^  includ­
ing disseminated intravascular coagulation. These find­
ings provide additional evidence that pre-eclampsia is as­
sociated with disseminated intravascular coagulation.
In tro d u c tio n
There is histological evidence of fibrin deposition on 
the vascular endothelium in cases of severe pre-eclamp­
sia/  ^ and in addition there are changes in both the 
blood-coagulation and fibrinolytic systems, which are 
significantly greater than those occurring in normal 
pregnancy.®'"® These features suggest that disseminated ; 
intravascular coagulation (d.i.c.) is associated with pre­
eclampsia. Soluble complexes of fibrinogen/fibrin-re- 
lated antigen (f .r . antigen) were found ; in plasma sam­
ples from patients with various hypercoa^lable and 
thrombotic conditions® arid were demonstrated in the 
plasma of a patient with severe eclampsia and corna as: : 
sociated with the coagulation changés of :fi.i.e.* This 
study was undertaken to see Whethér soluble complexes 
could be detected iri pre-eclampsia.
P atien ts , M a te r ia ls , and M eth o d s
Three groups were studied^teh patients, with pre-eclampsia i 
(group i), ten normal, pregnant women (group ii), and ten nor­
mal, non-pregnant women (group in).
Pre-eclampsia was diagnosed in patients developing hyper­
tension, with a diastolic biopd-pressùre ^éater than 90 
mm Hg on at least two occasions, and proteinuria.in excess of 
0*5 g per 24 hours. All patients were normotensive arid did not : 
have detectable proteinuria at their first antenatal visit. The ' 
signs developed after the 24th week of pregnancy and resolved : 
after delivery. The two pregnant groups were matched for age, 
parity, and gestation. When thé p^sma samples were taken the 
diastolic blood-pféssure was 101 ±9 imm Hg (irieah+l s.ri.) in 
group I and 73±8 mm Hg in group ii (p<0 001). Proteinuria 
in group I ranged from 0^ 75 to 12;0 g/24 h (5/3+4-1 g/24 h). 
No patient in group ii had detectable proteinuria. In addition . 
oedema was present in all patients in group i and in none of 
the control group II. Group iii consisted of ten normal, riulli- ' 
pairpus women, who were not taking oral contraceptives. They ■ 
were matched for age with women in groups i and ii.
Blood-samples. were collected by careful venepuncture and -, 
anticoagulated with sodium citrate (final concentration 0 013 
mol/1). S-amihocaproic acid and aprotinin were added to pre­
vent in-vitro proteolysis. 6% agarose-gel filtration was per­
formed using ‘Biogel’ A5 M mesh size 200-400 (Bio-rad 
Laboratories Ltd.)® * The F.R.-antig;en concentration of eluant 
fractions was measured by radial immunodiffusion. Details of 
the method have been published elsewhere.’ Statistical analy­
sis was performed using Stviderit’s if test. :
Representative examples of p.R.-antigen curves from 
each of thé three groups (matched samples) are shown 
in fig. 1; F.R.rantigenic màtérial was eluted earlier in 
normal pregnancy (group ii) at.81*5±3- 5 ml than in the 
non-pregnarit control group (group iii) at : 90 • 5 ± 2 • 0 ml. 
In pre-eclampsia (group i) the F.R.-antigenic material 
\yas eluted at 63±2*5 ml; There) are significant dif­
ferences between the results for groups i and ii 
( p < 0 * 0 0 1 ) .
Soluble fibrinogen/fibrin complex concentration was 
estimated by measuring the areas under the elution 
curves as shown in fig. 2. As :any, pure protein will elute 
from the column with small “ trails” on both ascending 
and descending limbs, approximately 2-3% of area *‘m”
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will always represent uncomplexed fibrinogen. The 
results for the three groups are shown in fig. 3. Area 
“m” represented 2-7±0‘4% of the total area in group 
in, 4*7+0*9% in group n, and 16 0±6'4% in group i.
240 Group I
200
160
80
40
Groupn
80
$ 120 Group HI
150too
ELUTION VOLUME (m l)  ;
50
Fig. 1—Representative F.R. antigen elution curves from matched sam­
ples.
Group 1 (pre-eclamptic patient), group ii (normal pregnant control), 
and group in (normal, non-pregnant control). Arrow indicates the 
volume at which F.R.-antigen was first eluted (concentration >0 5 
mg/dl).
240
200
160
80
40
50 150
ELUTION VOLUME (ml )
Fig. 2—Elution curve showing areas “ m ” , “ n” , “ p” , which were calcu­
lated by extending the ascending and descending limbs of the main 
peak to the baseline.
 ^ Area “m” consists mainly, of soluble F.R.-antigen complexes, 
although.a small amotint of normal fibrinogen was also present (see 
text). Areas were expressed as a percentage of total area.
28
ÏÏ 20
Group I  Group H Group XU
Fig. 3—Results of measurements of area " m "  in groups 1, II and III.
Mean ±1 s.D. is shown.
These differences are statistically significant (group i w. 
group II, p<0*001; group li vs. group iii, p<0 001).
Discussion
Most blood coagulation factors ii^crease during nor­
mal pregnancy and this together with a depression of 
fibrinolytic activity has led to the hypothesis that normal 
pregnancy represents a hypercoagulable state. In this 
study we found a small, but significant increase in sol­
uble fibrinogen/fibrin complex concentration in associ­
ation with normal pregnancy. This accords with the 
observations of Hafter et al,, who used optical density 
rather than f  .R.-antigen curves. ‘ ^
Pre-eclampsia was, however, invariably associated 
with a further, highly significant increase in soluble 
complex concentration. In addition the more seriously ill 
the patient, as measured by standard clinical criteria, 
the greater was the concentration of soluble complex.
The exact nature of soluble fibrinogen/fibrin com­
plexes is still uncertain. In-vitro experiments have shown 
that they may contain units of fibrin monomer, 
fibrinogen, and fibrinogen/fibrin degradation pro­
ducts.*  ^ The action of thrombin (or a thrombin-like 
enzyme) seems to be essential for their production,* "  
and they are found in plasma samples from patients with 
hypercoagulable or thrombotic disease.*”*
Our results, therefore, strongly support the concept of 
hypercoagulability in normal pregnancy with some con­
version of fibrinogen to fibrin occurring within the cir­
culation. The higher concentration of soluble complexes 
found in each pre-eclamptic patient suggests that the 
conversion of fibrinogen to fibrin may be occurring at an 
increased rate. Alternatively, clearance of soluble com­
plexes from the circulation could have been inhibited. In 
such circumstances it is possible that deposition of in­
soluble fibrin has occurred.
Our observations produce further evidence to support 
the hypothesis that pre-eclampsia is associated with 
D.I.C. Although the d.i.c. may be secondary to an unr 
known primary pathology, it would explain many of the
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signs and symptoms of the disease. It has often been sug­
gested that a controlled trial of anticoagulant therapy, 
possibly with antiplatelet agents, would be useful in pre- 
eclampsia. The technique we used could be valuable in 
monitoring the effects of such therapy.
: We thank the Wellcome Trust and the Medical Research Couitcil 
for financial assistance.
Requests for reprints should be addressed to C.McK., University 
Department of Medicine, Royal Infirmary, 86 Castle Street, Glasgow 
G40SF.
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S u m m a ry  An acute lethal myopericarditis has been 
observed in four out of fifteen patients 
receiving high-dose combination chemotherapy which 
includes cyclophosphamide 45 mg/k^day for four days. 
In all cases the myopericarditis occurred 5-9 days after 
the initiation of chemotherapy, with dyspnoea, tachycar­
dia, orthostatic hypotension, fluid retention, decreased 
voltage on electrocardiography, and pericardial effusion 
documented.by echocardiogram, and progressed in 2 to 
6 days to a fatal low-output state despite vigorous treat­
ment. In three of the four patients, necropsy was permit­
ted and revealed the unique pathological finding of 
fibrin microthrombi in capillaries, fibrin strands in the 
interstitium, and fibrin strands within the heart-muscle 
cells. \ ■-
In tro d u c tio n -,'
H igh-dose chemotherapy utilising primarily cyclo­
phosphamide (CYT) has been used in varying doses and 
combinations as a preparatory regimen before bpne- 
marrow transplantation. Buckner*  ^ has reported fatal 
myocardial failure in two patients shortly after they had 
received 240 mg/kg and 200 mg/kg of CYT given in 
each case over 4 days. Santos^"* has described fatal 
myocardial necrosis in one patient who received 270 
mg/kg of CYT over 10 days. Initial studies at the 
National Cancer Institute employing a 4-day CYT pro­
tocol (total dose =  180 liig/kg) suggeried that this dose 
provided inadequate immunosuppression and antileukœr 
mic effect in patients with refractory leükæmià. In an 
effort to gain more immunosuppressive and antineoplas­
tic effects, Graw and associates* developed a 4-day com­
bination chemotherapy protocol utilising bis-chlorethyl 
nitrosourea (B), cytosine arabinoside (A), cyclophospha­
mide (C), and 6-thioguariinc (T) (BÀCT). O f fifteen pa­
tients treated on this protocol, four have died of an acute 
lethal myopericarditis which appears to be a unique 
clinical and pathological entity.
M a te r ia ls  an d  M e th o d s
The basic techniques employed for bone-marrow transplan­
tation have previously been reported.* ’ Three of the four pa­
tients in this report were given the 4-day BACT regimen con^  
sisting of CYT 45 m^g/day (total dose 180 mg/kg); 
6-thioguanine (6-t.g.) 100 m^m* every 12 hours for 3  ^days 
(total dose 700 mg/m )^; cytosine arabinoside (Ara-C) 100 
mg/m  ^every 12 hours for 3 | days (total dose 700 mg/m?); and 
bis-chlorethyl nitrosourea (b.c.n.u.) given as a single dose of 
200 mg/m  ^ on the 3rd day. The fourth patient received the 
6-day BACT regimen, a modification of the above with CYT 
given for 6 days (total dose 270 mg/kg), cytosine arabinoside, 
and 6-thioguanine given for 5  ^days each (total dose of 1100 
mg/m*), and the nitrosourea as a single dose of 200 mg/m* on 
day 3. 24 hours after the last dose of chemotherapy, all four 
patients received an infusion of either allogenic or autologous 
bone-marrow. The patients were evaluated clinically by 
members of the transplantation team and cardiac consultants. 
Electrocardiograms and echocardiograms were reviewed by 
the cardiac consultants. The necropsy protocols and pertinent 
histological slides of three patients were reviewed by one of us 
(V.F.). Paraffin blocks from the formalin-fixed hearts were 
recut. Sections were stained with hæmatoxylin and eosin, 
celestine bluo-B and eosin, phosphotungstic-acid hsematoxylin 
(p.t.a.h.), methyl-green/pyromn-Y, and the periodic-acid/ 
Schiff (p.a.s.) method with and without prior digestion with 
diastase. Thin transmural sections of the left ventricle were 
obtained at necropsy and fixed overnight; in cold, 3% phos­
phate-buffered glutaraldehyde. Small blocks from these sec­
tions were post-fixed in 1% phosphate-buffered osmium tetrox- 
ide, dehydrated in a graded series of akbhpls, and embedded 
in ‘Maraglas’. For light microscopy, semifine sections (T-1 |4m 
thick) from the maraglas-emlWded tissues were stained with 
alkaline toluidine-blue. For electron microscopy, ultrathin sec­
tions from these blocks were stained with iiranyl acetate and 
lead citrate.
C ase-records
FIRST CASE
The patient was a 17-year-old White male' with Burkitt's 
lymphoma which was progressive despite four courses of com­
bination chemotherapy using CYT 10Ô0 nig/na* intravenously 
(i.v.), vincristine 2 mg i.v., and methotrexate 30 mg intrathe- 
cally and 60 mg i.v. in each course, and 2000 rads of radiation 
to the whole aWomen: He was therefore admitted to the hospi­
tal for high-dose ; ablativk chemotherapy ahd infusion of his 
autologous bonc-niarrow which had been harvested and frozen
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F igure 1
pa ir% of polypeptide chains (Ac^ , b B , ^  ). Thé length
weight. The fibrinopeptidès are ir^ ica te d  by thé so lid  dots 
(#  ). The chains are held together by disulphide bbndS;, 
which are placed in  an a rb itra ry  fashion in  the diagram^
molecule (adapted fro m  M arder; j^d a yn sk i and James,
C =
N =
-'A#'!
-V
c N N
A &  "I
B p
FIBRINOPEPTIDE 
DISULPHIDE BOND
Figure 1
ÿ ' ;. ' '  ' ' ' ' ' . ' ' '  ' ' ' ' .  '  - ' 'a :  ^..." : ';'■
a . . , a , . .  . ' :■"'
. .  ?
,aa <,
Figure 3
A model of the coagulation ’^cascade”  based on that proposed 
by M acfarlane (19|4)* The Homan N um erica l System fo r 
the c lass ifica tion  of the coagulation factors is  used. The t  ; 
sm all le tte r "a** a fte r thé number indicates the activated 
facto r (e. g. Ila  & throm bin). The so lid  arrow  indicates 
^transform ation” , w h ile  the broken arrow  indicates ” action” , 
m  = n w -c ro a s im e d m ^
Ib = broBBiinKed fibrin. ‘
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Figure 9
fibxiuogen to  insoluble fib rin» adapted from  that proposed by 
Laskowski, Kakowitz; and Scheraga (1952)* Throm bin is  
only required fo r step i* Steps i i  and i i i  are reve rs ib le .
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Thrombin
I
I
Soluble Ÿ  Soluble
fibrinogen ^  fibrin + 2 (fibrinopeptide A) + 2 ffibrinopeptide b ).
monomer
Soluble ______ Soluble
fibrin ^  -    ^  fibrin  ________ __________________ ______________
monomer polymer
Soluble ______ Insoluble
4 ---------  fibrin ............................................................................ .
polymer
Figure 3
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F igure 4 
A mode
by Mpmbauk» Hogg# Oariund <t a l, (1975)* Rectangular 
bakes are  u 0 d  as bu ild ing un its and these are  jo ined in  a 
double molecule having a tw o-fo ld  a^cis Of sym m etry* (Une 
sîiaded box and one unshaded box to  each m olecule). The 
binding s ites A A* -  aa* are thought to  be situated at the 
opposite ends of the broad sides of th t boxes» w h ile  the 
binding s ites B B f -  b b l a re  located at opposite ends of the 
harrow  sides of the bihcea (shown as the "top** and ’ ’bottom** 
of the boxes ih  th is  diagram ). The open headed arrow s 
{ ) indicate the position  of the binding sites which are
hot v is ib le  in  the diagram . A polym er a rises through "end- 
io rend" po lym érisation involving binding of the s ites a and A 
on one m #ecule to  the complementary s ites A* and a* oh the , 
adjacent molecule ( ^  ). In  a s im ila r manner,
"s id e -to -s id e ’  ^ po lym erisation takes place between b and B 1 
sites on one molecule and thé com plem entary B* and b* sites 
cm an adjacent molecule ( ). Branching of the
in itia l polym er can therefore take plàce. ?
Figure 4
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F igure  6 ' ^
Fÿ à d iagram atic representation of the form ation of fibrinogen
e: ?■
f  igure 1* (The displphlde bcmds are om itted h i th is  diagram ).
m olecular weight and so shortening of the chain indicates 
digestion. The ea rly  fibrinogen X  fragm ent iO ècmsjdefèd 
tiabé clo ttable by throm bin, the other fragm ents are  unclottable 
(adapted from  M arder, Budaynski and James, 1972 and 4 ^
6udz)mSki, M arder and Shainoif, 1974). f
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Figure 6 '.K-
The basic fib rln o g e h o ly tic /lib rin o ly tlc  jpatliway is!^s^ 
t Hs so lid  a rro #  indicates ^^transforüaàtiiim’ and the broken 
arroiw indicates ’^actlcm’^ as in  F igure v
T\'-
v:.;
Fibrinogen
Plasminogen Activator
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I
Fibrin
I
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I
I
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F igure  7 >
A comj[)artmental model of the synthesis, m etabolism  and 
d is tribu tion  of fibrinogen and its  deriva tives (adapted from  
that of Beeve and Franks, 1974). The compartments bOKed 
w ith  so lid  lines ( — ) and the open arrow s ( ) indicate
the "fib rinogen  core system ", which is  thought to be the 
physio logical pathway. The other pathways (so lid  arrow s
 ► ) are thought to  0|ie ra te  m ainly in  pathological
conditions. (Much of th is  diagram  is  speculative e. g. the 
existence of in te rs titia l f ib r in  monomer and Fragm ent X ,
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m o n o m er
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polymer 
breakdown 
site
Plasma I 
fibrinogen
Interstitial
fibrinogen
Fibrinogen 
Core 
System "
Piasma '  In terstitialPlasma 
Fragment X Fragm en t X
monomer
Fragment X 
breakdown 
site
Fibrinogen
breakdown
site
Urinary fibrinfogen) 
degradation products
 ^ Low molecular weight fragments 
litDerated by catabolism of 
fibrinfogen) and derivatives
Figure 7
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m erisation basod on hydrogen bond fdrm ation.
F: fibrinogen, in  which only hydrogen bond Receptor
groups (h is tid y l residuesÿ^ ) are avjailablo^
f; fib r in  monomer, form ed by the rem oval of fib rih c ^
(ty ro sy l residues, T J  ) to become available.
f-f*-f: soluble fib r in  polym er 
; (s e e F ig u re .3 )j: .
f-F : soluble fib rin b g e n -fib rin  d im er.
(adapted from  L a ta llo , ÏG75)
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fib rin o g e n -fib rln  degradation products, because these degradation 
products may possess donor o r acceptor groups su ffic ien tly  
s im ila r to  those found in  fibrinogen and fib r in  mcmomej^  “(F igure  ^
yii"-
Ba) to  allow  polym erisation; Such complexes are  shown 
involving fibrinogen Fragment Y (Y), fib r in  f  ragment y (y) and 
fibrinogen Fragm ent P (D) (adapted from  La ta llo , 1075).
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A  com parison of plasma fibrinogen chromatography and I
fibrinogen scan resu lts  oh a su rg ica l patient (adhpted from
the resu lts  of F le tcher and A lk ja e rs ig , 1972)* P re ropèra tiye ly
the scan technique (Leg scan negative, >ve). The plasma
(m l) on the X  axis and the flbrixiôgeh**fîbrin antigenic 
cm centra tioh (fibrinogen m g /m l) on the Y axis. The so lid
p u rifie d  fibrinogen solution is  analysed is  shown by the v e rtic a l 
dotted lin e . On the f ir s t  post-operative day (Day 1) the patient 
developed evidence on f i^  of loca l throm bosis in  the
leg veins (Leg scan positive , -nre). : Oh Day 1 t l ^
ff
suggesting the presence of soluble compiexhs. By the fourth 
pc^t-operative day (Day 4) a "s h ift to  the right** was found using
■' ' > ■ :
Pre- operation Day 1 Day 4
Leg scan — ve +  ve + v e16
FIBRINOGEN
mg/ml
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0 4
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Figure 9
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Figure 10
, The cumulative volume
tiie  experim ent ( i. e. when the p ro te in  is  lu lle d )  is  plotted 
on the X  axis and the p ro te iri cm centraticm  (mg/lQO m l) on 
the Y axis. Using method 1 is  measured as # e  volume
(in  th is  example the p e î^  prp teto  concentration is  120 m g /
100 m l* there fore  50 percent of th is  is  60 m g/100 nd* giving 
a of 100 m l fo r  th is  prbteinJ^ U 2 the ascend-
lin e . The volume at which the two lines cross is  considered 
as the 
(Stained).
o f the p ro te in  (in  th is  example a of 96 m l ise e ,
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F_F% '#:io r# itioa of the d iffe ren t types of soluble complexes î ¥
Approxim ate inâleeular w eig lits are shown in  bracket#,-pj
#F E*E*Sà : re ticu lo -endothe lia l system
F X m  : fac to r X III or Eibrin-Stabilizimg Factor.
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The form ation of soluble complexes (norm al plasma i  lysed
.P
i urokinase) in  v itro  demdhstrated by plasma f âbrlnogen 
chromatography using the method of F le tcher and colleagues 
(adapted from  resu lts  published by F letcher and AUcjaersig* 
1672). The cum ulative effluent (or eluticm) volume (m l) is  
plotted on the X  axis and the fib rin o g e n -flo rin  re lated antigen 
C èncentratiw  re m its  on the Y axis (fibrinogen, m g /m l).
•F.v-
cbncentration o i antigen found when a p u rifie d  fibrinogen 
solution is  analysed. I t  can be seen that the soluble 
complexes Caused a sh ift to the le ft”  and the fibrinogen
: : .
degradation prc^ucts caused a "s h ift to  the rig h t" .
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Figure 12
Plasma fibrinogen concentrations (m g /100 m l) were measured 
in  thé same samples by two d iffe ren t methods. The X axis
methCKl (M ancini, Carbbnara and Heremans, 1906) and thé
pro te in  method (Batnoff and Menzie, 1951). The equation of 
the lin e  calculated by lin e a r regression analysis was: ^
; y = 38.4 + 0.6%
C orre la tion  coeffic ien t (r) ^  0, 931#
. (2 o< (b.bol). ,
y .
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F igure 14 '.  ; '  T '" ':r:.::': -
D iagram  of the equipment used fo r agarose gei filtra tio n * 
The p ro te in  sample was applied to  the top of the chrom ato-
.'i
re s e rv o ir was allowed to  wash through the packed column . 
at a constant flow  ra te  contro lled by the pump. The bu ffe r 
eluting from  the packed column was collected in  aliquots 
in  the fra c tio n  co lle c to r. The d irection  o f flow  of bu ffe r 
is  shown by the arrow s ( ----- ^  ). An estim ate of the
m onitoring of the op tica l density (at 280 nm) of the eluant 
buffer using the spectrophotometer and pen reco rde r.
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(T. C. 1% ) and tha throm bin clottabie pro te in  (T .C . P. ) 
ra tio s . A typ ica l elution curve fo r a j& -alanine 
precip ita te  of norm al plasma is  shown, the eluant
and thron ib in  clottable p ro te in  tests. The cum ulative 
elution volume (m l) is  plotted on the K axis and the 
resu lts  0Ï the T .C .  T . test (seconds) on the Y axis.
The elution volume over which a positive T .C .P . test 
was recorded is  shown as an inset ( ) above the
X  axis. To calculate the ra tio s  the fo llow ing volumes 
were measured:-
t  = the cum ulative elution volume a l which
the f ir s t  positive T . C. P, test was recorded 
T  = the cum ulative elution volume at which the 
f ir s t  positive T* C. T . tost was recorded 
( i .e .  ^8 0  seconds)
8- 4 3the' Cumulative:', elution volume at which the 
shortest T . C. T. test was recorded,
T .G .T . ratio-i^'Yv 
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Figure 16
a
p u rifie d  fibrinogen solution was dilu ted to give concen-^ 
tra tio ns  o f 40, 30, 20, 10, 6 and 2* 6 m g /100 n il. Thesb 
d ilu tions were then analysed in  duplicate us iiig  the m odified 
ra d ia l im m unodiffusion technique (M anciai, Carhbnara and 
Heremans, 1965) and the diam eter of the p re c ip itin  Fings 
(D) measured and the mean value used. The iib rin b g e h - 
fib r in  re lated (F B -) antigen coricentratipn (m g /100 m l) is  
plotted on the X  axis and 0  (mm ) on the Y axis. I t  can
the two measurements. TheTine calculated hy lin e a r 
regression analysis w as:-
co rré la tion  coefficient (T) ™ 0.969
m m
100 r
in
2
90
80
60
50
D = diameter of ring 
in mm.
40
30
20
20 30 40
FR-ANTIGEN CONCENTRATION- mg/lOOml
Figure 16
A domputeÿ "p rln t"ô ü t*' of the fibrinogen ùhrbmàtography 
resu lts  fo r a plasma sample from  à patient w ith  "post­
operative throm bophlebitis" (adapted from  F letcher and 
A ik ja e rs ig , 1972). The so lid  black line  ?ind so lid  dots 
indicate the actual fib rin o g e n -flb rin  re lated W ti# h ic  
elution curve. The computer analyses th is  in to  three 
components (polym er, fibrinogen and f ir s t  deriva tive) as ; 
shown by the dotted lin e  curves. The position of the 
maximum concentration of fib rin o g e n -fib rin  r
same column system, is  shown by the v e rtic a l dotted line . 
The percentage concentratim  of po lym er, fibrinogen and 
f ir s t  deriva tive  are calculated and shown at the foot of the 
diagram .
Polymer 2 5%  fibrinogen 26 4 %  first derivative
Figure 17
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Figure 18
used by Haf 1er, Èchneebauer, T afu l et a l. (1975% The 
elution p ro file  of a -alanine prec ip ita te  of plasma is  : 
calculated by measuring the optica l density (0.1>, a rb itra ry  
units) of the eluant fractions a t 325 nm ahd subtracting th is  
f rom the optica l density (a rb itra ry  un its) at 280 nm, This 
resu lt IS then plotted oh thé Y axis w ith  the cum ulative 
elution (m l) volume on the % axis . The elution çurV^ W  
then divided as shown. The void volume area is  excluded
proteins. The ascending lim b  of the m ain pèàk is  extended 
to the base-line and a v e rtic a l lin e  is  drawn from  the base­
line  to the top of the main peak. Areas A and are then
Î
Soluble complex concentration = y —■g.;X';lO0, 
(percent total, area) /^;,v L';
: ■'1-
' A.
O.D.
280-325nm 
0 4
0 3
02
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Figure 19
The method used in  th is  thesis fo r calculation of resu lts  
(areas m, n and p) from  the fib rin o g e n -fib rin  related 
antigen elution curve. An elution curve from  a |S -   ^
alanine p recip ita te  of plasm a is  shown. The antigenic 
concentration (m g /100 m l) measured by the m odified 
ra d ia l im m unodiffusion technique is  shown on the Y axis 
and the cum ulative elution volume (m l) on the X  axis. In 
order to calculate the areas the ascending and descending 
lim bs of the mean peak were extended to the base-line and 
areas m, n and p measured p la n im e trica lly . The soluble 
complex concentration (area m) was then calculated using 
the fo rm u la :-
' -V. i ' V- : ' V : . : ' • T": :
area m ' *  x 100
, (percent to ta l ■ ^
area)
The fib rin o g e n -fib rin  degradation product concentration (area 
p) was calculated using the form ula: -
«
.:K
The "uneomplexed, non-degraded fibrinogen" (area n) was 
calculated using the form ula: -
% l ^ e n t  to ta l m  i n p ^
' ' ■ area)
(published in  McKîUôp, Hbwle, Forbes et a l, , 1970).
 '' ' " ' ' ^ '    ' ' -
300
f ib r in o g e n / fib r in
RELATED ANTIGEN 
mg/lOOml
200
100
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Figure 19
A typ ica l elution curve of a ^  -alanine p recip ita te  of 
norm al plasma is  shown» the eluant fracticm s being
technique. T*he cum ulative elution volume (m l) is  plotted 
on the X  axis and the fib rin o g e n -fib rin  re la ted (FE -)  
antigen concentration (m g /100 m l) on the Y axis. To 
calculate the fR -an tige n  ra tio  two volumes were measured: 
a F the cum ulative elution volume at which 
FR-antigen was f ir s t  detected using the " 
rad ia l im m unodiffusion technique, 
b = the cum ulative elution volume at which the 
peak concentration of FR-antigen was 
detected using the ra d ia l im m unodiffusion 
technique. \
The FR-antigen ra tio  was then calculated using the form ula: 
FR --a irtlgenratio  = I  /
300
FIBRINOGEN/FIBRIN
RELATED ANTIGEN 
mg/lOOml.
200
100
15010050
ELUTION VOLUME — ml.
Figure 20
The Staphylococcal Cluïïiping^Teét (SÇT) was perform ed
clumping factor solutioh to 0.1 m l o f thè sample. A fte r 
m ixing, 0.5  in l buffer ( tr is  (hyd rp l^m ethy l| methylam ine 
0 .0 5 ^  sodium chloride 0 .1_M; pH adjusted w ith  1 M 
hydroch loric acid to  7 .4) was added. The m ixtdre  Was
add add
mix
0 1  ml 
sample
0 0 5 m l
staphylococcal
0'5m l
buffer
SOmins 
at room 
temperature
suspension
o o
o
o
POSITIVE NEGATIVE
Figure 21
The eluticm p ro file s  fo r fou r solutes (Blue 0extrah , flpo;^ 
polysàedWrWey hbrlnogem and album in, see Tah#'2)V 
The cum ulative elution volume (m l) ié shown on the X  
axis and the to ta l p ro te in  concentration# measured by the 
optica l density (d /D . in  a rb itra ry  units) a t 280 nn i, on the 
Y axis. 3.% -
Æ ,, '
n . . j
'4
Fractionation Range
BLUE
DEXTRAN
LIPOPOLYSACCHARIDE
ALBUMIN
15010050
ELUTION VOLUME -  nnl
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Figure 23
Tlie logarithm  to the base 10 of the m olecular weight plotted
.m c (V ,, « l )m » .« x e a  by■ . - - - :  g. ; -. " ,-
method 1 (F igure 10) plotted on the Y axis fo r d iffe ren t
solutes. A part from  the resu lts  fo r B ac itrac in  (m olecular
■'
mlts)was:-
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Figure 23
A comparison of the elution curves found using p u rifie d  
flhrinogen (Kabi) and norm al plasma. The cum ulative 
elution volume (m l) is  shown on the X  a^is whÛe the 
optica l density (O. D ., a rb itra ry  un its) at 280 nm, the
fib rin p g e n -fib rin  re la ted (FR-)-antigen (m g/lQ 0 m l) and 
the throm bin c lo tting  tim e ( Ï .  C. T ., seconds) resu lts  a re  
shown on the Y axis.
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Figure 26  ^ '
A comparison of the elutibni curves found using plasnia and
and the opticar density (0$ D ./J in  a rb itra ry  dn nih^
and the fib rin o g é n -fib rin  re latbd (F i - )  antigen (m g /100 m l) 
resu lts  are shown on the Y a x is .,
O.D. at 280 nm FR-antigen  
mg/100 mlNormal plasma
3 0
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A com parison of the elution curves found using plasma 
(2 m l), a p  -alanine p recip ita te  of 9 m l o f plasma from  
the same donor and the supernatant (2 m l) from  the j§ -  
alanine p rec ip ita te . The cum ulative elution volume (m l) 
is  shown on the 3i axis and the op tica l density (0 . 0 . ,  in  
a rb itra ry  un its) at 280 nm, the fifo rinogen-fib rin  related 
(F E -) antigen (m g /100 m l) and the throm bin c lo tting  tim e  
(T .C , T , , seconds) resu lts  on the y  axis.
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Figure 2Î
of thrombin (see details in text and Table 4). The 
cumulative elution volume (ml) Is plotted on the % axis 
and the total protein concentration (oj^ical density, O. D* , 
in arbitrary units, at 280 hm^ j is shown on the ¥  axis.
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The same series of experim ents (a-h) is  shown as in  3 fi^ re  
27, The cum ulative elution volume (m l) is  p lo tted  oh the ; 
X axis and the th roh ib in  clotüng tim e (T , C, T#, seconds) r 
resu lts  are shown on the Y axis,
L:-
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Figure 28
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The same series of experim ents (a-h) isi^how h as in  F igures 
27 and 28, The cum ulative elution volume (m l) is  plotted on 
the axis and the fib rin o g e n -fih rin  re la ted (FR -) antigen 
(m g/100 m l) resu lts  are shown on the Y axis, in  certa in  
elution fractions "c lo ts " form ed on standing at room  tem per- 
ature overnight. These are marked "c lo tte d " (-4-------- >  ).
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Figure 29
SuperiinpQsed throm bin c lo tting  tim e (T iC . T* ) and fibrinogen^ 
fib r in  re lated (FR -  ) antigen eïutiph curves fo r fou r of the 
experim ents shown m F i^ ire a  28 and 29 (a, b^ c? and ©);)
The cum ulative elution volume (m l) is  shown oh the X  axis 
and the resu lts  of the T .C . T . (seconds) and FB-antigeh 
(m g/ldO  m l) assays on the^K f  > ,
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lengths of tim e (see tW  fo r deta ils). The cum ulative 
e lu tio i volume (m l) is  shown on the X  axis and the to ta l pro te in
concentration (t^ tie a i density, O, D ., in  a rb itra ry  un its , at
280 nm) the Y axis, of fibrinogen
and the fibrinogen degradation products (X, Y , 0  and E) are 
shown at the foot of the diagram  (calculated frOm M arder,* l t
Shulman and C a rro ll, 1 0 # ),
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A series qf experim ents (are) is  shqwA-iri;which^glasma):/: 
was incubated w ith  ancrod a h d /o r stréptokinase^ 0  
(see deta ils in  text and Table 5). tThe cum ulative elution 
volume (m l) is  shown cm thb X  axis, and thC  density 
(O .D ., a rb itra ry  un its) at 280 nm on the Y  a ^ s ;%
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Figure 33
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Figure 33
.The same series o t experim ents (a-^e) is  shewn as in  F igures 
32 and 33. The cum ulative elution volume (m l) is  plotted on
m l) resu lts  on the Y axis.
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Figure 35 ■  ^ .
Superimposed throm bin c lo tting  tim e (T* C, T , ) and 
C ibrinogen-fibrin re la ted antigen elution curves fo r the 
experim ents shown in  F igures 33 and 34. The cum ulative 
elution volume (m l) is  shown on the X  axis and the resu lts  
of the fib rinogen-*lib rin  re lated antigen (mg/XOO m l) and 
the r .  C. T. (seconds) assays on the Y axis in  each case. 
Note the changes in  the flbrinogen**flbrin  re la ted antigen 
scales, ' y:;
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The cum ulative elution volume (m l) is  shown on the X  axds ? 
and the fib rin o g e n -fib rin  (F È -) antigen (mg/iOO m l) and 
throm bin c lo tting  tim e (T .C . T . , seconds) resu lts  on th e Ÿ  
axis. Thé inset abdve the X  axis shows the Tèsuité of the 4 
throm bin clo ttable p ro te in  (T. C i P. ) incubation test 
{ E S S 3  )• Thé elution volume (V.,) of p u rifie d  fibrinogen
4 ■ , • ' - . 4 / . . ' .  -1-.7 ' e  .y .i- y 4  ■ 7,
using th is  column system  is  indicated.
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Figure 37
in  v ivo  (adapted from  Gaffney arid B rasher; 1974)» P o lym erg 
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Figure 38
blood samples taken from  a patient (W .McG. ) p re -trea tm ent 
and a fte r 3, 6 and 24 hours intravenous ancrod infusion.
The to ta l p ro te in  concentration^ as measured by the optica l 
density (O. D ., in  a rb itra ry  un its) at 280 nim, is  shown on 
the T  axis. .
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^  0 5K
Ph-
6 hours
24 hours
aO
15090 12030 60
ELUTION VOLUME -m l
Figure 38
F igw e 39a
on samples a patient (W# McG. ) takph pre-^treatment  ^
and a fte r 6 and 34 hcmrs i# ra y m # 8  a # rW  infùëion. The 
cum ulative elutiCMi volume (m l) is  showh on the X  axis and
'oh’ihe"Y-axis.J: ': ;'U . '  ;;c  ^ i
{published in M cK illop i E d g a r,-^  , 1975b and c).
: Ml
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Figure 39a
y ig u re  3#
ort sa iip le s  from  a ( J * M c K *  ) taken p re -tre a tm au l 
mû a fte r 0 and #  intravenous ancrod inMsfon. The
cum ulative elution volume (m l) is  shown on the X axis and the 
lib rinogen-^librin  related antigen (m g /100 m l) da the Y  axis, 
(published m. McEiUop, Edgar, Forbes et a l* , 1975c).
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Figure 39b
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fcJup^rimiJosed fib rm g g e n -iib i'in  re la ted (FE-) aatigGu and 
throm oin c lo tting  tin ie  (r.U .1%  ) e lution curves on samples 
obtained from  two patients %  8. and d .H , ) a lta r ii hours 
intravenous ancrod Infusion, The cum ulative elution 
volume (m i) is  shown on the axis and tire TH-antigea 
(m g /100 m l) and T , C, T . (seconds) resu lts  on the Y axis.
clottablg pro te in  (T .C ,P , ) incubation test ( ).
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Figure 40
F lgüre;41- . ' '. . ^
Changes il l area m fo liow ing the s ta rt o i intravenous ancrod 
in i’usion in  5 patients. The f ir s t  samples were taken before 
the tim e of s ta rting  treatm ent, which is  shown by the arrow * 
The tim e (in hpuris) a fte r s ta rting  treatm ent is  shown on the ‘ 
X  axis and the a rfa  m re su lt (percent to ta l area) is  shown 
on the Y  axis. The resu lts  from  each individual patient ' 
'a re connected,fay'tho'solid lin e s , '
5 ANCROD PATIENTS
2
S
0 6
ANCROD INFUSION TIME
24 
( hours)
Figure 41
'■r'
Figure 42
5 patienin.'- The f ir s t  samples wercf:'taken before th a tlp lè  
of S tarting treatiptent, wttioh is  shown hy fhe The
an^'the irè â  p resu lt.(percent to ta l-a r^ ). |s;;sh0w on the:, 
9LMB* The resu lts  from  each ind ividual patient a re
ccmnected by the so lid  lines.
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Figure 42
Figures 49, 50 and 61 ' ' '
In  tîiëse sets o lfig u re s  the sequential plasma fibrinogen , 
chromatography results are shown fo r three pre-eclam ptic  
patients (Patient 3 in  fig u re  49, Patients *jf, in  fig u re  and 
Patient 9 In f ig u re  91). ’ The results are p la c # #  tim e 
sequence sta rting  w ith  the upper le ft quadrant, followed 
toy the upper rig h t quadrant^ than the lower le ft quadrant 
and fin a lly  the low er rig h t quadrant. The cum ulative 
e lution volume (m l), is  shown on the axis in  each 'case. 
The fitorinogen-fitorin re la ted antigen (m g /100 m l) and 
thromtoin c lo tting  tim e (T, C. T ,, seconds) results are 
shown on the Y ax is, ÿhé elution volume over which a 
positive thromtoin clo ttable pro te in  incubation test was 
found is  shown by the shaded area ( K/2Q ) inset above 
the X  axiSé ' The results of the staphylococcal clumping 
test t it re  at the void volume (SCT. ¥  J  are also shown.
The arrow  ( ^  ) indicates the elution volume at which 
fito rinogen-fib rin  re lated antigen could f ir s t  be detected 
by the ra d ia l im m unodifhision technique. The gestational 
\ age (weeks) at the time of blood sam pling and the packed 
gel column system  (e. g. B Ï (H) ) are a lio  shown.
AREA p 
fper cent 
total area) 24
20
16
12
GROUP I GROUP II
S T
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8
1 Î 1
Figure 48
The resu lts  fo r. area p (percent to ta l area) are shown'for, 
the same samples as in F igure 4 Î.  ^ The mean -  single ' 
standard deviation is  shown to  the rig h t of the scatte r of 
resu lts .
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Figure 47
The resu lts  of area m .,{peFcehttotal'area)Tor ,samples from  
10 pre-»eclamptic patients (Group l) i 10 matched norm al 
pregnant women (Group ÏÏ)  and 10 norm al non-pregnant 
women (Group III) , The mean -  single standard deviation 
is  shown to  the rig h t of thé scatter o f resu lts .
'(published in  M cK illop ,-. Howie, Forbes' et; a i. , 19?G).
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Figure 46
Figure 46
» I win m mu ■ I ■' I n i ww IJ WI
are
aliowîi fo r a set of matched resu lts  fo r samples fro m  a 
pre«te iam ptio  patleut (Group I ) /  a uorm al pregnant control 
woman (Group H) and a norm al non-pregnant con tro l 
woman (Group III). The cumulative elution volume (m l) 
is  -showm oh the axis and the '-iib rlnogen-fib rin  related ' 
antigen concentration (m g /100 ml) is  shown on the Y axis. 
The arrow  ( ▼ ) indicates the elution volume at which
technique. '
(published in  M cK illop , Howie, Forbes èt a l . , 1B*?6).
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eoinplexes do H clW  in  W act (X chain dhring intravenous 
ancrod W uAW i are showMi. Much of th is  diagram  rem ains 
hypothetical; '
p. A.G. Electrophoresis in S.D.S. and 2 ME.
Six hour samples
W. McG. J.McK.
Main peak
Q)O
C
5
s
<
Intermediate 
V zone
Void volume
Aoc B/3 y Aoc B/3
Figure 44
Figure 44
■•y 1 irr Mil '■ m ihrwihif jigi’Éniii^
Polyacrylamide g^l eleetrpphoreaW résulta obtained by 
the method of Webér ànd Osborn (1Û00) Wing the same 
eluant fraetim a from  plasma giaznples from the same 
patients as in F l^ rO  43. Meroaptoethanol (8 M E) was 
added with the sodiu^ dodecyl sulphate % .D , 8. ) to 'cleave 
the disulphide bon# linking the chains in the fibrinogen- 
rëlated molecules, th é  electrophoresis results are 
shown as densitom etrlc scans with the absorbance 
measured at 600 am using a Gilford spectrbphotometer. 
th e  m igra tion posiim aa of the A , B ^  and ^  chains 
Of standard fibrinhgen are shown. ' S im ila r results were 
obtained w ith  samples from the other patients studied. '
■ (published'-in M cÈ iliop , Edgar, Forbes at a l. , 1976b and 
c).- -  '%
RA.G. E l e c t r o p h o r e s i s  in S .D.S.
S ix  h o u r  s a m p l e s
W.McG. J.McK.
<DOcro
o
CO.Q< Main peak
Intermediate zone
Void volume
Figure 43
F ilt r e  43 . .
Pùlyaerylami@E> gel eïeetrophpreaW  y e m l#  ô b ta i# d  by 
the method of WeWy and Osborn (1969) uaing varions 
eluant fractions in  sodium  dodeoyi sulphate (8, D. $, ),
The êluânt frac tions Selected %ore #rbm the gel filtra tio n  
'èsperim onts w ith  plasma sapplas obtained from  two 
patients (W. M e#, and J* MefC# ) ^  hours a fte r s ta rting  
ancrod in fh s im (se b  F igure  39a and b)K The selected 
.e luant'fractions were from:-* .
:■ (i) the top of the main fib rln o g ê n -fib rin  
: re la têddntigen peak (main peak).
( ii)  the void volume,-' a.
( ii i)  '-an interm ediate .%dne between the void ■ ;''••■>■
_. volume and the main peak.
The electrophoresis re su lts  are shown as densitom etric 
scans w ith  the absorbance measured at 600 nm using a 
0 Ilfo rd  spectrophotom eter. The m igration positions of 
standard fib rin o g m  (F ).and its  degradation products (K , Y»
' Brand Ë) are shown. S im ila r resu lts  were obtained w ith  
samples from  the other patients studied*
(published in  M cK illop , Edgar, Forbes e f a t , 19?6c),
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Figure 49a:- Results for Pre-eclam ptic Patient 3 (M.H.).
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Figure 49b:- Results for Pre-eclam ptic Patient 3 (M.H. ).
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Figure 50a:- Results for Pre-eclam ptic Patient 7 (M.M.).
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Figure 50b:- Results for Pre-eclam ptic Patient 7 (M.M. ).
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Figure 51a:- Results for Pre-eclam ptic Patient 9 (A.McN. ).
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Figure 51b:- Results for Pre-eclam ptic Patient 9 (A.McN. ).
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Figure 51c:- Results for Pre-eclamptic Patient 9 (A.McN. ).
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In th is  sot of figu res the sequential laboratory resu lts  are 
compared w ith  the c lin ic a l findings fo r s ix  pre**eclamptiq 
patients (Nos* 3, 5, 7, 9, 10 and 11 respective ly). T im e 
is  shown on the X  axis. During the ante-natal period 
th is  is  expressed as the gestational age (weeks) and post? 
partum  as days, w ith a break in  the scale before the post* 
natal v is it (P .N . V. ). The broken v e rtic a l line  indicates 
de live ry. Each figu re  is  set out in  the fo llow ing way, 
s ta rtin g  from  the top :-
(i) plasma fibrinogen (m g /100 m l) ^  ^
( ii)  serum  fib rin o g e n -fib rin  degradation 
products (FD P /fdp; in  p g /m l) 
measured by the tanned red ce ll 
haemagglutinaticm inh ib ition  immuno­
assay
( t il)  staphylococcal clumping test t it re  at 
the void volum e, (SCT ¥ ; negative 
logarithm  to base 2)
(iv) area m (percent to ta l area)
■V- ■ .... ■
(v) area p (percent to ta l area)
(vi) quantitative p ro te inu ria  (Q. P, f  t  
g /24 hours)
(v ii) d iasto lic  blood pressure (D .B .P v;
' mmHg).
The stippled areas indicate the range of resu lts  (mean -
. 'L,
single standard deviation) found in  norm al single pregnancies 
(Tables 51 and 53).
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F igure 52: - Results fo r pre-eclam ptic Patient 3 (M .H .).
The blood sample on the day of de livery was taken 10 minutes 
after placental separation.
® "in te rfe r in g  substance" present in  urine.
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Figure 53:- Results for Pre-eclamptic Patient 5 (J. T. ),
M.M.
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Figure 54:- Results for Pre-eclamptic Patient 7 (M.M. ).
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Figure 55:- Results for Pre-eclamptic Patient 9 (A.McN. ).
A blood sample was taken the day before delivery and also
15 minutes after placental separation.
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Figure 56:- Results for Pre-eclamptic Patient 10 (D.F. ).
The blood sample on the day of delivery was taken 5 minutes
after placental separation.
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Figure 57:- Results for Pre-eclamptic Patient 1 (M. C.)*
The blood sample on the day of delivery was taken following
induction but before the onset of eclamptic seizures and delivery.
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. f r- ' ■>■. Figure 8$â"6 - .
In  th is  set of figures the sequential re su lts  fo r area m and 
area p are shown together w ith  the c lin ic a l index (Howie,
Purdie, Begg et aU , 1970) fo r four pre-eclam ptic patients
(Nos. 3, 7, 9 and 10 respective ly). T im e (as gestational a
age in  weeks) is  shown on the X axis. The broken v e rtic a l 
line  indicates de live ry . The area m (percent to ta l area).
un its) resu lts  are shown on the Y axis.
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Figure 58a:- Results for Pre-eclamptic Patient 3 (M.H. ).
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Figure 58b:- Results for Pre-eclamptic Patient 7 (M.M. ).
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Figure 58c:- Results for Pre-eclamptic Patient 9 (A.McN.).
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Figure 58d:- Results for Pre-eclamptic Patient 10 (D.F.).
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ThL s#0,uential r e iiilts  fo r àrea area p and tW  cHnKcal 
-  \: index (HpwW, P nrd le ; B<^8g et a L , IBfO) fo r,a  p re n a n t ,
patient (T .Â * ) w ith chronic renal diaoasc, rim e  (as 
gestational age in  weeks) is  shown on th\ X  axis* The /
' broken ve rtica l line  indicates the day of de live ry . The
area m (percent to ta l area), a r #  #  (percent to ta l #rea)^ -
on the \  axis.
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Figure 59
I 4 ....
ixi th is  set of figu res the resu lts  fo r area m (percent to ta l 
area. F igure QO), SCT titre  at (negative logarithm  to 
base 2, F igure 01), area p (percent to ta l area. F igure 02) 
and serum  fib rin o g e n -fih rin  degradation product (serum  
F D P /fdp ; p g /m l) measured uy the tanned red c e ll haem*» 
agglutination inh ib ition  immunoassay (F igure 03) are shown 
fo r tiie  main groups of patients studied in  th is  thesis. In 
each case the scatter of resu lts  is  shown together w ith  the 
mean « single standard deviation. ISiote that in  these figu res 
the zero on the X  axis is  shown on the rig h t. 4
Î. V‘. -  intravenous.
Pre^eclam psia Tota l -  re su lts  in  Chapter V I. 4.
Pro «^eclampsia Group I  -  resu lts  in  Chapter V. 4.
LD vG .K . "  in trau te rine  growth retardation.
N orm al on **p ill”  norm otensivo women taking oestrogen*- 
■ containing o ra l contraceptive drugs.
'4*’;' -
" : 4 : 4 r
4---
V
3 , '
" 4 '^ 4 4 4 '% ;  4  .
44'
6 hours I.V.
ANCROD • ••
P R E -E C L A M P S IA  , p ,
TOTAL % #  *  # e e e  #  #### *  ##  # e  #  #
P R E -E C L A M P S IA  
G R O U P  I • •
E S S E N TIA L  H Y P E R TE N S IO N  
IN P R E G N A N C Y # ## *
C onfirm ed I.U .G .R .
## ## #
N O R M A L
P R EG N A N T
N O R M A L  
O N  "p i l l '' • *
N O R M A L  
N O N -P R E G N A N T
HH
30 25 20 15 10 5 0
AREA m -  per cent
Figure 60:- Area m (percent total area) Results.
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Figure 61: - SCT t it re  at (negative logarithm  to base 
2) Results.
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Figure 62:- Area p (percent total area) Results.
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Figure 63:- Serum FDP/fdp (jug/ml) Results,
In th is  figu re  the fibrinogen*<ïibrin re ia téd (FB^) antigen : 
ra tio  is  p lbtted on the X  axis and the area m (percent to ta l 
area) re su lt fo r the same samples oh the Y  axis. The
studied in  the thesis (i. e. npn-pregnaht con tro l women,
contraceptive drugs, norm al pregnant women and pro* 
e c la m ^ ic  patients). X
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T his figu re  shows the same data as F igùrè  64a^ w ith  the
separate group, f t  can foe seen that the fou r groups can
■^4:
■4 ?-.
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This figu re  shows the theory behind Ï  igura 6@i A réà  p 
(percent tc^al area) is  p lotted on the X  axis and làrea m 
(percent to ta l area) on the Y axis. The lin e  of complete 
iden tity is  drawn th ro n g  a ll points having the £^me area 
m and area p re su lts . When the resu lts  f r W  a sample 
are plotted on th is  graph those ly ing  on the line  w ill hayb > 
"balanced coagulation and fib rin o ly s is /fib rin o g e n o ly s is ".
a predom inant abnorm ality of "coagulation". S im ila rly ,
the degree o f abnorm ality.
.f t .’:
' . r
V
- •; ( .4
.4'' ■ >
Increased
coagulation
Area m  
per cent
Balanced increased 
coagulation and 
fibrinolysis
( fibrinogenoiysis)
Area p —  per cent Increased
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( fibrinogenoiysis )
Figure 65
This figu re  is  la id  out in  thé same way as F igu re  65| i.  e. 
area p (perdent to ta l aréa) is  shown on the X  axis and 
area m (percent to ta l area) on the Y  axis. The resu lts  
shown are fro m  the fou r main groups of subjects^ 
in  the thesis (i. e. non«pregnaht con tro l women, normor-
ceptive drugs, norm al pregnant women and pre-ee lam ptic 
patients). '■ ::
AREA m 
per cent
25
20
•••
• t
2520155 10
AREA p ~ per cent
Figure 66a
T h is figu re  Isliows the same cîiità as F igure oha, w ith  the 
ad iiitioa  of the areas occupied foy thv resu lts  fro m  éaeh 
separate group. The liu e  of complete iden tity (area m «
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Figure 66b
The plasma flbnnog»-a chromatography resu lts  (F igure^ §0- 
02 and Table 80) show a range of abnorm ality ( f ^  ).
(shown in  the boxes). No cases of eclam psia have boon 
studied during the stage of convulsions and coma» but a case 
repo rt has shown high; soluble leve ls (G raeff and von Hugo» 
1972).
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An adaptation oî the "in n e r vicious c irc le  o l pre-eclam psia
and acla|njp3ia*’ of Page (1972) is  shown incorporating the 
formatiCHi of soluble fifo rinogen-fib rin  complexes and
Î
eclampsia studied m th is  thesis.
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In these figu res the seQueatial laboratory resu lts  are ; 
com ijared w ith  the c lin ic a l findings fo r two patients (IL  S,. 
and J.W , ) who were considered to  be "a t r is k "  of develop­
ing pre-eclam psia and who both received a fo rm  of an ti­
throm botic therapy. T im e is  shown on the X  axis and is  
expressed as gestational age (weeks). The broken.vertica l 
line  indicates de live ry . The duration of an ti-th rom botic 
therapy is  shown by the so lid  v e rtic a l lines. The fo llow ing 
resu lts  are shown s ta rting  from  the top :-
(i) plasma fibrinogen (m g /100 m l)v ÿ f
( il)  serum  fib rin o g e n -fib rin  degradation ; J ;
products (F D P /fdp ; in p g /m l) , 
measured by The tanned red ceU haem- 
agglutinatlon Inh ib ition  immunoassay
( i i i )  staphylococcal clum ping test t it re  at 
the void volume (SOT V ; n e ^ tlv e  
lo g a rith m  to  base 2)
;(iv) area m (percent to ta l area)
( t)  area p (percent to ta l area)
(v i) quantitative p ro te inu ria  (Q. P. ; 
g /24  hours)
(v li)  d ias to lic  blood pressure (D. B . P. ;
mmHg)
The stippled areas indicate the range o f resu lts  (mean r  
one standard deviation) found in  norm al single pregnancies 
(F igure 89) and tw in  prêghàncles (F igure 70) -  see Tables 
61-64. '
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Figure 69:- Results for ’’High Risk” Patient (R. S. ).
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Figure 70:- Results for ”Hlgh Risk” Patient (J.W. ).
Table 1
TYPE Ï TYPE n TYPE m
interm ediate
oligom ers
Complexes clo ttable 
w ith  throm bin
Complexes unclottable 
w ith  throm bin
f " f V ® ' ■ x-y
f"F x -Y  .
x -x x -F x-D
x -X fg -y
A.
f-X  .
f.y
f-Y  "
f-D
The various types of soluble fibrlnogen-fibrin complexes
suggested by Wegr»ynowics5, Kopec and L a ta llo  (1071).
F -  fibrinogen
f  -  fib r in  monomer produced by throm bin
(deprived of fibrinopeptides A and B)
~ fib r in  monomer produced by ancrod o r Heptilase 
(deprived of fibrinopeptlde A)
X , Yf D, K •* successive degradation products form ed by plasm in 
digestion of fibrinogen (FDF)
y, d, e -  successive degradation products form ed by plasm in
digestion of fib r in  (fdp)
Table Z
Solute M.W. Logj^M.W. V InmL
Blue Dextran '■ 2,000,000 ' 0.3010 62
Lipopolysaecharide 500,000 0.1761 72
(S. typhosa) ; '
Thyroglofoulin 070,000 5.8261 90
Fibrinogen 340,000 5.6315 105
Albumin 09,000 4,8388 142
Trypsin 23,800 4.3766 161
Bacitracin 1,411 3.1496 175
M olecular weight (M. W. ), logarithm  to base TO of m olecular  
weight (log|Q M. W. ) and elution volume (¥^) of purified so lu tes
analysed by gel filtration technique. Data used to construct 
graph shown in F igure 23. ^
TabW
’ Sample ' Mo. of V (ml) V fibrlnogan
an alyses (ml)
Blue Dextran ' 3 6 9 .5  î  1 .3  .* -
Fibrinogen' 3 - 96.7  ^ 0.3
-XKàbl)' ' . . -y , -
Plasm a, " " 8  ' -  ' 9 G .# -0 .5
-alanine '10 ' 8 5 ,4 - 0 .6 -
precipitate of ■■ .
plaâma ' .„ - . ■
Void volum e (Ÿ ) and elution volum e iY J  of fibrinogen estim ated  
on, Columns A i and A3 (Batch 1 gel). Beauits, are  shown aa the 
mean * 1 standard deviation. T here is  m  significant d ifference . 
(unpaired **!’* test); in the of fibrinogen.- ' (Purified fibrinogen / 
plasm a, t  «  0 .1 4 9 , 2p (0 .90 ; p la sm a /jS  -alanine-precip itate, 
t.-« 0 .6 4 4 , 2p (0 .60; fibrinogen / -alanine-precipitate,-1 *® , , . 
0 ,6 9 3 , 2 p < 0 .# ) .  ^  y '
Table 4 , . ■ ■ ■ '
TteoiMfein (units) ; Heparin (units)
a . 250 ■ ■>
b ' 0,02 , , ' 260
Q ' 0,04 / *  ■ 500 ■
â ' 0,06 , ' /  . ■ 750 ■ ; ,
e 0,08 1,000
f  0.10 1,250
,g- 0,12 , 1,600
I»; ' 0.20 2,000 .
to the set of experim ents shown in  fig u re s  27 -  88; 25 mg 
of fibrinogen was incuteted w ith  successively increased ,
tXirombia was ''neutralised** w ith  appropriate eoneentrationa
of heparin a s  ehawn*
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Table 6
Case Mo,
(M tials)
8ex Age
(Years),
C lin im  D eta ils
Ê (W .F .) M aie
4 (J .B .)  Maie
7 (W .M eG J Maie
72 (1) ISevére pe riphe ra l à rte r la l disease.
(2) Ihcip ient gangrene of le ft foot
42 (1) • D e #  venons throm bosis of right leg
(2) Ischaem ic heart disease
66 (1) Dgep yenons throm bbsls of r iÿ i t  leg
(2) Carcinoma of caecum f  m étastasés
26 ; ( l) /r ia é p  venons throm bosis of rig h t leg
 ^(2) bhroh ic pyelonephritis "
6 (J .M cK .) Female 60
6 (L B .)  Female 60
(1) incip ient gangrene of rig h t foot /
/' following frail'-bite-
(2) A lcoholism  '
(1) Incipient gangrene of rig h t loot
(2) Severe pe riphe ra l a rte ria l disease
(3) Diabetes
22 (1) Right'sided a x illa ry  vein throm bosis
C lin ica l de ta ils of patients included in  ancrod study.
Tàble 7
Patient 
. No,
Plasma fib rtn og en  Bevels (mg/iOQ m l)
P re-trea tm ent 0 hoars
treatm ent
24 hours
treatment
2
3
4 
6
7
286
364
268
226
421
619
166
130
822
6
60
126
263
0
12
f t
0
0
6
mean
M
SO
320
123
128
122 6
Plasma fibrinogen leve ls (mg/100 m l) pA e-treatm ent and a fte r 
6 and 24 hours aneroft infusion. ■„-Means- -  standard deviations 
are shown fo r each group of resu lts .
P re -tre a tm e n t/6  hours t » 6,746 2p <0* CIÔ6 
6 h o u rs /M  hours i   ^ t 2.767 2p (0.05
Tablé 8a
Sérum FD Ë/fdp Layela :  t .R .C .m  k  l.
Patient
NO..;-
P ro -trea tm en t 6 hours 
treatm ent '
24 hours 
Treatm ent,.,
T 7  : ■■ N .D .
%È ■ ' , " 8 , ' ; m
2 . 10
- 4 :.2‘ ' /  "  /  : 9 ^ 10
"6 ; : 10 10
" o' '
.
.. T1 " 10
7 '\T 0 ' 9
V mean
. A ' v 
. 8D' '  '
. . . I " : » ; . : '
■
; y "  9 .7 '
„4'' " -  
1 .0
9.8 ■
,- .-1  / 
0.4
(T .E .Ç .- ÏÏ. Î .Ï ,) ’ ■
p ré A rça tm m t and  ^$ àndt 24 hours a fte r sta rting  ancrod Infusion; 
because of the v^ery high values the resu lts  are ex p ress#  as the 
negative logarithm  to the base 2 of the la s t d ilu tion  to  give à 
positive  reaction  (cf. titre ). Means -  standard deviations 
are shown fo r each group of resu lts . D ifferences between 
groups (paired **t" te s t);-  
P ré^trea tm é n t/6  hours t  = 16.413 2p(0.001 
0 hours/24  hours t  ^ 0 .8%9 2p(0. 8 (N8).
P atlsnt 
#0 . ..
Î
■a
3
4
6
meaà
8b
Sas) .I,i%v<&l;% "k:15CTT tltare;eriiB
W.D,
: j
■ 0- 
0 
0 
0
■ o ' 
0
6 àtntrs "24 hours
treatiaent ' .treatm cnf
 ^ W.,B. .; ■ N .D . ■
4 >10
> iO  8 ' '
9 - 1 -
>10  8
. . ' > 4 0 ' :
,: 9 - '
8
a
8. or 8 .8
1.4
glerum FD P/W p lbv%8 measured by tbe Btuphyloeeeeul Clumping 
Test ($CT) If  esults eaprêssed as the negative logarithm
to the base 2 L Meana ^ ataadard devlatioae are showa. 
DmSreaees between groupa (paired test). 
P ra -tre a tm e a t/S b o u ro  t  « 8,888^4 2^(0# 801 , <
e h o u rs ;;/a 4 h # rs  t \ ;0 # W /2 p (0 .8 (N m  
The eorralatitm  eoefEicient (v^ )' for-data la Tables- 8a aad b 
ealeUlated by l in # r  regreesion analysis was 0# 804 (8 o( (0.001).
Table. #a
FB^antigeii (m g /100 m l) measured by the
Patient ■ 
Ho,
■ M ancini téchniqué at
P ra«trèàtm ent 8 hours 
• . treatm ent
24 hours
treatm ent
1 a;. D. H .D , H D .
2 . H#D, ' K D , H .D .
S M .D. K D , H ,D .
. 4 1 ,0 12,0 4 ,5
. : 5 0 7 .0 18.5
■6 ' 4. :: s . 18,0 24.6
9 i# $
mean
■ .±- 
8D
2.1
±
8 /8
10/8
■ '■ -t
11.0
t  ' 
10.8
F E -an tige ii eoncentratlim s (m g /100 m iy meaaured by thé ra d ia l 
im m iin o d illiis io îi (M axieiiii) teehaiciue bn the yoM volum e (¥^) 
frac tions fro m  samples obtained pre^treatm ent and a fte r 6 and 
24 hoars ancrod infusion. Means *  standard deviatidns are 
shown. D ifferences between groups (paired ” t*’ tes t);^  
P rO '^treatm ent/# hours t  » 5,08? 2p(0. 0^ :
6 h o u rs /24 hours t  ^ 0.111 2p (0.88 (MS),
f  able 9b
8CT T iW  at V0
(negative logarithm  to  base 2)
Patient
No..V s '
P re^treatm ènt . 6 hcwrs 
treatm ent
24 hours 
treatm ent
1 N .D . N .D . ' N .D .
N .D . H ,D .
. 3 ■- H .D .; K D # " . N .D ,
4' 0 ' <5 / 3
5 . - () ' ' ' ' : / .  ■ 8 , 7
i  ' 8 B
7 0 ■ ' 7 . . . . .  0
mean
' #N
8D
i ,  3
' i" ■ ■
2I 5
8/5 5.8
. - t  '
at. 2
fE -a n tig en  éoneentratlpns m easured by the 8CT titre  on the . 
sam e void volum e ( ¥ J  fractions .shb^ndn.:f able 9a, E esu lts  
are expressed as the n ega tive foga^M m  to W  base 2*. - 
D ifferences between groups (paired t#st):^
Pre"tfeatm ent/8 hm rs t * 4,785 2p (0,02 
S h o u r s /2 4 -hours t » 0 .8 7 8  2p (0 /5  (H8).
The correlation coefficient (y) fo r the data in  Tables 9a and h 
calculated by lin e a r regression am ilysis was 0 .804 (2 ex. (0 .01),
TabW 10
‘ Ârem m
Patient' ■ 
Ho,
F*:@-tréatme»t , 6 honrs 
treatm ent
24 hours 
treatm ent
1 # . D .   ^ ^ ,, ,' . N .D , '. N .D .-
2 , - 0 .' N .D . N.D.
'■ ' . 20.9 26.6
: 9 .0 30*2 32.8
- G ' . ; 8 .2 21.6 • ‘ 12.^9 '
'  8 ' 3 .0 8 .0  ' 18.6
; - 4 .1  , , 19.S ' V 18.6
mean . s. 4 19.6 21.9
,>: wj. , . 1- . 4-
• : 2 .0 8.0 7 .6  .
Soluble complex eohcantratlons (areà m* percent to ta l area;
Means
W standard deviations are shewn. D ifferences between groups , 
(paired.’ *t*Vteat)î ** ■ ' : ^
P rertreaW ent^O  hours t  « 4,081 2p(0#01
i  hdurs/24 hWrs  ^ t « 0* 888 Bp (0,8 #8)#
«T a W e ll
& V
•I:. ;
Patient
Mo. ' " ’ '■
Pre#treatm eht - 0 h o n r^ '' ' 
treatm ent
,34 hoars 
treatm ent
'! ' . '■: : ' M m . 'C
. "-'"-K D . - ,.
M.D. '  ^ ' t  
" : M D .
' . , . - - ,3
. 3' i& 7 \ 3:8, ? ■ 29. 3 . , '
' 7 .e ' ' ' ; \  \ I W  ' ' 2:8.2
5 9,9 23.6 37.3
. \0 ' . ' '  ^ ' ' ' :4D.Q. " -56. 0 // v " ' " '
' ' .  7 /   ^' . f '  3 ' 30.9 28.9
: '" " 4
■ mean 
SD
9.0
4"' ,. ■
L 4
28,1
V /- , . T
34.8
12.8
tptai area# oaleuWed as described;# Chapter I I .  4(k) ) for
anérod W uéleà/ Means /  standard di viatima are shown. 
Differences beWeen grcmps' (paired■|*P* test):- 
Pre-treatm ent/ Ù hours t 4,4I& B|1(0*02 r 
6 hours/24 hours ' • . t « 1. 652^p(0.2 (MS).. ■..
'  /  ;  ,  ■ '  '  :  ^ . ,
Table 12
Patiënt
Ho.
ê hours 24 hours
treatm ent
3
4
5 
8
7
H .D . 
K D .  
86.0 
66; 2 
81.8  
87.0  
80.7
M .D . 
H .D . 
40.4  
60.6 
64. t  
62.0  
61.0
H m .
H .D l
4 4 .1
4 4 .8
68.8 
86
52.7
mean 86.1
: ' ■*}■'
3.1
6^2* ,8-
8*6
43,,5
it ■
10.4
W én-degrMèdf umcomplemed (ihrhiog#** (area n, ' percent 
to ta l area, calculated as described m Chapter H. 4(k) ) for
samples obtainW  pre^treatm ent and a fte r 0 and 24 hours 
ancrod infusion. Méans *  standard deviations are shown.
Prettreatm ent/  6 hours t  16.266 2p(0.0Ùl
0'h o u rs /24 hours t  1.818 'ip(§# 2 {MS).
Tablé 13
Patient ' P re -trea tm ent 6 h c ^ s 24 hours
No# troàtm pnt treathtent
; ''1 0.86, ' ;  . -  ' 0. 66 • 0.69
. .  2( , -' ^  . , 0.80 '  6. 68 0.69
, 3 0,60 0.63 0.62
. 4 ' ; , 0.69 ' ■ 0.68 0.62
• • 5 : 0.98 ■0.89 0.60
. ^ ^ 0.06 ■■■-■0.08 . 0.68
'  ' 7 - - " : 0.69 0.69
mean ■ . ' 0 . 9 6 / ■ 0*69 0.08
t  ' ■ • ■ ' t
8D 0 .0 8 '/ : ' ' 0.02 .. 0.04
FB-antigen ra tio s  (ca lcu la ted 'as described in Chapter H. 4(k) ) 
fo r samples obtained pre-treatment and after 0 and 24 hours 
ancrod infusion, .. Means t  standard-deviations are #ow n . 
Differences between groups-(paired'"*^’ test):- ■ 
Pre-treatm ent/8 hours, t-«  3/000 2p{0.026 
.#'h o u rs /24 hours " ;t * 1.316 2p(0#3
Table 14
TCP Ratios
Patient P re -trem tm W .  ê hours
treatment
'  r
."’à
4'
0
6
-■r
meau;
- -, -> ' M>
N ,D . 
5», 56 
0,61 
0.74 
0.84 
0. 68 
0.9:9
k n
4".-m
0.08
N.D.
8.66
8.66
0.65
0.66
0.92'
0.69
0 .09
4*#
0.08
TCP ratios (calculated as deêeribed W Chapter II. 4(1) ) for
Infusion. (Résulta could net be calculated W  24 hour 
samples because no T .C . T . results were recorded (8 
minutes). Means -  standard deviations are shown. 
Differences between groups (paired té8t):- 
$ r^ e-treatment /  6 hours t ' œ 1 .254  2p (0 .8  (MB).
Tablé 15
T .C .T . Ratios
Patient
Ho,
P re-trea tm en t
1
2 
a
■# 
ê 
f
mem 
, t
SO'
0.89
0.81
0.84
0.91
0.88
0.86
0.90
0.89
m
0.04
6 hours
treatment
0.88 
0.68 
0.00 
0.88 
0.68 
0.94 
0.09
0,88
+
0.03
f .C .T #  ratios (calculated as deseribW in Chapter IL 4(1)) for 
aam pl# cbtahied pÿê'^treatmeat aW a f t#  6 hours aucrod 
in fud ipu /; No T . C# T , résu lte  {3 mhiUtes were recorded 1» the 
24 hour suuiples; Means  ^Standard deyiatione are shown# r
!*#
PrO-treatment/ 6' hours, t  12 .001 2p(0,001,
ÛEOUP ï  
Group m
Group ÏU
fa b le  16
10 pr0-ecM m püe patients
10 âgé/:-parity m d  gestation matched 
pregnant control women
10 age'matched non-pregnant control
women
Subjeeta included inTaltlal'pre-eclam psia-study.
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' _ Table 18a • ‘ '
Systolic Blood P ressure Beadfeags (mmHg)
Group I  Group I I  Group IH
" 1 160 110 120
k 160 120 100
; 3 170 140 100
4 ' 120 ISO , 110
- 160 - ' 180 110
' 0 .  ^ ' -<■.  ^ ' . 130 110 105
1 160 110 115
8 . " 165 100 120
9 145 90 : - 105
; 130 :: 130 110 V
mean i  SD 1 4 9 -1 7 117 -  16 110 i  7
Systolic blood pressure readings on subjects in  Groups I, H 
and IB  (sea Table 1§) at tim e of blood sam pling. Means -  
standard deviations (Sp) fo r each group are shown. D ifferences 
between groups (unpaired ” t¥  te s t):- 
Group I/G ro u p  I I  l  é 4,359 2p (0. 001 
Group B /G roup IB  t  é. 1.300 |p  <0,30 (K8)
Grtmp I/G ro u p  B I t  6.710
Table 18b
GroppT,'- Group I I . Group 111
/  ‘ 1 '  110 ' . ; / 76' '
■ 2 , - i i p , ; 8() ( 8()
a 110 80
' 4 A 60- : ' .:76' / 70
5 -100 80 70
90 : : " 7 0  ' 70
■ V. .
70 80
8 60 78
Q - 60 60
10 106 ■ ' 75 '
- ' tfmean - 8D 101 Ï  9 ' 7 3 - 8  - "A , 70 -  7
Diastolic blood pressure readingâ of subjects in Groups I, II 
and in (see Table 16} at time of blood sampling. Means r 
standard deviations (SD) for each group are shown. Differences 
between groups (unpaired "t" test);- 
Group I/Grbup II t = 8.000 2p(0.0bl 
Group H/Group III t = 0.785 2p(0.%p (NS)
Group I/Group a i  t = 8.211 2p <0.001
Tablé 18c
Proteinuria and Oedema
Group I
Quantitative Proteinuria " ' 
tg /2 4  hours)
Oedema 
(face and hands)
' t 1 % , ' 6
2 - ' 6 - ' : / .
' , . ':3'' " ' A, : , ■ -k
/  4 ■' 1 .7  X ■ ' '
5 - , 8.1 444
G.O 4
■ ' \ " 7 / é  ' 1 . 8 4 4 , 4
3 .1 trace
trace
9 .8 4 4
: m ean i  8D 5.3  Î  4.1
Queiîtitatiya proteinuria resu lts  and a ssessm en t of oedema at
patients)# Subjects in Group II (normal pregnant controls) 
dldémt have s ig n if ic a #  proteinuria or oedema o î face and 
hands at tim e of blood sam pling. Subjects in Group IK
protein uria  or oedem a.
Table 10
Plastna Ftbriaogen Lèvels (mg/100 ml)
Group I Group #  .. , Group III
jT ' ' : aïoo 268 245
■ ; -  446 r 387 ■ ; 172
3 380 238
4 : 34() : ' 860 237
236 , ,  %807' ■ 207
■' i' . '
.6  t / 346 ; , 287 <' ' ISO
; 1 -  é., 803 205 166
'.a ; 200 489 . 167
269 A- ' /  180 ' ' 262
10 \ - : 220 . ' 180 ■/215 ■
mean'v-rj ■:/ 281 ■ 301 207
i - -1-m -
84 88 38
[, U ana in
(see Tablé IS). Means -  standard deviations are sbowa for each 
growp. Differehces between the groupé (unpaired "t" test):- 
Group I/Oroup II t = 0.504 2p (0. 70 (NS)
Group Ü/Grott# r a t  = 3.079 |!p <0.01 
G rûu/l/G roup III t = 2. 546 2p <0, 025
Table 20
Serum W p / W  Lèvels -  T .R # C . L I .  W /m l)
Group I Group I I Group IB
r t - , ' ' .^^ 10 ' \  - 3,75 2 ,5
2 :'5 2 ,5
3 ■ 10 -  0/. 2 .5
4 110 " ■ 5 2 .6
5 10
4 ' .
5 : 2 ,5
6 30 2 ,5 1.25
7 : / v - 0 , 5 2 .5
8 10 5 2 .5
9 5 V 10 5
10 10 2 .5 0
mean ; 9, 7 
4 ,3  :
•"4*9'
4- 
2,1
2.4
t
1.2
H ISerum F B F /M p  va lues 'fo r sample’s from  Groups I, n  and 
(see-Table 16). Measurements by the tanned red ce ll haem- 
agglutination Inh ib ition  immunoassay (T. R, € v lL  L  I. ). Means 
i  standard deviations are #o w n  fo r each group. Differences 
between the groups (im paired "F ' te s t);- 
Group l/G rm p  n  t  » 3.316 2p (0,006 
Group n /G ro U p m  t «= 3,264 2p (0,005 
G ro u p I/G ro u p IB  t  5,374 3p(0,001
Table 21
titre
G roupÎ Group ÏI Group Ml
1 SI- ' ' /'y; - ' 0 =
2 .: . ' 0 ' '' t» . . ■ 0 ■
. ' ■ • 0 _ 0 " 0
:"'-4 ■"1 • I) 0
-- -0 ' : ' ' ' <) , 0
() , 4 : 0
- "7 / 0 -A ■ 0
8 - 0. li ' ' J 0-, . . 
0 ()
10 2 .,/P.  ^ ^ 0
mean  ^ •■
*}’
0.76
4' ■', ■■■ ■
/ O ' - ; ' . - '
8D ; '
. 1
iO. 9
ie ru m  fP F /fd p  value® 'for aamples fro m  Group® 1# M and î î ï  ' 
(see Table 16), Measurements by BtapbyWoceal plumping 
Test "(SOT) t itre . Means'? standard deviation® a re  shown fo r 
each group. DlMerences b e tw e #  grw ps (unpaired **t”  te s t):- 
G ro u g l/ëro u p #  t«: 2.677 2p(0 .02 
G rO u p T /G rm p m t«  2.677 2p<0.02
Table 22
-  CQKljiartaon of T .B . C. M. L  I.
and BCT t itre  measurements
2 cx
Group i  
alone
Group B  >- 
alone
Group m
alone
Group la n d  11 
Group I I  and n i 
Group I, I I  and I I I
4 0* 635
: o A
0 •'•
4^ 0.702
0
0/703
(O.OB
(0.001
(0*001
Comparison 0Î serum F D F /fd p  measurements using the tanned 
red' c e ll haemagglutination inh ib ition  immunoassay (T .E .C .H , 1*1. 
Table 20) and the staphylococcal clumping test (SCT titre , Tab le- 
21) by lin e a r regression anàiysis. Values of co rre la tion  co­
e ffic ien t (f ), and p robab ility  values (2 ot ) are shown.
' , Tablé 28 ' :
: FH -Antigen Ratios 
Group 1 Group I I Group IB
' 1 0.62 0.85 0 . #
. 2 ■ 0.62 0,81 0.86
0.60, , 0.80 6.88
6. 60;/A 0.80 0,88
i  ' 0. 60 0.80 0.88
6 0.60 0.83 0.89
7 . 0.61 0.76 <). 88
' a 0.61 0.87
0. 60 (). 0.88
10 0.61 ().7B 0.88
mean 0.61 <). 8(> 0.87
4 t
SO' 0.01 0.Ô3 0.01
as
described in  Chapter ïL  4 (k)) fo r samples from  Groups I, I I  
and I I I  (see Table 16). M eans? standard deviations are Shown 
fo r eaoh group. D ifferences between groups (m ipaired " t "  
te s t):-
G ro # )i/G ro u p  I I  t  1? ,1M  3p (6. 001 
G roupM /O roup m  t f  6.194 2p (0 .001 
Groupl/Qroup0g=64.88^^^
Tabled
Plasma Fibrinogen Levels/FR-antigen ratios
.T :4  ' .B 'cx ./
K À î W  >0.1 (H8)
4 0.108 >0.1 (H8)
-0 .4 0 ¥  >0.1 (H8)
4 0.147 >0.1 (N8)
^0.488 , .(0.05
- 0 . %  >0.1(N8)
Group I
a lone,
Group l i
alone ■ ./
Group IH  
alone
Group I  and I I  
Group Ï Ï  and I I I  
Group I> I I  and I I I
antigen ra tio s  (Table 33) fo r the same samples using line a r 
regression analysis. The groups are shown separately and in 
com bination. . ^
Table 25
T titres (V^) -  
(negative loga rithm  to  base 2)
Group 1 '■ Group E Group i l l
0 ()
\ : 2  . 4 ' 2 / 0 •'
■' 3 : ' G À- ;■ 0 0
' / t  - -g: ,4  ' 0 '■ : 0
6 ii.O 0
0 ' . = ' 4 / 2 0
. , : ' ' 5 4 - '  . 1 0 - ' '
8 • s 0 a: 0
0 ’a,,"'-' ■ 0
4 . 0
mean 3.9 1.0 0
■ , ■ "..4 -
;-SD„^ 1.0 V ' , ]l. 3 A
Staphylpco.ecal dum ping  Test (BCT) titre® at the void volume 
(V J  expressed as the negative logarithm  to  the base 2 for 
samples in  Groups' I, 11 and H I (see Table 18), Means ?
'standard deviations'are shown for each group, ' D ifferences
between groups (unpaired te s t):- 
Group I/Group K t = 6,263 3p (0.001
qroup B /G r o u p in t  »^ 2.237 2p (0,06
Group I/G ro u p  IB  t = 11.705 2p (0.001
*p a tie n t 6 was studied ea rly  in  the p ro ject, before the SCT titre 
was measured, however, the undiluted sample gave a strongly 
p o s itive  re s u lt.
Table 28
'FB-antigen (m g/100 m l) m ea#red  by M aaeini
'. teehni#ih at V,0
Group 1 ' G ro #  I I G rw p  m
0 0
2 , A 1.0 0 0 „
a - - 'i.'o : O": • 0
4 '■ 0 ■ /- , 0
6 ii.o 0 0 /
d 4 .0 Ô
7 1.0 " ■ ( /O 0
" 8 9.0 0 0
9 31# 5 0 0
10 2 .0  . 0 0
mean
■ t
8D ^
2.2
1.4
0 0
.FR-antigen (m g /100 m l) measured bg/the ra d ia l im m unodiffusion 
technique (M ançini) at the same void volume fractions as shown
I . '
in  Table 25. Means -  standard deviations are phown fo r each 
group. D ifferences between groups (unpaired ” t "  te s t):- 
GrOup I/G ro u p  I I  t  = 4.485 2p (0. 001 
Group 1 /Group r a t  = 4.435 2p <0.001
Table 27
Two Techniques
X ' 2cx
Group I  
alone
-  0.658 ;  )0 .1(N 8)
Group II
alone
Group H I ■ ■ ■ ■ ' ft; ■ ■
alone . < ■Î
Group land  II 4 0 ,‘424 >0.1 (NS)
Group I I  and I I I ' Q ■ ■ *»
Group I, I I  and HI 0.542 <0.01
Comparison, of the resu lts  of the fib rla o g e ii-fib riH 're la te d  (FH)- 
antigen concentration in the void volqme fractions (¥^) measured 
by two different techniques (Tables 25 and 28) using linear 
regression analysis. The groups are 'shown separately and 
in combination. ■ ,
Table 26
-> ' T .C .Ï* . Ratios ... :  '
Orbap I  Group I I  Group I I I
0.04 0.67 0.88
;■ a : 0.64 0<63 0.80
à . "- ' A ■ . - i 0.88
0,88 0.60
4 0 .8 2 , . 0.80 0.64
.."5 4  ' 0.61 ' ' ■ 0.86 À';: ' 0,88
6 0.60 0.60 0.93
? , . V 0.60 0.66 0.90
, . 8 ' 0,61 0.84 0.87 ;
0.60 0.67 0.88
16; 0.60 0.83 0.86
mean 0.61 . . ' 0.86 ’ - 0.86
' t'- ■1- +
■ so 0.02 ■ 0.03; ■' 0.03
Throm bin C lottablo P ro te in  (T . C .P . ) ra tio s  (calculated as 
descritjed in  Chapter II. 4(1) ) fo r samples from  Groups I, I I  
and IE  .(see. Table 18). Means standard deviations are shown 
fo r each group. D ifferences between groups (unpaired " t "  test);- 
Grbup 1 /Group E t  = 28.004 2p <0. OOl 
Group H /G roup IE  t  = 3.288 gp <0. 006 
Group I/G ro u p  H I t  = 27.060 2p <0. 001
Table ae
Plasm a F ibrinogen L e ve le /T .C *P , R atios
r 2 ex
Group I  ° ,,*,0.680 (0.06 =
alone
Group I I  
alone
+ 0.019 ) 0.1 # 8 )
Group I I I -  0.104 > 0.1 IMS)
alone
Group 1 and 11 + 0.166 , ) 0.1  (MS)
Group 11 and II I -0 ,3 1 0 ) 0.1 (NS)
Group I, n  and HI -  0.181 > 0.1 (NS)
Comparison of .plasma fibrinogm W e is  (Table 19) m û  T&C. P,
ratios (Table 28) for the same samples asing linear regression
analysis. The gronps are shown separately and in combination.
Table 90
Group I  
alone
Group I I
alone' ,
G&mwpin
alone ^
Group I  and I I  
Group II and IH 
Group4  H an d 51
r
4 0 J 1 6
,^# 1 5 5
+ 0. 316
t  P. # ;  
+ 0.494 
+ 0.861
2 (X 
<0.08 ;
>0.1 (NS)
)0 .1 (NS)
<0.001 
<0.05 , /  
<0.001
Coiinparison of i'B -aatigea (Table 23) and T . C .P . ratios (Table
26) fo r the same samples using linear regression analysis. The
groups are shown separately and in Combination.
Table 31
T. G, T, Ratloa
Group I Group Î Ï Group 111
1 0.90 0V92 0*80
% 0.30 0,33 0.92
3 0.90 0,91 (). 93
4 ' ' 0.36 0.91 0,69
8 0*90 0*37 0.93
6 0.89 0,00 0.98
7 ().9(> 0.90 (>.98
3 0.30 0.91 0*92
■ 9 0.39 0,90 0.98
10 0.39 0U63 0.90
mean 0 .3 3 0.90 0.92
-î‘ H:’m
8D 0.02 (L02 0.02
Thrombin clotting tim e (T, C .T. ) ra tio s  (calculated as described 
in  Chapter I I.  4(1) ) fo r samples in  Groups % H and M  (see Table 
1(3). j&leafks sd:a:idb&r<l ck&ifiatju&nus s&Kmvii fcwr (wawGh igrotip. 
Differences between groups (unpaired "t^ * ' '
Grtmp I/fflsTOtap H t *c 31,37% %jp (().:& (BfS;)
(Gircyui) Il/fflroup 8:1 t * 2.739 3%p (<),02
(lipoup ]f/(:%rou%> HI t "= <1.810 2%, (0. ()0]l
Table 82
Arm  m 
, Group 1
(percent total area) 
Group 11 . Group m
' , .1 ' 16.0 . / : ' - ' 6 ,6  : :&» 6
■■-2 7.1 (i, 5 3 .1 - -
26,7 3 ,3 --
" 4. 21,3 ;.6.i5 - ' - . 2 ,9 ; /
' 5 16.3 3 .3 ^ 2.4
6 ■ : € 3 ' ' ' 's..7 ' ' sa, 1 ^
\  T : 31.8 %.3
a , : 18.8 9 ,
8 23.9 ■V- ' . .4. 1s: - ' 2 . 8
10 ; 4 .0  , ' 2 . f
mean ; ' 1Ô. O-0- ' : ;2.7
4- - .. . ' / $  '= '
6,9 0.4
Sblukle Complex ombehtratlons (area w , percent total arm»
calculated as described la Chapter IL  4(h) ), fo r samples in  
Groups %» H and H I (see Table 1 6 ).. Means i  standard
deviations are shown" fo r eàcb group* Differences between
groups (unpaired ” t*H est)î-
Group l/a ro u p  H t  == 6,532 2p (0, 001
G rrnp ll/G ro u p  m  t  ^ 6,134 2p <0, 001
Group I/G ro u p  111 t  « 6.346 2p (0*001
Tabla 33
a:
2(X
Groüp I
alone
Group «  
alone . -
Group H l 
alone %
Group î  and U
Group H and n i
Group î, I I  and HI
-  6*056 
4 0 ,3 #
4 0.086
-0 .0 6 3  
4 0.023
4 0.016
(0.06 
>6/1 (m )'
>0.1 (N8)
(0.01 
(0.01 
>0.1 (N8)
Comparison of plasma fibrinogen (Table 19) and area m (Table
32) for the same samples using linear regression analysis. The
groups are shown separately and together.
Table 34
Area m values/serum  EDP/Wp levels
r 2 cx
Group I - 0.205 >0.1 (N8)
alone
Group I I -  0. 210 )o.i(m)
alone '
Group I I I 4 0.233 >0.1 (N8)
alone
Group I  and I I 4 0.395 (0 .K N 8)
Group Hand IE 4 0.44$ (0.06
Group I, I I  and IE 4 0.572 <0.001
Comparison of serum  F D P /fdp  levels (Table 20) measured by the 
tanned red c e ll haemagglntination Inh ib ition  immunoassay {T .B .C .H . 
L  I. ) and area m (Table 32). The groups are shown separately 
and together.
Table 3S
Area p (percent to ta l area)
Group I  . Group U Group m
1 1 .4 " ' - ■ B.o 6.7 .
2  ^ 3.1)
3 ' ■ " - € e  ■ 3 .2 ' 2 .0 - :  , .
\ 1 .6 3 ,0 St.9
5 19.5 9 .0 ^  3 .6
= ■ & .141 ; . <5 . 3 , 4 .0
14.8 , ‘4 ':/':4.1 4 .6
8 2.1 " 1.2
. .  -',15»,,.:;, 7 .9 ^ .'1 ,7 .^ ,.-
10 M %  \  , ' ' 4 .7 - " 2*7
mean
""" .K ,
9 .1 4 .8
:¥ ■
3.4
, 4
8D as. 2 1 .6
area, calcuW ed as described in  Chapter II. 4(k) ) fo r eamples 
in  Groups I,  H and 111 (Table 16). Means -  standard deviations 
are shown fo r each group. D ifferences between groups (unpaired 
"P 'to s t) :-
Group I/G ro u p  H t  = 2.180 2p <0. OS 
Group U /G roup I I I  t  = 1.595 2p <0.2 (NS)
G roupT/G roup lû  t  = 2. 961 2p (0.01
Table 36
Area p values/p lasm a fibrinogen leve ls
IT 2 c (
Group I -0 *20 1 > o . i ( m
alone
Group I I 0,731 <0.05
alone
Group I I I -0 ,0 1 7 ) 0 ; i (N8)
alone
Group I  and I I -0 .3 3 2 >0.1 (N8)
Group I I  and I I I -0 *2 0 5 >0.1 (N8)
Group I, I I  and IE -0 .0 5 9 J 0 .K N 8 )
Comparison el plasma fibrinogen (Table 19) and area p (Table
35) for the same samples using linear regression analysis.
The groups are shown separately and together.
Area p values/8em m  F M /Id p  levels
r 2 c x
Group I
alone- = .. .
Group I I  
a loaè:/
Group IE  
alone .
Group I  and H 
Group n  and m  
Group Ij a  aod m
135
4 0.119 
T 9 U 7 $
4 0.210 
+ 0.288 
+ 0.372
)0 .1 (MS)
>0.1 (MS)
>0.1 (Mg)
>0.1 (MS) 
>0.1 (MS) 
<0.08 •
Comparison of serum  F D F /îd p ië v e ls  (Table 20) measured by the
'.B .C .
H. 1.1. ) and area p (Table 86). Croups are shown separately and 
t% ethm '. ' ■■■■'■- , -
TnbW 36
Area m vaW@/areu p values
■ . ■ Y 2 04,
Group I  ''' -  0.102 >0.1 (NS)
alone
Group H 4 0.069 >0.1 (NS)
alone v'-
Group I I I  
alone
-0 .1 3 7 >0.1 (NS)
Group Ï  and Î Ï + 0,314 <0,1 (NS)
Group I I  and E l -1-0.205 >0.1 (NS)
Group 1, I I  and H I . ' +0.442 ': , . . <0.06
Comparison of area m (Table 3?) and area p {Tablé 39) fo r the 
same samples using lin e a r regression analysis. The groups 
are shown separately and together;-’ ' .
Table 38
Area n (percent to ta l area)
Group I Group, I I G rO ip III
1 -... 83.2 86-6 89.2
87.0 : 92.9 : 93.0
3 67.3 "9 2 .3 . ; 94.6
4 \ 77.0 90.3 ' : 83. 8 '
5 64.0 . 9 1 . 6 ■ . J93 ;9  ...
r ' t  ' ' ■ 70 .5 ; ' . - ,',87.9, ; 93.9 ,
7 '7 6 .0 ' : . -9 2 .0 ; ; ; » . 03.0 : ■;
8 78.2 91.9 96.3
S 60.8 88.2 . ' ;95 .;3  : " -
10 75.8 X';:;. ..8 l.:8y ; 94.6
mean
-1- ■ V ■
75.0 90.4
' 1 -
93.7
V
SD 8.2 ' , "2 .4 :. ' , - \ ; 1 . 8  .
mcpihplexëd fibrinogen" (area n» p # # n t  total 
area, calculated as described in Chapter IL4(k) ) for samples in  
Groups I, H and H I. Means $ standard-deviations are  shown. 
Differences between groups (unpaired "t" test):- •' 
GroupI/GroupH t «  6.689 2p (0,001 
GroupH/GroupHI t %: 8.489 ap^OOB -
G roupT/G rw% m ^^ %
TabM 40
Area n va lues/p lasm a fibrinogen leve ls
T % cX
Group I
■alone
Group I I  
Mpne
Group I I I  
alone .
Group I and H
Group H and III 
Group :, II # d  n i
 ^ 0.617
4. 0,803
-  0,177
0.397
-0,17%
 ^ 0,0003
<0,1 (N8)
>0.1 < m
>0,1 (N8)
<0,1 (H8) 
>0,1 (N8) 
>0,1 W )
Obmparison of plasm Kflbrluogen (Table 19) and area n (Table 39)
for the same samples using linear regression analysis. The
groups are shown separately and together.
Table 41
Area n  values/serum  FBF/Idp levels
>r % cx
Group I  
alone
Group H 
alone
Group Ï Ï Ï  
alone
Group I  and ï ï  
Group n  and H Î 
Group I, H and H I
-I 0. %02
-0 ,0 2 3  
4-" 0.084
-  0,389
- 0.379
-  0.572
>0.1 (H3) 
>0.1 (NS)
>0.1 (m )
(0 ,1 W )
<0.1 (MS) 
<0.001
Comparison of serum FDP/fdp (Table 20) and area n (Table 39)
for the same samples using linear regression analysis. The
groups ar^ shown separately and together.
Table 42
Group I Group I I
Plasma 
fibrinogen 
m g /100 m l
Serum FDP 
M g/m l 
( ra c H ii)
FE-antigen 
R atio
SOT titre - 
at
TCP R atio
Area m'm
Area p 
(%)
281
■■i--
84
4.2  
0.61* 
0.01
3,9*  
1.0 
0.61* 
0.02 
10.0* 
6.4
0,1*H-
5.9
89 
■ 4^9*
2.1
0.80*
0.03
1,0*•r
1.3
0.85*•>{.
0.03
4-Y* :
0 .9
4 .8
■ 4'
2.2
Group m
207i"
2 .4-j,
.
1.2
0.87
0.01
0
0..8S
m
0.03
2,7i*
0.4
V
1.0
A sum m ary of resu lts  expressed as a mean -  single standard 
deviation fo r Groups I, H and H I (see Table 10). Abbreviations 
as bn previous tables and at the beginning of Tables Section. 
R esults marked w ith  a s te rix  (*) d iffe r s ign ifican tly  (w ith leve l 
of significance taken as 2p (0.05) from  those of appropriate 
con tro l group shown on column to  rig h t.
p o s t-m ta i v w a
Patient A rea '-/ -A rea Berum. Plaohu
'M o .,:, w  -
'V ' :
F D P /fdp fi# in 6 g i
■• 1 * ÿ" • \  1. 0 ' V ., 0 ; -. - v W ' ; : :''v;,248,,.
' , '4.0 ' - b ::'Vy:r„;.2.,6 ■ V
8 *
- A -
\ '' 8.;% .. : ,7 .'0 '\ 0 \ " ; / ■. ■ 5 "V'.
4 .0 \0 .6 v . -V. 0; y 0
.. - 
' ' iSO';.
■ g ; ' :!.. 7.4 8 .0  X, 4 . " ; ();. ' : ' ' 168;'
t ’ . ' '4 *1- -y 0 - .-v  ■ ; 212
8 * - 7.0 4  ' ; ' 5 240
/  1.^:^ ' 0. 'Vr 200
' r Vi 
10 8.4 8,1 . .%,5 282'
mean 8.0=;\'- 8 .0 0.6 . 4 .5 :V -;-,222
'f  % ■ ' ' «# t ' rj-* <#/
ao i..8 < :T :,v '8 .,7 '" V - <14'-'
^Laboratory roaults pbtaibb^ blWd samples taken at Ui0 post­
natal v isit from the patioAts in Oroup% Chapter Vl (Mo sample 
was obtained from Patient 4)^  Patièht 6 wab thé only paUent  ^
receiving oral contraceptive therapy at this time. PaUents 
marked with asterix (*) were etui hypertensive.. The Fg^ êjults 
were computed with those from the Aon-pyegnant Control group 
(Group n» .Chapter V):using $he m ^ ^ e d  "t" test;- 
Plasma fibrinogen t « 0. 616 %p ((>.$; (M8)
A re a m  } t  *  0.013 %p (6.4 ^ ) "  .
SCT t it re  at V^ t  = 1.0%2 %p (0..3(M8) ;
$ e iW F D P /fd p  t «  1.070 : :
W a  p t « 0.405 2p (0. 7 (M8)
Tabla 44
Patient
-Mo.
1 
%
10
Bampie 
: Mo.
- '■ I  ...
(during labour)
1 •
2
8
A
2
'% . - 
:. - '<[: .
(a fte r L U ,D . )
^  ' .u :
(a fte r L  )
1 r'-'V
2
3
a
8
4
§
C lin ica l hidex 
P rereclan ipsia  N orm al pregnancy
26; 8 
89.2
27.8
-2*7
9*4
28,4
38.1
2,0
15.7 
N .D ,
29.8 
N .D .
19.5
23.0 
28.8
21.1
10. Q
"10.7
"10.7
4 8 .4
7 .8  
0.8
18,0
38t5
34.7
29.7
28.4 
28.0.
-13 .4
-13 .4
-  8.0
8.0
8.0
-13 .4
^13.4
-,.9 .p
-13 .4
-13 .4
Table'-45a
C orre la tions Betweeh C l W eal indices (see Table  44)
iM.ij.li wi]iii*Ci‘ t M»wffinwm]rrriii'TT~>.i n it irni.ri|-nT f iminr'i riTiin in i' r  'in"r--t ' ir      <'ir ' iji i Mwrn* »'i# i*t>u u«m w w P'fW 'f * » iiiiirtMMM
and Laboratory Results
tz iin lc a l Index 
' and -  '
a r ea m
aCT t itre  at V.
area p
sérum  F D P /fdp
o
r
p. 10% 
0.290 
0.005 
0.063
o(
>0.1
)P - i
>0.1
>0.1
Table 46b.
C lin ic a l index 
and -
area m
SCT t it re  at .V^
area p - ,. 
sefuna T O P /fdp
T
.0 .137
0.630 
0.224 
0.395
2o(.
>0.1
nearly 
,« 0,05
>0.1
>0.1
The co rre la tion  coeffic ients (r) calculated by lin e a r regression
measurements from  the to ta l ante-natal p i e-eclam ptic data (à) 
and the data from  the la s t sample taken before de live ry  o r ih tra* 
u te rine death from  the pre -eclam ptie  patients (b).
. c -  V  ■■
c:'.
■Table 44 V .
' - C lin ica l indices"' (Howie, Furd le , Hogg et a l . , 1976) fo r
tiu" pro-eclam ptic ija tlants (to ta l ante-natal p rc-eclam ptic  
y  data oh patients m Group I, Chapter V) and norm al p re^m nt 
iyw ôm cn (Group XL Chapter: V*) at the tim e oX blood sampling.
. whën samples 2'and 4 were taken from  i*atient 5. The, =
samplh before de livery d r in trau te rine  death (I. U'.D. ) was
ro (iu ired .'' ... r  - '-y.-:, % '■ 'y-:-'
;
i>ïî.
j: /
». 'A-
■n;.. r
:
îf&
■ t-
/■■'i
■-A ■ . " ' ' :#
= # - r .
' "A.;.
Table 45c
C orre la tion  Coefficient (r)
P a tie n ts  Patient 7 Patient 9 Patient 10
Area m
SCT t itre  at Vp
Area p..
0.953* 
0.861 
-0.473
8erum FD B/fdp. 0. 401
0.048 
0.866 
0.926
0
0.912*
0.140 
■0.844* ■' 
•0. 978***
0.166. 
-0.342 
-0 .961** 
-0.673
The co rre la tion  coefficients (r) aalculated by line a r regression 
analysis fo r ante-natal sample data from  four ind ividual p re ­
eclam ptic patients.
. a«< <0.06 >  :  ■
2, «X, <0.01 . * *
' a o< <0.001 * * *
Table 46d
r*
Ç lih îca l Index 
and -
area m
BdT t itre  at
areà p
aernm F Î)P /fd p
,C lin ica l index „ 
and "
area m
8CT t it re  at V 
area p
serum F D P /ïdp
+0.487 
+0 .4S3 
+0.371 
+0.302
WWtlB— 'iUJtw.i.T
Table 48a 
r
1-0.702 , 
-î-0.746 
+0.808 
■1=0. 578
<0.01 
(0.01 
<0.05 
<0.08
2cK
<0.001 
<0. 001 
<0.08 
<0,01
the laet sample taken before de livery o r in trau te rine  dea# (e)
in  Groups I  and i l ,  Chapter V.
Tabla 46a
C lin ica l Qatcdme in  the Fregnancies Studied in  
Groups I  and Chapter V
' P re-B clam psia ,
Patient - T im e In te rva l
Mo, between - Diagnosih
and Delivery '
;  (weeks)'V.
' Foetal 
Outcome
P ercentile
B irth
W eight
-0
6
7
8
9
10
<1
1
2
a
1
2
<1
2
Prem ature 
8; B .
L ivp
Prem ature
M .M .D .
Live
L U .G .R .
L U. D.
L U .D .
L ive
L U .O .B .
(1) 8 .B .
(2) I .U ,p .
Prem ature 
■' Live 
L U .0 .%
Live ■ 
Premature
75-90 
10 - 25
<10 '
10 . 25
(10
(1) (10 
(2) (10
26 ** 60
<10
C lin ica l outcome in  thé pre-eg lam ptic pregnancies included in  Group I, 
Chapter V. (PatWnt 1 developed eclampsia during labour).
8 ,B . -  s t ill-b ir th  ,
M .M .D . « neo-natal death -
L U .G .R . » in trau te rine  growth re ta rdation
• Ï.Ü .D . -  intrauterine death , '
pe rcen tile  b irth  weight calculated according to  Lubchenco at ml. » 1963.
' = T a b l e .T:/
N orm al Pregnancy ;  ,
Foeta l Outcome P ercentile  B ir th  Weight
' 1 . . - - - 2 6 -É 0 - " r
\2  "/L iv e  „ ' 25-50y : - '
S '  "" L iv e '' " ' " ' ' 60-70 _
4 L ive  60-75
6 L ive  26-50
;6 ; ' L ive  " ' *' 28-60
.7 L ive  ' , 60-76. ,;
' 8 ’■ L ive ; . ■ " 78-60
6 ' / ;  L ive ' ; . 80-76 ' :
10 .. L ive  = . .. 10-25 ..■
Ôhapter V. P ereeritile  b irth  weight calculated according to 
Lubchenco et a l, , 1083.
' Table47a
Comparison of Laboratory Data Grouped on the B a sis  
P erinatal Deaths or L ive,B irths (see  Table 46)
Perinatal Deaths L ive Babies
area m 15.0 -  C>. 6  1 4 .0  » 6 .4
SCI' t itre  at 2 .9  1.0 2. '? ~ 1.7
area p 9. 0 -  4 .2  10.4 i  6. tÿ
serum  i'O P /fd p  8.2 8 .9  8.1 ± g. S
Means '-'Standard deviations of total ante-natal resu lts  on the p re­
eclam ptic patients grouped on the b asis  of perinatal deaths or 
live  b irths. D ifferences between groups (unpaired "t" test):-
a re a m  t « 0 .# 1  2p <0.5 (MS)
iSCT titre #  t « 0.325 ,». 2p (0.8  (MS) .
area p " t == 0,424 2p <0.7 (MS)
sérum F D P /fdp  t  =: 0.733 2p <0.5 (N8)
Tablé 47b
P erina ta l Deaths L ive  Babies
area m ■. 18, 3 -  0 .5  ■ 16. O -  8.4
SCT t it re  at V „ . 4 . 0 - 1 . 4  3.4 ~ 1 .5o
a m a p  8 . 7 - 3 . 1  1 0 . 8 : 8 . 4
serum  F D P /M p -/ 11, 6 :  4 .8  " 8.1 A 4.7
Means « standard deviations of resu lts  from  la s t samples taken 
before de livery or in trau te rine  death from  the pre-eclam ptic, 
patients grouped on the basis of pe rina ta l deaths o r liv e  b irth s . 
D ifferences between groups (unpaired "P* tost): «
area m .t = 0 . 857 2p (0;8 (MB)
8CT t itre  at t  = 0. 607 2p (0 .8 (N 8) - ^
area p t  = 0.626 2p (0.7 (MB) .
serum  F B P /fd p  t  = 1.045 %p (0.4 (N8) , :
Table 47c
P erinata l Deaths L ive  Babies
o
area m 
SOT titre  at V 
area p
serum FBF /  fdp
15. 9 i  0, 8 
: 2 .8 1.6 
8 .6  -  4.2 
0.2 i  3. 9
10.6  -  6.8 
2.1 - 1,8 
8.8 -  5. 4 
6.0 1 3.4
Means -  standard deviations of resu lts from  a ll the ante-natal 
samples taken from  the pre-eelam ptic and no rm a l pregnant 
patients (Groups I  and l i ,  Chapter V)» the resu lts  being grouped 
oh the basis of pe rina ta l deaths and liv e  b irth s . DiÈerences 
betv/een groups (unpaired " t "  tes t);-
area m t = 2.337 2p <0* 0:5
SCT t itre  at t  = 1.203 2p (0. 3 (MS)
hrea p t  = 0.726 2p (0; 6(N$)^
serum F D P /fdp  t = 1.966 2p (0.1 (N8)
' A:,.
; > 
4\ :■
i / -
TaMe 4?d
P eriaa ta l Deaths
o
area m
8 C r t it ré  at V. 
area 'pr.T ' 
8era% PDPyMp.%
18.3 t  f c t  
4.0 ,1 l,.4',, 
% B .'l l  S .l ’■
11* 6 -" 4*'8' '
L ive  Babies
8 , ? Ï 7 * 4
i f Ü Ï l . G
e . B Ï 5 . G
5 .8 ^ 9 .%
j .  „ ‘ ■' ' ' '
Means -  standard deviations .ot resu lts-from  the last'sam ple taken 
before de live ry  or in trau te rine  death .from  the pre^eolam ptlc 
patients and norm al pregnant -dontrolwomen, the re su lts  being
area' n i -1 .'= 2 / 8 #  2p (0.09
B C T t i t r o a tV ^  t « ^ * ^  %
a re a p  '  t  = O /W
.f“  ;
Table 48a
(10th P ercentile )10th P ercentile
o
■area m 
güOï' tiüüeEü 
i&rea p
serum F D P /fdp
12.? : 6; a
:^ :3, 1,7
11, 6:^648 
8.1 > 3.5
16. Ï  > 7.1
a. 8 ± 1.6
8 .4  ± 8.3 
8 .9  ± 4.2
Means -  standard deviations of to ta l anté-natàl resu lts  on the p ro - ■ 
eclam ptic patients grouped on the basis of baby b irth  weight (below 
or above the 10th pe rcen tile ). D ifferences between groups ■ 
(unpaired " t "  to s t);- ■ -■
area m 
8CT t itré  at V 
area p
t  = 1.822 2p <0.2 #*8)
Q t  = O.INÜ&; 2p (O.G (N60
t  « 1.81# 2p (0. 2,(N8)
serum F D P /fdp  t  = 0.617 2p. <0.7 (N8)
#bWv48b % ' ' ' ; 'T
(IW h ) lp tb  Percehtüé
'àraa:,m;.. ' X ’■ >  ^ 18,9 -  6#4 . '.v, ' ' 18,0 ï  9.8
m T 'U tp e a tV - ' S .8 .3 'i.O  '- V " :-3.9 ± 1.8
a r# .p , ,,y ' " '■,■ ■ 12.8 ± 8.7 ' \  ’^ ’ ;
A r u m ' F # / #  ■ ,10.0-'C'3.0' ,. ■' . ,10.:6.±5.7:
Means -  standard deviations of the re a n lts jro ih  the la s t sample
patients* the re su lts  being grouped on the basis p i baby b irth . - 
. weight" (belpw o r above the lOth-pèreent% ), ' ' BlÉerenéeà; between ^ 
groups (% paired **t" te s t):-
a re a m  t :6 Ù ,2 1 9 r2 p < 0 ,0 (M 8 )
^ 8 C ft it re -a t.y ^ /. t  V ' '% ^  . -
a re u p  t  *  1^266,.:2 p .^ $ ,(W ) . - ; '
serüm  F Ï)P /M p^ t :«  0,128 2p # 0 6 (N 8 )   ^ ' X
■Afcv^
/
Tablé 48c
(lO th Percentüe >10th P ercentile
area m 12.7 ± 8.8 12.1 ± 8 .1
é C ï t it re  a t ¥ „  S ± 1.7 2 .0  ± 1.7, o . , ■ .
area p 11. 5 ± 8 .8  7.0 ± 3.3
serum  FB I»/fdp 8.1 = 3.5 7.4 ± 4 .0
Means ± standard deviations oî the resu lts  fro m  a ll the ante-natal 
samples taken fro m  the pre-eclam ptfc -and norm al pregnant 
patients (Groups I  and II, Chapter V), the resu lts  being grouped
on the basis of baby b irth  weight (below or above the 10th
percentile ). D ifferences between groups (unpaired te s t):-
area m G ^  0.219, 2p (Ô. 9 (N8)
8CT t itre  at t  « 1.620 2p (0.2 (N8)
aréa p t  t^ 2.688 2p <0.02
serum  F D P /fd p  t^^  0.406 2 p < 0 . 7 ( # )
arable «AadL
^lOth PerceptUe )10th P ercentile
a re a m  1 6 . 8 ^ 5 * 4  9.1 Ï B .  9
SCï' t it re  at V  ' ,8.8 ± 1 . 0  ‘ ■ ■ " ' 1.8 ± 1 .9
area p ' ' .« ; /  ';. ' '  12.6 ± 8 .ï  ' ' , 0 .7  ± 2.7
oèrum f  .D P ./fdp ' ■ ■ ,' 10. 0 ± 5; 0 . 6.6 ± 4 .4
Means ± standaM déviations d f resu lts  îrom  the la s t sample taken 
before de live ry  o r in trau te rine  death from  the pre-ee lam ptic patients 
and norm al pregnant ôbhtro l women, the: resu lts  being grouped on 
the,basi% of baby b irth  weight (bélç# o%* above the lO ih peroentàe).
aream t 1. 736 2p <0.2 (NS)
S C T tÿ r e a t  t » 1.804 2p <0^1 W )
area p : \  t % <0.02
seV um FD P/fdp t  1.141 %  <0.$ ( # )
Tabid 49
, % ■ -
' V :. , '. ■ '
Total
pre-eèlamptiC
grcmpl
Total ;
■normal''
pregnant
group
■.V.t : (
Plasma
fibrinogen
.(m g /fW 'in i) _
267 ± 87 
(33)
828 1 88
. - ■ { 1 4 ) '
'■.2.'004V
= 0.05
area m ■ y . 
percent
14. 8 ± 6.2  
(35)
4 .4  ± 1 . 0 
(14) ;
6.176 <0.001 V
:80T titre  at !
..
(i&g. logy to 
base 2)
3 .0  ± 1 . 6 . 1.2 ± '4 .4  ■ ■ '
..1 1 1 ) -- ' ' .. i' ■ '■ ■
3.076
.:
; ,5. 463'-:
<0.005; 1  '
' V '*
FR-antigen 
ratio -
0. 66 ± 0.08 
■ ' (33)^;
0. 80 -  0.03 
(11)
:;,|î <0.001
TCP ratio 0. 65 ± 0.08 ;
; . (3 4 ) -  ■ ;;
0.84 ± 0.8V,: . 
(11) .ÿ :'
v,...y;z^ g^48. <0,001 ; '..
/ ,
area p 
'.p e r# n t . .
. 0,- 7 '± 4 .8  
■' (35)
,5.1 ±2 .3 .  . y -3.947 ,, . .<OV005(vy
- - '
serum FDP /
,  f #  . '
; w /m l)  .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
' ,8.9 5- 4.1, ■ 
 ^ (32) , ; ,
i .9±'T.9-: ' '- '  
:■ (12)
8,272
\: 'v (  '
- v : ^ . , . . . , . . . . . . . . . . . . . . . . . . . . 1 . , , . . . ,
. <0.005 V ,
 ^ ;
:  ^ ■; ,
t V  -  ■ ' ' , . ...,«
Differences between-:##' tdtal ante-natal d&ta from pre-ecla^j^ ic
women (14 samples fVdm 1 4 'patients, Table 68, Chapter ¥11) 
analysed using the unpaired test# Numbers in brackets' 
W ieatè  number of dbseiwations.  ^ ^
t. . r ;
.;r;j . . .
Table 90
# io u p I
, (Chapter ¥ ) -
Total
pre-eclamptic
group
t V--. . ,  : g p " :
Plasm a 
fibrinogen- 
(m g/100 m l)
281 ± 84 
(10) .
jV.x 267,±87
(33)
0.461 <0.7 (NS)
area m ■’ 
percent
18.8  ± 6.4. 
: V(10) :
: 14 .8 '± ‘ 6.2 
/  V (86) •
0.532 <0.6 (m )
8CT titre  at
%r
(%&g. log. to 
base 2)
-V-3.8'-' 1 .0 ■
- r  /  -  V
3.0 ± 1 .6  
(26)
1.517 <0.2 (n 8)
F ll-a ritig a n  ' 
ra tio
0 .6 1 1 01, 01 
(10)
0.86 ± 0 .0 8  
?:.(38) '
1L887 <0.1 (WS)
TCP ratio 0. 61 ± 0,02 
(10)
0(8B±8«08
'  : ’(34 ) - -^ . .
1.713 .... <0,1 (MS)
area p
percent
8.1.-'±,8.9
.. m
.0. 7 ± 4.8 '  
(35)
0.288 <0*8 (HS)
serum F D P / 
fdp
(pg/m l)
' - -K?. ± 4 .2  
(10) -■
-. 8.9(±:4.1^ 
, (32)
.0.870 : ' <0.8 (NS|-
" ?.
D ifferences between the. selected-group of data included in  0  rpup I, 
Chapter V and the to ta l ante-natal pre-eclàm ptic da tâ i$9  sam]ples 
from  l6  .patients), . Numbers, in  brackets indicate number of 
observations, . - . .y -, " .
Table SI
Single Pregaahciéâ
Age
(years)
parity Gestation-:
(weeks) (miaHg)
D.B,Pg
(hiniHg)
Complications-..
. - 1 16 ' 24 110 75 : None
2 27 ■0+^ 27 is o 50 ■ ' “ 1» *
’v 20 1 . 0 !%8 110 70
tf
4 - , 23 O t ® " 25 180 76 -
■ 5- 39 0 4 ^ ' - 30 140 80 #1
36 4 ^ 0 32 ; 'IBS' ' 80 1*
27 ' 1 . 33 ■ 12§ - ' 76 /n  ,
■ 8 22 . . o , - 0 ' "  #4 ' . ■:,liO" ■ 70
- 9"' 24 2- .  i 34 ■„.; # 50
io ■ 17 „ ■: 'o .o 34 120 80
11 29 0 . 0 35 110 70 fT
" 22 0 .  0 35 100 V 50 :<■' ' ■ „
13 25 0 + 0 35' 120 50
w ' 22 1 . 0 39 130 tfy
mean ; .2#.■ ‘i*. 324"" " 110i" Y
SD , ' 8 -- ,14. :
; 27 0 + 0 . 82 120 .76 - Hypertension 
at 35 weeks
placed separately at # #  foot of the table. Means ~ standard deviations
are shown.
Table #2
Tw in Pregnancies
Age
(years)
■ Parity Gestation
% (weeks)
S.B. F .
(mïïi|îg)
D .B .P .
(msnHg)
Complications
15 28 1\  0 -i- 28 110 ■ ' ,, 80 - None:.., .
V 17 ' ' 16 : o . « . : ' 120 ■-';78 "n'.
18 90 0 . 0 34 180 80
19 38 0 + ® 89 n o ■. 66- ÎÎ ' ' -
mean 27 82 ‘ 123 ' V.-78
- ,-1 .5, i f ■ + m
80 7 . ■ 10 • 7
i 20 20 ' 1 ® , .80 , n o 80 Hypertension 
at 85 weeks t
21 37 l - , . « 84 120 89
, '.-f
Hypertension 
at 87 weeks
C lin ica l data on the apparently norm al tw in pre^m nciés .studied,
are
. "f
; Means'
-  standard deviations of the resu lts  from  the rem ain ing 4 patients 
are shown.
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Table 5B
M
Gestation 
M ate i'% l. age " ■
■ x S .B .p . ; , .  ■
Flasm a fibrinogen
-Serum F D P /fd ï) .
Area m -
.V.Area n
Area p
: /  - , , "rv
SGT t it ra  at w
FE-antigen K a tio  ' 
TCP R atio
01283
0.638
0.488
0.368 
0,816 
0. §11
1, 044 ; 
1.836 
4 .127 
2.138'.
1.288
3.278
(0. 8 (NS) 
(0. 8 (NS) 
(0.7 (NS) 
<0* 6 (NS) 
<0.9 (Nb) 
<0. 7 (NS) 
<0,1 (NS) 
(Oi l  (NS)
<0. 3 (NS)
nearly ■ 
= 0.08
<0, 3 (NS)
<0, 01 '
unpaired " t "  tes t.
-84 analysed by the
Age
(years)
./'P a rity ' Gest^ation 
when shmple 
taltéh 
' (weeks)'.'
8 .B .P .
(mmHg)
D .B .P .. ' 
(mmHg)
4 25 S6',:“ ■ .' ' ' 78
2 20 0 + ^ ", 37 . iV-'"' 125 80
sr ' \ 31 2 + ® 8%, 120/ 7 0 - - .  ■
-4'.- 0- . '4 4* ' - ■ - 3 7 -  , ,. 110, , 70
"/''9 22 37 , : 100 00
"6" 19 i  4. 130 ' 80 ,
V:':7 :  ' 30 4 3 + 4  .., : 3 ; r  " ' , 120 " , .70
' ■ Ô 33 , 0 "  ; ■// 38 ./(V . "‘/ ■ l i o . 80/ :
32 120 88 ,
10 23 /  37' 188 ■' W
mean .'27 36 , 110 , ■ 76
■  ^f *» +... .
: . V .. ■ B ■
... 7 .
Clinical data' op th# 10 pàtienté studW  with a diagnosis of 
suspected intrauterine grow th re ta r# tio a . ' Where relevant
v-i'-i 4*means -
Table 55b
Suspected in tra u t# lu e  growth retaa^datioii patients
Approxim ate 
gestational 
■ age at b irth  
(weeks)
8ex
of
baby
B irth  
weight 
‘ ÇKg)
P ercentile
bW hiW eight
Other
com plications
1;: ; . 36 2 ,0 . f o Prem ature
,2 40 M ;&,6 , (io None .
3 , 39-40 F 3.2 SO-75 None
-4' 42 F 2.7 10-25 None
39-40" F 4 <10 - ■ N one
5 \ 39 a& ' 3,4 f 50-78,. None
? 39: / '  . ; . 3 2. G : 10-25 ,' Ndhe
8 ' ^ ^ ^ 3 5 - ' - ;  ' m 1, tt <10 ... Prem ature
e 38 : M 2 4 "4
/ ; , ■ Hypertension at 37 weeks (B. P, 
140/90 mmHg), 
No p ro te inu ria .
10 39 .M  ': 3 .0 25-50 Bidne
C lin ica l data on tW  10 patients studied w ith  a diagnosis of suspected
in trau te rine  growth re tardation,
&i = &%aie % '
= aremale
Table 67
Gestation
"(week's);
1 
2 
- 3
■'■4'
'-.6:
:;.;6
■ 8 
1 9 
10
mean
8D
wwnwwwwiiMgmi
07
30
37
37
37
37 
34
38 
37
36
; 4
a-
Plasm a ' 
F ib rlnogm  
(m g/100 m l)
431 
322 
: 220
332
234
210
322
300
32G
305
-X:'-
67
Serum F D P /fdp  
(p g /m l)
5:0
2 :5
2 .5
2 .5
5.0 
3.75
2.5
6.0 
2,5; 
;7a::5 .
3,0
4' V
1.7
Plasma fibrinogen and serum  F D P /A p  resu lts  for samples from  '
patienta with suspected intrauterine growth re ta rdation  (Table 56),
4 ' <Means -  standard deviations are  shown.
Table 53
Gestation
(weeks)
Waema
Fitelnogesï
(la g /lO O a il)
Serum FDP/fO p 
W /m l)
'*
, 1 ' .</ ;4 3 1 ,  - ' ' - . 5 . 0  ■
37 :. ' "'''322 '2 .8  . . .
37 :/*n>:-322 ' .. • 8 .0  '
/  & $22 .. ,■ 8 .0  .
0 ■'/ 8 6 / ' " " .8eo: '_y ■ 2 . 8 , ' ' ' : . '
mean ■ 86 ■ 381 ;■ 4 .0
■'h ■ -f
SP 1.2 . 47
: - - : V ' - OiagtnéslB Not con firm 'ed; - - -
' ,'3'_ \ 39 229 2,5
-"4 : 3? 297 " 2U5 ' ; . '
.21. ,234, ' 1' 3,7
■7-' . ' ,37' • 210 2.5
10 ■ 87 .. 328 7+Gr" '
mëan :3B.4 289 8.7 / , . ^
i- 4", '■ , 1 •»■■
5%)'. . , . 4 .8  , ' ' , ■/ 49 .,,..3.2 ;■
Plasm a fib ria o g m  and serum  F] 
patients In Table 56» grouped record ing to  whether the diagnosis
the baby's percbntile birth weight or-not*  ^ The gestational age of
Means
■f standard déviations a ra  shown*
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Table 6Î
aiagnosis
rom  # e  5 patients h i whoM 
the dia^OGle was not confirm ed
Gestation *
j&go . . ^
I X
D .B .p , "  ::
Plasm a fibrii^pgen
aerum F b P /M p  ,
area.,m /  
area n „',^,v ' 
a reap  . ' - \ '  -.
8CT t it re  at V;:'
ÿE  -antigen ra tio
TCP ra tio
t
0.272\
o .sW
' .' ■‘■iV
0.861
0. SOO,'/
'3,019;
0.227
:3V8®8 
e.’'24B- 
2» 623
o.ssp
0.720 
0.275,
2p
<0.8;<NS):
,<o. 0 ; n s )
.{0.8 I 
{0 .9 (1 # ).,
(O iO f::'" :
<0, 9 (NS)
(O.'Ot: '■;,: 
(0.001 
(0.06 , . ■
<0.'6(NS)/
(O. B (NS) ■
(0.8 # 8)
b irth  weight and those
^orc entile
te s t:
Table 62 ,
Comparison oî data from  tbs § patients in  whom the 
kgnosis of intrauterine growth retardation 
was confirmed and that from 1.4 norm al
2p
Gestation 1.901 (0.1 (N6)
Age ' 1*050 (0.4 (N8)
8.B.P* 0.365 <0.8 (N8)
D .B .P . 0.610 (0. 8 (NB)
Plasma fibrinogen 0.683 <0.8 (NB)
8erum FDP/fdp OiSMMF ' <0.4 (NB)
area m <0.001
area n %.091 <0;m i
areap  . 3 .3 # <0.005
8CT titre at;;; , 0 0,553 < (0 .0  (NB)
FÊ-antigen ratio , 0,188 <0. 9 (NB)
TCP ratio 1,939 <0.9 (N8)
The data from 5 patients in whom the diagnosis of Intrauterine 
growth retardation was confirmad (Tables 66, 58 and GO) and  ^
the 14 normal single pregnancies (Tables 51 and 53) analysed 
using the unpaired "t" test*
Table 88
Comparison of data from  the 5 patienta in  whom the 
diagnosis of in trau te rine  growth re tardation 
was not confirm ed and that from  14
%
Gestation 1.28B <0. 3 (NS)
Age ' , . 0.425 <0.7 (NS)
S .B .P . 0.301 (0.8 (NS)
0.421 <0.7 (NS)
Plasma fibrinogen ‘ 1.612 <0.g(NS)
Serum F D P /fdp 1.107 <0. 3 (NS)
area m 1.410 (0 ,2  (NS)
area n 1.345 ; 0 . 2 (NS)
area p 0.798 (0. 6 (NS)
SQT titre  at V ' 1.079 ,(0. 3 (WS)
FB-antigen ra tio 1.108 (0.3 (NS)
TCP ra tio 1.008 (0.8 (NS)
The data from  the 5 patients in  whpm the diagnosis of in tra ­
u te rine  growth re tardation was not confirm ed (Tables 56» 68 
and 60) and the 14 norm al single pregnancies (Tables 61 and 
68) analysed using the unpaired " t "  test.
. Table.64 ■ ' . '
Compariapn of data from  tim 5 patWata m whom the 
diagnoaia of ihtrauWrlae growth rotardation waa 
: qmiflrmod aM  that from 10 pre-oclampti
C roupi)
tv " /  . ; %
Oeatation " <0,08
.Age i . $ é  ' <0.3 (MB)
K B Æ . 1^" -  ' - 
D .& jp . . -
8 .8 #
5.260
<0.008
<0.001
Plasm a fibrinogen ..: i . ' W x <0, 8 (NS)
Serum F D P /fdp : ,  J .0 M  . ' <0.02
a re a m  . y .
ar<#in ' \  
a re a p :-," '. . . . . .
2. @10 
.. 2.0,98. 
O. OBë '
<0.,02S 
(0.1 (NS)
, <0. @75 (NS)
s e t  t it re  at
. O r
4.089 ., <0.006
rR-m%tigéh ra tio 14)889 ., ,  ._<0..001 , - -
ra tio  14. 530 (0.001
The data fro m  the. 5 patients in  whom the diagnosis of in tra ­
uterine growth re ta rdation  was confirm ed (Tables 56, 58 and
GD) àW  the 10 pre-oelam ptle patients (10 aamploa) studied in  
Group I» C hap& i''V  anaiyaed using tW  unpaired teat.
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Æabie m
women .with
.Gestation
S.B.Ï».- '■ .
Dlafima fibrinogen
Berum F O P /fdp
area m . 
arma a 
area p
SCT t itre  a t ¥ „  o .
PS-antigen ra tio  
TCP ra tio
8 .i8 0
i.-foS,
3&711
‘Ï.126,.
p. 876' 
0,602
LO IS  
0. # P  
0.338
0.800
0.66&
1.166
.<0.06' "v  
,<ô. 2 (W )
<0.006
■'<pi.,p01- —
< ,i.l (NS)
<0. V (NS) '
(0 .4  (NC) 
<0.96HHS) 
p.8,(W S)
<0.8  (NS)
<0. 4 # # ) ,
<P<|';-CNS)
" t ”  test. ■
 ^ Table 6B; - ,  ' <
Comparison of data from  thé B pregnant women w ith  
essential hÿpêrtensWa and that f:*o m ia p re '*  
8#hwnpüefMükM#8(ô#eupI)
:■ ■' ' ^ ' ■ ' .  
Gestation 1.736 ; <0.2 (IMS)
&e . :, '  ^ 1.000  ^ O.T (W )
S .B .P . ' - ' 0.606 - ,. <0*0 (N8)"
D .B .P . - • . . 0.481 ; ;- <0.7 # 8 )
Plasmà fibrinogen ■. : , ,0 .2 4 8 ; . <0.9 (NS)
,ge rnm F D P /M p :' - , 2.,S33 (0.025
area m ' ■- . 4.181 (0,008
a re a n  -  ^ 4.020. <0.008
.area p . ' ' . . .  'l.^O T  ■ <0.3 (NS)
SCT t it re  at ¥ „  "s.O lO  <0.008
o , -. .
PB-antigen ra tio  34.803 <0. 001
TCP ra tio  ■ ' . 18.300 . . <0.001
-The data frcwtt the B patienté w ith  essential hypertension in  ' 
pj^egnaiAey (Tablée #  and 00)'and the 10 pre^^eclamptic patient# 
(10 eiiznjplea;) etndWied in  (Snowjp I, CWaaijptewp If awaaJ^ yèHscEiwüsing; th® 
nnpaiFed ” t’* test*:, ■"
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Table 71
Cpnaparieon of data S^m gaant patients w ith  chronic 
rena l disease and that fro m  14 norm al pregnant women
' . t  - . ap
ess^feewAcWitiM
Gestation : ;’, . 0.S04; : ■, (0 .7  (M8)
:Age ■ \  2..0ie , (0 .1  :(M#)
,S.B.1>. B.ÔB2 (0.001
0 .B .P . ;;'0.3'9O^ ■ ■ (0.001 ■
Plasma fibrinogen ' 0. 688 (0. 4 (NS)
Serum ro p / fd |)  ■ 3,278 • ,, (0. 01 \
-'area m 0. 670 (0.4 (NS)
a re a n  1.341 <0.2 (NS)
area p 1.007' (0 .2 (NS)
:SC'F t itre  a t 0 .1 3 6 ."/'  , (0 .8  (N8)
FÏS-antigen ra tio  . 2 .2 1 1 ’ (O.OS
TCP ra tio  . • 8.873: . ' <0. 005
The data from  the i  patients w ith  chronic renal disease in  pregnancy 
(Tables 69 and 70) and the 14 norm al single pregnancies (Tables 61 
and 03) analysed using the unpaired " f ’Teat, '
' - \  Table '
Comparison of S pregnant patient# w ith  chronic rena l 
disoaoe (? w ith  auperimpoaed pre*-@clamp8ia) and 
:ient8 w ith  pre-ecian%peia
Gestation
j&SSe
e .B .p .
D .B .P ,
Plaema fibrinogen 
F D P /fdp
area m
area n 
area p
aCT t itre  at. o
F R -an tigsji ra tio  
TCP ra tio
1.820 
2.186
1.486
0.207
1.743 
O.iSO
4.107
3.108 
0.334
4.880
8.378
7.663
2p
(0. S (NS) 
(0.00
• <0.2 (NS) 
<0.8 (HS)
<0.2 (HS)
<0.7 (NS)
<0.008 
<0.01 
<0.8 (NS)
<0.005
<0.001
<0.001
The data from  the 5 patients w ith  ehroaic rena l disease in  
pregnancy (Tables 69 and 70) and from  the 10 pre-eclaaaptic 
patients (10 samples) studied in  Group Ï, Chapter ¥  analysed 
usih® the unpaired " t "  test.
Tablé, 73
Horm otensive women taking oeatrogen-contatning o ra l
Age
(years)
S .B .P .
(mniHg)
D *B *P .
(minHg)
Plasma
■ ' fibrinogen '■ 
(m g /100 m i)
Sémm 
F D P /fdp  
(fig /m l) ^
■ 1 26 120 80 230 2,'6- "
26 115 . 78 177
3 28 115 70 181 0 ■ .
'
S!8 110 70 216 1.25
5 ' - . 2? 105 60 203 ; . -2 .4
'"'0' ' 20 116 00 244 2.8  ■
7 . 20 110 60 ,187-: 0
. ,8 ' 21 78 214 e
9 24 118 80 101 2.6  . ,,
10 21 100 60 228 , 2.5
mean 24 , 111 71 \ 202 1.9
«• t  / 4' . . ■{'Mt
0 8 33 1.6
C l W ea l data on 10 healthy, nor m otenaW  women taking oeatrogen»
containing o ra l contraceptive drags (eth inyl^oestrad io l o r m eatranol ' 
50, #g per day)*. . Plasma fibrinogen and aerum F D P /fd p  resu lts  on 
samples taken fro m  tiiese women are alep given. Means standard 
deviations are  shown* -
Table 74
tea takb 
o ra l contraceptive drags
m
(percent)
- '/ ^
(percent)
P
(percent)
SCT t itre  : 
at V (neg.
log. to  base
2) r \ V
m -a n tig e n  TCP 
ra tio  ra tio
8 .8 90 3.8
f.
0 0.87 0.84
. 2 5.1 ' - 92.9 1.7 0.88 <). 91
J 4 .6 91.6 4 .4 6.5 0.85 0.89
.4, 3:4 91,7 . 4 , 9  ' 0 0.89 0.88
- 8 , 4 . 4 93.5 1.9 0 0.89 0»88
0 5.7
■ if
87.4 6.8 0 0,88 0.86-
■ : . 4 ,0 93.4 2.7 ,9 ■ ■ / 0.87 0 .9 0  ^
2 .7 91.5 5.4 0 . 0.85 0.92
9 4 ,0 : 92.8 3.1 0 0.89 0.88
10 '"4 .2  - 94.5 1,3 , 0 0.85 0.85
mean
' " Ï  
m
4&4': .
' . :i.o  - " \
91.9
4'
2.1
3 .6
. •» 
1.8
0.1 0.87
0.02
0.88
« • 
0.03
Plasma fib r in o g ^  chrom atograpliy data on samples fro m  the 10 normo^
(Table .’73). ' Means ■> standard deviations are shown.
Tablé 75
women
eontaiolng o ra l contraceptive drugs ând that 
(rom  10 normotonalvô women not takina these
.t ' 2p
•Agé . 0.994 <0,.J (NS)
8 .B .P . '■ 0.349 
, 0.294
<0. 8 (NS) 
, <0. 8 (NS)
Plasma fibrinogen 0.802 <0.8 (NS)
Serum F B P /fd p  ' 0.784"' : <0. B (NS)
area m 
area n 
area p
e.ots
2.002
0.223
<0.001 
<0.1 (NS) 
<0. 9 (NS)
SCT t it re  at ¥ „
, -
i.poo <0.4 (NS)
FH-antigen ra tio ,0.079 <0.4 (NS)
TCP ra tio  - 0 .93S <0. 4 (NS),
The data fro m  the 10 norm otensive women taking oestrogen- 
containing o ra l co iitraceptive drugs (Tables 73 and 74) and the 
10 norm otensive women not taking any drug therapy (Group in , 
C M pter V) anaiysed using the unpaired " t "  test.
ComparWoa o f dath fro m  10 wommi taking o$ 
cohtainWg o ra l contraceptive druj^e and tim t from  
nornu
Ag#
D .B .P .
Plasm a fibrinogaa
Serum PDP /  fdp
area m - /
a r #  a 
Urea p
BCT t it re  at V  '
Cl
TCP ra tio
iwîî*^!ie»rti*!?pasiWfWîcŸî^ f^
0.2W :
1 .570 : 
0.820
4.
». wI ' rï#r/
2.7
%
(0. 8 W  
(0 .2  (m )
<0.5 (m )
(0.976 (NS)
<0.2 <m ) 
<0.1 tm )
<0.02
The data from  t 
containi 
14' horun 
the uuj
poga
3iv0 wom m  talcing oestrogen'* 
ptive dm gs (Tables 73 ,and 74) and tho 
en (Tables 61 and 62) analysed using
Table 77
Ü8 w ith  m s m e W
1-
i
a
4
i
mean
Age 8.B .P* D .B iP . Plasma Serum
(years) (mn%Bg) (mmHg) fiWinogen FDP/fdp
(m g /100 ml) Wg/ml)
m
45
41
44
20
33
33
.f.
: a
190
140
.100
19Ô
170
103
19
120
90
110
110
113
109
■ f' 
12
lïB
2Ô3
218
306
218
260
+ , m
30
2.5
7 .5  
3.0, 
2 ;5
5 .0
4 .6
2.1
Clinical data on 5 patients with mepected **pill#related Iiypez'tensidnY, 
Plasma fibrinogen nnd serum FDP/fdp result# oh samples taken , 
from these women are # # o  gW n. Meane  ^ standard deviations 
are  ahown.
Table 78 
Hypertensive women ta
m
(percent)
' n ', 
(percent)
P ' 
(percent)
8CT t it re  
at V (neg. 
log, to  base 
2)
FE'-antigen
ra tio
TCP
ra tio
1 7,3 80.7 O .l.-''" 2 ..- 0.78 ^ 0,86
2 2.7 93.9 3.5 •■ 1 ■' 0.85 0.87
a : 2;0 94  ^6 3.5 0 .5 0.87 0.87
4 7.9 87.6 4 .5 3 , 0.80 0 .8B
•5 4 . 2 / '/ ,8 8 .5  . 7 .4  : 8 , 0.84 0.86
mean ■ 4.3 90.2 5.0 1.9 0.83 ' 0.80
-i' t 4 "f t 1^1* ■ tm +.
8D 2.7 3.7 1.7 1.1 0.04 0.01
Plasma fibrinogen chromatography data on the 6 patients w ith  suspected 
upili#^related hypertension" (Table 77). Means -  standard deviations 
are shown.
Table 79
Comparison of data from  & patieats w ith  suspected 
"p iü -re ia te d  hypertension^* and that from  the 10 
norm otensive women takhig oestrogoh^containing
%1'WA
 ^ -■ \  '■ , 2p , ;
Age / 6.104 V <0.001
8 .B .P . 8.796 (0.001
D .B .P . 7.348 . <0.001
Plasma fibrinogen '2 .788 <0.02
8erum ]B!pP /  fdp 2.737 , <0.02,
area m 0.466 <0.7 (NS)
area n 1 .1 # <0. 8 (MB)
area p 1.48Q :' - <0.2 (NS)
@CT tit re  nt 6.280 <0.001
FE-antigen ra tio  ' . 8.254 <0.01
TCP ra tio  ,■■:■ 1.74s <0.2 (NS)
The data from  the 6 patiente w ith  auspeeted "p ill-re la te d  
hypertension" (Tables 77 and 78) and the 10 normoteneive 
women taking oestrogen-containing o ra l contraceptive drugs 
(Tables 73 and 74) analysed using the unpaired *%** tes t.
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table 81
Y V n a o<.
area m 
area p 
area m 
or éa p 
area m 
ire a  m 
area m
8CT titré Ut V 
aéT  titre at V
o
o
area m
Plasma fibrinogen 0.007 
Plasma fibrinogeà ' -:-û. 088 
Sérum F D P /#  0.170
SCT titre at Vo
0.190
FB-autigen ra tio  -0.040
-0.004
a iitigan^ra tia  -0.040 
TCP ratio -6 .004
Areà' p . %. i-G
188
VÎ83
l lë
119
180
109
>0.1 (N8)
<0.00 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
(6*001
The paired laboratory re#ults (X and Y) for 0 #  samples (u number 
o l pa irs) described in  th is  thesis. The co rre la tion  coefficient ( ) 
and 8cK values are shown.
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Table ea
Local Véïitms Thr.omboale
âge Sex Diagnoses
% 54
8  40
3 88*
4 '^-
0 "  56*
ier g5*
Male (IX le o ir re a t lleo-fem ora l. vein thrombosis „ 
w ith  pulmoxmry #%mhollam.
M etastatic carcinom a -  primary never 
discovered, several hepatic secm daries.
(2)
Male (1)
Mate (1)
Male (1)
(2)
(3)
Male a )
(2)
Male i t )
, (2)'
secondaries.
ipoè t-traum atic).
C lin ica l de ta ils  of th e  S patients w ith  established lo ca l venous’throm bosis 
studied. * included in  the aherod study (Chapter I f ) ,  \  -
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Table 85
tbrombôsW  and mat from  1
Plasm# flb rb n ^e n
$erum F D P /fdp
area m 
area n \  
area p
8CT t itre  a t V
■■■,;' .. . 
FB -ant ig e ii ra tio
TCP ra tio
2 .58B
4.751 
0.050 
4: # 0
8.807
8 .0 #
0.878
(0 .0  (N8)
<0, Ô85
(6.001
(0.001
(0.001
(0,08
(0.006
(0.001
The data fro m  tM  0 patients w ith  deep venous throm bosis 
(Tables 83 and # )  and the 10 heaWiy^ non-preghaht women 
(Group m , Chapter V) analysed using the unpaired y t" test.
